downregul
gene
express
encod
sarcoplasm
reticulum
sr
ca
atpas
regulatori
protein
sr
ca
atpas
isoform
phospholamban
pln
play
crucial
role
myocardi
decompens
due
impair
intracellular
ca
cycl
report
pln
express
peripher
blood
mononuclear
cell
pbmc
translat
myocardi
set
also
significantli
decreas
dog
degen
mitral
valv
diseas
aim
studi
clarifi
effect
target
gene
reflect
hemodynam
overload
primari
determin
myocardi
distress
healthi
laboratori
beagl
n
young
dog
patent
ductu
arteriosu
pda
n
pulmon
stenosi
ps
n
enrol
studi
none
patient
treat
previous
cardiovascular
medic
pda
patient
subclin
stage
wherea
ps
patient
sever
stenosi
mrna
level
pln
pbmc
evalu
one
week
surgic
intervent
use
quantit
realtim
pcr
plasma
concentr
ntprobnp
also
measur
refer
cardiac
biomark
compar
control
group
foldchang
target
gene
significantli
low
pda
ae
ae
pln
well
ps
ae
ae
pln
pair
comparison
preand
postoper
express
level
significantli
increas
one
week
surgic
correct
pda
ae
ae
pln
ps
ae
ae
pln
meanwhil
plasma
level
ntprobnp
surgeri
differ
pda
surgeri
ae
pmoll
one
week
surgeri
ae
pmoll
ps
surgeri
ae
pmoll
one
week
surgeri
ae
pmoll
addit
express
level
pln
significantli
correl
hemodynam
indic
fraction
shorten
laao
ratio
pda
peak
pressur
gradient
ps
p
furthermor
receiveroper
characterist
analysi
show
high
valu
area
curv
ae
pda
ae
ps
pln
ae
pda
ae
ps
conclud
pln
express
pbmc
may
effect
abl
reflect
myocardi
distress
determin
hemodynam
chang
cardiac
biomark
test
melani
hezzel
john
rush
elizabeth
rozanski
suzann
cunningham
mark
oyama
univers
pennsylvania
pennsylvania
usa
tuft
univers
massachusett
usa
measur
ntprobnp
plasma
pleural
fluid
sampl
use
tradit
elisa
previous
shown
differenti
cardiac
noncardiac
caus
pleural
effus
felin
patient
emerg
patient
rapid
result
obtain
use
pointofcar
test
could
signific
clinic
benefit
purpos
studi
investig
whether
use
pointofcar
ntprobnp
test
plasma
pleural
fluid
sampl
would
similar
util
tradit
elisa
blood
pleural
fluid
prospect
collect
cat
present
pleural
effus
emerg
room
two
univers
teach
hospit
caus
pleural
effus
determin
case
attend
boardcertifi
cardiologist
basi
echocardiogram
histori
physic
examin
result
addit
diagnost
test
perform
cardiologist
blind
measur
ntprobnp
ntprobnp
measur
use
secondgener
quantit
plate
bnpquant
pointofcar
bnppoc
version
felinespecif
elisa
continu
data
report
median
interquartil
rang
group
compar
use
mannwhitney
u
test
fisher
exact
test
appropri
receiv
oper
characterist
roc
curv
construct
deriv
cutoff
differenti
cardiac
noncardiac
caus
pleural
effus
diagnost
accuraci
assess
calcul
sensit
specif
posit
neg
likelihood
ratio
thirtyeight
cat
studi
pleural
effus
determin
cardiac
origin
cat
noncardiac
origin
cat
signific
differ
weight
p
age
p
heart
rate
p
respiratori
rate
p
detect
group
plasma
plasma
vs
p
pleural
fluid
vs
p
ntprobnp
bnpquant
left
atrial
aortic
root
ratio
laao
vs
p
proport
male
cat
vs
p
cat
murmur
vs
p
gallop
rhythm
vs
p
higher
cardiac
vs
noncardiac
group
cutoff
pmoll
plasma
bnpquant
yield
sensit
ci
specif
ci
posit
likelihood
ratio
ci
neg
likelihood
ratio
ci
cutoff
pmoll
pleural
fluid
bnpquant
yield
sensit
ci
specif
ci
posit
likelihood
ratio
ci
neg
likelihood
ratio
ci
plasma
bnppoc
yield
sensit
ci
specif
ci
posit
likelihood
ratio
ci
neg
likelihood
ratio
ci
pleural
fluid
bnppoc
yield
sensit
ci
specif
ci
posit
likelihood
ratio
ci
neg
likelihood
ratio
could
calcul
denomin
conclus
first
studi
demonstr
plasma
bnppoc
differenti
cardiac
noncardiac
caus
pleural
effus
sensit
specif
similar
bnpquant
howev
pleural
fluid
bnppoc
test
limit
clinic
util
sinc
posit
result
nondiagnost
find
due
low
specif
although
neg
result
help
rule
cardiac
caus
pleural
effus
evid
human
patient
congest
heart
failur
chf
therapi
design
achiev
certain
reduct
ntermin
probtyp
natriuret
peptid
ntprobnp
improv
outcom
one
previou
studi
dog
chf
experienc
lower
ntprobnp
follow
convent
therapi
surviv
longer
persist
high
measur
unknown
whether
possibl
purpos
chang
plasma
ntprobnp
concentr
adjust
medic
therapi
dog
aim
present
studi
determin
whether
prespecifi
therapeut
algorithm
would
result
reduct
plasma
ntprobnp
concentr
dog
chronic
chf
secondari
mmvd
dog
recruit
within
day
initi
diagnosi
chf
secondari
mmvd
dog
clinic
stabl
time
recruit
receiv
least
mgkg
furosemid
per
day
mgkg
enalapril
bid
mgkg
pimobendan
bid
dog
exclud
follow
episod
chf
requir
medic
therapi
receipt
diuret
prior
onset
chf
histori
chronic
kidney
diseas
system
hypertens
supraventricular
tachyarrhythmia
signific
diseas
dog
examin
occas
day
interv
first
visit
blood
pressur
measur
radiographi
echocardiographi
measur
ntprobnp
blood
urea
nitrogen
bun
creatinin
perform
ntprobnp
adjust
exist
medic
made
physic
examin
measur
circul
marker
perform
next
visit
group
ntprobnp
creatinin
mgdl
group
therapi
escal
follow
current
furosemid
dose
mgkgday
dose
increas
current
furosemid
dose
mgkg
day
aldactazid
mgkg
sid
ad
current
dose
furosemid
mgkgday
dog
alreadi
receiv
aldactazid
daili
pimobendan
dose
increas
dose
adjust
made
diagnost
test
repeat
next
visit
creatinin
mgdl
dog
withdrawn
studi
repeat
measur
mix
model
use
evalu
chang
variabl
time
fifteen
dog
recruit
first
visit
dog
assign
group
dog
group
second
visit
ntprobnp
two
dog
group
dose
adjust
made
thu
dog
treatment
escal
base
plasma
ntprobnp
decreas
significantli
time
group
b
confid
interv
ci
p
chang
group
dog
b
day
ci
p
rate
chang
significantli
differ
group
p
serum
bun
b
mgdlday
ci
p
creatinin
b
mgdlday
ci
p
increas
significantli
time
group
chang
group
dog
p
respect
rate
chang
significantli
differ
group
p
respect
serum
creatinin
mgdl
one
dog
third
visit
vertebr
heart
size
decreas
significantli
time
group
p
wherea
left
atrial
aortic
ratio
chang
group
p
conclus
prespecifi
treatment
escal
algorithm
dog
stabl
chf
due
mmvd
result
signific
decreas
plasma
ntprobnp
concentr
time
serum
bun
creatinin
measur
significantli
increas
baselin
dog
suggest
care
monitor
renal
function
necessari
therapeut
escal
studi
warrant
determin
whether
target
reduct
ntprobnp
result
improv
outcom
dog
chf
secondari
mmvd
biolog
variabl
ntermin
probrain
natriuret
peptid
adult
healthi
cat
autumn
harri
amara
estrada
alexand
gallagh
brandi
mincey
kenneth
lamb
mari
bohannon
janci
hanscom
celin
mainvil
univers
florida
gainesvil
fl
usa
lamb
consult
west
saint
paul
mn
usa
idexx
laboratori
inc
westbrook
usa
ntermin
probnp
increas
human
dog
cat
variou
cardiac
disord
shown
distinguish
healthi
cat
subclin
diseas
congest
heart
failur
respiratori
diseas
dyspneic
cat
biolog
variabl
ntprobnp
impact
diagnost
util
biomark
unknown
healthi
cat
cardiac
diseas
purpos
studi
determin
biolog
variat
ntprobnp
within
day
weektoweek
healthi
adult
cat
adult
cat
prospect
evalu
cbc
biochemistri
total
echocardiographi
ecg
blood
pressur
exclud
underli
system
cardiac
diseas
thirteen
adult
healthi
cat
enrol
blood
sampl
obtain
time
point
period
hr
hr
hr
hr
hr
week
intraindividu
cv
interindividu
cv
g
biolog
variat
along
refer
chang
valu
rcv
calcul
intraassay
cv
variat
previous
determin
median
daili
weekli
ntprobnp
concentr
popul
pmoll
rang
pmol
l
rang
median
daili
weekli
cv
popul
rang
rang
median
daili
weekli
rcv
popul
rang
rang
thu
chang
individu
ntprobnp
concentr
greater
would
need
healthi
cat
denot
true
chang
biolog
assay
variat
microrna
signal
network
canin
model
mitral
regurgit
seungwoo
jung
ray
dillon
auburn
univers
auburn
al
usa
microrna
mirna
neg
regul
downstream
target
gene
heart
diseas
may
play
role
novel
molecular
biomark
valvular
degener
regulatori
network
mirna
mitral
valv
dog
mitral
regurgit
need
establish
enhanc
understand
valvular
pathogenesi
studi
aim
test
hypothesi
uniqu
mirna
profil
regul
downstream
signal
network
determin
molecular
pathway
mitral
valv
dog
earli
stage
mitral
regurgit
six
healthi
beagl
dog
recruit
baselin
examin
confirm
normal
cardiovascular
statu
base
physic
examin
cbc
serum
biochemistri
system
blood
pressur
echocardiographi
electrocardiographi
follow
hemodynam
measur
gener
anesthesia
mild
degre
mitral
regurgit
creat
three
dog
mr
group
transven
surgic
disrupt
mitral
valv
chorda
tendinea
three
dog
use
control
group
week
postop
monitor
dog
underw
human
euthanasia
harvest
mitral
valv
leaflet
immedi
process
mirna
isol
subject
mirna
sequenc
via
highthroughput
next
gener
sequenc
ng
platform
illumina
mirnaseq
data
mr
dog
compar
control
group
quantit
revers
transcriptas
polymeras
chain
reaction
qrtpcr
util
valid
ng
data
bioinformat
analysi
ng
data
conduct
identifi
subset
downstream
gene
target
differenti
express
mirna
median
length
small
rna
read
bp
rang
bp
princip
compon
analysi
show
signific
differ
express
profil
mr
dog
control
p
use
pair
sampl
design
express
profil
mirna
found
differenti
regul
mr
dog
control
involv
stem
cell
differenti
highli
express
associ
cardiac
hypertrophi
neg
regul
mirna
mitral
valv
mr
dog
quantifi
rna
sequenc
p
upregul
p
predict
target
gene
phosphodiesteras
downregul
via
qrtpcr
valid
p
gene
ontolog
analysi
reveal
differenti
express
mirna
regul
set
gene
involv
signal
pathway
myxomat
mitral
valv
degener
includ
tgfb
wnt
result
suggest
mirna
express
profil
downstream
target
gene
may
character
earli
molecular
event
dog
mild
mitral
regurgit
diseas
progress
deterior
advers
prognost
factor
canin
myxomat
mitral
valv
diseas
studi
perform
elucid
relat
volum
overload
left
atrial
phasic
function
healthi
dog
six
healthi
beagl
anesthet
intub
swanganz
cathet
place
measur
mean
pulmonari
capillari
wedg
pressur
mpcwp
preload
increas
intraven
infus
lactat
ringer
solut
mlkgh
minut
transthorac
echocardiographi
perform
minut
minut
start
infus
timepoint
apic
fourchamb
imag
record
analys
softwar
base
twodimension
speckl
track
echocardiographi
deriv
timeleft
atrial
area
curv
left
atrial
total
passiv
activ
fraction
area
chang
indic
reservoir
conduit
booster
pump
function
respect
calcul
left
atrial
phasic
area
curv
acut
volum
overload
significantli
increas
mpcwp
minut
compar
minut
fraction
area
chang
total
passiv
activ
minut
significantli
increas
compar
minut
signific
posit
correl
observ
mpcwp
fraction
area
chang
result
indic
left
atrial
phasic
function
enhanc
volum
load
load
condit
consid
evalu
left
atrial
phasic
function
indic
deriv
left
atrial
phasic
size
studi
aim
evalu
noninvas
valu
dpdt
dpdt
dog
differ
stage
chronic
mitral
valv
diseas
cmvd
correl
valu
systol
diastol
echocardiograph
index
left
ventricular
function
crosssect
prospect
observ
clinic
studi
dog
cmvd
perform
patient
stage
stage
without
congest
heart
failur
chf
stage
c
chf
physic
exam
systol
arteri
blood
pressur
thorac
radiographi
electrocardiogram
transthorac
echocardiographi
obtain
dog
chf
present
lower
dpdt
mmhg
p
p
p
dpdt
mmhg
p
p
p
compar
without
chf
mmhg
p
p
mmhg
p
p
despit
fact
eject
fraction
fraction
shorten
differ
valu
dpdt
correl
diastol
index
ivrt
r
p
eivrt
r
p
e
wave
r
p
lvdd
r
p
dpdt
dpdt
neg
correl
laao
ratio
r
p
r
p
conclud
dpdt
complementari
index
assess
diastol
function
dog
cmvd
studi
dpdt
effici
detect
impair
systol
function
routin
use
index
possibl
due
lower
load
depend
patent
ductu
arteriosu
pda
common
congenit
heart
defect
usual
diagnos
close
young
dog
due
poor
longterm
prognosi
herein
describ
clinic
characterist
dog
least
year
age
diagnos
pda
novemb
octob
data
includ
signal
physic
exam
concurr
cardiac
diseas
heart
size
treatment
obtain
medic
record
dog
present
clinic
sign
respiratori
weak
syncop
heart
diseas
n
evalu
asymptomat
murmur
n
left
basilar
continu
murmur
present
dog
predomin
femal
n
median
age
year
rang
median
weight
kg
rang
dog
classifi
small
n
larg
n
breed
common
mix
n
german
shepherd
n
concurr
heart
diseas
diagnos
predomin
degen
valv
diseas
n
pulmonari
hypertens
n
concurr
congenit
heart
diseas
rare
lefttoright
shunt
bidirect
present
diuret
therapi
requir
hospit
prior
closur
arrhythmia
identifi
common
ventricular
n
atrial
fibril
n
mean
ae
sd
rang
present
follow
vertebr
heart
size
n
ae
left
ventricular
intern
dimens
diastol
systol
index
bodi
weight
lviddn
lvidsn
ae
ae
respect
fraction
shorten
left
atrial
enlarg
document
base
mmode
measur
pda
closur
consist
transcathet
occlus
amplatz
canin
duct
occlud
acdo
coil
vascular
plug
surgic
ligat
complic
includ
femor
arteri
surgic
site
hemorrhag
n
intraop
acdo
dislodg
n
lviddn
lvidsn
post
closur
recheck
ae
ae
respect
echocardiograph
residu
flow
document
within
hr
dog
resolv
develop
day
diuret
therapi
discontinu
dog
closur
closur
perform
owner
declin
recommend
n
immedi
indic
due
concurr
diseas
n
dog
age
year
present
hemodynam
signific
pda
concurr
heart
diseas
common
clinic
improv
possibl
follow
closur
homocystein
level
commonli
measur
monitor
cardiovascular
renal
diseas
human
medicin
howev
studi
measur
homocystein
address
relationship
homocystein
diseas
veterinari
medicin
purpos
studi
estim
serum
homocystein
concentr
dog
investig
relationship
myxomat
mitral
valv
diseas
mmvd
fiftythre
mmvd
dog
enrol
patient
system
problem
includ
neurolog
renal
hepat
neoplast
diabet
adren
thyroid
diseas
exclud
studi
ten
healthi
beagl
dog
select
control
group
comparison
mmvd
dog
mmvd
dog
classifi
accord
american
colleg
veterinari
intern
medicin
scheme
serum
homocystein
tropoini
level
measur
enzym
chemiluminesc
immunoassay
respect
serum
homocystein
level
mmvd
dog
significantli
differ
control
result
demonstr
signific
correl
homocystein
sever
heart
failur
control
ae
acvim
b
ae
acvim
c
ae
acvim
ae
p
addit
homocystein
level
correl
troponini
r
p
serum
creatinin
r
p
systol
blood
pressur
r
p
laao
ratio
r
p
posit
correl
cardiovascular
diseas
studi
demonstr
posit
relationship
homocystein
sever
heart
failur
thu
infer
elev
homocystein
level
use
biomark
heart
failur
risk
predict
dog
mmvd
echocardiograph
diagnosi
outcom
constrict
pericardi
diseas
dog
case
justin
thomason
marc
krau
maryann
radlinski
karen
cornel
elizabeth
howerth
tiffani
fallaw
clay
calvert
kansa
state
univers
manhattan
ks
usa
univers
georgia
athen
ga
usa
cornel
univers
ithaca
ny
usa
constrict
pericard
cp
result
inflamm
fibrosi
cp
secondari
neoplasia
infect
idiopath
purpos
retrospect
studi
describ
echocardiograph
featur
outcom
dog
cp
studi
popul
compris
clientown
dog
addit
standard
echocardiographi
physiolog
function
use
record
respiratori
cycl
mmode
record
septal
motion
blood
flowveloc
measur
pulsedwav
doppler
could
correl
phase
respir
male
femal
mean
age
bodi
weight
median
rang
year
kg
respect
pleural
effus
present
accompani
ascit
pericardi
effus
absent
echocardiographi
consist
normal
systol
function
absenc
dilat
chamber
ventricular
interdepend
demonstr
mmode
find
consist
constrict
physiolog
present
dog
examin
pulsedwav
doppler
fifteen
dog
treat
pericardiectomi
dog
etiolog
idiopath
pericard
aliv
overtli
healthi
least
year
surviv
less
month
postpericardiectomi
dog
suspect
proven
neoplasia
conclus
cp
consid
dog
pleural
effus
absenc
minim
pericardi
effus
absenc
dilat
chamber
suspicion
increas
characterist
echocardiograph
find
prognosi
nonmalign
etiolog
favor
pericardiectomi
echocardiograph
assess
diastol
function
prove
challeng
cat
partial
due
transmitr
flow
pattern
fusion
eafus
secondari
elev
heart
rate
clinic
reduc
heart
rate
transmitr
flow
waveform
may
separ
detect
diastol
dysfunct
aid
earli
detect
cardiomyopathi
timolol
ophthalm
nonselect
betablock
use
cat
glaucoma
demonstr
safe
transient
decreas
heart
rate
clinic
trial
hypothes
topic
timolol
ophthalm
suspens
decreas
heart
rate
allow
e
wave
separ
echocardiogram
without
signific
advers
effect
addit
timolol
may
rapidli
demonstr
effect
betablockad
cat
oral
betablockad
consid
fourteen
healthi
cat
enrol
studi
sixlead
electrocardiogram
complet
echocardiogram
evalu
minut
one
drop
timolol
ophthalm
solut
administ
right
eye
cat
respiratori
diseas
ophthalm
diseas
cardiac
arrhythmia
exclud
wilcoxon
matchedpair
signedrank
test
reveal
signific
median
heart
rate
reduct
bpm
timolol
p
cat
eafus
separ
timolol
p
four
cat
without
initi
eafus
remain
separ
timolol
e
ratio
significantli
differ
p
bradyarrhythmia
note
administr
resolut
dynam
right
ventricular
obstruct
observ
cat
ocular
timolol
safe
reliabl
reduc
heart
rate
cat
gener
reproduc
chang
echocardiograph
paramet
may
facilit
diastol
assess
may
rapidli
elucid
cat
respons
beta
blockad
helic
ventricular
myocardi
band
anatom
basi
left
ventricular
lv
fiber
architectur
help
redefin
cardiac
motion
function
recent
evalu
myocardi
motion
quantifi
mean
noninvas
advanc
echocardiographi
speckletrack
echocardiographyst
provid
deform
strain
deform
rate
strain
rate
longitudin
circumferenti
radial
plane
lv
twist
motion
along
long
axi
anoth
import
key
featur
lv
systol
function
human
cardiolog
evid
postnat
cardiac
matur
myofib
infant
grow
differ
contract
profil
children
adult
strainstrain
rate
valu
lv
twist
sought
evalu
chang
biomechan
left
ventricl
giant
dog
breed
perform
standard
advanc
echocardiographi
month
old
great
dane
puppi
adult
great
dane
older
year
popul
compris
puppi
adult
great
dane
mean
age
month
dog
present
cardiac
murmur
dog
older
one
year
age
underw
hour
holter
record
dog
present
arrhythmia
standard
echocardiograph
paramet
enddiastolicsystol
volum
index
bodi
surfac
area
mmode
bmode
area
length
allometr
scale
laao
ratio
epss
within
normal
rang
publish
dog
breed
ste
paramet
includ
longitudin
circumferenti
radial
strain
strain
rate
basal
rotat
apic
rotat
twist
net
differ
apic
basal
rotat
torsion
net
twist
lv
diastol
length
great
dane
puppi
adult
statist
differ
heart
rate
bpm
vs
bpm
select
standard
echocardiograph
paramet
p
circumferenti
radial
strain
strain
rate
longitudin
strain
rate
differ
two
group
longitudin
strain
net
twist
torsion
significantli
differ
two
group
p
puppi
less
neg
basal
rotat
compar
adult
ae
vs
ae
p
differ
found
apic
rotat
two
group
ae
vs
ae
ns
conclus
studi
identifi
age
depend
effect
longitudin
strain
valu
twist
torsion
mechcan
lv
great
dane
appear
reflect
least
partial
matur
myocardi
architectur
alreadi
establish
human
pediatr
cardiolog
purpos
studi
determin
whether
oral
supplement
larginin
could
reach
plasma
concentr
lcitrullin
surrog
nitric
oxid
gener
associ
pulmonari
vascular
hemodynam
improv
human
pulmonari
hypertens
three
clinic
healthi
staff
own
dog
treat
pilot
studi
mgkg
q
hr
larginin
po
one
week
plasma
sampl
obtain
pretreat
baselin
bl
steadi
state
trough
tr
hour
dose
plasma
lcitrullin
larginin
analyz
hplc
peak
concentr
plasma
larginin
median
um
rang
plasma
lcitrullin
median
um
rang
consist
seen
hour
post
dose
hr
howev
increas
plasma
lcitrullin
bl
target
human
reach
dog
median
rang
eleven
clinic
healthi
staff
own
dog
treat
mgkg
hr
larginin
po
one
week
plasma
larginin
concentr
increas
median
rang
um
bl
um
hr
plasma
lcitrullin
concentr
increas
median
rang
um
bl
um
hr
dog
show
increas
plasma
lcitrullin
concentr
dog
dose
larginin
mgkg
hr
plasma
lcitrullin
concentr
greater
mean
um
associ
pulmonari
vascular
hemodynam
improv
peopl
median
system
systol
diastol
mean
blood
pressur
significantli
differ
bl
sbp
mmhg
dbp
mmhg
mbp
mmhg
tr
sbp
mmhg
dbp
mmhg
mbp
mmhg
hr
sbp
mmhg
dbp
mmhg
mbp
mmhg
sbp
p
dbp
p
mbp
p
median
heart
rate
significantli
chang
bl
bpm
tr
bpm
hr
bpm
p
chemistri
profil
analyz
dog
chang
seen
hr
compar
bl
result
studi
show
bl
plasma
lcitrullin
concentr
appar
higher
dog
median
um
rang
compar
human
mean
um
sem
ae
larginin
dosag
mgkg
po
hr
exceed
peak
human
target
concentr
um
dog
treat
studi
underway
dose
larginin
clientown
dog
pulmonari
hypertens
see
whether
peak
lcitrullin
concentr
specif
chang
lcitrullin
concentr
associ
clinic
hemodynam
improv
pulmonari
hypertens
left
atrial
volum
obtain
biplan
simpson
method
healthi
dog
bodi
weight
bodi
surfac
area
rodrigo
p
franco
evandro
zacch
e
rafael
r
camacho
fabr
marinho
fernando
rosa
aparecido
camacho
univers
mar
mar
paulo
brazil
paulo
state
univers
jaboticab
paulo
brazil
left
atrial
volum
lav
obtain
echocardiograph
determin
biplan
simpson
method
consid
prognost
marker
evalu
left
atrial
enlarg
heart
diseas
dog
simpson
method
atrial
measur
still
rare
use
therefor
refer
valu
case
assess
left
atrial
enlarg
left
atrial
performedtoaort
diamet
ratio
la
ao
thu
aim
studi
determin
lav
bodi
weight
bodi
surfac
area
bsa
use
simpson
biplan
method
healthi
dog
purpos
evalu
healthi
dog
subdivid
four
group
kg
kg
dog
consid
healthi
show
abnorm
clinic
featur
includ
cardiac
auscult
systol
blood
pressur
also
complet
blood
count
serum
biochemistri
electrocardiograph
echocardiographi
evalu
lav
en
diastol
systol
obtain
atrial
measur
use
biplan
simpson
method
obtain
left
parastern
longaxi
four
two
chamber
view
valu
group
compar
analysi
varianc
anova
tukey
post
hoc
test
subsequ
valu
lav
bodi
weight
submit
pearson
correl
test
presenc
statist
signific
valu
index
bsa
vaedixd
lavsixd
result
shown
tabl
ae
ae
b
ae
c
ae
c
signific
differ
observ
presenc
signific
correl
lavd
r
lav
r
bodi
weight
valu
vae
correct
bsa
identifi
lavdixd
ae
mlm
lavsixd
ae
mlm
approv
normal
test
thu
possibl
determin
lav
base
differ
bodi
weight
well
valu
index
canin
bsa
ana
paula
p
felip
k
adam
wilmer
z
restan
h
g
moranza
p
innocent
marlo
g
sousa
guilherm
c
ferraz
aparecido
camacho
paulo
state
univers
jaboticab
paulo
brazil
feder
univers
paran
curitiba
paran
brazil
exercis
becam
wide
use
diagnost
tool
prognost
therapeut
human
cardiolog
studi
dog
scarc
determin
lactat
threshold
dog
heart
diseas
nonexist
literatur
aim
studi
determin
lactat
threshold
increment
exercis
test
dog
degen
mitral
valv
diseas
dmvd
anim
divid
group
base
left
atrial
aortic
root
ratio
laao
group
laao
group
la
ao
group
laao
test
perform
motor
treadmil
slope
increas
speed
ms
increment
last
minut
blood
sampl
collect
second
step
venou
cathet
place
jugular
vein
test
finish
anim
show
sign
fatigu
exponenti
regress
use
determin
v
v
veloc
blood
lactat
concentr
reach
mmoll
data
submit
normal
test
analysi
group
perform
use
repeat
measur
oneway
anova
p
interact
group
p
v
group
lower
valu
group
p
valu
ae
ae
ae
respect
group
lower
valu
v
group
p
valu
ae
ms
ae
ms
ae
ms
possibl
determin
lactat
threshold
dog
later
stage
dmvd
need
anaerob
pathway
contribut
support
physic
effort
sudden
cardiac
death
young
dog
previous
report
german
shepherd
dog
english
springer
spaniel
identifi
four
relat
young
rhodesian
ridgeback
die
suddenli
month
age
two
die
sleep
two
die
brief
period
exercis
excit
object
studi
evalu
possibl
famili
relationship
arrhythm
caus
sudden
death
rhodesian
ridgeback
collect
pedigre
well
postmortem
report
three
four
dog
die
addit
collect
clinic
inform
includ
holter
monitor
read
echocardiogram
possibl
relat
surviv
dog
famili
two
male
dog
die
suddenli
month
age
fourteen
surviv
dog
includ
parent
litterm
deceas
dog
evalu
holter
monitor
three
addit
dog
femal
determin
affect
base
increas
ventricular
ectopi
vpc
per
hour
respect
parent
affect
dog
zero
vpc
hour
holter
monitor
echocardiographi
one
affect
dog
postmortem
evalu
two
dog
die
sudden
death
identifi
structur
lesion
singl
femal
zero
vpc
either
mother
two
dog
grandmoth
three
dog
sudden
death
affect
dog
addit
four
five
affect
share
singl
father
zero
vpc
famili
two
litterm
male
femal
die
suddenli
within
day
month
age
three
litterm
found
frequent
ventricular
ectopi
holter
monitor
vpc
four
litterm
normal
holter
monitor
vpc
mother
vpc
mother
one
affect
one
unaffect
litterm
avail
echocardiographi
structur
lesion
observ
post
mortem
evalu
perform
one
sudden
death
dog
structur
lesion
observ
father
famili
unavail
evalu
overal
eleven
dog
femal
male
determin
affect
base
increas
ventricular
ectopi
sudden
death
four
dog
two
famili
famili
distantli
relat
sever
dog
pattern
inherit
appear
consist
autosom
recess
pattern
base
presenc
fairli
equal
gender
distribut
least
famili
presenc
affect
dog
unaffect
parent
howev
autosom
domin
mode
incomplet
penetr
complet
rule
conclus
describ
famili
form
ventricular
ectopi
sudden
cardiac
death
young
rhodesian
ridgeback
autosom
recess
pattern
inherit
like
inbreed
strongli
discourag
ntprobnp
troponin
ctni
level
screen
biomark
irish
wolfhound
william
tyrrel
steven
rosenth
jess
buch
melissa
beall
janci
hanscom
franc
abram
mariellen
dentino
chesapeak
veterinari
cardiolog
associ
cvca
leesburg
va
usa
chesapeak
veterinari
cardiolog
associ
cvca
towson
md
usa
idexx
laboratori
inc
westbrook
usa
irish
wolfhound
foundat
yellow
spring
oh
usa
nephrolog
associ
evansvil
usa
variant
dilat
cardiomyopathi
dcm
combin
atrial
fibril
af
common
cardiac
ailment
within
irish
wolfhound
iwh
breed
sought
evalu
normal
level
ntprobnp
high
sensit
ctni
iwh
whether
biomark
level
could
use
screen
tool
af
maintain
left
ventricular
systol
function
combin
left
atrial
enlarg
iwh
type
dcm
nineti
irish
wolfound
dog
screen
two
separ
irish
wolfhound
club
america
sanction
show
march
may
focus
cardiac
physic
examin
electrocardiogram
ecg
doppler
echocardiographi
perform
dog
medic
histori
famili
histori
cardiac
diseas
concurr
medic
record
patient
biochem
panel
ntprobnp
level
high
sensit
ctni
run
patient
thirti
two
male
femal
screen
mean
age
year
year
mean
bodi
weight
kg
kg
dog
classifi
one
eight
major
group
normal
n
inconsequenti
mitral
andor
aortic
valv
insuffici
n
iwh
type
dcm
af
n
af
equivoc
iwh
type
dcm
n
equivoc
elev
left
ventricular
outflow
tract
lvot
veloc
msec
n
presenc
ventricular
arrhythmia
vpc
normal
echocardiogram
n
lone
af
n
chemodectoma
n
ntprobnp
ctni
level
run
dog
result
summar
base
normal
dog
studi
refer
interv
upper
limit
ntprobnp
ctni
calcul
ngml
respect
ntprobnp
ctni
correl
well
cardiac
diseas
small
sampl
cardiac
diseas
irish
wolfhound
show
signific
differ
group
kruskalw
test
p
p
respect
ntprobnp
show
promis
screen
tool
differenti
presenc
equivoc
overt
dcmaf
absenc
dcmaf
irish
wolfhound
auc
roc
like
significantli
increas
absenc
dcm
dog
lone
af
lesser
potenti
exhibit
ctni
auc
roc
screen
tool
iwhtyp
dcm
followup
studi
echocardiographi
ecg
irish
wolfhound
found
either
elev
ntprobnp
andor
ctni
along
normal
echocardiographyecg
requir
determin
ntprobnp
may
predict
factor
develop
overt
cardiomyopathi
andor
atrial
fibril
breed
dog
arteri
thromboembol
ate
common
devast
complic
felin
cardiovascular
diseas
limit
evid
support
efficaci
tradit
strategi
ate
prophylaxi
cat
apixiban
novel
oral
factor
xa
inhibitor
superior
warfarin
prevent
stroke
system
embol
peopl
nonvalvular
atrial
fibril
apixaban
fda
approv
indic
well
treatment
secondari
prophylaxi
deep
vein
thrombosi
dvt
pulmonari
embol
pe
peopl
preliminari
pharmacokinet
pk
pharmacodynam
pd
data
singl
oral
dose
pure
apixaban
cat
obtain
previou
studi
colorado
state
univers
howev
multidos
pk
pd
data
use
commerci
avail
tablet
need
purpos
studi
obtain
pk
pd
data
multidos
oral
administr
commerci
avail
apixaban
tablet
establish
appropri
oral
dose
dose
interv
formul
addit
side
effect
associ
multidos
administr
document
three
appar
healthi
purpos
bred
cat
use
pilot
studi
base
previou
studi
cat
administ
mg
commerci
avail
tablet
po
bid
follow
placement
indwel
jugular
cathet
day
initi
pk
data
obtain
day
follow
first
oral
dose
apixaban
administ
oral
twice
daili
day
peak
trough
plasma
concentr
determin
pd
activ
assess
day
determin
effect
apixaban
factor
xa
fxa
activ
use
commerci
avail
assay
singl
dose
administ
day
plasma
concentr
determin
washout
period
cat
monitor
side
effect
associ
multidos
administr
drug
apixaban
predict
inhibitori
effect
fxa
activ
cat
result
fxa
activ
within
therapeut
rang
compar
baselin
use
human
patient
rang
correspond
therapeut
intern
normal
ratio
note
cat
multipl
time
point
furthermor
pd
data
cat
show
cyclic
inhibit
fxa
activ
typic
novel
oral
anticoagul
drug
properti
consid
import
safeti
profil
pk
data
pilot
studi
show
lack
drug
accumul
consist
elimin
halflif
first
last
oral
dose
approxim
hour
cyclic
inhibit
fxa
activ
appear
correl
directli
plasma
concentrationtim
curv
one
cat
becam
letharg
vomit
day
remov
studi
interestingli
peak
plasma
concentr
cat
significantli
differ
trough
concentr
averag
higher
cat
sign
resolv
discontinu
drug
bleed
note
cat
result
pilot
studi
show
apixaban
safe
effect
anticoagul
cat
consid
use
treatment
prevent
felin
ate
pk
pd
data
obtain
pilot
studi
necessari
subsequ
clinic
trial
felin
patient
heart
diseas
irish
wolfhound
iw
commonli
affect
atrial
fibril
af
dilat
cardiomyopathi
dcm
studi
report
longterm
outcom
iw
appar
lone
af
compar
age
gender
match
control
cohort
iw
western
europ
n
underw
physic
examin
standard
echocardiographi
electrocardiographi
av
dog
follow
longitudin
owner
report
date
circumst
death
kaplanmei
surviv
curv
construct
group
compar
use
logrank
mantelcox
test
dog
lone
af
develop
dcm
median
ae
yr
overal
death
occur
af
group
cardiac
death
account
approxim
die
suddenli
ae
yr
diagnosi
develop
chf
die
ae
yr
die
noncardiac
reason
ae
yr
diagnosi
develop
dcm
prior
death
iw
control
cohort
without
lone
af
surviv
significantli
longer
dog
lone
af
p
median
vs
day
lone
af
associ
increas
mortal
develop
dcm
iw
repres
strong
predictor
cardiac
death
irish
wolfhound
dilat
cardiomyopathi
caus
death
claudia
vollmar
bruce
keen
barbara
kohn
andrea
vollmar
small
anim
clinic
freie
berlin
germani
north
carolina
state
univers
cvm
raleigh
nc
usa
small
anim
clinic
dr
vollmar
bonn
wissen
germani
dilat
cardiomyopathi
dcm
common
irish
wolfhound
iw
purpos
studi
compar
surviv
iw
preclin
dcm
atrial
fibril
af
sinu
rhythm
sr
versu
dog
congest
heart
failur
chf
report
incid
cardiac
death
sudden
cardiac
death
sd
death
due
chf
iw
western
europ
n
examin
physic
examin
standard
echocardiographi
electrocardiographi
av
dog
longitudin
follow
owner
instruct
report
date
circumst
death
kaplanmei
surviv
curv
construct
date
diagnosi
date
death
compar
logrank
mantelcox
test
dcm
andor
af
diagnos
longterm
followup
death
possibl
dog
common
reason
noncardiac
death
osteosarcoma
pneumonia
soft
tissu
cancer
paraparesi
old
iw
surviv
curv
cardiac
allcaus
mortal
dog
without
chf
compar
dog
dcm
af
sinu
rhythm
without
chf
surviv
dog
chf
significantli
shorter
dog
without
chf
regardless
underli
rhythm
diagnosi
dog
without
chf
differ
surviv
dog
af
sr
prietoramo
simon
swift
andrea
corda
brendan
corcoran
kim
summer
sanz
ann
french
univers
glasgow
glasgow
scotland
uk
univers
edinburgh
edinburgh
scotland
uk
univers
florida
gainesvil
florida
usa
univers
sassari
sassari
itali
cavali
king
charl
spaniel
ckc
predispos
degen
atrioventricular
valv
diseas
preval
echocardiograph
chang
age
ckc
report
studi
ckc
male
femal
age
year
mean
underw
echocardiographi
anim
year
recruit
uk
region
breed
club
echocardiograph
examin
perform
boardedcertifi
cardiologist
cardiolog
resid
supervis
boardedcertifi
cardiologist
echocardiograph
paramet
measuredcalcul
compris
left
ventricular
diamet
diastolesystol
lvdd
left
atrial
la
diamet
longaxi
view
la
aorta
ratio
la
ao
shortaxi
mitral
valv
mv
thicken
mv
prolaps
mv
regurgit
tricuspid
valv
regurgit
tr
pulmonari
hypertens
tr
veloc
ms
fraction
shorten
marker
remodel
defin
increas
lvdd
lvd
la
size
la
ao
ratio
dog
mitral
valv
thicken
regurgit
mv
prolaps
found
sever
tr
seen
pulmonari
hypertens
identifi
dog
la
ao
increas
wherea
la
longaxi
view
enlarg
lvdd
increas
lvd
increas
one
two
three
four
marker
remodel
increas
respect
one
marker
remodel
report
popul
age
ckc
show
echocardiograph
evid
degen
atrioventricular
valv
diseas
howev
low
preval
marker
diseas
sever
found
aim
compar
interobserv
agreement
differ
method
measur
left
ventricular
lv
wall
thick
left
atrial
la
size
evalu
magnitud
differ
measur
method
twodimension
mmode
mm
echocardiographi
record
cat
variabl
phenotyp
four
train
observ
agre
measur
techniqu
independ
measur
lv
septal
ivsd
free
wall
lvfwd
thick
mm
view
ivsd
measur
lead
edg
lead
edg
trail
edg
lt
la
size
measur
mm
lamax
long
axi
lad
short
axi
la
ao
la
ao
measur
endsystol
es
enddiastol
ed
interobserv
repeat
calcul
use
intraclass
correl
coeffici
icc
confid
interv
ci
pair
measur
blandaltman
method
icc
rang
agreement
best
mm
lamax
icc
worst
la
ao
es
bia
ivsd
mm
lt
versu
la
ao
bia
ed
versu
es
ivsd
bia
mm
short
axi
versu
mm
lvfwd
bia
mm
versu
mm
interobserv
agreement
vari
measur
method
magnitud
differ
lt
method
measur
lv
wall
thick
suffici
chang
diagnosi
lv
hypertrophi
equivoc
equivoc
normal
result
la
ao
measur
es
ed
interchang
measur
method
lv
wall
thick
la
specifi
els
consensu
reach
standard
hypertroph
cardiomyopathi
hcm
cat
difficult
easili
rapidli
detect
clinic
practic
physic
examin
sub
clinic
clinic
affect
cat
auscult
heart
insensit
diagnosi
even
clinic
affect
cat
rapid
reliabl
diagnosi
desir
decis
eg
sedationanesthesia
therapi
acut
dyspnea
screen
breed
purpos
standard
diagnost
tool
echocardiographi
radiographi
sampl
blood
analysi
biomark
time
consum
alway
afford
unavail
simpl
rapid
easili
avail
method
diagnos
hcm
would
benefici
mani
clinician
client
electrocardiograph
abnorm
report
subclin
clinic
affect
cat
simpl
electrocardiograph
instrument
would
simplifi
detect
purpos
pilot
studi
evalu
iphon
ecg
ipecg
use
alivecor
veterinari
heart
monitor
could
use
detect
hcm
cat
unit
small
plate
contain
microprocessor
flat
electrod
attach
cover
iphon
control
app
seventeen
normal
cat
six
cat
hcm
examin
record
togeth
standard
ecg
limb
lead
ii
stecg
echocardiographi
ecg
record
iphon
left
side
thorax
cardiac
region
ipecg
record
left
side
thorax
telephon
parallel
long
axi
heart
heart
locat
auscult
middl
telephon
place
point
maxim
heart
sound
ensur
electrod
place
one
cranial
heart
base
one
distal
heart
apex
ecg
record
iphon
ipecg
store
read
blindli
later
magnif
screen
iphon
cat
qr
durat
sec
ipecg
stecg
categor
abnorm
comparison
ipecg
stecg
reveal
normal
cat
qr
durat
ecg
produc
two
fals
posit
use
ipecg
ipecg
cat
qr
durat
includ
cat
posit
hcm
echocardiographi
sensit
specif
j
stecg
lead
ii
cut
qr
durat
detect
hcm
produc
fals
neg
fals
posit
sensit
specif
j
statist
signific
differ
p
found
qr
durat
amplitud
normal
cat
cat
hcm
use
ipecg
ipecg
easi
rapid
record
compar
stecg
despit
limit
number
hcm
cat
result
pilot
studi
suggest
screen
hcm
select
case
refer
echocardiographi
could
accomplish
iphon
ecg
studi
expand
number
case
warrant
chordal
trunk
origin
pm
rang
trunkspm
arbor
margin
ventricular
chorda
tendinea
ct
subservi
one
leaflet
number
chordal
trunk
mural
pm
greater
septal
pm
p
thirtysixti
percent
septal
leaflet
ct
trunk
origin
directli
ventricular
septum
wherea
mural
leaflet
ct
trunk
origin
pm
tva
morpholog
variabl
alter
structur
might
influenc
phenotyp
heterogen
felin
cardiomyopathi
merit
studi
urin
aldosteron
creatinin
ratio
ualdo
c
use
spot
sampl
correl
urin
aldosteron
excret
dog
evalu
ualdo
c
use
assess
statu
patient
reninangiotensinaldosteron
system
raa
aldosteron
major
effector
molecul
raa
associ
perpetu
progress
heart
failur
monitor
ualdo
c
may
help
guid
pharmacotherapi
determin
patient
may
benefit
mineralocorticoid
receptor
blockad
ualdo
c
normal
year
old
dog
author
laboratori
ae
lgg
one
dog
ualdo
c
greater
prospect
studi
report
herein
examin
ualdo
c
normal
dog
greater
year
age
better
approxim
cohort
dog
acquir
heart
diseas
student
staffown
dog
histori
system
illnessdiseas
prospect
recruit
evalu
via
complet
histori
physic
examin
brief
chemistri
panel
bun
creatinin
alp
alt
pcvt
ua
five
millilit
urin
collect
free
catch
pm
dog
urin
aldosteron
assay
perform
michigan
state
univers
diagnost
center
popul
anim
health
use
radioimmunoassay
siemen
coatacount
measur
free
aldosteron
one
abund
metabolit
aldosteron
glucuronid
twentysix
dog
evalu
five
exclud
due
abnorm
physic
histor
andor
clinicopatholog
find
twentyon
dog
includ
spay
femal
castrat
male
mean
age
ae
rang
year
mean
bodi
weight
ae
kg
mean
ualdo
c
lgg
ae
dog
ualdo
c
greater
differ
ualdo
c
group
older
dog
differ
younger
laboratori
dog
p
data
normal
distribut
refer
interv
calcul
lgg
percentil
confid
interv
lower
limit
lgg
upper
limit
lgg
although
evalu
dog
requir
establish
exact
refer
interv
seen
ualdo
c
rare
exce
lgg
normal
dog
ualdo
c
appear
chang
significantli
age
normal
dog
cardiac
arrhythmia
often
transient
might
detect
use
convent
electrocardiographi
holter
monitor
zio
patch
zp
irhythm
technolog
inc
san
francisco
california
singlelead
lightweight
adhes
ambulatori
ecg
monitor
devic
made
human
patient
extern
lead
wire
singleus
lowprofil
design
waterresist
button
press
mark
clinic
event
studi
aim
prospect
assess
usabl
monitor
boxer
dog
consid
healthi
affect
arrhythmogen
right
ventricular
cardiomyopathi
studi
consist
part
optim
placement
electrod
investig
use
standard
cardiac
event
monitor
amplitud
qr
complex
measur
electrod
place
differ
posit
thorax
posit
associ
tallest
qr
complex
chosen
place
zp
zp
place
dog
thorax
accord
manufactur
recommend
maximum
record
time
qualiti
ecg
trace
differ
everyday
situat
complic
document
first
hour
studi
period
dog
also
wore
holter
monitor
ventricular
ectop
beat
manual
count
observ
jl
full
disclosur
report
obtain
devic
optim
record
obtain
place
zp
left
side
anim
thorax
intercost
space
slightli
dorsal
costochondr
junction
midventricl
orient
either
vertic
perpendicular
spine
diagon
vertic
posit
parallel
long
axi
heart
concav
edg
zp
alway
direct
caudal
dog
zp
remain
attach
entir
studi
period
day
one
dog
remov
zp
hour
develop
sign
stress
coliti
mild
moder
skin
irrit
document
dog
time
zp
remov
resolv
spontan
dog
analyz
time
total
wear
time
record
provid
unambigu
rhythm
diagnosi
rest
walk
run
play
caus
intermitt
motion
artifact
could
impair
accur
ecg
interpret
zp
result
compar
obtain
holter
monitor
first
hour
studi
period
median
number
prematur
ventricular
complex
couplet
triplet
run
ventricular
tachycardia
obtain
zpholter
monitor
respect
conclus
extend
monitor
zp
day
feasibl
dog
provid
interpret
record
diagnosi
precapillari
hypertens
ph
challeng
dog
due
nonspecif
natur
associ
clinic
sign
cost
technic
requir
direct
indirect
evalu
pulmonari
pressur
cardiac
biomark
evalu
human
ph
limit
data
avail
regard
cardiac
biomark
profil
dog
naturallyoccur
ph
base
exist
knowledg
ph
could
lead
rightsid
cardiac
remodel
andor
damag
caus
releas
ntermin
probtyp
natriuret
peptid
ntprobnp
ntermin
proatyp
natriuret
peptid
ntproanp
cardiac
troponin
ctni
circul
dog
hypothes
plasma
concentr
biomark
would
higher
dog
ph
compar
dog
clinic
sign
compat
ph
echocardiograph
evid
ph
ph
consid
present
peak
tricuspid
regurgit
pressur
gradient
trg
mm
hg
identifi
echocardiograph
absenc
pulmon
stenosi
moreov
hypothes
plasma
concentr
biomark
would
posit
correl
trg
blood
sampl
prospect
obtain
dog
period
determin
plasma
concentr
ntprobnp
ntproanp
ctni
dog
categor
posthoc
two
group
ph
evid
cardiovascular
diseas
affect
group
ph
evid
cardiovascular
diseas
presenc
respiratori
clinic
sign
compat
ph
control
group
twentysix
dog
met
criteria
categor
affect
group
n
control
group
n
age
sex
weight
bodi
condit
score
significantli
differ
group
affect
group
dog
mild
ph
trg
mmhg
dog
moder
ph
trg
mmhg
dog
sever
ph
trg
mmhg
plasma
concentr
ntprobnp
ntproanp
ctni
significantli
higher
affect
group
control
group
p
p
p
respect
moder
posit
correl
ntprobnp
ntproanp
ctni
level
trg
r
r
r
respect
cutoff
pmoll
sensit
specif
ntprobnp
distinguish
dog
ph
dog
respiratori
sign
ph
respect
cutoff
fmoll
sensit
specif
ntproanp
distinguish
dog
ph
dog
respiratori
sign
ph
respect
cutoff
ngml
sensit
specif
ctni
distinguish
dog
ph
dog
respiratori
sign
ph
respect
dog
ph
echocardiograph
sign
cardiac
remodel
significantli
higher
biomark
level
dog
ph
echocardiograph
normal
heart
morpholog
biomark
could
use
tool
detect
ph
dog
distinguish
dog
affect
condit
dog
respiratori
sign
ph
relationship
periodont
pathogen
cardiovascular
diseas
dog
unknown
purpos
studi
examin
presenc
dna
periodontopath
bacteria
heart
specimen
dog
mitral
regurgit
total
dog
mitral
regurgit
refer
nihon
univers
specimen
left
atrium
left
ventricl
mitral
valv
harvest
mitral
valv
repair
distribut
anim
periodontopath
organ
porphyromona
gula
p
gula
addit
human
periodontopath
bacteria
includ
porphyromona
gingivali
prevotella
intermedia
treponema
denticola
tanneralla
forsythia
campylobact
rectu
aggregatibact
actinomycetemcomitan
fusobacterium
nucleatum
examin
polymeras
chain
reaction
pcr
speciesspecif
set
primer
oral
swab
specimen
dog
also
collect
analyz
distribut
periodontopath
bacteri
speci
pocket
depth
bleed
probe
design
tooth
measur
clinic
paramet
pcr
analysi
identifi
periodontopath
bacteria
studi
anim
among
eight
periodontopath
bacteria
studi
four
speci
p
gula
forsythia
f
nucleatum
c
rectu
detect
heart
specimen
detect
rate
p
gula
forsythia
f
nucleatum
c
rectu
heart
sampl
respect
oral
specimen
subject
detect
frequenc
p
gula
forsythia
f
nucleatum
c
rectu
respect
result
suggest
periodontopath
bacteria
relat
bacteremia
may
contribut
develop
cardiovascular
diseas
regen
potenti
cardiospherederiv
cell
cdc
ischem
heart
diseas
demonstr
mice
rat
pig
recentlycomplet
clinic
trial
regen
potenti
cdc
dog
heart
yet
test
show
canin
cdc
produc
adult
dog
heart
cell
display
similar
phenotyp
comparison
previous
studi
cdc
deriv
rodent
human
be
canin
cdc
differenti
cardiomyocyt
smooth
muscl
cell
endotheli
cell
vitro
addit
condit
media
canin
cdc
promot
angiogenesi
inhibit
cardiomyocyt
death
doxorubicininduc
mous
model
dilat
cardiomyopathi
intraven
infus
canin
cdc
improv
cardiac
function
decreas
cardiac
fibrosi
histolog
reveal
inject
canin
cdc
engraft
mous
heart
increas
capillari
densiti
studi
demonstr
regen
potenti
canin
cdc
mous
model
dilat
cardiomyopathi
sepsi
defin
system
inflammatori
respons
occur
infect
myocardi
dysfunct
one
import
featur
although
cardiovascular
alter
human
patient
sepsi
studi
year
data
small
anim
minim
thu
aim
studi
correl
serum
concentr
tnfa
creactiv
protein
echocardiograph
paramet
bitch
sepsi
due
cystic
endometri
hyperplasiapyometra
complex
purpos
includ
studi
bitch
sepsi
due
cystic
endometri
hyperplasiapyometra
complex
prior
hysterectomi
day
day
anim
underw
blood
sampl
collect
complet
echocardiograph
examin
left
ventricular
intern
diamet
correct
bodi
surfac
area
biomark
evalu
creactiv
protein
crp
tumor
necrosi
factor
alpha
tnfa
interleukin
beta
biomark
result
logarithm
transform
submit
spearman
correl
test
echocardiograph
paramet
p
result
summar
tabl
accord
result
studi
possibl
observ
invers
correl
echocardiograph
paramet
log
log
tnfa
log
crp
log
confirm
myocardi
involv
dog
natur
occur
sepsi
prospect
crosssect
studi
conduct
evalu
durat
correct
qt
interv
qtc
qt
dispers
electrocardiograph
trace
bitch
pyometra
compar
healthi
bitch
breed
size
similar
age
order
evalu
possibl
chang
consid
prolong
qt
relat
arrythmia
predisposit
human
anim
qtc
calcul
use
bazett
qtc
fridericia
qtcqt
equat
rr
qt
interv
obtain
lead
ii
qt
dispers
qt
max
qt
min
calcul
among
lead
ii
iii
avr
avl
avf
rv
cv
rl
v
cv
v
cv
lu
v
mm
qtc
significantli
prolong
pyometra
dog
calcul
bazett
equat
qtc
control
ae
ms
vs
qtc
pyom
ae
ms
p
qtc
calcul
fridericia
equat
qt
dispers
significantli
differ
prolong
qtc
pyometra
dog
evalu
bazett
equat
suggest
increas
suscept
arrhythmia
group
lack
differ
use
fridericia
equat
must
better
evalu
larger
sampl
variabl
assess
prospect
studi
includ
outcom
arrhythmia
occur
surgeri
dog
myxomat
mitral
valv
diseas
mmvd
class
c
congest
heart
failur
chf
show
clinic
sign
along
progress
diseas
chang
size
heart
chamber
rhythm
cardiac
heart
rate
particip
autonom
system
multivari
analysi
use
subdivid
class
c
use
clinic
data
echocardiograph
holter
examin
dog
mmvd
cluster
analysi
variabl
describ
determin
three
differ
group
within
class
c
three
factor
determin
princip
compon
analysi
first
factor
contain
inform
total
varianc
tv
relat
autonom
nervou
system
varianc
heart
rate
obtain
holterecg
second
factor
contain
inform
tv
repres
chamber
wall
heart
function
obtain
echocardiographi
third
factor
includ
inform
tv
correspond
inner
diamet
right
ventricl
obtain
echocardiographi
degre
heart
murmur
tricuspid
focu
physic
examin
factor
plot
cartesian
plane
graphic
biplot
repres
horizont
axi
particip
autonom
nervou
system
vertic
axi
size
heart
chamber
get
four
quadrant
allow
obtain
three
group
differ
dog
mmvd
class
c
chf
exercis
wide
use
diagnost
tool
prognost
indic
well
therapi
adjuv
human
cardiolog
chang
autonom
cardiovascular
respons
includ
increas
parasympathet
activ
confirm
human
be
heart
diseas
physic
activ
initi
lead
increas
patient
surviv
howev
despit
exist
evid
peopl
limit
clinic
trial
dog
cardiac
diseas
perform
assess
effect
exercis
autonom
nervou
system
therefor
studi
aim
evalu
chang
autonom
nervou
system
dog
myxomat
mitral
valv
diseas
undergo
treadmil
exercis
week
fifteen
adult
beagl
dog
mitral
valv
diseas
use
anim
enrol
three
group
accord
laao
ratio
laao
n
laao
n
laao
n
exercis
perform
time
week
minut
treadmil
veloc
dog
base
lactat
threshold
obtain
previou
increment
exercis
test
heart
rate
variabl
hrv
indic
calcul
use
holter
digit
record
perform
prior
exercis
week
treadmil
train
timedomain
hrv
variabl
includ
sdnn
sdann
sdnnidx
rmssd
data
underw
normal
test
follow
student
test
check
differ
well
anova
verifi
whether
differ
exist
group
differ
determin
exist
moment
well
among
group
spite
visibl
improv
aerob
condit
improv
hrv
indic
document
dog
vari
degre
myxomat
mitral
valv
diseas
suggest
chang
occur
autonom
nervou
system
anim
treadmil
train
howev
studi
anim
train
longer
period
time
might
clarifi
whether
exercis
might
play
benefici
role
sympatheticparasympathet
balanc
dog
cardiac
diseas
circul
fatti
acid
concentr
decreas
dog
congest
heart
failur
chf
supplement
fatti
acid
benefit
peopl
dog
cardiac
diseas
cat
hypertroph
cardiomyopathi
hcm
howev
higher
serum
concentr
docosahexano
acid
dha
total
fatti
acid
rais
question
whether
fatti
acid
supplement
would
benefici
cat
cardiac
diseas
therefor
goal
studi
determin
serum
fatti
acid
concentr
relat
surviv
time
cat
hcm
cat
hcm
serum
fatti
acid
profil
avail
outcom
known
elig
studi
cat
exclud
signific
concurr
diseas
eg
cancer
diabet
chronic
kidney
diseas
receiv
fish
oil
supplement
echocardiographi
perform
cat
serum
fatti
acid
analysi
perform
use
chloroform
methanol
extract
ga
chromatographi
fatti
acid
categor
high
median
group
low
median
group
date
death
determin
contact
owner
primari
care
veterinarian
studi
approv
cum
school
veterinari
medicin
tuft
univers
clinic
studi
review
committe
kaplanmei
curv
logrank
test
use
compar
surviv
time
cat
high
vs
low
fatti
acid
concentr
use
commerci
statist
softwar
cat
hcm
elig
studi
median
age
year
rang
year
castrat
male
spay
femal
breed
includ
domest
shorthair
domest
longhair
persian
ragdol
himalayan
initi
present
chf
n
arteri
thromboembol
ate
n
asymptomat
n
median
surviv
time
day
rang
day
cat
still
aliv
time
analysi
serum
eicosapentaeno
acid
epa
dha
concentr
significantli
differ
cat
without
chf
cat
without
ate
cat
chf
p
ate
p
significantli
shorter
surviv
time
compar
asymptomat
cat
cat
high
epa
concentr
significantli
longer
surviv
time
compar
cat
low
serum
epa
concentr
p
signific
differ
surviv
time
cat
high
vs
low
dha
concentr
result
retrospect
studi
suggest
supplement
fatti
acid
particularli
epa
may
benefit
cat
hcm
prospect
studi
need
aim
studi
compar
clinic
efficaci
safeti
angiotensin
convert
enzym
inhibitor
acei
imidapril
ramipril
dog
myxomat
mitral
valv
diseas
mmvd
medic
histori
canin
patient
mmvd
treat
imidapril
ramipril
review
dog
treat
either
imidapril
solut
contain
mg
per
ml
ramipril
tablet
contain
mg
per
tablet
treatment
administ
oral
day
dose
imidapril
ramipril
mgkg
mgkg
respect
treatment
efficaci
evalu
clinic
efficaci
scale
stage
overal
clinic
efficaci
day
initi
treatment
shown
good
good
dog
imidapril
group
versu
dog
ramipril
group
howev
statist
signific
differ
overal
clinic
efficaci
treatment
group
rate
good
good
p
distribut
efficaci
score
level
p
advers
event
associ
treatment
group
observ
studi
period
conclus
studi
demonstr
acei
imidapril
good
clinic
efficaci
treatment
dog
congest
heart
failur
chf
caus
mmvd
moreov
result
indic
imidapril
inferior
earlier
acei
ramipril
treatment
imidapril
welltoler
myxomat
mitral
valv
diseas
mmvd
common
acquir
canin
heart
diseas
character
variou
sever
clinic
sign
asymptomat
state
sudden
death
potenti
deleteri
consequ
high
preval
mmvd
veterinari
medicin
import
detect
progress
diseas
earli
accur
tool
evalu
myocardi
function
tissu
doppler
imag
tdi
strain
imag
rel
recent
techniqu
independ
load
condit
compar
convent
echocardiographi
although
valuat
tdi
strain
imag
perform
mmvd
dog
classif
quit
broad
examin
chang
progress
diseas
therefor
sought
investig
alter
tdi
strain
imag
mmvd
dog
differ
stage
divid
group
addit
aim
investig
correl
variabl
convent
echocardiograph
tdi
strain
imag
examin
studi
dog
consist
healthi
dog
dog
mmvd
classif
mmvd
dog
use
studi
basi
isach
scale
class
n
class
ii
n
class
iiia
n
class
iiib
n
mmode
echocardiographi
doppler
examin
perform
dog
unsed
state
convent
echocardiographi
color
tdi
examin
conduct
shortaxi
view
radial
circumferenti
motion
longitudin
view
iv
lv
motion
radial
strain
strain
rate
seem
decreas
sever
longitudin
motion
show
systol
diastol
tdi
strain
variabl
increas
moder
stage
class
ii
iiia
decreas
sever
stage
intraventricular
dyssynchroni
measur
differ
timetopeak
lv
iv
observ
mmvd
dog
high
preval
dyssynchroni
among
segment
wall
also
reveal
mmvd
dog
left
atrial
aortic
ratio
posit
correl
mitral
e
wave
peak
earli
diastol
veloc
lv
basal
segment
eem
fraction
shorten
fs
eject
fraction
ef
posit
correl
radial
strain
mitral
e
wave
veloc
neg
correl
lv
systol
timetopeak
strain
timetopeak
circumferenti
variabl
signific
correl
convent
echocardiograph
variabl
coccyg
arteri
blood
pressur
measur
better
toler
radial
arteri
measur
cat
discord
result
common
purpos
studi
assess
impact
age
bodi
condit
score
bc
muscl
condit
score
mc
radial
coccyg
blood
pressur
measur
privatelyown
cat
enrol
may
decemb
bc
mc
determin
investig
blood
pressur
measur
per
acvim
consensu
guidelin
order
measur
site
random
prior
studi
cat
posit
right
later
sternal
recumb
respect
radial
coccyg
pressur
measur
associ
blood
pressur
measur
variabl
assess
correl
coeffici
ancova
sixtysix
cat
enrol
interrat
reliabl
bc
mc
high
interobserv
correl
signific
effect
order
pressur
collect
radial
versu
coccyg
first
coccyg
radial
arteri
pressur
correl
p
differ
consist
posit
neg
see
figur
radial
arteri
pressur
correl
age
p
mc
p
base
partial
correl
analysi
associ
radial
arteri
pressur
mc
reflect
confound
influenc
age
age
posit
correl
radial
arteri
result
f
p
coccyg
arteri
measur
significantli
correl
age
bc
mc
use
coccyg
arteri
blood
pressur
measur
recommend
reduc
impact
age
sarcopenia
interpret
result
cat
sought
evalu
feasibl
repeat
quantit
assess
canin
mitral
valv
transthorac
echocardiographi
data
examin
healthi
dog
use
defin
refer
interv
dimens
normal
canin
mitral
valv
mv
measur
midsystol
threedimension
dataset
acquir
normal
dog
leftparastern
apic
view
analyz
dedic
softwar
normal
canin
mitral
valv
spheric
index
ae
annulusheighttocommissuralwidthratio
ae
characterist
confer
ellipticalsaddl
shape
follow
logarithm
transform
annulu
diamet
circumfer
area
anterior
leaflet
area
length
posterior
leaflet
area
significantli
relat
bw
p
agreement
allometr
assumpt
overal
dataset
analyz
dog
higher
feasibl
character
second
half
studi
period
dataset
analyz
interobserv
intraobserv
repeat
analysi
coeffici
variat
cv
measur
cv
two
differ
acquisit
individu
two
differ
time
annulu
area
anterior
leaflet
area
length
tent
height
area
volum
conclus
normal
dog
ellipt
saddleshap
annulu
allometr
relationship
exist
mv
size
bw
feasibl
gener
repeat
method
assess
mv
normal
dog
feasibl
improv
time
result
experi
higher
cv
deriv
measur
two
dataset
dog
hypertroph
cardiomyopathi
hcm
import
felin
heart
diseas
character
ventricular
hypertrophi
absenc
dilat
left
ventricl
human
preval
individu
famili
hcm
occur
least
case
mutat
sarcomer
gene
relat
hcm
famili
cat
hcm
autosom
domin
genet
diseas
similar
human
hcm
mutat
myosin
bind
protein
c
gene
observ
main
coon
cat
hcm
ragdol
cat
hcm
associ
mutat
gene
differ
codon
highli
conserv
felin
speci
breed
persian
british
shorthair
norwegian
forest
also
evid
famili
hcm
type
genet
inherit
unknown
persian
cat
present
high
incid
hcm
report
famili
hereditari
compon
mutat
genet
inherit
discov
yet
studi
popul
persian
cat
assess
echocardiographi
electrocardiographi
laboratori
test
blood
pressur
determin
anim
classifi
accord
presenc
hcm
blood
sampl
experiment
group
older
cat
without
hcm
cat
hcm
subject
dna
extract
genotyp
pcr
sequenc
cardiac
alphaactin
gene
exon
myosin
bind
protein
c
gene
exon
subsequ
correl
presenc
mutat
hcm
evalu
popul
hcm
preval
older
male
cat
occur
anim
asymmetr
hypertrophi
basal
region
septum
common
one
singl
nucleotid
polymorph
snp
posit
exon
gene
three
snp
intron
gene
identifi
polymorph
addit
delet
observ
region
gene
gene
despit
snp
observ
studi
fit
criteria
hcm
causal
mutat
caus
chang
amino
acid
occur
exclus
anim
hcm
thu
causal
mutat
hcm
persian
cat
elucid
mutat
two
exon
cardiac
gene
seem
caus
hcm
breed
addit
screen
cardiac
gene
necessari
identifi
genet
molecular
caus
felin
diseas
persian
cat
autosom
domin
polycyst
kidney
diseas
pkd
character
presenc
multipl
cyst
renal
parenchyma
occasion
liver
pancrea
caus
punctual
mutat
exon
gene
import
caus
chronic
kidney
diseas
preval
genet
diseas
cat
affect
mainli
persian
cat
correl
breed
cat
pkd
present
clinic
cours
similar
pkd
diseas
human
cardiovascular
complic
main
caus
morbid
mortal
human
patient
pkd
report
associ
pkd
heart
diseas
hypertens
consequ
ventricular
hypertrophi
diastol
dysfunct
valv
morpholog
chang
valv
prolaps
develop
aneurysm
studi
evalu
incid
hypertens
pkd
cat
howev
studi
correl
presenc
ventricular
hypertrophi
valv
abnorm
systol
diastol
chang
felin
pkd
prospect
observ
studi
persian
cat
evalu
electrocardiographi
echocardiographi
ultrasound
laboratori
test
blood
pressur
measur
pcr
perform
identifi
mutat
exon
gene
anim
classifi
pkd
posit
group
n
control
group
n
differ
heart
rate
weight
age
sex
distribut
electrocardiograph
paramet
observ
group
mean
systol
blood
pressur
mmhg
cat
pkd
mmhg
control
cat
differ
group
echocardiograph
evalu
differ
observ
regard
diastol
function
appear
movement
leaflet
well
valv
flow
myocardi
hypertrophi
observ
anim
pkd
posit
group
cat
control
group
howev
proport
hypertrophi
statist
higher
anim
pkd
p
cat
hypertrophi
present
normal
blood
pressur
normal
valu
urea
creatinin
total
rule
caus
myocardi
hypertrophi
persian
cat
pkd
mutat
present
higher
preval
myocardi
hypertrophi
even
chang
arteri
blood
pressur
renal
function
hypertroph
cardiomyopathi
hcm
also
preval
condit
persian
cat
consid
differenti
diagnosi
studi
necessari
evalu
causal
relationship
pkd
hypertrophi
genet
associ
pkd
hcm
conclus
necessari
cardiovascular
evalu
pkd
posit
cat
may
cardiovascular
abnorm
import
includ
pdk
even
earli
stage
differenti
diagnosi
hcm
persian
cat
assess
effect
carvedilol
cyclosporina
sildenafil
citrat
doxorubicininduc
cardiomyopathi
experiment
model
rabbit
fernando
rosa
felip
k
adam
murillo
kirnew
fabio
n
gava
aparecido
camacho
paulo
state
univers
jaboticab
paulo
brazil
unicastelo
univers
descalvado
paulo
brazil
doxorubicin
one
effect
chemotherapeut
agent
current
avail
howev
use
limit
cardiotox
effect
especi
use
long
time
lead
iatrogen
cardiomyopathi
relat
cumul
dose
administ
refractori
cardiotox
effect
prevent
play
singular
role
purpos
carvedilol
cyclosporin
sildenafil
citrat
test
assess
cardioprotect
action
experiment
model
doxorubicininduc
cardiomyopathi
rabbit
forti
botucatu
rabbit
random
four
experiment
group
anim
group
receiv
doxorubicin
mgkg
intraven
twice
week
week
group
name
n
doxorubicin
n
doxorubicin
carvedilol
mgkg
n
doxorubicin
cyclosporin
mg
kg
n
doxorubicin
sildenafil
mgkg
drug
doxorubicin
given
oral
day
echocardiograph
evalu
perform
first
last
doxorubicin
administr
statist
analysi
perform
analysi
varianc
follow
tukey
test
tissu
doppler
evalu
rabbit
group
demonstr
relationship
peak
earli
diastol
veloc
mitral
annulu
e
peak
annular
diastol
veloc
atrial
contract
less
one
e
last
doxorubicin
administr
observ
doxorubicin
treatment
also
signific
increas
left
ventricl
systol
diamet
reduct
eject
shorten
fraction
indic
signific
left
ventricular
systol
dysfunct
group
result
show
doxorubicin
induc
left
ventricular
diastol
systol
dysfunct
rabbit
could
prevent
concomit
treatment
carvedilol
cyclosporinea
sildenafil
citrat
twodimension
echocardiographi
wide
use
year
assess
left
ventricl
lv
systol
function
howev
limit
use
convent
measur
lv
eject
fraction
ef
twodimension
speckl
track
imag
simplifi
angleindepend
echocardiograph
tool
recent
use
evalu
quantit
global
region
ventricular
function
syngo
veloc
vector
imag
vvi
speckl
trackingbas
method
direct
analysi
myocardi
motion
purpos
studi
investig
left
ventricl
systol
function
septal
free
wall
global
use
vvi
healthi
awak
beagl
dog
purpos
use
clinic
healthi
beagl
dog
weigh
anim
restrain
right
later
recumb
echocardiograph
evalu
perform
acuson
premium
edit
siemen
medic
solut
usa
inc
echocardiograph
clip
obtain
right
parastern
shortaxi
lv
papillari
muscl
view
evalu
offlin
vvi
softwar
syngo
veloc
vector
imag
tm
siemen
medic
solut
reliabl
endocardi
trace
singl
frame
manual
drawn
endocardi
border
automat
track
throughout
cardiac
cycl
accuraci
border
track
visual
confirm
view
cardiac
cycl
slowmot
border
inform
display
systol
manual
select
move
left
right
cursor
onset
qr
complex
end
wave
respect
dog
mean
result
consecut
cardiac
cycl
use
besid
lv
global
peak
systol
circumferenti
strain
st
time
peak
tpk
mean
valu
peak
systol
circumferenti
strain
rate
sr
also
consid
valu
obtain
ventricular
septum
lv
free
wall
cardiopulmonari
resuscit
cpr
often
perform
dog
follow
cardiopulmonari
arrest
patient
pulseless
electr
activ
pea
asystol
intraven
therapi
vasoact
medic
epinephrin
vasopressin
current
recommend
cpr
cathet
placement
may
challeng
due
concurr
chest
compress
placement
saphen
vein
sv
may
technic
easier
critic
ill
dog
preexist
cathet
place
readili
access
cathet
may
chosen
purpos
studi
evalu
time
reach
heart
follow
intraven
administr
contrast
materi
sv
cephal
vein
cv
jugular
vein
dog
euthan
unrel
purpos
donat
teach
hospit
death
enrol
dog
weight
record
cathet
place
jv
cv
sv
within
minut
death
order
simul
cpr
iodin
contrast
materi
inject
kg
flush
salin
monitor
cardiac
silhouett
use
fluoroscopi
time
start
inject
appear
contrast
materi
right
heart
record
second
salin
flush
contrast
materi
seen
heart
total
ml
inject
inject
contrast
materi
took
longer
second
reach
heart
record
second
order
inject
random
time
group
compar
use
kruskalw
test
pvalu
consid
signific
correl
time
bodi
weight
evalu
fourteen
cadav
dog
enrol
rang
size
kg
median
kg
time
reach
heart
significantli
longer
p
saphen
vein
median
second
rang
second
cephal
vein
median
second
rang
second
jugular
vein
median
second
rang
second
nine
saphen
vein
inject
reach
heart
within
second
one
inject
reach
heart
less
second
correl
bodi
weight
time
contrast
materi
reach
heart
fluoroscopi
use
evalu
time
reach
right
heart
concurr
cardiac
compress
perform
may
influenc
time
reach
heart
howev
result
studi
support
use
either
cephal
vein
jugular
vein
intraven
inject
medic
cpr
congest
heart
failur
chf
dynam
neuroendocrin
diseas
process
character
complex
pathophysiolog
inflamm
thought
play
role
progress
proinflammatori
mediat
may
exert
effect
cardiac
structur
function
contribut
progress
cardiac
diseas
mild
inflammatori
infiltr
commonli
seen
myocardium
cat
cardiomyopathi
contrast
human
canin
literatur
publish
report
examin
presenc
system
inflamm
cat
cardiac
diseas
prospect
studi
evalu
whether
system
inflamm
present
cat
cardiac
diseas
differ
exist
anim
without
chf
two
cardiac
biomark
cardiac
troponin
hsctni
ntermin
prohormon
brain
natriuret
peptid
ntprobnp
acut
phase
protein
app
serum
amyloid
saa
creactiv
protein
crp
haptoglobin
hp
alpha
glycoprotein
agp
analyz
serum
cat
cat
diagnos
cardiac
diseas
without
chf
cardiac
case
individu
respect
hsctni
ntprobnp
concentr
refer
rang
twelv
cat
increas
agp
chf
median
concentr
hsctni
ntprobnp
agp
significantli
higher
anim
chf
wherea
median
concentr
saa
crp
hp
roc
curv
demonstr
agp
ntprobnp
hsctni
good
indic
chf
cat
result
confirm
cat
cardiac
diseas
experi
degre
system
inflamm
particular
cat
congest
heart
failur
yang
et
al
freeman
et
al
bodi
size
relat
left
ventricular
hypertrophi
adult
cat
freeman
et
al
faster
earli
growth
might
increas
risk
hcm
later
life
object
describ
morphometr
echocardiograph
echo
measur
cat
earli
growth
twentyfour
femal
european
short
hair
cat
born
week
fed
ad
libitum
sinc
birth
examin
month
age
morphometr
measur
includ
bodi
weight
bw
head
length
hl
head
width
hw
echo
measur
includ
diastol
mmode
interventricular
septum
left
ventricular
intern
dimens
left
ventricular
free
wall
lvwd
left
atrium
short
axi
growth
rate
rel
growth
correl
matrix
morphometr
measur
determin
pearson
correl
coeffici
adjust
fals
discoveri
rate
method
multivari
stepwis
regress
bonferroni
correct
analyz
relationship
growth
rate
morphometr
echo
measur
month
signific
correl
month
bwhw
p
bwhl
p
hlhw
p
month
bwhl
p
signific
relationship
found
month
bwlvwdmmode
p
r
growth
rate
hwlvwdmmode
p
r
first
studi
describ
morphometr
echo
measur
cat
st
year
life
research
need
investig
possibl
associ
growth
rate
young
age
develop
cardiac
patholog
later
life
studi
aim
evalu
effect
dantrolen
dan
mesenchym
stem
cell
msc
acut
spinal
cord
injuri
sci
sixti
threemonthsold
male
wistar
rat
divid
five
group
msc
msc
dan
dan
posit
control
pc
trauma
placebo
neg
control
nc
trauma
placebo
procedur
perform
accord
principl
adopt
nih
guid
care
use
laboratori
anim
ethic
committe
anim
use
ceuaufmg
protocol
number
laminectomi
perform
level
anim
follow
weightdrop
model
sci
except
nc
group
one
hour
later
msc
dan
dan
group
receiv
mgkg
dan
intraperiton
day
msc
msc
dan
group
receiv
msc
intraven
time
group
receiv
volum
placebo
basso
beatti
bresnahan
bbb
scale
perform
day
access
neurolog
statu
spinal
cord
evalu
histolog
immunohistochemistri
antineun
qrt
pcr
assess
quantit
gene
express
neurotroph
factor
bdnf
antiapoptot
bclxl
proapoptot
protein
bax
four
milimit
rostral
caudal
epicent
lesion
traumat
anim
show
paraplegia
signific
neurolog
recoveri
group
ctm
ctm
dan
th
th
day
respect
p
compar
cp
sever
spinal
cord
injuri
character
axon
degener
neuron
loss
extend
rostrocaud
epicent
group
show
averag
number
neunposit
neuron
significantli
higher
compar
cp
p
sci
pc
group
result
reduc
bdnf
bclxl
gene
express
increas
bax
express
compar
nontraumat
rat
nc
treatment
signific
increas
bdnf
express
msc
msc
dan
dan
group
compar
pc
group
p
express
higher
msc
dan
dan
group
cranial
segment
p
dan
group
caudal
one
p
bax
express
significantli
lower
msc
dan
p
dan
p
express
significantli
lower
dan
msc
msc
dan
group
p
conclud
dan
msc
associ
promot
function
recoveri
neuroprotect
neurotroph
antiapoptot
effect
syndrom
earli
onset
weak
exercis
intoler
describ
jack
russel
terrier
jrt
puppi
palmer
lennon
posit
respons
edrophonium
chlorid
challeng
note
decrement
respons
compound
muscl
action
potenti
cmap
repetit
supramaxim
nerv
stimul
support
disord
neuromuscular
transmiss
endplat
defici
nicotin
acetylcholin
receptor
achr
confirm
recent
two
intact
male
weekold
jrt
present
ontario
veterinari
colleg
evalu
gener
weak
similar
origin
jrt
posit
respons
edrophonium
chlorid
decrement
respons
cmap
repetit
nerv
stimul
endplat
achr
defici
identifi
inherit
pattern
chromosom
segment
encompass
gene
encod
achr
subunit
evalu
jrt
famili
use
microsatellit
marker
chrne
identifi
candid
insert
exon
chrne
predict
frameshift
prematur
stop
codon
homozyg
affect
puppi
heterozyg
parent
dna
origin
jrt
case
test
harbor
ident
mutat
mutat
identifi
unaffect
jrt
although
carrier
rate
low
mutat
persist
jrt
popul
year
loss
deep
pain
percept
dog
type
disc
diseas
thought
repres
function
spinal
cord
transect
poor
prognosi
recoveri
ambul
previou
studi
report
outcom
rang
howev
known
variabl
determin
patient
ultim
recov
medic
record
parapleg
dachshund
present
veterinari
medic
teach
hospit
univers
california
davi
review
assur
deep
pain
absent
pelvic
limb
tail
patient
myelopathi
local
includ
patient
underw
advanc
imag
decompress
hemilaminectomi
outcom
measur
includ
return
deep
pain
percept
ambul
urinari
contin
prognost
factor
evalu
includ
speed
onset
clinic
sign
durat
paraplegia
prior
surgeri
durat
surgeri
durat
anesthesia
length
decompress
hemilaminectomi
complet
durotomi
bodi
condit
score
age
sex
total
dog
met
inclus
criteria
regain
deep
pain
percept
total
regain
abil
ambul
regain
voluntari
urin
patient
becam
ambulatori
requir
continu
manual
bladder
express
contrast
nonambulatori
patient
regain
voluntari
urin
none
prognost
factor
evalu
shown
significantli
correl
function
recoveri
facet
patient
histori
physic
neurolog
examin
diagnost
proceed
care
review
prognost
function
outcom
singl
factor
definit
util
determin
deep
pain
neg
patient
recov
furthermor
client
inform
return
deep
pain
percept
guarante
return
voluntari
urin
like
import
consider
long
term
manag
serolog
analysi
indic
infect
hors
borrelia
burgdorferi
common
howev
diagnosi
equin
lyme
neuroborreliosi
lnb
rare
limit
descript
literatur
retrospect
studi
provid
detail
descript
clinic
diagnost
data
hors
histolog
diagnosi
lnb
case
identifi
via
review
medic
record
univers
pennsylvania
via
acvim
listserv
queri
inclus
criteria
includ
possibl
exposur
b
burgdorferi
histolog
find
consist
previou
report
lnb
without
evid
etiolog
agent
thirteen
hors
identifi
addit
evid
lnb
includ
document
intrathec
antibodi
product
detect
spirochet
cn
tissu
b
burgdorferi
pcr
warthin
starri
stain
clinic
sign
variabl
includ
ataxia
muscl
atrophi
cranial
nerv
deficit
fascicul
neck
stiff
uveiti
hyperesthesia
dull
fever
serolog
analysi
neg
b
burgdorferi
infect
case
test
csf
abnorm
present
case
test
includ
xanthrochromia
elev
total
protein
median
mgdl
rang
mgdl
lymphocyt
neutrophil
pleocytosi
median
nucleat
cellsll
rang
nucleat
cellsll
pcr
csf
neg
case
diagnosi
equin
lnb
challeng
due
variabl
clinic
present
lack
sensit
specif
diagnost
test
neg
serolog
normal
csf
analysi
exclud
diagnosi
lnb
mean
sd
age
present
year
age
rang
domest
short
hair
cat
overrepres
median
durat
neurolog
sign
day
rang
iqr
common
neurolog
abnorm
found
order
frequenc
propriocept
deficit
n
obtund
mentat
n
nystagmu
n
cat
diagnos
foramen
magnum
herniat
concurr
caudal
subtentori
herniat
total
cat
suffer
subtentori
herniat
alon
focal
rostrotentori
lesion
observ
cat
caudal
fossa
lesion
diagnos
diffus
multifoc
diseas
common
mri
base
diagnos
neoplasia
n
inflammatori
brain
diseas
n
cat
focal
rostrotentori
lesion
concurr
brain
herniat
show
sign
brainstem
dysfunct
addit
subgroup
cat
present
nystagmu
studi
suggest
cat
focal
rostrotentori
lesion
concurr
brain
herniat
may
higher
proport
brainstem
dysfunct
previous
observ
walmsley
et
al
dog
proport
cat
present
nystagmu
also
seem
higher
previous
report
studi
dog
poli
lacticcoglycol
acid
plga
polym
use
drug
deliveri
system
bypass
blood
brain
barrier
via
direct
brain
implant
mri
visibl
plga
achiev
gadolinium
conjug
safeti
intraparenchym
administr
contrast
evalu
temozolomid
chemotherapeut
consid
standardofcar
treatment
glioma
human
object
evalu
safeti
mri
visibl
plga
microcylind
conjug
temozolomid
gadolinium
canin
brain
four
beagl
receiv
six
microcylind
gadolinium
two
receiv
twelv
microcylind
gadolinium
microcylind
contain
mg
temozolomid
mri
perform
implant
immedi
later
cerebrospin
fluid
analysi
perform
day
neurolog
statu
evalu
day
day
dog
sacrif
necropsi
histopatholog
brain
dog
normal
neurolog
exam
complet
studi
dog
blank
microcylind
mild
inflamm
dog
moder
sever
inflamm
within
brain
histopatholog
increas
higher
gadolinium
concentr
mild
inflamm
present
within
mani
cerebrospin
fluid
sampl
microcylind
gadolinium
identifi
implant
plga
microcylind
gadolinium
temozolomid
brain
toler
healthi
beagl
higher
concentr
gadolinium
caus
increas
inflamm
unnecessari
appropri
evalu
method
chemotherapi
deliveri
dog
brain
tumor
numer
stabil
techniqu
describ
treat
canin
atlantoaxi
instabl
yet
current
littl
data
compar
method
main
object
studi
compar
biomechan
properti
anatom
reduct
safeti
ventral
atlantoaxi
stabil
techniqu
canin
cadav
beagl
dog
cadav
randomli
assign
stabil
techniqu
includ
transarticular
screw
fixat
tsf
multiimpl
construct
respect
compos
screw
embed
polymethylmethacryl
cement
screw
place
base
separ
studi
defin
ideal
implant
placement
beagl
unpublish
data
use
new
drill
guid
prototyp
design
improv
accuraci
implant
placement
spinal
segment
extract
comput
tomographi
imag
obtain
assess
anatom
reduct
safeti
implant
placement
ventral
flexion
bend
moment
failur
stiff
construct
subsequ
determin
compar
group
ventral
stabil
achiev
success
cadav
major
technic
issu
encount
use
drill
guid
prototyp
signific
vertebr
canal
violat
identifi
screw
intervertebr
apposit
significantli
better
tsf
group
compar
multiimpl
group
p
bend
moment
failur
significantli
lower
tsf
ae
compar
ae
p
ae
p
mean
stiff
measur
significantli
differ
group
tsf
provid
better
intervertebr
apposit
significantli
less
resist
ventral
flexion
compar
multiimpl
fixat
techniqu
beagl
cadav
model
comput
tomographi
guid
sterotax
navig
canin
thoracolumbar
spine
nichola
archambault
joan
coat
patrick
pithua
stephen
frey
fred
wining
univers
missouri
columbia
missouri
usa
rogu
research
inc
montreal
quebec
canada
veterinari
specialti
servic
manchest
missouri
usa
implant
placement
canin
thoracolumbar
spine
carri
formid
risk
vertebr
canal
violat
disrupt
juxtavascular
neural
structur
surgic
plan
use
cross
section
imag
stereotaxi
guid
implant
placement
mitig
surgic
complic
purpos
studi
investig
safeti
clinic
applic
comput
tomographi
ct
guid
stereotact
techniqu
use
implant
placement
canin
thoracolumbar
spine
ct
studi
use
mm
slice
thick
perform
vertebr
segment
medium
size
cadav
bilater
dorsal
approach
thoracolumbar
spine
use
simul
exposur
vertebra
stereotact
navig
achiev
commerci
avail
neuronavig
softwar
novel
subject
tracker
ct
reconstruct
use
registr
process
mechan
air
drill
allow
bicort
vertebr
bodi
trajectori
via
ct
guid
navig
stereotact
guid
trajectori
store
steinmann
pin
place
drill
hole
trace
trajectori
postop
ct
vertebr
bodi
disarticul
remov
visual
examin
canal
violat
stereotact
guid
trajectori
postop
ct
trajectori
angl
depth
valu
compar
statist
use
wilcox
rank
sum
analysi
signific
valu
total
trajectori
drill
vertebr
canal
violat
partial
full
fifti
three
trajectori
involv
vertebr
midlin
contralater
vertebr
bodi
mean
differ
stereotact
guid
trajectori
postop
ct
trajectori
angl
ae
degre
rang
degre
mean
differ
stereotact
guid
trajectori
postop
ct
trajectori
depth
ae
mm
rang
mm
signific
differ
stereotact
guid
postop
ct
trajectori
angl
depth
measur
comput
tomographi
guid
vertebr
stereotaxi
provid
accur
mean
implant
placement
canin
thoracolumbar
vertebr
column
reduc
risk
damag
vital
structur
spinal
cord
disrupt
addit
ct
guid
stereotact
navig
afford
excel
bone
purchas
purpos
studi
evalu
pharmacokinet
zonisamid
administ
per
rectum
via
commerci
avail
encapsul
powder
mix
either
steril
water
polyethylen
glycol
determin
whether
dose
mgkg
mgkg
would
result
target
serum
concentr
mcgml
eight
healthi
mixedbre
dog
randomli
assign
group
dog
crossoverdesign
studi
zonisamid
administ
rectal
suspens
steril
water
polyethylen
glycol
dose
mgkg
mgkg
blood
sampl
collect
predetermin
time
point
washout
period
group
receiv
altern
treatment
group
receiv
treatment
serum
concentr
zonisamid
analyz
via
highperform
liquid
chromatographi
serum
concentr
zonisamid
within
target
rang
time
point
rectal
administr
dog
concentr
reach
hour
n
dog
hour
n
dog
remain
dog
serum
concentr
zonisamid
target
rang
time
point
basi
result
rectal
administr
mgkg
mgkg
zonisamid
via
steril
water
polyethylen
glycol
suspens
use
present
studi
recommend
convent
valv
shunt
treatment
hydrocephalu
associ
complic
high
one
studi
report
complic
includ
dislodg
occlus
infect
ventricl
collaps
subdur
hematoma
necess
shunt
revis
surgeri
report
sever
author
human
complic
frequenc
relat
young
age
studi
patient
level
complic
associ
ventriculoperiton
shunt
assum
higher
rate
young
dog
cat
author
sought
differ
method
treat
obstruct
hydrocephalu
small
anim
human
infant
may
preferenti
treat
endoscop
assist
rd
ventricl
fenestr
subarachnoid
space
basilar
cistern
size
young
canin
felin
ventricular
system
howev
prohibit
small
altern
procedur
later
ventricl
fenestr
design
one
member
team
procedur
success
shortterm
outcom
patient
lost
followup
dsh
kitten
week
old
labrador
puppi
week
old
follow
obstruct
hydrocephalu
diagnosi
use
advanc
imag
clinic
sign
resolv
improv
period
month
followup
imag
demonstr
patenc
fenestr
reduc
ventricl
size
present
demonstr
indic
techniqu
procedur
includ
preoper
postop
imag
author
conclud
shortterm
result
procedur
benefici
treatment
obstruct
hydrocephalu
puppi
kitten
easi
perform
result
complic
electrograph
seizur
es
defin
ictal
discharg
consist
rhythmic
pattern
definit
evolut
frequenc
amplitud
andor
morpholog
persist
least
second
electrograph
statu
epilepticu
ese
ictal
discharg
note
greater
minut
human
es
ese
often
manifest
without
overt
sign
convuls
report
critic
ill
patient
popul
delay
diagnosi
treatment
may
lead
increas
mortal
studi
seek
better
understand
risk
factor
characterist
outcom
eses
veterinari
patient
eeg
suspect
seizur
complet
medic
record
identifi
dog
cat
data
analyz
preval
eses
eeg
pattern
associ
risk
factor
outcom
eses
detect
felin
signific
risk
ese
younger
anim
eeg
abnorm
signific
risk
es
patient
nonconvuls
seizur
subtl
clinic
find
like
twitch
chang
temperatur
respiratori
rate
coma
although
statist
signific
import
note
eses
case
die
hospit
compar
non
eses
group
eses
rel
common
patient
suspect
seizur
often
subtl
clinic
manifest
clinic
characterist
differenti
eses
control
case
highlight
necess
eeg
make
distinct
prospect
multicent
studi
need
defin
true
incid
differ
popul
better
defin
risk
factor
outcom
best
treatment
option
felin
dysautonomia
fd
diseas
domest
cat
characteris
extens
degener
autonom
nervou
system
first
report
uk
also
report
usa
uae
new
zealand
sever
european
countri
aetiolog
condit
remain
unknown
clinic
patholog
similar
primari
dysautonomia
affect
dog
hare
rabbit
hors
fd
report
caus
varieti
clinic
sign
includ
reduc
tear
secret
dri
oral
mucosa
dri
nasal
planum
mydriasi
prolaps
nictit
membran
bradycardia
regurgit
oesophag
dysmotil
constip
propriocept
deficit
dysuria
anal
areflexia
clinic
sign
typic
develop
matter
day
less
third
affect
cat
surviv
diagnosi
demonstr
chromatolyt
chang
within
neuron
autonom
ganglia
clinic
score
system
css
ocular
pharmacolog
test
opt
propos
antemortem
diagnosi
sharp
njh
gookin
jl
bsava
manual
small
anim
neurolog
nd
ed
opt
includ
reduct
pupil
size
within
minut
topic
applic
pilocarpin
retract
prolaps
nictit
membran
within
minut
topic
applic
epinephrin
uk
fd
studi
group
investig
suspect
case
fd
within
uk
report
us
veterinarian
use
data
assess
propos
css
ocular
pharmacolog
test
sinc
decemb
suspect
case
fd
report
outcom
case
unknown
case
surviv
median
follow
period
day
rang
case
clinic
sign
improv
remain
case
die
median
day
follow
present
rang
case
cat
euthanas
suspect
diagnosi
fd
base
css
case
classifi
css
posit
fd
probabl
inconclus
necropsi
perform
case
die
case
sampl
submit
histopatholog
case
submit
tissu
contain
autonom
ganglia
remain
case
fd
histopatholog
confirm
case
exclud
case
associ
clinic
find
fd
diagnosi
case
assess
binari
logist
regress
aspect
signal
age
breed
sex
individu
clinic
sign
radiograph
find
propos
css
significantli
associ
histopatholog
diagnosi
fd
median
css
score
fd
case
total
nonfd
case
clinic
sign
strongli
associ
fd
bradycardia
less
bpm
odd
ratio
ci
dysuria
bladder
atoni
opt
perform
singl
nonfd
case
test
posit
fd
case
test
neg
pilocarpin
epinephrin
find
suggest
propos
css
opt
reliabl
mean
antemortem
diagnosi
fd
also
possibl
fd
singl
condit
syndrom
sever
caus
vari
histopatholog
find
addit
test
rest
heart
rate
variabl
heart
rate
respons
intraven
atropin
may
prove
benefici
diagnosi
fd
von
frey
anesthesiometri
vfa
provid
object
sensori
threshold
st
measur
util
monitor
recoveri
spinal
cord
injuri
sci
purpos
studi
determin
util
vfa
sciaffect
dog
quantit
recoveri
sensori
function
time
compar
normal
dog
st
electr
vfa
determin
four
limb
normal
dog
dog
acut
thoracolumbar
sci
caus
spontan
intervertebr
disc
extrus
st
assess
three
separ
time
point
normal
dog
day
follow
decompress
surgeri
dog
sci
st
valu
compar
group
correl
locomotor
recoveri
sciaffect
dog
use
olbi
spinal
cord
injuri
scale
st
significantli
higher
consist
hypoalgesia
pelvic
limb
sciaffect
dog
day
postop
compar
normal
dog
p
signific
differ
thorac
limb
st
valu
observ
group
progress
decreas
pelvic
limb
st
valu
occur
sciaffect
dog
time
consist
improv
toward
normal
sensat
develop
allondynia
find
correl
invers
locomotor
score
p
r
rang
declin
thorac
limb
st
also
observ
across
test
session
normal
sciaffect
dog
may
result
patient
acclim
oper
train
effect
sciaffect
dog
effect
analges
medic
studi
support
use
vfa
assess
differ
st
normal
sciaffect
dog
howev
futur
studi
must
focu
techniqu
minim
compens
clinic
environment
behavior
factor
may
impact
measur
st
valu
clinic
set
endoscop
laminectomi
techniqu
dog
hansen
type
disc
diseas
natalya
ulanova
andrei
tarassov
veterinari
clinic
best
novosibirsk
russia
southeast
valley
veterinari
hospit
sandi
ut
usa
endoscop
laminectomi
techniqu
wide
use
human
medicin
commonli
use
veterinari
medicin
perform
surgeri
januari
decemb
hospit
use
endoscop
approach
treatment
hansen
type
intervertebr
disc
diseas
dog
present
clinic
sign
acut
paraparesi
durat
sever
hour
sever
day
dog
dachshund
french
bulldog
pekinges
english
cocker
spaniel
russian
spaniel
mix
breed
dog
one
dachshund
absent
deep
pain
hour
prior
present
hospit
age
dog
year
neurolog
examin
dog
neuroloc
spinal
segment
dog
neuroloc
patient
diagnosi
confirm
mri
use
mri
surgic
techniqu
use
karl
storz
endoscop
equip
karl
storz
neurosurg
system
easygo
perform
surgeri
needl
place
near
spinal
process
mark
correct
intervertebr
space
placement
confirm
later
view
xray
patient
place
ventral
recumb
surgic
field
asept
prepar
confirm
disc
space
made
mm
skin
incis
locat
spinal
process
vertebra
remov
luer
rongeur
punctur
needl
instal
degre
base
remov
spinal
process
sequenti
dilat
use
bloodless
access
bone
surgic
field
expos
instal
throacar
degre
rotat
head
throacar
rotat
head
use
allow
endoscop
movement
spinal
canal
surgic
field
visual
point
surgeri
guid
continu
endoscop
vision
remnant
muscl
tissu
remov
forcep
bleed
stop
bipolar
electrocauteri
shaver
use
drill
bone
irrig
suction
use
remov
bone
particl
kerrison
rounger
use
widen
entranc
spinal
canal
extrud
disc
materi
grasp
forcep
remov
spinal
canal
spinal
cord
evalu
via
endoscop
visual
two
adjac
disc
space
fenestr
closur
surgic
wound
dog
becam
ambulatori
surgeri
dog
return
normal
gait
day
day
post
oper
month
follow
patient
neurolog
deficit
describ
techniqu
provid
great
benefit
surgeon
well
patient
comparison
standard
hemilaminectomi
fold
magnif
allow
superior
visual
surgic
field
spinal
cord
nerv
root
improv
differenti
anatom
structur
result
gentler
manipul
nervou
structur
reduc
risk
bleed
two
adjac
disc
space
fenestr
via
incis
dilat
system
smaller
incis
reduc
muscl
trauma
postsurg
pain
owner
pleas
see
smaller
incis
elizabeth
parsley
elizabeth
rozanski
katherin
weiss
tuft
univers
north
grafton
usa
neurolog
diseas
includ
paresi
paralysi
commonli
evalu
emerg
basi
small
anim
medicin
prompt
imag
decompress
warrant
consensu
dog
present
urgent
sign
address
purpos
studi
evalu
offhour
diagnost
surgic
approach
dog
evid
spinal
cord
compress
internetbas
survey
distribut
acvecc
listserv
survey
consist
question
includ
demograph
question
scenario
one
question
regard
myelomalacia
scenario
respond
ask
respond
current
approach
hospit
survey
anonym
respond
request
limit
respons
one
per
hospit
respons
receiv
major
respond
work
privat
specialti
practic
work
academia
respond
acvecc
diplom
practic
although
diplom
hour
abl
perform
myelogram
comput
tomographi
ct
scan
magnet
reson
imag
mri
busi
hour
offhour
neurologist
sand
neurolog
resid
surgeon
surgeri
resid
oper
major
case
share
basi
practic
neurologist
staff
remain
practic
neurologist
time
boardcertifi
neurologist
bcn
evalu
case
hour
least
time
time
bcn
practic
veterinari
surgeon
time
case
evalu
hour
ofhour
imag
read
radiologist
radiolog
resid
case
teleradiolog
servic
practic
oper
least
dog
per
month
spinal
cord
compress
potenti
myelomalacia
discuss
dog
respond
dog
deep
pain
sensat
respond
scenario
respons
section
given
dachshund
present
pm
motor
deep
pain
sensat
respond
would
proceed
imag
surgeri
night
dog
arriv
respond
would
wait
dachshund
arriv
pm
deep
pain
acut
would
proceed
immedi
imag
surgeri
pm
would
proceed
imag
surgeri
would
wait
would
recommend
euthanasia
dachshund
arriv
without
deep
pain
pm
hour
sinc
last
known
ambulatori
would
recommend
immedi
imag
surgeri
tetraparet
rottweil
increas
present
saturday
even
respond
would
proceed
imag
surgeri
night
wait
sunday
wait
monday
labrador
present
later
sign
chase
ball
noon
holiday
respond
would
pursu
mri
immedi
would
wait
follow
day
respond
comment
approach
direct
avail
wish
facil
neurologist
surgeon
appar
differ
univers
privat
practic
urgent
neurosurg
emerg
common
current
polici
appear
base
avail
prefer
clearli
guid
evid
riluzol
dantrolen
shown
neuroprotect
reduc
neuron
apoptosi
brain
spinal
cord
injuri
sever
anim
model
neurolog
disord
studi
investig
effect
associ
riluzol
dantrolen
experiment
spinal
cord
injuri
sci
twentynin
wistar
rat
laminectom
divid
five
group
gi
n
underw
laminectomi
alon
treat
placebo
gii
n
underw
laminectomi
follow
sci
treat
placebo
giii
n
underw
laminectomi
follow
sci
treat
riluzol
placebo
min
h
laminectomi
respect
giv
n
underw
laminectomi
follow
sci
treat
placebo
dantrolen
min
h
laminectomi
respect
gv
n
underw
laminectomi
follow
sci
treat
riluzol
dantrolen
min
h
laminectomi
respect
compress
trauma
perform
induc
sci
euthanasia
spinal
cord
evalu
use
light
microscopi
tunel
stain
immunochemistri
antineun
procedur
perform
accord
principl
adopt
nih
guid
care
use
laboratori
anim
ethic
committe
anim
use
ceuaufmgprotocol
number
anim
treat
associ
riluzol
dantrolen
show
larger
number
neunposit
neuron
adjac
epicent
injuri
p
furthermor
tunel
stain
similar
anim
treat
riluzol
dantrol
receiv
spinal
cord
trauma
p
result
show
riluzol
dantrolen
protect
spinal
cord
tissu
traumat
sci
decreas
apoptot
cell
death
especi
use
associ
zonisamid
zn
levetiracetam
lev
util
increas
frequenc
firstlin
anticonvuls
medic
dog
epilepsi
littl
inform
avail
regard
use
purpos
studi
evalu
clinic
outcom
idiopath
epilept
dog
administ
zon
lev
monotherapi
compar
dog
phenobarbit
pb
monotherapi
medic
record
retrospect
search
dog
diagnos
idiopath
epilepsi
administ
either
zon
lev
pb
monotherapi
inform
durat
therapi
advers
effect
outcom
collect
medic
record
refer
veterinarian
owner
questionnair
total
case
includ
dog
lev
dog
zon
dog
pb
dog
pb
group
younger
time
first
seizur
compar
lev
zon
group
p
mean
durat
therapi
similar
group
day
lev
zon
pb
respect
dog
aliv
time
write
pb
group
like
still
monotherapi
lev
zon
group
p
seizur
frequenc
common
reason
monotherapi
failur
group
incid
advers
effect
higher
pb
group
compar
lev
zon
group
p
although
incid
sedat
similar
result
suggest
compar
pb
zn
lev
monotherapi
associ
fewer
advers
effect
dog
although
addon
therapi
might
requir
sooner
purpos
retrospect
studi
describ
use
efficaci
midazolam
continu
rate
infus
cri
dog
cluster
seizur
cs
statu
epilepticu
se
medic
record
dog
admit
emerg
seizur
receiv
midazolam
cri
review
signal
seizur
histori
result
neurolog
examin
diagnosi
initi
therapi
record
midazolam
cri
initi
dose
timefram
dose
increas
breakthrough
seizur
highest
dose
given
total
time
receiv
total
time
hospit
surviv
discharg
document
total
dog
includ
studi
dog
cs
dog
se
dog
previou
histori
seizur
dog
divid
genet
epilepsi
structur
epilepsi
unknown
epilepsi
reactiv
seizur
median
dose
midazolam
cri
result
seizur
resolut
mgkghr
median
time
seizur
resolut
hour
dog
seizur
resolut
achiev
upon
start
cri
mean
time
midazolam
infus
hour
mean
length
hospit
day
overal
dog
achiev
seizur
resolut
midazolam
cri
repres
dog
genet
epilepsi
structur
epilepsi
unknown
epilepsi
reactiv
seizur
dog
surviv
discharg
nonrespond
structur
epilepsi
midazolam
cri
appear
safe
effect
therapi
dog
cs
se
purpos
retrospect
studi
describ
magnet
reson
imag
mri
characterist
canin
atlantoaxi
aa
sublux
identifi
associ
neurolog
deficit
multicent
review
medic
record
mr
imag
dog
diagnosi
aa
sublux
conduct
signal
neurolog
grade
time
onset
sign
mri
characterist
record
evalu
mri
characterist
includ
spinal
cord
compress
degre
joint
sublux
integr
odontoid
ligament
structur
presenc
den
presenc
cord
signal
intens
presenc
syringohydromyelia
hydrocephalu
chiarilik
malform
control
popul
age
breed
match
dog
normal
aa
junction
also
evalu
review
blind
affect
statu
mr
imag
dog
affect
aa
sublux
review
compar
control
dog
major
affect
dog
yorkshir
terrier
median
age
month
median
weight
kg
control
popul
median
age
month
median
weight
kg
common
breed
maltes
pomeranian
dog
affect
less
week
affect
one
week
one
month
affect
greater
month
neurolog
grade
rang
spinal
pain
tetrapleg
without
nocicept
affect
dog
ambulatori
tetraparet
grade
associ
mri
characterist
affect
statu
dog
aa
sublux
control
neurolog
grade
assess
logist
regress
associ
mri
characterist
perform
use
spearman
pearson
correl
student
ttest
analysi
varianc
kruskalw
test
appropri
differ
note
affect
control
dog
respect
presenc
syringohydromyelia
hydrocephalu
chiarilik
malform
signific
differ
control
affect
dog
note
respect
presenc
den
apic
ligament
transvers
ligament
presenc
cord
signal
intens
associ
affect
statu
increas
aa
joint
caviti
size
percentag
crosssect
cord
compress
level
den
midbodi
associ
found
cord
compress
appear
den
cord
signal
intens
neurolog
grade
affect
dog
associ
presenc
cord
signal
intens
increas
joint
caviti
size
associ
den
appear
cord
signal
intens
den
abnorm
associ
greater
sublux
distanc
odontoid
ligament
absenc
associ
increas
joint
caviti
size
dog
affect
aa
sublux
higher
incid
chiarilik
malform
syringohydromyelia
hydrocephalu
control
dog
neurolog
grade
associ
mri
find
howev
lack
den
andor
odontoid
ligament
associ
larger
sublux
main
object
studi
propos
object
method
determin
ideal
implant
placement
atlantoaxi
joint
develop
mathemat
model
allow
calcul
implant
posit
assess
valid
mathemat
model
current
literatur
atlantoaxi
anatomi
ventral
atlantoaxi
stabil
techniqu
review
identifi
safe
bone
corridor
bone
corridor
geometr
simplifi
ideal
implant
placement
defin
axe
center
within
simplifi
corridor
ct
imag
craniocerv
junction
obtain
dog
previous
defin
ideal
implant
posit
use
osirix
implant
insert
point
exit
point
safeti
margin
point
local
mathemat
equat
calcul
project
angl
proja
safeti
angl
safa
point
coordin
determin
sampl
simul
implant
randomli
select
angl
mathemat
calcul
compar
direct
measur
obtain
osirix
measur
tool
observ
x
repeat
bone
corridor
ideal
implant
placement
could
object
defin
osirix
could
use
success
simul
ideal
implant
posit
case
excel
agreement
calcul
measur
valu
proja
q
c
safa
q
c
absolut
differ
calcul
measur
valu
respect
ae
ae
ae
ae
observ
new
method
determin
ideal
implant
placement
provid
semiautom
calcul
ideal
implant
posit
could
develop
use
method
clinic
efficaci
safeti
zonisamid
monotherapi
dog
newli
diagnos
idiopath
epilepsi
akinori
nomura
miyoko
saito
daisuk
hasegawa
naoyuki
watanab
keiko
uchida
seiichi
okuno
masahiro
nakai
kensuk
orito
ds
pharma
anim
health
co
ltd
osaka
japan
azabu
univers
kanagawa
japan
nippon
veterinari
life
scienc
univers
tokyo
japan
watanab
anim
hospit
shizuoka
japan
acplaza
kariya
anim
hospit
tokyo
japan
anim
clinic
kobayashi
saitama
japan
zonisamid
antiepilept
medic
use
canin
felin
epilepsi
inform
clinic
efficaci
monotherapi
howev
limit
studi
anticonvuls
efficaci
safeti
zonisamid
consav
evalu
multicent
openlabel
uncontrol
studi
dog
newli
diagnos
idiopath
epilepsi
fiftyseven
dog
enrol
antiepilept
drugnaiv
seizur
per
week
mgkg
zonisamid
administ
oral
twice
daili
data
mainten
period
compar
histor
baselin
period
four
dog
exclud
efficaci
evalu
one
final
diagnos
symptomat
epilepsi
other
drop
titrat
period
forti
dog
judg
respond
reduct
seizur
frequenc
respond
averag
dosag
zonisamid
mgkg
averag
plasma
concentr
lgml
twentynin
dog
becam
seizur
free
dog
anorexia
weight
loss
reduc
activ
vomit
diarrhea
constip
erythema
itch
observ
advers
event
sever
disappear
immedi
mainten
period
studi
demonstr
zonisamid
monotherapi
effect
welltoler
dog
newlydiagnos
idiopath
epilepsi
meningioma
repres
half
primari
intracrani
tumour
dog
limit
compar
studi
regard
variou
treatment
modal
aim
studi
compar
palli
therapi
surgeri
stereotact
radiosurgeri
canin
meningioma
data
collect
retrospect
dog
refer
one
institut
period
histopatolog
confirm
mri
consist
meningioma
dog
group
anatom
site
supratentorial
infratentorialt
spinal
therapeut
option
palliationp
surgeri
radiosurgeryr
surgeri
goal
total
resect
tumour
linac
base
vmat
radiosurgeri
perform
fraction
serial
clinic
mri
examin
conduct
signal
clinic
sign
neuroanatom
tumour
locat
relaps
specif
advers
event
best
respons
overal
surviv
os
time
evalu
os
estim
calcul
use
kaplanmei
method
differ
compar
group
use
logrank
analysi
multivari
analysi
perform
use
cox
regress
dog
e
palliat
dog
e
treat
stereotact
radiosurgeri
dog
e
surgeri
os
pe
day
pt
day
ps
day
day
rt
day
rs
day
se
day
st
day
ss
day
predict
variabl
os
localis
therapi
option
dog
suffer
meningioma
undergo
stereotact
radiosurgeri
superior
result
compar
treat
surgeri
palliat
suspect
hydrat
nucleu
pulposu
extrus
associ
dorsal
longitudin
ligament
dog
mario
dolera
luca
malfassi
giovanni
mazza
sara
finesso
massimo
sala
silvia
marcarini
simon
pavesi
nanci
carrara
la
cittadina
fondazion
studi
e
ricerch
veterinari
romanengo
cr
itali
aim
studi
describ
magnet
reson
imag
mri
surgic
cytolog
find
patient
hydrat
nucleu
pulposu
hnpe
cervic
disc
extrus
associ
dorsal
longitudin
ligament
prospect
studi
follow
inclus
criteria
conduct
highfield
mri
examin
videotap
microsurg
decompress
cytolog
examin
remov
materi
follow
mri
featur
assess
grade
spinal
cord
compress
intervertebr
space
involv
signal
intens
distribut
materi
spinal
cord
signal
thick
signal
intens
disc
surgic
find
consid
macroscop
appear
materi
local
relationship
dll
thirtysix
patient
includ
anatom
site
case
mri
lesion
signal
intens
similar
csf
sequenc
distribut
central
case
thick
correspond
disc
slightli
reduc
case
signal
intens
nucleu
pulposu
normal
case
slightli
reduc
sequenc
spinal
cord
compress
rang
surgeri
materi
found
intraligament
liquid
consist
gelatin
compon
case
plain
liquid
liquid
frustul
cytolog
examin
allow
exclud
presenc
inflamm
bacteria
mycosi
neoplasia
foreign
materi
hpne
diagnos
dog
extrud
disc
materi
intraligament
local
observ
studi
need
clarifi
pathophysiolog
aim
studi
investig
magnet
reson
spectroscopi
mr
spectra
canin
brain
diseas
patient
underw
brain
mri
mr
patient
intracrani
lesion
group
inflammatori
ig
neoplast
ng
hepat
encephalopathi
affect
group
mr
perform
twice
use
short
use
long
cm
voi
use
studi
metabolit
glutamineglutam
glx
nacetylaspart
nacetyl
aspartyl
glutam
naa
cholin
deriv
cho
myoinositol
naacr
chocr
mycr
ratio
analyz
presenc
lipid
lactat
motor
unit
number
estim
mune
electrophysiolog
techniqu
quantifi
number
motor
unit
valuabl
biomark
neurodegen
diseas
canin
degen
myelopathi
mune
determin
divid
maximum
compound
muscl
action
potenti
averag
singl
motor
unit
potenti
smup
dog
one
studi
report
mune
increment
method
use
l
vasquez
method
requir
small
success
increment
stimuli
collect
smup
howev
stimul
function
smup
also
collect
frespons
mune
use
frespons
method
requir
small
stimulu
increment
frespons
method
also
free
altern
major
problem
increment
method
studi
evalu
mune
use
frespons
method
stashuk
nerv
stimul
multipl
point
mpsf
method
along
deep
peron
nerv
innerv
extensor
digitorum
brevi
muscl
two
trial
set
perform
examin
testretest
reliabl
six
healthi
dog
mune
obtain
dog
multiplepoint
better
singlesit
stimul
regard
abil
obtain
smup
number
mune
number
first
trial
left
right
second
signific
differ
mune
valu
intraclass
correl
coeffici
first
second
trial
left
right
studi
indic
mpsf
method
use
mune
techniqu
dog
method
thirteen
tumorbear
dog
enrol
dose
escal
phase
studi
dox
doseescal
ctx
cohort
po
daili
subsequ
dog
random
receiv
mtddox
alon
combin
metronom
ctx
peripher
blood
mononuclear
cell
pbmc
collect
day
begin
therapi
analysi
treg
number
result
phase
dose
cohort
well
toler
dox
ctx
mgm
combin
deem
safe
subsequ
random
dog
toler
combin
without
signific
toxic
signific
differ
observ
rel
absolut
treg
number
dog
receiv
dox
vs
dog
receiv
doxctx
howev
dox
alon
combin
ctx
result
signific
decreas
absolut
lymphocyt
count
trend
toward
decreas
absolut
treg
number
conclus
metronom
ctx
publish
dosag
safe
given
concurr
mtddox
tumorbear
dog
like
differ
treg
number
result
addit
metronom
ctx
mtddox
chemotherapi
observ
due
lymphocyt
deplet
caus
dox
alon
small
cohort
background
transit
cell
carcinoma
tcc
commonli
diagnos
tumor
canin
urinari
system
overal
surviv
tradit
chemotherapi
diseas
improv
mani
year
addit
research
new
therapeut
target
need
hedgehog
signal
regul
normal
embryon
develop
repres
one
target
activ
adult
cell
hedgehog
signal
promot
oncogenesi
found
play
central
role
human
bladder
cancer
method
studi
tcc
cell
line
highli
express
hedgehog
pathway
mediat
treat
inhibitor
cyclopamin
downregul
pathway
confirm
real
time
rtpcr
patch
cell
growth
assess
hour
inhibitor
treatment
cell
viabil
assess
alamar
blue
assay
apoptosi
assess
annexin
v
stain
result
hedgehog
pathway
mediat
includ
ihh
found
express
canin
transit
cell
carcinoma
cell
line
indian
hedgehog
express
tumor
cell
canin
bladder
tumor
tissu
normal
canin
bladder
tissu
inhibit
hedgehog
signal
cyclopamin
confirm
decreas
express
downstream
target
gene
led
significantli
decreas
cell
prolifer
lesser
effect
apoptosi
conclus
studi
suggest
hedgehog
signal
role
pathogenesi
canin
tcc
studi
use
silenc
rna
techniqu
inhibit
signal
alon
combin
chemotherapi
may
provid
addit
evid
import
pathway
canin
tcc
provid
basi
futur
clinic
trial
vc
award
winner
platinum
compound
includ
cisplatin
cddp
highli
activ
anticanc
agent
use
solid
tumor
like
chemotherapeut
platinum
compound
toxic
nontumor
tissu
develop
unwant
side
effect
includ
neuropathi
nephrotox
often
limit
treatment
dose
durat
mechan
side
effect
particularli
neurotox
undefin
howev
accumul
platinum
spinal
cord
tissu
associ
develop
neuropathi
remark
clinic
histolog
featur
cddpinduc
neurotox
similar
seen
vitamin
e
defici
use
preclin
model
epitheli
ovarian
cancer
test
hypothesi
adjuv
would
improv
cddp
antitumor
efficaci
reduc
cddpinduc
oxid
stress
nontumor
toxic
tumorbear
immun
compet
femal
rat
receiv
one
treatment
regimen
salin
week
cddp
cddp
regimen
administ
period
week
necropsi
tumor
burden
reduc
undetect
level
cddp
treat
rat
compar
rat
treat
cddp
alon
cddp
decreas
indic
tumor
prolifer
measur
immunohistochemistri
p
cddp
decreas
tumor
prolifer
p
compar
salin
importantli
adjuv
decreas
accumul
platinum
spinal
cord
tissu
p
without
alter
tumor
platinum
level
compar
rat
treat
cddp
alon
interestingli
presenc
tumor
salin
treat
rat
increas
plasma
metabolit
level
compar
nontumor
control
without
cddp
return
level
nontumor
control
final
adjuv
prevent
cddpinduc
plasma
tissu
deplet
data
first
document
abil
adjuv
improv
chemotherapeut
antitumor
efficaci
decreas
tumor
prolifer
improv
antioxidantoxid
stress
statu
immun
compet
tumorbear
anim
elucid
abil
adjuv
improv
antitumor
efficaci
qualiti
life
outcom
essenti
develop
improv
treatment
regimen
human
veterinari
patient
last
year
surviv
time
dog
osteosarcoma
osa
treat
surgeri
postop
adjuv
chemotherapi
chang
therefor
new
treatment
approach
need
antiangiogen
chemotherapi
hypothesi
propos
tumor
growth
tan
millimet
without
recruit
blood
vessel
suppli
oxygen
nutrient
neoplast
cell
one
major
player
new
blood
vessel
growth
vascular
endotheli
growth
factor
vegf
dog
aggress
tumor
osa
higher
circul
activ
vegf
compar
dog
benign
lesion
propos
vegf
play
role
develop
metastasi
former
race
greyhound
present
ohio
state
univers
veterinari
medic
center
appendicular
osa
evid
metastas
thorac
radiograph
treat
amput
affect
limb
chemotherapi
amput
chemotherapi
follow
metronom
chemotherapi
prior
initi
chemotherapi
dog
underw
physic
examin
complet
blood
count
cbc
serum
chemistri
profil
urinalysi
thorac
radiograph
dog
treat
protocol
suramindoxorubicin
everi
week
treatment
prior
treatment
physic
examin
cbc
repeat
thorac
radiograph
repeat
fifth
treatment
everi
three
month
thereaft
start
june
dog
owner
given
option
use
metronom
chemotherapi
protocol
complet
suramindoxorubicin
treatment
metronom
chemotherapi
protocol
consist
artemisinin
holley
pharmaceut
tustin
ca
mg
po
h
toceranib
phosphat
palladia
zoeti
florham
park
nj
mgkg
po
monday
wednesday
friday
cyclophosphamid
mgm
po
tuesday
thursday
saturday
dog
protocol
develop
metastas
death
cbc
serum
chemistri
profil
urinalysi
thorac
radiograph
done
three
month
visit
surviv
time
st
diseas
free
interv
dfi
gener
use
kaplanmei
method
compar
use
log
rank
analysi
p
valu
less
consid
signific
greyhound
treat
dog
receiv
metronom
chemotherapi
complet
standard
chemotherapi
receiv
suramindoxorubicin
protocol
three
dog
still
aliv
one
die
due
unrel
caus
censor
dfi
st
analys
signific
differ
dfi
st
dog
treat
chemotherapi
alon
compar
treat
chemotherapi
plu
metronom
chemotherapi
dfi
day
chemotherapi
group
day
chemotherapi
metronom
group
p
surviv
time
day
fro
chemotherapi
day
chemotherapi
metronom
group
p
osteotrop
neoplasm
includ
felin
oral
squamou
cell
carcinoma
oscc
canin
prostat
carcinoma
pc
oral
malign
melanoma
omm
osteosarcoma
os
manag
ioniz
radiat
therapi
yet
treatment
respons
durabl
detoxifi
enzym
overexpress
human
tumor
remain
uncharacter
veterinari
oncolog
deoxynyboquinon
dnq
potent
substrat
result
reactiv
oxygen
speci
gener
consequ
cell
death
hypothes
express
osteotrop
solid
tumor
serv
druggabl
target
improv
cytotox
activ
radiat
therapi
western
blot
immunohistochemistri
identifi
cell
line
enzymat
activ
assay
determin
presenc
function
protein
one
cell
line
per
tumor
histolog
select
demonstr
tempor
dosedepend
regul
radiat
cytotox
effect
irradi
dnq
investig
treat
select
cell
line
measur
surviv
fraction
cell
conjunct
fluoresc
microscopi
identifi
doublestrand
dna
break
via
biomark
express
malign
cell
line
enzymat
activ
confirm
select
cell
line
cell
shown
upregul
radiat
therapi
irradi
dnq
therapi
alon
combin
cytotox
result
indic
express
malign
solid
tumor
express
upregul
follow
irradi
dnq
potent
substrat
induc
cytotox
alon
combin
radiat
support
investig
dnq
target
treatment
osteotrop
solid
tumor
clinic
set
use
doxorubicin
chemotherapi
protocol
without
lasparaginas
canin
patient
shown
efficaci
treatment
bcell
lymphoma
particularli
multipl
dose
doxorubicin
administ
canin
monoclon
antibodi
mab
target
potenti
improv
treatment
outcom
bcell
lymphoma
patient
treat
minim
chemotherapi
protocol
studi
evalu
safeti
progressionfre
surviv
pf
overal
surviv
os
combin
abbrevi
protocol
lasparaginas
doxorubicin
mab
treat
bcell
lymphoma
dog
n
newli
diagnos
bcell
lymphoma
measur
peripher
lymph
node
enlarg
enrol
prospect
openlabel
studi
phase
subject
treat
three
dose
doxorubicin
mgm
everi
three
week
seven
dose
mab
mgkg
period
fourteen
week
relaps
nine
eleven
dog
elig
particip
phase
treat
addit
dose
doxorubicin
mgm
four
dose
mab
mgkg
two
dog
treat
phase
never
relaps
one
still
aliv
os
day
start
phase
dog
abl
receiv
dose
lasparaginas
nineteen
twenti
dog
enrol
receiv
treatment
mab
total
treatment
dog
withdrew
prior
mab
administr
three
dog
administ
mab
experienc
mab
infusionrel
reaction
reactiondog
one
twenti
dog
administ
doxorubicin
total
treatment
experienc
doxorubicin
toxic
third
dose
doxorubicin
intenttotreat
popul
data
demonstr
initi
median
pf
day
median
pf
day
follow
treatment
phase
median
os
day
dog
per
protocol
popul
n
receiv
three
doxorubicin
treatment
initi
median
pf
day
median
pf
day
phase
median
os
day
data
suggest
addit
mab
protocol
includ
lasparaginas
doxorubicin
safe
treatment
condit
may
provid
benefit
dog
b
cell
lymphoma
chronic
lymphocyt
leukemia
emili
rout
robert
burnett
courtney
abbott
stacey
georg
ann
averi
colorado
state
univers
fort
collin
co
usa
canin
b
cell
chronic
lymphocyt
leukemia
cll
common
dog
share
mani
featur
human
cll
human
cll
immunoglobulin
ig
gene
usag
mutat
statu
import
marker
diseas
behavior
factor
assess
canin
bcll
sequenc
immunoglobulin
heavi
chain
variabl
region
vh
gene
neoplast
peripher
blood
b
cell
dog
bcll
thirteen
vh
gene
use
exclud
boxer
breed
commonli
use
gene
nonneoplast
b
cell
commonli
use
gene
gene
use
bcll
patient
greater
mutat
compar
germlin
sequenc
classifi
mutat
unmut
case
use
one
third
use
unmut
gene
case
use
use
mutat
gene
overrepres
boxer
bcll
preferenti
use
boxer
bcell
neoplasm
boxer
dog
bcll
sequenc
use
unmut
gene
find
suggest
antigen
select
may
play
role
pathogenesi
bcll
boxer
data
lay
foundat
correl
vh
gene
usag
mutat
statu
outcom
dog
establish
canin
patient
good
model
human
cll
identifi
group
like
boxer
may
use
studi
pathogenesi
cll
imatinib
potent
antitumor
activ
canin
mast
cell
tumor
mct
carri
ckit
mutat
although
tumor
initi
respond
well
imatinib
eventu
develop
resist
molecular
mechan
confer
imatinib
resist
neoplast
mast
cell
investig
use
imatinibsensit
canin
neoplast
mast
cell
line
vimc
carri
kit
activ
mutat
two
imatinibresist
sublin
establish
cultur
vimc
cell
increas
concentr
imatinib
sublin
second
kit
mutat
c
recombin
kit
second
mutat
insensit
sensit
imatinib
effect
imatinib
phosphoryl
kit
downstream
signal
protein
examin
use
sublin
kit
erk
constitut
phosphoryl
sublin
phosphoryl
suppress
imatinib
cell
howev
kit
erk
phosphoryl
supress
cell
phosphoryl
erk
cell
also
diminish
src
famili
kinas
sfk
inhibitor
dasatinib
second
mutat
kit
may
play
import
role
imatinib
resist
neoplast
mast
cell
furthermor
kitsfkindepend
activ
erk
would
involv
imatinib
resist
neoplast
cell
expos
higher
concentr
imatinib
gemcitabin
antimetabolit
chemotherapi
agent
clinic
activ
number
human
malign
gemcitabin
activ
cytotox
triphosph
form
dfdctp
concentrationdepend
manner
compet
incorpor
dna
induc
apoptosi
wherea
intracellular
accumul
dfdctp
schedul
depend
reli
achiev
maintain
optim
extracellular
plasma
concentr
excess
gemcitabin
plasma
concentr
inhibit
critic
activ
process
current
standard
dose
scheme
use
gemcitabin
felin
patient
cancer
purpos
studi
identifi
fixeddos
rate
fdr
gemcitabin
result
optim
plasma
concentr
opc
cat
cancerbear
client
own
cat
variou
malign
enrol
studi
gemcitabin
administ
fdr
intraven
iv
hour
plasma
collect
administr
end
infus
plasma
protein
precipit
pellet
plasma
gemcitabin
quantit
hplc
fdr
mgm
min
hour
fail
achiev
opc
fdr
mgm
min
achiev
opc
hour
fdr
mgm
min
achiev
opc
hour
infus
fdr
mgm
min
achiev
opc
hour
howev
exceed
opc
within
hour
data
suggest
ideal
fdr
cat
lie
mgm
min
due
mainten
opc
hour
follow
studi
evalu
gemcitabin
cat
use
fdr
mgm
min
recommend
current
underway
metformin
use
manag
noninsulin
depend
diabet
mellitu
human
clinic
evid
suggest
patient
take
metformin
reduc
lifetim
incid
cancer
metformin
mechan
action
understood
may
target
amp
activ
protein
kinas
ampk
induc
glucos
uptak
blood
muscl
upstream
regul
ampk
wellrecogn
tumor
suppressor
studi
purpos
determin
pharmacokinet
oral
bioavail
metformin
facilit
clinic
trial
evalu
metformin
effect
dog
lymphoma
seven
healthi
adult
mix
breed
dog
enrol
random
crossov
design
studi
consist
pair
ivor
crossov
washout
period
treatment
dog
given
mgkg
metformin
iv
mgkg
metformin
oral
administr
time
hour
administr
blood
sampl
collect
via
indwel
cathet
drug
analysi
metformin
serum
concentr
determin
use
valid
lcmsm
method
pharmacokinet
paramet
estim
individu
dog
serum
concentrationtim
curv
noncompartment
method
use
graphpad
prism
softwar
concentrationtim
profil
demonstr
threecompart
kinet
meanaesd
pharmacokinet
paramet
estim
cl
mlminkg
ae
v
area
lkg
ae
k
h
ae
h
ae
oral
f
ae
c
max
ngml
ae
max
h
ae
gener
disposit
pattern
metformin
dog
similar
report
cat
human
develop
secondari
highgrad
lymphoma
indol
lymphoid
malign
report
human
commonli
refer
richter
syndrom
similar
condit
also
report
dog
recent
construct
new
genescan
analyt
system
use
multicolorlabel
primer
capillari
electrophoresi
detect
rearrang
immunoglobulin
heavi
chain
igh
tcell
receptor
gamma
chain
tcrc
gene
dog
herein
use
genescan
analysi
differenti
clonal
origin
cell
dog
develop
two
differ
type
lymphoid
malign
five
dog
initi
diagnosi
margin
zone
lymphoma
mzl
n
bcell
chronic
lymphocyt
leukemia
bcll
n
tzone
lymphoma
tzl
n
develop
secondari
highgrad
bcell
lymphoma
diffus
larg
bcell
lymphoma
dlbcl
year
initi
diagnosi
genescan
analysi
reveal
singl
peak
igh
gene
length
primari
mzl
bcll
secondari
tumor
dlbcl
dog
indic
secondari
dlbcl
evolv
preexist
primari
indol
neoplasm
clone
singl
tcrc
peak
identifi
tzl
sampl
howev
subsequ
dlbcl
sampl
dog
reveal
singl
peak
igh
gene
instead
peak
therebi
suggest
differ
origin
lymphoid
neoplasm
develop
subject
studi
indic
genescan
analysi
would
conveni
accur
method
determin
clonal
origin
lymphoid
neoplasm
dog
purpos
studi
compar
lomustin
content
fda
approv
compound
capsul
priori
accept
rang
state
capsul
content
capsul
obtain
fda
approv
manufactur
nextsourc
biotechnolog
nation
usa
compound
pharmaci
mg
mg
capsul
nearest
avail
content
replic
capsul
per
sourc
strength
assess
valid
high
pressur
liquid
chromatographi
ultraviolet
detect
method
content
capsul
empti
individu
methanol
yield
state
concentr
mgml
vortex
second
sonic
minut
sampl
vortex
centrifug
dilut
methanol
final
state
concentr
lgml
lomustin
concentr
determin
compar
standard
curv
methanol
fda
approv
capsul
capsul
strength
within
state
content
compound
mg
mg
capsul
respect
within
compound
b
mg
mg
capsul
respect
within
compound
c
mg
mg
capsul
respect
within
product
failur
state
content
conclus
compound
lomustin
capsul
fail
state
amount
drug
fda
approv
formul
contain
state
amount
drug
clinic
implic
use
compound
lomustin
may
includ
treatment
failur
increas
risk
tumor
resist
alimentari
lymphoma
common
neoplasia
cat
system
chemotherapi
indic
treatment
although
cat
achiev
complet
remiss
chemotherapi
relaps
associ
multidrug
resist
occur
use
cytotox
agent
previou
intrins
cellular
resist
provid
transmembran
protein
decreas
intracellular
drug
bioavail
furthermor
lung
resistancerel
protein
lrp
known
human
major
vault
protein
found
overexpress
mani
chemoresist
primari
tumor
differ
origin
includ
lymphoma
express
pgp
aim
studi
investig
lrp
express
cat
alimentari
lymphoma
immunohistochemistri
perform
sampl
cat
alimentari
lymphoma
without
previou
treatment
use
monoclon
antibodi
mous
antipglycoprotein
enzo
mous
antilrp
santa
cruz
biotech
lrp
immunoreact
analys
degre
label
intens
express
strong
express
lymphoma
classifi
b
cell
cat
one
small
larg
cell
cell
cat
small
cell
express
well
lrp
higher
cat
b
cell
lymphoma
cell
lymphoma
surviv
time
longer
cat
express
slightli
express
even
b
cell
lymphoma
observ
lrp
studi
necessari
verifiy
express
could
associ
complet
partial
respons
surviv
time
alimentari
lymphoma
compris
one
common
neoplasia
cat
antigen
express
prolifer
cell
phase
cell
cycl
found
metallothionein
mt
low
molecular
weight
protein
increas
significantli
oxid
stress
protect
cell
citotox
dna
damag
properti
contribut
antiapoptot
function
mt
well
repres
poor
prognost
factor
dlbcl
goal
studi
investig
mt
express
cat
alimentari
lymphoma
immunohistochemistri
paraffin
sampl
perform
cat
alimentari
lymphoma
without
previou
treatment
use
monoclon
antibodi
mous
clone
invitrogen
polyclon
rabbit
dako
mous
clone
dako
mous
antimetallothionein
clone
dako
immunoreact
determin
count
cell
field
metallothionein
analyz
degre
label
intens
express
strong
express
six
cat
bcell
one
small
cell
larg
cell
tcell
small
cell
lymphoma
mean
express
cat
bcell
tcell
lymphoma
p
median
surviv
time
month
respect
one
cat
express
mt
grade
associ
low
level
long
surviv
time
conclus
relat
immunophenotyp
surviv
time
mt
rare
express
alimentari
lymphoma
cat
surgic
resect
primari
tumor
effect
treatment
mammari
neoplasm
dog
nevertheless
surgic
stress
respons
may
provid
condit
persist
residu
minim
diseas
develop
preexist
micrometastas
sever
mechan
underli
process
propos
includ
postop
suppress
cellmedi
immun
firstlin
defens
mechan
cancer
exist
data
human
patient
suggest
increas
level
interleukin
interleukin
combin
decreas
helper
cellinduc
cytokin
product
interleukin
interferon
gama
ifnc
could
account
profound
suppress
natur
killer
cytotox
activ
periop
period
given
lack
relat
studi
evalu
immun
respons
associ
mastectomi
dog
aim
studi
evalu
serum
concentr
periop
period
unilater
total
mastectomi
utm
alon
associ
ovariosalpingohisterectomi
osh
bitch
mammari
tumor
purpos
includ
studi
bitch
mammari
tumor
submit
utm
utm
associ
osh
venou
blood
sampl
taken
preoper
end
surgeri
hour
hour
hour
hour
day
postop
serum
level
data
logarithm
transform
submit
friedman
test
differ
moment
within
group
mann
whitney
test
moment
group
signific
differ
moment
group
studi
paramet
result
summar
tabl
condit
studi
base
observ
result
conclud
utm
alon
associ
osh
induc
signific
chang
serum
level
postop
period
increas
secret
pituitari
hormon
activ
sympathet
nervou
system
releas
cytokin
acut
phase
protein
main
metabol
chang
associ
surgic
trauma
intens
organ
respons
depend
magnitud
durat
natur
stimuli
minor
surgeri
commonli
induc
smaller
respons
compar
medium
larg
procedur
excess
releas
hormon
humor
mediat
surgic
trauma
may
respons
multipl
advers
event
postop
period
includ
high
protein
catabol
metabol
acidosi
blood
hypercoagul
interstiti
edema
immun
depress
delay
heal
given
lack
relat
studi
evalu
metabol
respons
associ
mastectomi
dog
aim
studi
evalu
serum
concentr
cortisol
glucos
albumin
periop
period
unilater
total
mastectomi
utm
alon
associ
ovariosalpingohisterectomi
osh
bitch
mammari
tumor
purpos
includ
studi
bitch
mammari
tumor
submit
utm
utm
associ
osh
venou
blood
sampl
taken
preoper
end
surgeri
hour
hour
hour
hour
day
postop
serum
cortisol
glucos
albumin
level
data
logarithm
transform
submit
twoway
anova
tukey
post
hoc
test
differ
treatment
across
time
differ
group
across
time
studi
paramet
result
summar
tabl
consid
anesthet
analges
protocol
use
studi
base
observ
result
conclud
utm
alon
associ
osh
induc
signific
chang
serum
level
cortisol
glucos
albumin
postop
period
anim
submit
utm
found
slight
increas
serum
glucos
level
end
surgeri
introduct
rapamycin
antifung
antibiot
agent
immunosuppress
anticanc
properti
inhibit
mtor
rapamycin
act
antiprolif
antiangiogen
agent
purpos
pilot
studi
determin
blood
concentr
rapamycin
achiev
follow
singl
dose
multipl
oral
dose
dog
method
five
healthi
purposebr
hound
dog
enrol
experi
dog
receiv
singl
mgkg
dose
oral
blood
collect
hour
experi
dog
receiv
mgkg
daili
day
blood
collect
hour
sampl
analyz
use
valid
lcmsm
assay
evalu
via
noncompartment
analysi
result
variabl
blood
concentr
singl
consecut
dose
note
mean
pharmacokinet
valu
experi
half
life
ae
hr
area
curv
auc
ae
ng
hrml
maximum
concentr
c
max
ae
ngml
mean
pharmacokinet
valu
day
experi
hr
auc
ae
ng
hrml
c
max
ae
ngml
conclus
rapamycin
administ
oral
mgkg
achiev
measur
blood
concentr
goal
ongo
studi
tumorbear
dog
determin
optim
dose
frequenc
achiev
clinic
relev
concentr
determin
toxic
introduct
recent
studi
document
activ
antihypertens
medic
minoxidil
murin
model
sarcoma
specif
minoxidil
inhibit
vitro
cell
migrat
mm
reduc
pulmonari
metastasi
mice
mgkg
propos
moa
involv
downregul
collagenmodifi
enzym
occur
mm
minoxidil
activ
minoxidil
role
druggabl
target
osteosarcoma
yet
investig
pkpd
data
need
clarifi
antimetastat
mechan
minoxidil
method
growth
inhibitori
effect
minoxidil
assess
osteosarcoma
srb
assay
ex
vivo
pulmonari
metastasi
assay
puma
use
examin
minoxidil
activ
metastat
progress
plasma
minoxidil
level
measur
mice
receiv
previous
report
activ
dose
express
modul
minoxidil
assess
via
ihc
wb
result
ic
minoxidil
mm
across
cell
line
puma
demonstr
metastat
inhibit
minoxidil
concentr
mm
plasma
minoxidil
concentr
achiev
mgkg
dose
low
micromolar
rang
express
osteosarcoma
three
speci
inconsist
knockdown
minoxidil
exposur
mm
note
conclus
minoxidil
activ
pulmonari
metastasi
ex
vivo
significantli
higher
dose
biolog
achiev
investig
vivo
effect
minoxidil
osteosarcoma
metastasi
mice
plan
intratumor
drug
level
measur
determin
whether
minoxidil
concentr
tissu
explain
discrep
low
plasma
level
achiev
high
exposur
requir
antimetastat
activ
modul
felin
acromegali
increasingli
recognis
endocrinopathi
caus
chronic
excess
serum
growth
hormon
concentr
produc
function
somatotrophinoma
par
distali
anterior
pituitari
gland
underli
pathogenesi
develop
human
somatotrophinoma
poorli
understood
major
human
somatotrophinoma
sporad
howev
famili
isol
pituitari
adenoma
caus
germlin
mutat
arylhydrocarbonreceptor
interact
protein
aip
felin
acromegali
phenotyp
biochem
similar
human
famili
aip
mutat
male
predomin
somatotroph
macroadenoma
resist
octreotid
therapi
object
studi
identifi
felin
aip
gene
identifi
snp
within
felin
aip
gene
compar
snp
report
human
aip
snp
store
pituitari
tissu
acromegal
cat
use
creat
amplifi
felin
aip
cdna
use
felin
specif
aip
primer
store
edta
blood
acromegal
cat
diagnosi
insulin
resist
diabet
mellitu
serum
ngml
pituitari
mass
mm
identifi
use
contrastenhanc
pituitari
comput
tomographi
necropsi
control
cat
histori
diabet
mellitu
greater
year
age
select
dna
extract
genotyp
use
pcr
agaros
gel
electrophoresi
sanger
sequenc
felin
aip
gene
identifi
encod
amino
acid
protein
protein
homolog
human
aip
protein
blast
search
reveal
gene
contain
exon
exon
specif
primer
creat
singl
nonconserv
snp
identifi
exon
aip
encod
amino
acid
chang
aspart
acid
glutam
acid
acromegal
patient
control
sampl
two
addit
conserv
snp
also
identifi
aip
c
aip
c
exon
encod
region
aip
protein
consid
essenti
aipaip
receptor
interact
although
differ
human
mutat
identifi
date
human
aip
mutat
yet
identifi
aip
ntermin
requir
stabil
aip
protein
ahrreceptor
complex
essenti
regul
transloc
nucleu
bind
aryl
hydrocarbon
receptor
nuclear
transloc
lead
activ
gene
thought
act
tumour
suppressor
loss
normal
aip
activ
thought
promot
somatotrophinoma
develop
possibl
aip
mutat
predispos
somatrotrophinoma
tumourigensi
two
affect
patient
studi
contain
larger
number
acromegal
control
case
would
improv
understand
aip
snp
mark
peterson
jade
guterl
rhett
nichol
mark
rishniw
anim
endocrin
clinic
new
york
new
york
usa
antech
diagnost
lake
success
new
york
usa
colleg
veterinari
medicin
cornel
univers
ithaca
new
york
usa
human
patient
measur
serum
tsh
commonli
use
firstlin
discriminatori
test
thyroid
function
even
evalu
serum
free
recent
report
indic
canin
tsh
assay
immulit
canin
tsh
siemen
use
measur
felin
tsh
may
use
help
diagnos
exclud
hyperthyroid
cat
suspect
diseas
high
circul
suppress
tsh
secret
serum
tsh
level
low
hyperthyroid
cat
possibl
even
serum
free
clearli
elev
suggest
find
measur
ctsh
hyperthyroid
cat
unlik
alon
use
rule
diseas
purpos
studi
investig
use
ctsh
measur
diagnosi
mild
sever
hyperthyroid
differenti
hyperthyroid
cat
n
healthi
cat
n
euthyroid
cat
suspect
hyperthyroid
found
diseas
n
inclus
cat
routin
laboratori
test
complet
serum
thyroid
panel
dialysi
tsh
thyroid
scintigraphi
subsequ
calcul
thyroidtosalivari
ts
thyroidtobackground
tb
ratio
use
confirm
exclud
hyperthyroid
previous
describ
thyroid
scintigraphi
find
cat
hyperthyroid
vet
radiol
ultrasound
press
median
serum
concentr
hyperthyroid
cat
lgdl
ngdl
pmoll
respect
significantli
higher
p
kruskalw
test
median
concentr
euthyroid
cat
suspect
thyroid
diseas
lgdl
ngdl
pmoll
clinic
normal
cat
lgdl
ngdl
pmoll
hyperthyroid
cat
high
serum
concentr
respect
euthyroid
cat
fals
high
valu
respect
calcul
sensit
diagnost
test
hyperthyroid
respect
wherea
specif
test
respect
median
serum
tsh
concentr
hyperthyroid
cat
ngml
significantli
p
lower
median
valu
normal
cat
ngml
euthyroid
cat
suspect
thyroid
diseas
ngml
signific
differ
exist
median
concentr
free
tsh
clinic
normal
cat
valu
suspect
cat
hyperthyroid
cat
measur
tsh
valu
wherea
tsh
concentr
level
quantif
contrast
tsh
concentr
detect
normal
cat
euthyroid
cat
overal
sensit
serum
tsh
diagnost
test
hyperthyroid
test
specif
hyperthyroid
cat
detect
serum
tsh
valu
mild
diseas
lgdl
moder
hyperthyroid
lgdl
none
cat
sever
thyroid
diseas
measur
tsh
valu
preval
detect
serum
tsh
valu
cat
mild
hyperthyroid
significantli
p
higher
preval
cat
moder
diseas
conclus
serum
tsh
concentr
suppress
hyperthyroid
cat
valu
inde
measur
cat
mild
moder
hyperthyroid
although
clinic
normal
cat
euthyroid
cat
suspect
thyroid
diseas
detect
tsh
concentr
euthyroid
cat
studi
also
serum
concentr
level
quantif
overal
serum
tsh
determin
repres
highli
sensit
poorli
specif
test
diagnosi
felin
hyperthyroid
use
combin
determin
radioiodin
effect
treatment
felin
hyperthyroid
optim
dose
restor
euthyroid
without
induc
hypothyroid
remain
unclear
posttreat
hypothyroid
lead
azotemia
reduc
surviv
object
prospect
longitudin
studi
compar
frequenc
persist
hyperthyroid
iatrogen
hypothyroid
cat
mildtomoder
hyperthyroid
thyroxin
lgdl
treat
either
lowdos
millicuri
mci
n
standarddos
mci
n
serum
concentr
thyroid
stimul
hormon
tsh
creatinin
assess
month
treatment
cat
categor
time
interv
persist
hyperthyroid
euthyroid
normal
lg
dl
tsh
ngml
overt
hypothyroid
low
high
tsh
subclin
hypothyroid
normal
high
tsh
tabl
categor
continu
data
analys
use
chisquar
wilcoxon
rank
sum
respect
p
consid
signific
baselin
differ
sex
age
serum
concentr
tsh
creatinin
treatment
group
cat
treat
mci
significantli
p
less
like
develop
overt
hypothyroid
month
compar
cat
treat
mci
signific
differ
persist
hyperthyroid
group
cat
dose
mci
significantli
p
higher
median
creatinin
concentr
mgdl
month
mgdl
cat
receiv
mci
mgdl
mgdl
respect
conclus
cat
mildtomoder
hyperthyroid
effect
treat
mci
reduc
risk
overt
hypothyroid
compar
cat
dose
mci
previou
studi
demonstr
glomerular
filtrat
rate
gfr
declin
hyperthyroid
treatment
independ
treatment
modal
hill
prescript
diet
yd
felin
control
iodin
food
use
manag
felin
hyperthyroid
howev
effect
renal
function
evalu
purpos
studi
assess
effect
yd
felin
renal
function
hyperthyroid
cat
hyperthyroid
diagnos
client
own
cat
base
total
thyroid
hormon
concentr
compat
clinic
sign
baselin
excretori
renal
function
assess
plasma
clearanc
technetium
diethylenetriaminepentaacet
gfr
serum
creatinin
scr
serum
symmetr
dimethyl
arginin
sdma
concentr
ultrasound
use
assess
muscl
mass
epaxi
muscl
diamet
emd
initi
transit
period
food
fed
exclus
month
baselin
paramet
reassess
ttest
use
evalu
chang
time
pvalu
consid
signific
feed
yd
felin
month
result
signific
declin
mean
vs
nmoll
scr
vs
mgdl
chang
gfr
vs
mlminkg
sdma
vs
lgdl
emd
left
vs
cm
right
vs
cm
observ
sdma
better
correl
gfr
scr
r
vs
although
cat
becameremain
euthyroid
studi
period
manag
yd
felin
reduc
without
decreas
gfr
emd
compar
scr
sdma
may
better
marker
renal
excretori
function
hyperthyroid
cat
keton
includ
beta
hydroxybutyr
bhb
produc
condit
chronic
neg
energi
balanc
andor
decreas
glucos
util
littl
known
howev
whether
serum
bhb
concentr
increas
catabol
state
diabet
mellitu
cat
primari
aim
studi
determin
serum
bhb
concentr
increas
cat
three
potenti
catabol
diseas
state
chronic
kidney
diseas
ckd
hyperthyroid
ht
hepat
lipidosi
hl
secondari
aim
determin
serum
bhb
concentr
correl
clinic
variabl
determin
serum
bhb
concentr
correl
urin
keton
measur
dipstick
primarili
measur
acetoacet
serum
bhb
concentr
measur
sampl
drawn
admiss
clientown
cat
ckd
cat
ht
cat
hl
compar
refer
rang
establish
base
serum
bhb
concentr
healthi
cat
variabl
clinic
relev
diseas
condit
includ
serum
concentr
creatinin
total
thyroxin
serum
activ
liver
enzym
examin
relationship
serum
bhb
use
kendal
correl
result
urin
keton
measur
dipstick
avail
compar
bhb
measur
incer
serum
bhb
concentr
refer
rang
mmoll
cat
ckd
cat
ht
cat
hl
ckd
ht
group
increas
serum
bhb
mild
affect
cat
mmoll
ckd
mmoll
ht
hl
group
increas
wider
rang
mmoll
mark
hl
cat
serum
bhb
concentr
mmoll
group
percentag
cat
serum
bhb
concentr
refer
limit
significantli
higher
would
percentag
expect
normal
popul
cat
p
group
clinic
variabl
evalu
total
hyperthyroid
group
correl
posit
bhb
p
cat
urin
dipstick
perform
within
hour
serum
bhb
sampl
none
posit
keton
howev
cat
serum
bhb
concentr
upper
limit
refer
rang
cat
serum
bhb
mmoll
increas
serum
bhb
concentr
occur
commonli
cat
ckd
ht
hl
may
provid
use
index
catabol
furthermor
serum
bhb
appear
sensit
urin
keton
measur
detect
ketonemia
popul
cat
catabol
state
diabet
mellitu
must
consid
evalu
serum
bhb
concentr
sick
cat
syme
jonathan
elliott
joy
archer
univers
cambridg
cambridg
uk
royal
veterinari
colleg
london
uk
sever
studi
attempt
identifi
reliabl
biomark
ckd
hyperthyroid
cat
littl
success
date
low
plasma
total
globulin
concentr
independ
associ
develop
azotemia
follow
treatment
hyperthyroid
one
studi
suggest
dysproteinemia
marker
concurr
ckd
characteris
dysproteinemia
possibl
serum
protein
electrophoresi
spe
investig
chang
occur
globulin
fraction
hyperthyroid
cat
possibl
associ
chang
presenc
concurr
ckd
warrant
sinc
might
provid
novel
biomark
ckd
newli
diagnos
nonazotem
hyperthyroid
cat
plasma
total
thyroxin
nmoll
group
healthi
control
nonazotem
euthyroid
nmoll
non
proteinur
urin
protein
creatinin
ratio
geriatr
year
old
cat
recruit
five
uk
first
opinion
practic
hyperthyroid
cat
monitor
develop
renal
azotemia
defin
plasma
creatinin
concentr
mgdl
urin
specif
graviti
four
month
period
follow
restor
euthyroid
nmoll
agaros
gel
spe
perform
calcul
serum
concentr
albumin
b
c
globulin
nonparametr
statist
use
compar
baselin
serum
concentr
b
c
total
globulin
hyperthyroid
control
cat
hyperthyroid
cat
develop
azotemia
follow
period
preazotem
remain
nonazotem
baselin
hyperthyroid
cat
restor
euthyroid
data
present
median
th
th
percentil
statist
signific
defin
p
hyperthyroid
cat
n
higher
serum
globulin
concentr
gl
vs
gl
p
lower
serum
c
globulin
concentr
gl
vs
gl
p
control
cat
n
follow
treatment
hyperthyroid
serum
total
globulin
concentr
increas
gl
vs
gl
p
serum
globulin
concentr
decreas
gl
vs
gl
p
serum
c
globulin
concentr
increas
gl
vs
gl
p
serum
total
protein
concentr
higher
preazotem
hyperthyroid
cat
compar
remain
nonazotem
gl
n
vs
gl
n
p
howev
signific
differ
serum
concentr
b
c
total
globulin
evid
preazotem
non
azotem
group
hyperthyroid
associ
select
dysproteinemia
c
globulin
fraction
mostli
resolv
follow
treatment
howev
chang
associ
presenc
concurr
ckd
pathogenesi
dysproteinemia
requir
investig
establish
reflect
alter
product
metabol
loss
protein
louvier
univers
georgia
cvm
athen
ga
usa
diabet
mellitu
cat
rel
easili
diagnos
endocrin
diseas
frustrat
treat
manag
prozinc
r
human
recombin
pzi
insulin
particularli
effect
cat
also
fdaapprov
veterinari
use
previou
studi
shown
prozinc
r
effect
clinic
control
diabet
mellitu
cat
howev
blood
lower
characterist
prozinc
r
studi
object
studi
evalu
blood
glucos
respons
prozinc
r
insulin
newlydiagnos
stablytr
diabet
cat
use
continu
interstiti
glucos
monitor
hypothesi
prozinc
r
effect
control
hyperglycemia
cat
diabet
mellitu
ten
cat
recent
diagnos
diabet
mellitu
receiv
insulin
therapi
recruit
studi
group
ten
diabet
cat
treat
prozinc
r
least
month
clinic
stabl
accord
owner
also
recruit
group
inclus
criteria
consist
diagnosi
diabet
mellitu
avail
complet
medic
record
current
rabi
vaccin
exclus
criteria
includ
presenc
ketosi
hyperosmolar
concurr
diseas
nonneut
statu
steroid
inject
within
past
day
current
steroid
treatment
complet
histori
physic
examin
cbc
chemistri
profil
urinalysi
urin
cultur
fructosamin
obtain
cat
sensor
minim
guardian
r
system
equilibr
calibr
cat
group
cat
start
prozinc
r
ukg
bid
mealf
low
carbohydr
diet
group
cat
given
prozinc
r
fed
accord
exist
regim
glucos
curv
obtain
hour
read
everi
minut
gender
includ
mn
fs
mn
fs
group
respect
averag
age
group
cat
yr
yr
averag
age
group
cat
yr
yr
group
cat
dsh
group
cat
includ
dsh
dlh
main
coon
group
cat
diagnos
day
previous
except
cat
diagnos
month
previous
group
cat
treat
prozinc
r
year
four
cat
group
fed
low
carbohydr
diet
cat
group
fed
low
carbohydr
diet
fed
free
choic
glucos
curv
data
group
cat
show
averag
onset
action
prozinc
r
min
min
durat
action
hr
hr
time
peak
activ
hr
hr
glucos
nadir
rang
mgdl
group
cat
receiv
averag
insulin
dose
ukg
ukg
cat
receiv
prozinc
r
bid
cat
sidbid
group
cat
averag
onset
action
prozinc
r
min
min
durat
action
hr
time
peak
activ
hr
hr
blood
glucos
nadir
mgdl
ownersuppli
followup
data
group
cat
reveal
cat
well
prozinc
r
given
twice
daili
cat
treat
daili
prozinc
r
one
cat
becam
euglycem
week
requir
insulin
clinic
sign
includ
plantigrad
stanc
cat
improv
complet
resolv
group
cat
cat
increas
prozinc
r
dose
cat
decreas
prozinc
r
dose
result
glucos
monitor
prozinc
r
effect
lower
blood
glucos
control
clinic
sign
cat
diabet
mellitu
year
onset
action
durat
action
prozinc
r
indic
bid
therapi
optim
control
howev
durat
action
prozinc
r
cat
greater
hour
may
use
per
day
therapi
owner
compli
twice
daili
insulin
administr
diabet
remiss
defin
abil
maintain
euglycemia
without
insulin
administr
occur
newli
diagnos
diabet
cat
provid
tight
glycem
control
institut
earli
diagnosi
howev
approxim
cat
remiss
relaps
requir
insulin
therapi
control
blood
glucos
major
diabet
cat
remiss
impair
glucos
toler
impair
fast
blood
glucos
indic
cat
normal
glucos
metabol
except
document
impair
glucos
toler
metabol
disturb
diabet
cat
remiss
poorli
understood
aim
studi
determin
metabol
profil
cat
remiss
use
ga
chromatographi
mass
spectrometri
gcm
compar
healthi
control
cat
studi
prospect
studi
felineonli
clinic
inclus
diabet
cat
achiev
remiss
insulin
therapi
insulin
withheld
minimum
two
week
remiss
clinic
sign
diabet
present
prior
test
twenti
diabet
cat
remiss
nondiabet
cat
frequencymatch
base
age
bodi
condit
score
particip
studi
blood
sampl
collect
cat
fast
hour
sent
metabolom
analysi
fast
blood
glucos
measur
cat
simplifi
glucos
toler
test
gtt
glucos
gkg
perform
control
cat
remiss
cat
mean
fast
blood
glucos
concentr
glucos
concentr
hour
post
glucos
administr
gtt
significantli
differ
remiss
control
group
twenti
metabolit
identifi
significantli
p
differ
remiss
control
group
major
amino
acid
alanin
asparagin
glutamin
homoserin
leucin
methionin
phenylalanin
prolin
serin
tyrosin
valin
significantli
chang
decreas
neg
correl
glucos
paramet
casual
blood
glucos
fast
blood
glucos
h
read
gtt
return
baselin
gtt
except
glycin
twofold
increas
posit
correl
glucos
paramet
three
fatti
acid
identifi
significantli
differ
adjust
bodi
condit
score
hexadeceno
palmitol
acid
octadecano
stearic
acid
decreas
moder
neg
correl
glucos
paramet
hexadecanoyl
glycerol
increas
littl
correl
glucos
paramet
major
cat
remiss
abl
maintain
normal
fast
blood
glucos
concentr
fast
glucos
concentr
higher
control
cat
analys
mass
spectrometri
sugar
alcohol
xylitol
decreas
remiss
cat
correl
neg
glucos
paramet
organ
acid
aketoglutar
acid
inorgan
acid
phosphor
acid
increas
decreas
respect
significantli
correl
glucos
paramet
urea
also
increas
approxim
remiss
cat
compar
control
cat
even
remov
cat
iri
stage
renal
diseas
posit
correl
hour
glucos
time
return
baselin
summari
promin
metabol
differ
diabet
cat
remiss
compar
control
cat
significantli
decreas
glucogen
amino
acid
neg
correl
increas
fast
glucos
suggest
increas
consumpt
glucogen
amino
acid
gluconeogenesi
increas
urea
may
reflect
urea
byproduct
glucosealanin
cycl
wherebi
muscl
provid
substrat
hepat
gluconeogenesi
pyruv
muscl
convert
alanin
transport
liver
convert
back
pyruv
releas
urea
use
gluconeogenesi
tca
cycl
conclus
result
studi
show
addit
fast
blood
glucos
concentr
glucos
toler
statu
diabet
cat
remiss
rang
metabol
disturb
compar
control
cat
may
reflect
increas
gluconeogenesi
diabet
mellitu
dm
common
endocrin
disord
cat
cat
form
dm
equival
diabet
human
one
new
therapeut
strategi
human
involv
use
synthet
incretin
hormon
includ
exenatid
hormon
agonist
use
alon
adjunct
treatment
insulin
improv
overal
glycem
control
promot
weight
loss
use
exenatid
recent
shown
safe
effect
lower
blood
sugar
concentr
promot
weight
loss
healthi
cat
given
signific
benefit
seen
peopl
similar
natur
diseas
cat
clinic
trial
assess
exenatid
diabet
cat
warrant
primari
object
studi
evalu
efficaci
safeti
combin
shortact
mimet
exenatid
glargin
insulin
protocol
compar
glargin
placebo
protocol
b
treatment
dm
overweight
cat
effect
treatment
protocol
versu
b
serum
concentr
specif
hormon
play
role
glycem
regul
insulin
glucagon
alter
insulin
sensit
resist
leptin
adiponectin
also
determin
doubl
blind
placebocontrol
crossov
design
studi
preform
eight
diabet
cat
bodi
condit
score
bc
without
evid
signific
concurr
diseas
base
routin
screen
test
recruit
cat
treat
glargin
insulin
maintain
stabl
bodi
weight
minimum
one
month
prior
enrol
glycem
paramet
monitor
includ
serum
fructosamin
fast
postprandi
blood
glucos
concentr
mean
blood
glucos
concentr
blood
glucos
curv
bcg
total
daili
dose
tdd
insulin
requir
fast
postprandi
blood
sampl
collect
measur
insulin
glucagon
fast
blood
sampl
leptin
adiponectin
day
arm
studi
assay
use
studi
previous
valid
use
cat
treatment
protocol
well
toler
two
cat
n
display
advers
sign
requir
decreas
dose
exenatid
clinic
sign
includ
anorexia
n
hypoglycemia
n
bgc
five
cat
experienc
asymptomat
hypoglycemia
bg
one
protocol
three
protocol
b
one
protocol
n
two
cat
went
diabet
remiss
protocol
n
averag
chang
tdd
insulin
enrol
unit
unit
unit
protocol
unit
protocol
b
three
cat
decreas
insulin
dose
protocol
wherea
one
cat
decreas
protocol
b
n
fast
blood
glucos
significantli
lower
cat
receiv
protocol
versu
protocol
b
p
averag
chang
bodi
weight
cat
kg
seven
cat
lost
weight
protocol
median
kg
kg
five
cat
gain
weight
protocol
b
kg
kg
signific
differ
hormon
concentr
evalu
cat
protocol
versu
b
two
cat
experienc
clinic
sign
requir
decreas
exenatid
dose
protocol
neither
owner
thought
sign
sever
enough
remov
cat
studi
n
cat
experienc
weight
loss
treatment
protocol
find
signific
treatment
protocol
chang
concentr
hormon
involv
glycem
regul
insulin
sensit
studi
reveal
treatment
protocol
includ
glargin
insulin
fix
dose
mimet
consid
safe
diabet
cat
sinc
weight
gain
common
problem
overweight
diabet
cat
treat
insulin
weight
loss
experienc
protocol
could
signific
benefit
warrant
evalu
treatment
protocol
report
describ
larg
canin
patient
popul
diagnosi
hyperadrenocortic
hac
time
death
concurr
diagnos
mortal
associ
hac
veterinari
teach
hospit
retrospect
studi
evalu
dog
hac
includ
twentyyear
subset
veterinari
medic
databas
signal
hac
presenc
absenc
etiolog
hac
describ
frequenc
comorbid
previous
associ
hac
caus
death
assess
dog
without
hac
frequenc
hac
steadili
increas
increas
age
time
death
hac
frequent
femal
signific
effect
steril
statu
hac
relat
comorbid
caus
death
minor
affect
dog
pdh
common
fat
fat
overrepres
caus
death
hac
death
hac
frequenc
overrepres
expect
miniatur
poodl
dachshund
unexpect
irish
setter
bassett
hound
breed
hac
dog
increas
risk
concurr
diabet
mellitu
urinari
tract
infect
urolithiasi
hypertens
gall
bladder
mucocel
thromboembol
diseas
compar
dog
without
hac
signific
differ
frequenc
skin
infect
ligament
tendon
ruptur
dog
without
hac
result
confirm
hac
significantli
associ
comorbid
condit
hac
signific
caus
mortal
dog
document
pattern
provid
multipl
target
prospect
clinic
research
intervent
glucagon
stimul
test
gst
import
tool
diabet
research
gst
describ
previous
cat
use
purifi
porcin
glucagon
formul
longer
avail
aim
studi
reestablish
protocol
gst
use
commerci
avail
recombinantdna
glucagon
rdglucagon
initi
dose
mcgcat
iv
second
use
five
healthi
cat
describ
kirk
et
al
ajvr
howev
lipsmack
abdomin
contract
occasion
vomit
observ
minut
post
inject
consequ
slower
iv
push
intramuscular
inject
lower
dose
attempt
im
side
effect
observ
howev
dose
result
inadequ
stimul
blood
glucos
concentr
bg
mcgkg
dose
significantli
increas
bg
baselin
mean
minut
preglucagon
bg
mean
ae
sd
ae
mgdl
peak
minut
ae
mgdl
bg
gradual
decreas
minut
return
baselin
minut
plasma
insulin
concentr
also
peak
minut
baselin
ae
ngl
peak
ngl
upper
limit
mercodia
felin
insulin
assay
still
significantli
increas
minut
ae
ngl
return
baselin
minut
conclus
im
inject
mcgkg
recombinantdna
glucagon
healthi
cat
result
peak
bg
insulin
minut
post
inject
without
caus
side
effect
safe
effect
altern
previous
describ
glucagon
stimul
test
cat
marco
thai
grunho
chen
gilor
univers
santo
amaronaya
especialidad
paulo
sp
brazil
univers
santo
amaro
paulo
sp
brazil
ohio
state
univers
columbu
oh
usa
daytoday
variabl
serial
blood
glucos
curv
bgc
imped
balanc
control
clinic
sign
avoid
hypoglycemia
diabet
daytoday
variabl
differ
insulin
formul
previous
report
porcin
lent
dog
report
daytoday
variabl
bgc
well
control
base
stabl
clinic
sign
includ
bodi
weight
dog
treat
humanrecombin
nph
n
insulin
detemir
n
dog
four
success
bgc
perform
home
owner
day
period
insulin
dose
meal
includ
quantiti
type
time
administr
etc
well
blood
sampl
time
remain
unchang
throughout
time
period
record
bg
paramet
includ
bg
obtain
prior
insulin
inject
bg
fast
bg
fast
maximum
bg
max
minimum
nadir
mean
bg
mean
delta
bg
fast
daytoday
variabl
calcul
previous
describ
fleeman
rand
javma
except
dog
paramet
extrem
valu
bgc
use
calcul
maxim
differ
delta
max
paramet
mean
ae
sd
cv
cvsdmean
delta
max
calcul
dog
insulin
group
present
conclus
paramet
mean
maxim
differ
smaller
bgc
detemir
group
compar
nph
group
suggest
overal
lesser
daytoday
variat
insulin
action
greater
confid
interpret
result
bgc
effect
glucosuria
urin
specif
graviti
usg
dog
ellen
behrend
samuel
mueller
denni
chew
holli
lee
auburn
univers
auburn
al
usa
ohio
state
univers
columbu
oh
usa
diabet
patient
histor
polyur
polydips
concentr
urin
addit
gdl
glucos
expect
chang
specif
graviti
water
commonli
held
belief
therefor
concentr
usg
diabet
patient
due
presenc
glucos
renal
concentr
abil
accur
assess
glucosuria
present
howev
effect
glucos
usg
evalu
thu
purpos
studi
assess
chang
usg
relat
degre
glucosuria
consecut
canin
urin
sampl
submit
urinalysi
yellow
glucos
dipstick
evalu
use
sampl
supernat
pool
base
usg
obtain
final
volum
ml
pool
divid
rang
usg
usg
name
rang
b
c
e
f
g
h
respect
five
pool
rang
solut
gml
glucos
ad
aliquot
pool
obtain
final
concentr
mgdl
serial
dilut
perform
remaind
pool
obtain
glucos
concentr
mgdl
usg
measur
undilut
sampl
spike
sampl
handheld
refractomet
reichert
ts
statist
comparison
chang
usg
undilut
sampl
calcul
divid
final
glucos
concentr
gdl
sampl
repeat
measur
anova
rank
use
compar
chang
usg
per
gdl
glucos
usg
rang
post
hoc
comparison
made
tukey
test
median
valu
report
signific
set
p
level
addit
mgdl
mgdl
glucos
chang
usg
per
gdl
glucos
significantli
differ
rang
addit
mgdl
glucos
overal
differ
rang
p
individu
pairwis
differ
identifi
addit
mgdl
glucos
chang
usg
per
gdl
glucos
significantli
differ
rang
chang
h
chang
addit
mgdl
glucos
chang
usg
per
g
dl
glucos
significantli
differ
rang
chang
g
chang
h
chang
chang
addit
mgdl
glucos
chang
usg
per
g
dl
glucos
significantli
differ
rang
chang
g
chang
h
chang
chang
therefor
chang
usg
per
gdl
glucos
significantli
affect
usg
urin
without
glucos
initi
usg
nonglucosur
sampl
increas
chang
creat
addit
glucos
diminish
significantli
addit
chang
usg
creat
presenc
glucos
small
clinic
insignific
thu
even
presenc
glucosuria
accur
estim
renal
concentr
abil
made
aim
studi
compar
new
cortisol
base
method
hour
post
acth
cortisol
measur
monitor
dog
receiv
trilostan
dog
diagnos
hyperadrenocortic
treat
trilostan
recruit
first
opinion
referr
practic
serum
cortisol
measur
time
point
dog
pretrilostan
prepil
hour
posttrilostan
postpil
hour
postacth
post
acth
clinic
control
assess
use
respons
owner
questionnair
nine
question
given
score
maximum
point
avail
total
score
divid
one
four
clinic
group
overcontrol
point
wellcontrol
point
moderatelycontrol
point
poorlycontrol
point
novel
algorithm
combin
prepil
postpil
cortisol
measur
devis
prepost
use
result
post
acth
stimul
cortisol
new
prepost
method
dog
also
place
four
categori
endocrin
control
weight
kappa
calcul
assess
level
agreement
actual
clinic
control
categoris
use
owner
questionnair
score
categoris
endocrin
control
accord
either
post
acth
cortisol
result
prepost
cortisol
result
pearson
correl
coeffici
use
compar
three
absolut
cortisol
result
total
score
owner
questionnair
univari
multivari
regress
analysi
perform
use
dose
frequenc
total
daili
dose
total
durat
therapi
durat
therapi
current
dose
signal
visit
number
weight
variabl
ascertain
effect
three
cortisol
result
total
test
analys
test
post
acth
cortisol
test
higher
prepil
postpil
cortisol
clinic
control
accord
result
owner
questionnair
correctli
categoris
use
post
acth
cortisol
test
compar
prepost
method
correct
test
method
correctli
recognis
one
overcontrol
dog
identifi
owner
score
weight
kappa
endocrin
control
use
postacth
cortisol
compar
owner
questionnair
score
categori
contrast
weight
kappa
prepost
trilostan
categori
compar
owner
questionnair
score
categori
indic
better
agreement
signific
correl
three
cortisol
concentr
best
correl
seen
prepil
postpil
r
p
result
also
signific
weak
correl
pre
r
p
post
r
p
post
acth
r
p
cortisol
total
score
owner
questionnair
multivari
analysi
male
neuter
dog
found
significantli
increas
prepil
cortisol
p
postpil
cortisol
p
compar
femal
entir
dog
dog
respect
dog
receiv
current
dose
month
cortisol
significantli
lower
postpil
p
post
acth
p
cortisol
timepoint
none
variabl
associ
effect
three
cortisol
result
novel
algorithm
prepost
trilostan
cortisol
better
reflect
clinic
control
evidenc
owner
questionnair
hyperadrenocortic
post
acth
stimul
cortisol
prepost
trilostan
cortisol
investig
monitor
tool
dog
receiv
trilostan
cat
nonthyroid
ill
nti
may
result
decreas
total
thyroxin
concentr
similar
euthyroid
sick
syndrom
dog
pathogenesi
phenomenon
complet
understood
may
involv
suppress
thyroid
stimul
hormon
tsh
reduc
thyroid
hormon
protein
bind
although
high
tsh
normal
concentr
report
human
chronic
kidney
liver
heart
diseas
low
serum
concentr
tsh
commonli
develop
sever
nti
human
serum
tsh
concentr
evalu
cat
nti
except
small
number
cat
mild
chronic
kidney
diseas
tsh
level
normal
object
studi
measur
tsh
larger
seri
cat
suffer
varieti
mildtosever
nti
determin
spectrum
tsh
concentr
report
human
also
develop
cat
serum
free
equilibrium
dialysi
tsh
concentr
measur
clinic
healthi
cat
cat
present
evalu
nti
median
concentr
tsh
compar
use
mannwhitney
u
test
p
consid
signific
sick
cat
ill
grade
mild
outpati
exam
n
moder
short
hospit
treatabl
condit
n
sever
intens
hospit
associ
substanti
morbiditymort
n
diseas
sick
cat
includ
cardiac
n
endocrin
n
hepat
n
infecti
n
neoplast
n
renal
n
respiratori
n
n
disord
median
serum
concentr
lgdl
vs
lgdl
pmoll
vs
pmoll
significantli
p
lower
sick
cat
compar
healthi
cat
respect
howev
signific
differ
median
tsh
concentr
detect
ill
healthi
cat
figur
compar
sick
cat
mild
diseas
cat
sever
ill
significantli
p
lower
median
serum
concentr
tsh
figur
one
cat
mild
neoplast
diseas
high
tsh
concentr
normal
identifi
figur
conclus
data
demonstr
median
serum
concentr
lower
sick
compar
healthi
cat
paramet
may
invers
correl
diseas
sever
overal
tsh
concentr
sick
cat
significantli
differ
healthi
cat
howev
tsh
level
cat
may
decreas
sever
ill
may
occasion
high
similar
find
human
nti
object
evalu
use
baselin
cortisol
predict
result
acthstimul
cortisol
concentr
popul
dog
pituitarydepend
hyperadrencortic
pdh
treat
twicedaili
trilostan
vetoryl
medic
record
dog
pdh
treat
twicedaili
trilostan
therapi
review
retrospect
result
acth
stimul
test
classifi
indic
inadequ
accept
excess
suppress
cortisol
product
detail
regard
clinic
visit
record
includ
comorbid
condit
clinic
sign
clinician
decis
regard
trilostan
dose
increas
chang
decreas
baselin
cortisol
concentr
evalu
correl
acthstimul
cortisol
concentr
clinician
decis
determin
predict
valu
twentytwo
dog
total
acth
stimul
test
evalu
use
baselin
cortisol
concentr
cutoff
lgdl
greater
result
neg
predict
valu
acthstimul
cortisol
concentr
would
indic
excess
suppress
howev
acth
stimul
test
baselin
concentr
cutoff
poststimul
cortisol
concentr
less
baselin
addit
substanti
overlap
baselin
cortisol
concentr
compar
clinician
decis
regard
trilostan
dose
exist
baselin
cortisol
concentr
popul
patient
predict
acthstimul
cortisol
greater
ugdl
howev
cutoff
guarante
accept
adren
reserv
capac
control
clinic
sign
therefor
routin
use
baselin
cortisol
sole
monitor
diagnost
trilostanetr
pdh
patient
recommend
hypertens
common
find
older
cat
varieti
underli
reason
hypertens
suggest
includ
hyperthyroid
estim
around
hypertens
diagnosi
literatur
date
predominantli
consist
studi
use
doppler
technolog
diastol
blood
pressur
determin
addit
studi
use
age
match
control
group
assess
data
blood
pressur
measur
use
hdo
sb
medvet
babenhausen
germani
oscillometr
devic
trace
visual
evalu
use
provid
softwar
assess
blood
pressur
curv
qualiti
adequ
amplitud
lack
signific
artifact
cat
measur
minim
restraint
cuff
place
tail
seri
read
taken
till
least
verifi
read
obtain
total
hyperthryoid
age
match
nonhyperthyroid
control
avail
analysi
systol
blood
pressur
hyperthyroid
mean
ae
mmghg
control
ae
mmhg
diastol
blood
pressur
hyperthyroid
mean
ae
control
ae
mean
blood
pressur
hyperthyroid
mean
ae
control
ae
heart
rate
hyperthyroid
mean
ae
control
ae
differ
base
pair
ttest
cat
blood
pressur
valu
categor
use
acvim
consensu
statement
valu
risk
target
organ
damag
systol
mild
moder
sever
diastol
mild
moder
sever
signific
differ
group
systol
blood
pressur
use
chisquar
p
accord
classif
hyperthyroid
group
sever
moder
mild
case
wherea
control
group
one
case
sever
moder
mild
hyperthyroid
group
diastol
blood
pressur
moder
mild
case
present
wherea
control
group
case
moder
case
mild
data
show
group
older
cat
hyperthryoid
cat
similar
blood
pressur
similar
percentag
cat
consid
risk
target
organ
damag
control
cat
hyperthyroid
cat
base
systol
blood
pressur
howev
hyperthyroid
group
higher
percentag
cat
sever
risk
target
organ
damag
diastol
risk
target
organ
damag
common
hyperthyroid
group
vs
though
gener
moder
mild
aim
studi
evalu
epidemiolog
characterist
adren
tumor
dog
retrospect
studi
conduct
base
clinic
record
consid
age
breed
sex
clinic
sign
laboratori
find
hormon
test
medic
surgic
treatment
histolog
find
surviv
dog
diagnos
januari
novemb
naya
especialidad
veterinari
clinic
among
dog
diagnos
femal
mean
age
ae
year
fortyfour
dog
purebr
mainli
shih
tzu
lhasa
apso
dachshund
mean
bodi
weight
ae
kg
median
kg
rang
kg
bodi
weight
kg
dog
polyuria
polydipsia
polyphagia
abdomin
distens
frequent
clinic
sign
increas
alp
alt
hyperlipidemia
low
urinari
densiti
thrombocytosi
hypertens
report
diagnosi
adrenaldepend
hyperadrenocortic
basi
nonsuppress
serum
cortisol
concentr
use
ldd
test
inappropri
high
serum
cortisol
concentr
acth
stimul
observ
respect
fortyeight
per
cent
dog
right
left
bilater
adrenalectomi
perform
dog
histolog
find
reveal
adenoma
carcinoma
pheocromocitoma
dog
twenti
dog
treat
trilostan
therapi
dog
still
aliv
year
follow
primari
incid
may
increas
especi
small
dog
kg
cortex
adren
tumor
common
anim
may
asymptomat
neg
ldd
acth
stimul
test
therapi
adrenalectomi
trilostan
encourag
pancreat
common
exocrin
pancreat
diseas
dog
multifactori
etiolog
endocrin
abnorm
hyperlipidemia
consid
risk
factor
aim
studi
investig
associ
acut
pancreat
diabet
mellitu
dm
confirm
hyperadrenocortic
hac
possibl
hac
adrenomegali
ultrasound
without
previou
diagnosi
hac
hypothyroid
hypot
hypertriglyceridemia
hypertri
hypercholesterolemia
hyper
chol
retrospect
studi
perform
dog
admit
privat
veterinari
hospit
paulo
brazil
dog
symptom
sonograph
diagnosi
pancreat
year
group
n
control
group
dog
without
sonograph
pancreat
alter
chronic
kidney
diseas
group
n
studi
past
histori
evalu
diagnosi
diabet
blood
glucos
mgdl
posit
glycosuria
hac
cortisol
low
dose
dexamethason
ugdl
post
acth
ugdl
hypot
thyroidstimul
hormon
ngml
dialysi
free
thyroxin
ngdl
fast
triglycerid
cholesterol
measur
hospit
identifi
presenc
hypertri
triglycerid
mgdl
hyperchol
cholesterol
mgdl
twentyon
dog
group
hypertri
hyperchol
adrenomegali
nine
diagnos
dm
five
diagnos
hac
two
diagnos
hypot
group
dog
hyperchol
five
hypertri
two
adrenomegali
two
diagnos
hac
two
diagnos
hypot
one
diagnos
dm
dm
adrenomegali
hypertri
show
signific
associ
p
pancreat
inclus
variabl
dm
logist
regress
model
show
signific
mainli
due
colinear
variabl
hypertri
dog
hypertri
adrenomegali
increas
odd
ratio
respect
confid
interv
pancreat
result
studi
suggest
hypertri
possibl
hac
repres
adrenomegali
associ
pancreat
dog
associ
suggest
develop
acut
pancreat
ap
concurr
endocrinopathi
includ
diabet
mellitu
dm
hyperadrenocortic
hac
hypothyroid
although
conclus
data
avail
confirm
moreov
much
debat
whether
hormon
imbal
directli
affect
develop
ap
andor
whether
hyperlipidemia
induc
endocrinopathi
might
play
role
object
present
studi
examin
preval
ap
dog
endocrinopathi
examin
associ
endocrinopathi
hyperlipidemia
dog
ap
medic
record
dog
newlydiagnos
ap
examin
presenc
absenc
hac
dm
hypothyroid
two
ageand
breedmatch
random
control
ap
dog
examin
endocrinopathi
match
casecontrol
analysi
perform
associ
hyperlipidemia
endocrinopathi
ap
group
subsequ
evalu
use
binari
logist
regress
analysi
dog
hac
odd
ap
time
dog
without
hac
dog
dm
odd
time
dog
without
dm
addit
signific
associ
presenc
dm
hyperlipidemia
ap
group
studi
show
hyperlipidemia
caus
dm
associ
ap
dog
associ
observ
hac
hyperlipidemia
dog
ap
howev
studi
necessari
clarifi
preval
ap
dog
dm
hac
dysregul
adipokin
describ
human
cardiovascular
diseas
inform
lack
concentr
circul
adipokin
dog
myxomat
mitral
valv
diseas
mmvd
object
casecontrol
observ
studi
determin
whether
serum
adipokin
concentr
differ
healthi
dog
dog
mmvd
initi
preliminari
studi
perform
clientown
dog
mmvd
healthi
dog
bodi
condit
score
sever
adipokin
measur
base
preliminari
result
serum
leptin
adiponectin
concentr
reevalu
dog
newlydiagnos
mmvd
divid
group
accord
intern
small
anim
cardiac
health
council
isachc
classif
preliminari
studi
serum
leptin
adiponectin
concentr
differ
significantli
dog
mmvd
healthi
dog
regardless
whether
congest
heart
failur
sign
absent
signific
differ
concentr
interleukin
il
tumor
necrosi
factora
resistin
visfatin
subsequ
studi
dog
classifi
isachc
class
iii
significantli
show
highest
serum
concentr
leptin
adiponectin
result
indic
dog
suffer
progress
mmvd
show
increas
serum
concentr
leptin
adiponectin
result
suggest
dysregul
adiponectin
leptin
might
least
play
role
pathogenesi
mmvd
dog
howev
studi
necessari
associ
adipokin
progress
mmvd
clearli
understood
diabet
mellitu
common
endocrinopathi
cat
character
impair
betacel
function
loss
current
knowledg
molecular
mechan
neg
affect
beta
cell
function
viabil
obtain
vitro
speci
cat
although
felin
diabet
similar
human
type
diabet
speciesdepend
differ
pathophysiolog
diseas
may
exist
therefor
establish
method
isol
cultur
pure
pancreat
islet
cat
aim
provid
vitro
tool
specif
diabet
research
cat
cat
die
euthan
endstag
disord
pancreat
diseas
includ
studi
initi
test
evalu
best
pancreat
infus
techniqu
pancreata
nine
cat
infus
within
one
hour
death
ml
collagenas
type
iv
mgml
worthington
major
duoden
papilla
perfus
pancrea
digest
shake
water
bath
degre
dissoci
islet
acinar
tissu
check
everi
min
examin
dithizon
specif
stain
zncomplex
beta
cell
phasecontrast
microscop
collagenas
digest
stop
nearli
islet
free
acinar
tissu
purif
islet
achiev
use
filtrat
method
discontinu
densiti
gradient
solut
biochrom
qualiti
puriti
final
islet
product
assess
dtz
stain
islet
viabil
assess
visual
assess
membran
integr
islet
cell
doubl
fluoresc
stain
fluorescein
diacet
propidium
iodid
fdapi
vitro
function
activ
purifi
islet
evalu
measur
amount
insulin
releas
mercodia
felin
insulin
upon
glucos
stimul
perfus
pancrea
situ
major
duoden
papilla
allow
complet
perfus
pancrea
compar
previous
describ
ex
situ
techniqu
markedli
improv
islet
yield
puriti
digest
time
rang
islet
yield
puriti
viabil
directli
depend
proport
perfus
pancrea
pancrea
perfus
situ
via
major
papilla
higher
quantiti
qualiti
islet
compar
infus
method
digest
felin
pancreat
islet
remain
viabl
day
amount
insulin
secret
upon
glucos
stimul
compar
achiev
mice
studi
current
studi
success
optim
isol
purif
felin
pancreat
islet
function
potenc
islet
upon
glucos
stimul
assess
first
time
speci
accord
find
yield
qualit
function
islet
may
provid
promis
sourc
islet
diabet
research
cat
mirtazapin
noradrenerg
specif
serotonerg
antidepress
shown
suppress
hypothalamicpituitari
adrenocort
hpa
axi
human
littl
inform
avail
effect
mirtazapin
hpa
axi
dog
object
present
studi
examin
whether
healthi
beagl
dog
endogen
adrenocorticotrop
hormon
acth
cortisol
concentr
affect
oral
administr
mirtazapin
laboratori
beagl
dog
oral
administr
mirtazapin
mgkg
maintain
daili
day
corticotropin
releas
hormon
crh
stimul
test
acth
stimul
test
perform
administr
day
day
administr
respect
circul
concentr
cortisol
acth
serotonin
leptin
measur
administr
mirtazapin
significantli
reduc
postcrh
acth
concentr
cortisol
concentr
postacth
cortisol
concentr
significantli
reduc
administr
mirtazapin
signific
differ
basal
acth
cortisol
concentr
reveal
serum
serotonin
concentr
significantli
increas
administr
mirtazapin
leptin
concentr
reduc
significantli
mirtazapin
administr
period
lowest
level
observ
day
result
suggest
mirtazapin
shortterm
suppress
effect
hpa
axi
healthi
dog
addit
serum
serotonin
leptin
level
might
influenc
mirtazapin
administr
effect
gastrointestin
parasit
viral
agent
fecal
concentr
puppi
romi
heilmann
aurelien
grellet
niel
utzner
jan
suchodolski
org
steiner
texa
univers
colleg
station
texa
usa
royal
canin
aimargu
franc
vetsuiss
univers
bern
bern
switzerland
previou
data
suggest
may
clinic
use
biomark
inflamm
human
dog
dog
chronic
gastrointestin
gi
diseas
fecal
concentr
increas
correl
sever
clinic
diseas
endoscop
chang
observ
intestin
sever
histolog
lesion
colon
higher
fecal
concentr
also
correl
neg
outcom
dog
inflammatori
bowel
diseas
howev
effect
gi
pathogen
fecal
concentr
dog
yet
report
inform
import
evalu
clinic
util
fecal
marker
gi
inflamm
thu
aim
studi
evalu
effect
presenc
number
parasit
well
viral
agent
known
caus
gi
sign
dog
fecal
concentr
larg
cohort
puppi
spot
fecal
sampl
collect
puppi
median
age
rang
week
differ
breed
french
breed
kennel
fecal
score
semiquantit
system
score
assign
fecal
sampl
test
isospora
spp
cani
ohioensi
toxocara
cani
giardia
sp
well
canin
coronaviru
ccv
parvoviru
cpv
quantit
realtim
pcr
qpcr
concentr
measur
fecal
sampl
use
establish
valid
inhous
ria
statist
analysi
perform
use
nonparametr
multiplegroup
comparison
nonparametr
correl
analysi
fecal
concentr
rang
ngg
significantli
higher
concentr
seen
dog
infect
isospora
spp
p
infect
cani
p
giardia
p
ccv
p
cpv
p
also
number
cani
p
ohioensi
p
cani
p
giardia
p
ccv
p
andor
cpv
p
influenc
fecal
concentr
age
found
affect
fecal
p
concentr
fecal
score
invers
correl
spearman
p
conclud
independ
number
presenc
parasit
genera
isospora
spp
lead
increas
fecal
concentr
wherea
toxocara
cani
giardia
sp
viral
pathogen
ccv
cpv
affect
fecal
result
puppi
thu
infect
isospora
spp
appear
import
differenti
dog
increas
fecal
concentr
etiolog
need
rule
prior
use
fecal
concentr
marker
diagnosismonitor
patient
chronic
gi
inflamm
associ
fecal
score
level
clinic
implic
whether
current
result
translat
adult
dog
warrant
research
caninespecif
pancreat
lipas
immunoreact
cpli
consid
specif
serum
biomark
diagnosi
pancreat
dog
report
week
oral
administr
prednison
mgkg
q
h
dog
significantli
affect
serum
cpli
concentr
steiner
et
al
howev
effect
longterm
exogen
glucocorticoid
administr
without
azathioprin
cpli
concentr
unknown
purpos
studi
determin
whether
prolong
exogen
glucocorticoid
administr
without
azathioprin
alter
cpli
concentr
dog
immunemedi
diseas
sixteen
clientown
dog
newli
diagnos
immunemedi
diseas
enrol
octob
octob
dog
clinic
sign
pancreat
eg
vomit
diarrhea
anorexia
studi
period
increas
cpli
spec
cpl
test
spec
concentr
present
prednisolon
administr
prior
referr
exclud
prednisolon
dosag
start
mgkgday
thereaft
gradual
decreas
everi
week
azathioprin
dosag
start
maintain
mgkgday
studi
period
preand
posttreat
sera
revisit
obtain
serial
measur
spec
peak
spec
concentr
studi
period
record
result
peak
spec
concentr
categor
normal
lgl
question
lgl
abnorm
lgl
serial
measur
spec
concentr
stop
spec
concentr
exce
upper
measur
limit
lgl
spec
concentr
decreas
previou
revisit
prednisolon
dosag
administ
less
mgkg
q
h
dosag
prednisolon
time
peak
spec
concentr
dog
also
record
comparison
peak
spec
concentr
prednisolon
alon
pred
group
prednisolon
azathioprin
predaza
group
perform
use
mannwhitney
utest
comparison
dosag
prednisolon
pred
predaza
group
perform
use
student
ttest
seven
dog
receiv
prednisolon
alon
pred
group
diagnos
immunemedi
polyarthr
impa
n
inflammatori
bowel
diseas
ibd
n
meningoenceph
unknown
etiolog
muo
n
inflammatori
colorect
polyp
icrp
n
combin
prednisolon
dog
also
receiv
azathioprin
predaza
group
consist
dog
muo
dog
impa
median
rang
studi
period
day
pred
group
peak
spec
concentr
classifi
normal
dog
muo
question
dog
ibd
abnorm
dog
impa
muo
icrp
predaza
group
peak
spec
concentr
classifi
normal
dog
muo
impa
question
dog
muo
abnorm
dog
impa
median
rang
time
reach
peak
spec
concentr
dog
day
pred
predaza
group
respect
peak
spec
concentr
significantli
p
higher
pred
group
median
lgl
rang
lgl
compar
predaza
group
median
lgl
rang
lgl
prednisolon
dosag
time
peak
spec
concentr
slightli
higher
pred
group
mean
ae
sd
ae
mgkg
compar
predaza
group
meanaesd
ae
mgkg
although
increas
signific
studi
demonstr
oral
prednisolon
administr
dog
natur
occur
immunemedi
diseas
could
caus
variou
degre
increas
spec
concentr
therefor
abnorm
spec
concentr
dog
receiv
prolong
oral
prednisolon
interpret
cautious
concurr
administr
azathioprin
increas
spec
concentr
increas
observ
administr
prednisolon
alon
probiot
administr
often
recommend
patient
gastrointestin
gi
diseas
goal
balanc
microbi
popul
intestin
tract
despit
aim
actual
impact
probiot
formul
intestin
microbiota
elucid
variou
studi
evalu
probiot
formul
contain
dose
rang
coloni
form
unit
cfu
demonstr
minor
transient
chang
bacteri
group
supplement
period
sivoy
tm
high
dose
probiot
cocktail
contain
mix
strain
lactobacillu
spp
bifidobaterium
spp
streptococcu
spp
total
billion
cfu
shown
antiinflammatori
properti
vivo
previou
studi
anim
model
howev
impact
fecal
microbiom
current
unknown
therefor
aim
studi
character
fecal
microbiom
healthi
dog
administ
probiot
sivoy
healthi
dog
random
receiv
either
probiot
sivoy
n
placebo
n
fecal
sampl
collect
baselin
day
supplement
dna
extract
use
zr
fecal
dna
kit
tm
zymo
research
corpor
irvin
ca
fecal
microbiota
analyz
illumina
sequenc
rrna
gene
quantit
pcr
perform
lactobacillu
spp
bifidobacterium
spp
e
coli
c
perfringen
streptococcu
spp
sequenc
percentag
qpcr
data
time
point
evalu
use
wilcoxon
ranksum
test
determin
differ
microbi
commun
group
analysi
similar
anosim
function
qiim
pipelin
version
use
base
unweight
unifrac
distanc
matrix
statist
signific
set
p
overal
microbi
commun
significantli
alter
either
placebo
probiot
group
bacteri
speci
rich
also
significantli
differ
either
placebo
probiot
group
quantit
pcr
reveal
streptococcu
spp
bifidobacterium
spp
significantli
increas
vs
probiot
group
median
log
dna
pvalu
vs
vs
respect
differ
bacteri
abund
base
qpcr
data
two
time
point
placebo
group
conclus
studi
reveal
increas
abund
streptococcu
spp
bifidobacterium
spp
fece
healthi
dog
receiv
probiot
sivoy
studi
may
warrant
evalu
effect
probiot
microbi
composit
within
upper
gi
tract
tritrichomona
foetu
tf
flagel
protozo
pathogen
respons
chronic
diarrhea
reproduct
failur
domest
felid
cattl
respect
safe
efficaci
prevent
treatment
felin
trichomonosi
previou
studi
identifi
two
surfac
antigen
express
bovin
tf
promot
surviv
pathogen
toward
host
epithelium
bovin
felin
tf
highli
similar
therefor
surfac
epitop
may
conserv
tf
genotyp
may
provid
similar
pathogen
benefit
felin
tf
studi
aim
determin
felin
tf
express
neutral
antigen
monoclon
antibodi
mab
amelior
intestin
epitheli
cell
destruct
indirect
enzymelink
immunosorb
assay
elisa
develop
semiquantit
evalu
abil
two
monoclon
antibodi
mab
target
bovin
tf
surfac
antigen
mab
recogn
felin
tf
elisa
posit
defin
two
standard
deviat
mean
neg
control
qualit
assess
perform
use
dot
blot
analysi
cocultur
porcin
intestin
epitheli
cell
mab
tf
perform
evalu
effect
surfac
antigen
intestin
epitheli
cytotox
bovin
tf
pentatrichomona
homini
ph
isol
use
posit
neg
control
respect
assay
perform
minimum
triplic
data
analyz
use
systat
p
felin
tf
identifi
express
surfac
protein
indirect
elisa
dot
blot
analysi
result
confirm
bovin
tf
immunodetect
assay
treatment
felin
tf
isol
mab
result
amelior
tfinduc
intestin
epitheli
destruct
compar
cell
infect
vehicletr
felin
tf
studi
demonstr
presenc
surfac
antigen
felin
tf
isol
antigen
particip
pathogen
felin
tf
conserv
across
multipl
isol
may
repres
novel
target
develop
vaccin
andor
rapid
bedsid
diagnost
assay
cyniclomyc
guttulatu
cg
gastrointestin
yeast
rabbit
cg
also
observ
fece
dog
gener
presum
cg
dog
nonpathogen
pass
organ
reflect
dog
consumpt
rabbit
fece
howev
clinic
signific
cg
infect
dog
remain
unclear
purpos
studi
determin
cytopatholog
characterist
clinic
pathologist
percept
pathogen
cg
observ
fecal
sampl
submit
us
commerci
veterinari
diagnost
facil
cytolog
report
gener
antech
diagnost
search
use
keyword
cyniclomyc
report
pertain
dog
cg
identifi
fecal
rectal
cytolog
review
patient
sex
age
breed
season
region
descript
refer
presenc
bacteri
dysbiosi
rbc
wbc
inflamm
mucu
organ
well
abund
low
moder
mark
perceiv
pathogenesi
pathogen
pathogen
uncertain
pathogen
cg
present
also
record
compar
purpos
similar
data
extract
fecal
rectal
cytolog
report
subset
dog
cg
identifi
subset
dog
enter
yeast
identifi
fisher
exact
test
use
examin
relationship
abund
cg
report
cytolog
find
well
calcul
odd
ratio
compar
dog
cg
two
differ
control
group
logist
regress
model
use
estim
probabl
odd
ratio
cytolog
find
given
exist
cg
adjust
relev
variabl
cyniclomyc
identifi
canin
cytolog
report
gener
antech
studi
interv
sixti
four
percent
n
sampl
fecalrect
cytolog
among
dog
cg
identifi
fecal
rectal
cytolog
signific
posit
associ
abund
cg
presenc
wbc
p
total
dog
fecalrect
cytolog
without
cg
report
identifi
use
control
yeast
present
n
enter
yeast
present
n
control
dog
time
like
concurr
bacteri
dysbiosi
ci
p
dog
cg
dog
cg
time
ci
p
like
wbc
time
ci
p
like
inflamm
present
fecal
rectal
cytolog
compar
control
dog
enter
yeast
identifi
signific
associ
observ
presenc
cg
fecalrect
cytolog
patient
sex
age
breed
season
region
n
canin
fecalrect
cytolog
report
cg
identifi
clinic
pathologist
opin
pathogen
cg
express
opinion
cg
nonpathogen
uncertain
pathogen
clinic
pathologist
complet
multipl
report
equivoc
among
report
common
correl
abund
cg
present
result
suggest
cg
significantli
associ
concurr
fecal
cytolog
evid
gastrointestin
inflamm
dog
pathogen
cg
howev
remain
enigma
base
result
investig
cg
pathogen
effect
dog
may
justifi
studi
would
aid
determin
signific
cg
whether
treatment
infect
warrant
dog
gastrointestin
diseas
biliari
sludg
associ
gallbladd
gb
dysmotil
mucu
hypersecret
suggest
factor
may
lead
gb
mucocel
biliari
sludg
progress
gb
mucocel
treatment
reduc
progress
sludg
warrant
aim
studi
determin
natur
histori
biliari
sludg
dog
use
serial
ultrasonograph
biochem
examin
seventyfour
healthi
dog
underw
ultrasonographi
fortytwo
biliari
sludg
subsequ
reevalu
threemonth
interv
one
year
follow
determin
percentag
gb
fill
sludg
mild
moder
moder
sever
sever
graviti
depend
sludg
gb
dimens
biochem
indic
alt
ggt
alp
total
bilirubin
triglycerid
cholesterol
mix
model
anova
friedman
chisquar
mantelhaenzsel
chisquar
test
kruskalw
test
perform
detect
signific
chang
paramet
year
followup
percentag
gb
fill
sludg
mild
moder
moder
sever
sever
signific
differ
time
preval
nongrav
depend
sludg
significantli
increas
p
dog
resolv
decreas
persist
increas
recurr
sludg
conclus
studi
biochem
indic
gb
volum
significantli
differ
time
among
group
biliari
sludg
preval
remain
asymptomat
rare
resolv
healthi
dog
period
year
gallbladd
content
becam
less
graviti
depend
may
indic
chang
consist
time
role
mast
cell
major
secretori
product
histamin
chronic
gastrointestin
diseas
crohn
diseas
ulcer
coliti
intens
investig
last
two
decad
human
medicin
histamin
releas
follow
mast
cell
activ
exert
action
bind
four
differ
histamin
receptor
histamin
receptor
dispers
throughout
bodi
differ
receptor
mediat
uniqu
respons
bodi
document
presenc
type
histamin
receptor
canin
gastrointestin
tract
provid
addit
research
opportun
explor
role
histamin
receptor
chronic
canin
enteropathi
well
therapeut
potenti
histamin
receptor
antagonist
full
thick
gastric
duoden
jejun
ileal
colon
biopsi
obtain
clinic
normal
healthi
adult
dog
immedi
human
euthanasia
immunohistochemistri
perform
use
commerci
avail
rabbit
andor
goat
histaminereceptor
antibodi
predict
react
canin
tissu
formalinfix
paraffin
embed
tissu
section
use
refin
avidinbiotin
detect
techniqu
tissu
evalu
light
microscopi
identifi
presenc
histolog
distribut
receptor
gastrointestin
tract
formalinfix
tissu
grade
canin
mast
cell
tumor
use
posit
control
stain
intens
immunoreact
histamin
receptor
gastrointestin
tract
qualit
grade
neg
weak
moder
strong
determin
differ
histamin
receptor
score
among
superfici
deep
mucosa
submucosa
lymphoid
tissu
smooth
muscl
ganglia
section
gastrointestin
tract
method
similar
nonparametr
friedman
test
conduct
specif
antibodi
evalu
use
western
blot
techniqu
tissu
lysat
canin
gastrointestin
tract
presenc
distribut
receptor
vari
among
tissu
cell
type
within
canin
gastrointestin
tract
receptor
locat
epitheli
cell
superfici
mucosa
gland
deep
mucosa
stomach
lymphoid
tissu
ileum
smooth
muscl
ganglia
tissu
receptor
stain
intens
significantli
greater
gastric
gland
deep
mucosa
epitheli
cell
superfici
mucosa
receptor
locat
superfici
mucos
epitheli
cell
deep
mucos
cell
intestin
gland
lymphoid
tissu
ganglia
duodenum
jejunum
ileum
colon
tissu
receptor
locat
smooth
muscl
ganglia
receptor
also
locat
ileal
colon
lymphoid
tissu
receptor
stain
intens
significantli
greater
epitheli
cell
colon
gastric
superfici
mucosa
compar
deep
mucos
cell
tissu
receptor
identifi
duoden
ileal
jejun
mucosa
except
one
dog
weak
stain
jejun
deep
mucosa
receptor
locat
ganglia
lymphoid
tissu
occasion
gastric
gland
deep
mucosa
densiti
distribut
receptor
gastrointestin
tract
decreas
comparison
histamin
receptor
western
blot
demonstr
specif
nonspecif
stain
receptor
antibodi
good
specif
receptor
antibodi
receptor
antibodi
compat
western
blot
techniqu
despit
excel
immunohistochem
specif
consist
histamin
receptor
identifi
canin
gastrointestin
tract
receptor
greater
distribut
receptor
valid
immunohistochem
techniqu
receptor
antibodi
success
addit
valid
method
receptor
antibodi
warrant
despit
nonspecif
stain
receptor
antibodi
western
blot
distribut
receptor
canin
gastrointestin
tract
similar
seen
human
gastrointestin
tract
studi
compar
densiti
distribut
receptor
dog
gastrointestin
diseas
need
intestin
dysbiosi
dog
defin
rel
shift
bacteri
popul
gastrointestin
tract
git
associ
chronic
enteropathi
ce
group
previous
report
small
intestin
fecal
dysbiosi
decreas
speci
rich
canin
spontan
inflammatori
bowel
diseas
howev
due
function
redund
bacteri
group
determin
biochem
chang
git
requir
direct
analysi
biomolecul
present
studi
aim
evalu
differ
fecal
metabolit
profil
dog
chronic
gastrointestin
inflamm
healthi
control
dog
fecal
sampl
collect
dog
histopatholog
evid
gastrointestin
inflamm
n
healthi
control
dog
n
fecal
metabolom
compris
metabol
product
host
microbiota
assess
use
untarget
approach
combin
lcm
gcm
platform
random
forest
analysi
use
rank
differenti
power
metabolit
mannwhitney
utest
follow
benjaminihochberg
adjust
pvalu
multipl
comparison
use
test
statist
signific
q
total
name
biochem
compound
identifi
significantli
alter
adjust
multipl
comparison
q
among
major
metabol
pathway
metabolit
associ
git
redox
homeostasi
alter
includ
significantli
increas
concentr
precursor
glutathion
q
cystein
q
glycin
q
cglutamyl
amino
acid
deriv
lysin
phenylalanin
valin
leucin
q
primari
bile
acid
gener
increas
dog
diseas
cholat
q
chenodeoxychol
q
secondari
bile
acid
gener
decreas
dog
chronic
enteropathi
deoxychol
q
lithochol
q
suggest
impair
bacteri
convers
primari
secondari
bile
acid
metabolit
within
aromat
amino
acid
biosynthesi
pathway
exhibit
signific
alter
tryptophan
metabolit
indoleacet
indolepropion
significantli
decreas
dog
diseas
q
respect
oxid
degrad
product
indoleacet
decreas
diseas
anim
q
toprank
discrimin
power
detect
metabolit
studi
demonstr
fece
rich
sampl
matrix
biomolecul
repres
host
microbi
metabolit
profil
sever
metabolit
identifi
may
investig
futur
biomark
may
help
elucid
etiopathogenesi
canin
chronic
enteropathi
cobalamin
b
folat
b
watersolubl
vitamin
essenti
compon
onecarbon
metabol
vitamin
influenc
biochem
process
includ
homocystein
remethyl
cycl
transsulfur
pathway
well
known
cobalamin
defici
alter
folat
metabol
decreas
intestin
absorpt
folat
also
increas
serum
folat
concentr
observ
dog
small
intestin
dysbiosi
previou
studi
compar
chang
serum
amino
acid
concentr
healthi
dog
hypocobalaminem
dog
dog
biochem
evid
cobalamin
defici
shown
signific
differ
serum
concentr
glycin
glutam
acid
methionin
tyrosin
tryptophan
lysin
dog
hypocobalaminemia
aim
studi
investig
chang
serum
amino
acid
concentr
healthi
normocobalaminem
dog
hypocobalaminem
dog
decreas
increas
serum
folat
concentr
fresh
serum
sampl
healthi
dog
n
collect
use
perform
serum
chemistri
profil
measur
serum
cobalamin
folat
concentr
healthi
dog
serum
cobalamin
folat
concentr
within
respect
refer
interv
ngl
lgl
surplu
serum
sampl
hypocobalaminem
serum
cobalamin
ngl
dog
prospect
enrol
nineteen
hypocobalaminem
dog
also
decreas
serum
folat
concentr
serum
folat
lgl
low
b
wherea
twelv
increas
serum
folat
concentr
serum
folat
lgl
high
b
previous
valid
ga
chromatographymass
spectrometri
method
use
quantifi
serum
glycin
glutam
acid
methionin
tyrosin
tryptophan
lysin
concentr
kruskalw
test
dunn
posttest
perform
compar
concentr
six
amino
acid
amongst
healthi
dog
dog
hypocobalaminemia
decreas
increas
serum
folat
concentr
result
summar
tabl
diseas
group
letter
row
statist
significantli
differ
pvalu
consid
signific
conclus
signific
differ
serum
amino
acid
concentr
observ
healthi
dog
hypocobalaminem
dog
either
decreas
increas
serum
folat
concentr
result
suggest
alter
absorpt
metabol
andor
degrad
amino
acid
associ
chronic
intestin
diseas
dog
chronic
intestin
diseas
exocrin
pancreat
insuffici
epi
common
caus
cobalamin
defici
associ
decreas
intestin
absorpt
cobalamin
also
reduc
avail
sever
amino
acid
digest
directli
affect
amount
pancreat
enzym
avail
food
breakdown
gastrointestin
tract
alter
amino
acid
concentr
variou
amino
acid
ie
glycin
glutam
acid
tyrosin
methionin
lysin
tryptophan
describ
human
gastrointestin
exocrin
pancreat
disord
aim
studi
investig
chang
serum
amino
acid
concentr
healthi
normocobalaminem
dog
hypocobalaminem
dog
without
epi
fresh
serum
sampl
healthi
dog
n
collect
physic
examin
use
perform
serum
chemistri
profil
measur
serum
cobalamin
canin
trypsinlik
immunoreact
ctli
concentr
healthi
dog
serum
cobalamin
ctli
concentr
within
respect
refer
interv
ngl
lgl
diseas
group
hypocobalaminem
serum
cobalamin
concentr
ngl
low
b
prospect
enrol
group
hypocobalaminem
dog
without
epi
group
hypocobalaminem
dog
epi
ctli
concentr
lgl
epi
enrol
previous
valid
ga
chromatographymass
spectrometri
method
use
quantifi
serum
glycin
glutam
acid
methionin
tyrosin
tryptophan
lysin
concentr
dog
enrol
kruskalw
test
dunn
posttest
perform
compar
concentr
six
amino
acid
amongst
healthi
dog
hypocobalaminem
dog
without
epi
result
summar
tabl
b
p
group
letter
row
statist
significantli
differ
pvalu
consid
signific
conclus
alter
serum
amino
acid
concentr
observ
among
healthi
dog
hypocobalaminem
dog
without
epi
exact
caus
chang
requir
investig
lack
digest
pancreat
enzym
dog
epi
could
play
role
decreas
absorpt
amino
acid
lead
alter
amino
acid
metabol
current
therapeut
option
canin
inflammatori
bowel
diseas
ibd
focus
reduc
intestin
inflamm
achiev
clinic
remiss
often
result
side
effect
especi
due
use
immunosuppress
drug
ibd
patient
activ
nuclear
factor
kappalightchainenhanc
activ
b
cell
nfjb
caus
intestin
inflamm
chondroitin
sulphat
cs
inhibit
nfjb
phosphoryl
therefor
could
help
reduc
inflammatori
respons
associ
ibd
largebowel
ferment
certain
resist
starch
increas
butyr
product
help
maintain
intestin
barrier
integr
oral
administ
prebiot
promot
growth
benefici
gut
microflora
aim
studi
evalu
multicentr
random
doubleblind
placebocontrol
trial
dog
ibd
effect
oral
nutrit
supplement
contain
butyrogen
resist
starch
cs
bglucan
mannanoligosaccharid
serum
biomark
intestin
histolog
canin
ibd
activ
index
cibdai
total
twentytwo
biopsyconfirm
canin
ibd
patient
receiv
either
placebo
group
n
oral
supplement
group
b
n
oral
daili
six
month
studi
dog
given
special
hypoallergen
diet
pre
post
treatment
serum
biochem
marker
histopatholog
cibdai
score
compar
biopsi
score
base
wsava
guidelin
assess
endoscop
intestin
biopsi
sampl
oneway
analysi
varianc
anova
repeat
measur
uncorrect
fisher
least
signific
differ
lsd
test
use
compar
valu
group
differ
time
treatment
unpair
test
perform
compar
pretreat
valu
group
analyt
follow
parametr
distribut
log
transform
appli
test
dog
group
b
show
increas
serum
concentr
cholesterol
one
month
treatment
compar
pretreat
valu
median
mgl
vs
mgl
p
cholesterol
median
uiml
vs
uiml
p
increas
serum
concentr
triglycerid
three
month
treatment
median
mgl
vs
mgl
p
chang
seen
placebo
group
could
indic
improv
intestin
absorpt
decreas
oxid
damag
associ
ibd
supplement
group
group
b
show
decreas
p
mean
histolog
sever
score
end
followup
limit
studi
initi
treatment
paramet
significantli
higher
supplement
group
p
compar
placebo
group
initi
signific
differ
p
mean
cibdai
group
median
group
group
b
signific
reduct
mean
cibdai
observ
group
six
month
might
due
special
diet
howev
supplement
group
experienc
faster
clinic
improv
shown
pronounc
decreas
mean
cibdai
especi
one
p
two
month
p
treatment
compar
placebo
group
p
p
respect
side
effect
relat
treatment
report
group
conclus
although
larger
prospect
studi
warrant
result
point
toward
benefici
effect
oral
supplement
contain
butyrogen
resist
starch
cs
prebiot
dog
ibd
improv
clinic
histolog
index
well
serum
biochem
marker
intestin
absorpt
oxid
damag
associ
side
effect
inform
lack
impact
lowdos
aspirin
without
omeprazol
develop
gastrointestin
diseas
dog
receiv
immunosuppress
dose
prednison
object
studi
compar
endoscop
mucos
lesion
dog
receiv
therapi
nine
research
dog
random
receiv
mgkgd
prednison
placebo
group
mgkgd
aspirin
group
mgkgd
aspirin
mgkgd
omeprazol
group
day
medic
administ
food
follow
ml
water
endoscop
evalu
biopsi
collect
perform
day
mucos
lesion
score
perform
blind
review
video
photo
complet
data
collect
mucos
lesion
score
treatment
day
compar
friedman
test
kruskalw
p
consid
signific
ulcer
lower
esophag
sphincter
develop
dog
per
group
respect
gastric
ulcer
develop
dog
median
total
endoscop
mucos
lesion
score
significantli
higher
treatment
group
differ
among
group
figur
letter
denot
signific
differ
administr
immunosuppress
dose
prednison
associ
signific
increas
endoscop
mucos
lesion
score
healthi
dog
lack
differ
group
could
reflect
type
error
due
small
number
dog
wide
interindividu
variat
esophag
gastric
ulcer
develop
glucocorticoid
therapi
without
aspirin
omeprazol
evalu
dog
histolog
immunohistochemistri
warrant
ongo
dysphagia
rel
common
disord
dog
result
abnorm
oral
pharyng
pharyngoesophag
esophag
phase
swallow
common
caus
dysphagia
dog
veterinari
univers
hospit
determin
util
videofluoroscop
swallow
studi
cohort
anim
comprehens
evalu
goal
retrospect
evalu
common
caus
dysphagia
dog
determin
associ
anim
dysphagia
signal
clinic
sign
diagnost
test
diagnost
procedur
comprehens
search
medic
record
univers
california
davi
vmth
canin
patient
dysphagia
perform
period
januari
januari
dog
dysphagia
directli
attribut
oral
caus
dental
diseas
stomat
cleft
palat
exclud
investig
cohort
dog
includ
survey
thorac
radiograph
inclus
criterion
dog
includ
studi
underw
videofluoroscopi
age
dog
rang
month
median
ae
month
commonli
affect
purebr
dog
labrador
retriev
golden
retriev
german
shepherd
common
caus
dysphagia
includ
megaesophagu
n
gastroesophag
reflux
ger
n
esophag
foreign
bodi
n
slide
hiatal
hernia
n
cricopharyng
dysphagia
n
dog
chronic
regurgit
unknown
caus
videofluoroscopi
help
diagnos
ger
hiatal
hernia
pharyng
weak
esophag
strictur
cricopharyng
achalasia
esophag
hypomotil
specif
caus
dysphagia
identifi
dog
studi
warrant
better
elucid
caus
dysphagia
anim
find
studi
help
priorit
workup
dysphag
dog
highlight
clinic
util
videofluoroscop
swallow
studi
definit
diagnosi
felin
infiltr
small
intestin
si
diseas
challeng
debat
exist
biopsi
techniqu
optim
ultrasound
may
use
select
biopsi
type
purpos
studi
assess
abil
ultrasound
examin
predict
presenc
locat
histolog
lesion
segment
tissu
layer
si
record
cat
abdomin
ultrasound
full
thick
si
biopsi
within
month
review
retrospect
ultrasonograph
imag
review
singl
radiologist
assess
lesion
abnorm
wall
thick
layer
echogen
mural
mass
pathologist
grade
histopatholog
sampl
accord
wsava
standard
ultrasound
biopsi
wall
layer
si
evalu
lesion
section
avail
review
abil
ultrasonograph
lesion
within
specif
wall
layer
si
predict
presenc
histolog
chang
wall
layer
assess
one
hundr
sixti
nine
cat
met
inclus
criteria
ultrasonograph
si
lesion
present
cat
duodenum
jejunum
andor
ileum
histopatholog
sampl
obtain
via
laparotomi
via
necropsi
diagnos
cat
si
patholog
includ
inflammatori
bowel
diseas
small
cell
lymphoma
intermediatelarg
cell
lymphoma
neoplasia
suspect
felin
infecti
periton
twenti
five
cat
histolog
lesion
overal
ultrasonograph
lesion
si
high
posit
predict
valu
ppv
histolog
si
lesion
duodenum
jejunum
ileum
poor
neg
predict
valu
npv
duodenum
jejunum
ileum
tabl
show
abil
ultrasound
predict
histolog
lesion
specif
si
wall
layer
confid
interv
ci
also
report
result
show
cat
si
mucos
ultrasonograph
lesion
mucos
histolog
chang
mucos
biopsi
may
effect
identifi
lesion
howev
si
musculari
ultrasonograph
lesion
predict
histolog
diseas
musculari
layer
suggest
full
thick
biopsi
may
essenti
obtain
diagnosi
cat
ultrasonograph
musculari
lesion
conclud
ultrasound
may
help
guid
decis
biopsi
type
perform
individu
cat
littl
inform
avail
outcom
dog
proteinlos
enteropathi
ple
aim
studi
evalu
clinic
clinicopatholog
find
dog
ple
secondari
chronic
enteropathi
ce
time
diagnosi
month
treatment
correl
surviv
month
shortand
longterm
surviv
order
identifi
risk
factor
outcom
record
dog
chronic
enteropathi
ce
concurr
ple
diagnos
three
referr
clinic
retrospect
analyz
inclus
criteria
histori
chronic
gastrointestin
sign
week
hypoalbuminemia
gdl
gastrointestin
origin
histopatholog
evid
gastrointestin
inflamm
biopsi
avail
follow
exclus
criteria
presenc
underli
concurr
disord
ple
secondari
ce
immunosuppress
therapi
use
within
week
intestin
biopsi
dog
classifi
either
shortterm
month
survivor
st
longterm
month
survivor
lt
clinic
clinicopatholog
variabl
investig
group
abil
predict
outcom
determin
multipl
regress
roc
analys
must
differ
treatment
group
sixtyeight
case
enrol
dog
classifi
st
lt
differ
bodi
weight
age
sex
distribut
lifestyl
complaintsclin
sign
canin
inflammatori
bowel
diseas
activ
index
cibdai
canin
chronic
enteropathi
clinic
activ
index
ccecai
clinicopatholog
data
group
time
diagnosi
onemonth
follow
cibdaiccecai
score
higher
serum
total
protein
globulin
total
cholesterol
lower
p
st
versu
lt
risk
factor
poor
outcom
month
cibdai
low
cholesterol
determin
month
diagnosi
accord
receiv
oper
characterist
roc
curv
analysi
cibdai
evalu
month
diagnosi
shown
best
predictor
poor
outcom
conclus
clinic
clinicopatholog
find
time
diagnosi
predict
outcom
dog
ple
cibdai
cholesterol
month
follow
predict
st
vs
lt
gastroduodenoscopi
commonli
perform
dog
chronic
enteropathi
sampl
qualiti
endoscop
biopsi
paramount
import
accur
histolog
diagnosi
mani
veterinari
specialist
use
reusabl
forcep
due
decreas
cost
unknown
whether
sampl
qualiti
decreas
repeat
use
point
becom
inferior
dispos
forcep
hypothesi
studi
biopsi
qualiti
reusabl
forcep
would
deterior
repeat
use
becom
inferior
biopsi
qualiti
obtain
dispos
forcep
twentyfour
dog
undergo
gastrointestin
endoscopi
diagnost
investig
includ
prospect
pathologistblind
studi
compar
dispos
reusabl
allig
standard
cup
biopsi
forcep
olympu
mm
mm
new
dispos
forcep
use
patient
five
reusabl
forcep
randomis
use
sampl
collect
stomach
duodenum
ileum
colon
onesampl
wilcoxon
test
use
compar
score
forcep
type
mannwhitney
test
use
compar
degrad
biopsi
score
time
signific
differ
adequaci
depth
crush
artifact
reusabl
dispos
forcep
intestin
area
first
use
forcep
use
reusabl
forcep
appar
degrad
sampl
qualiti
time
least
dog
sampl
reusabl
forcep
without
signific
effect
tissu
qualiti
adequaci
compar
dispos
biopsi
forcep
studi
suggest
reusabl
biopsi
forcep
provid
financi
advantag
dispos
forcep
reusabl
forcep
adequ
least
dog
prokinet
effect
commonli
use
antiemet
evalu
ultrasonograph
healthi
dog
hour
fast
use
random
control
blind
crossov
design
start
h
motil
evalu
metoclopramid
mgkg
h
dolasetron
mgkg
h
maropit
mg
kg
h
salin
administ
subcutan
cisaprid
mgkg
h
given
oral
dog
fed
h
receiv
morn
treatment
contract
relax
crosssect
antral
surfac
measur
triplic
antral
contract
cf
count
minut
regular
interv
h
postprandi
pp
motil
index
mi
calcul
result
evalu
use
mix
model
repeat
measur
anova
dog
random
effect
treatment
time
fix
effect
signific
set
p
placebo
mi
increas
first
min
pp
reach
plateau
start
decreas
h
pp
compar
placebo
metoclopramid
significantli
increas
mi
preprandi
min
h
pp
dolasetron
also
significantli
increas
mi
preprandi
h
pp
maropit
significantli
increas
mi
preprandi
cisaprid
mi
significantli
higher
placebo
preprandi
h
pp
test
drug
metoclopramid
caus
pronounc
sustain
increas
mi
meal
fast
mi
increas
dug
howev
postprandi
mi
mostli
unchang
metoclopramid
antiemet
drug
highest
prokinet
activ
gastric
antrum
abnorm
interact
gi
microbiom
immun
system
thought
major
contribut
factor
etiolog
inflammatori
bowel
diseas
ibd
treatment
canin
ibd
often
includ
judici
use
antimicrobi
metronidazol
aim
studi
prospect
evalu
impact
metronidazol
administr
fecal
microbiom
healthi
dog
twentyfour
privat
own
healthi
dog
enrol
assign
one
group
dog
control
dog
intervent
group
dog
treat
soybas
hydrolyz
diet
week
administr
metronidazol
mgkg
po
h
week
dog
maintain
usual
diet
administ
dose
metronidazol
week
fece
blood
collect
day
day
coincid
initi
discontinu
metronidazol
treatment
fece
frozen
within
hour
collect
analyz
batch
later
qpcr
panel
target
bacteri
group
interest
gastrointestin
health
use
analysi
fecal
microbiota
variou
phylogenet
level
faecalibacterium
spp
bifidobacterium
spp
lactobacillu
spp
streptococcu
spp
ruminococcacea
c
perfringen
e
coli
blautia
spp
serum
cobalamin
folat
concentr
analys
autom
chemiluminesc
assay
differ
serum
cobalamin
folat
bacteri
abund
among
group
timepoint
evalu
use
repeat
measur
anova
follow
tukey
posthoc
test
statist
signific
set
p
nine
healthi
dog
receiv
metronidazol
produc
yellow
soft
liquid
fece
one
occas
medic
happen
untreat
control
group
signific
chang
observ
serum
concentr
cobalamin
folat
group
control
dog
e
coli
show
signific
chang
abund
time
p
contrast
sever
bacteri
group
show
signific
chang
abund
time
respons
group
similar
combin
statist
analysi
signific
increas
abund
compar
baselin
observ
metronidazol
administr
e
coli
p
streptococcu
spp
p
bifidobacteria
spp
p
day
p
day
contrast
signific
decreas
abund
observ
faecalibacterium
spp
p
p
ruminococcacea
p
day
p
day
blautia
spp
p
signific
chang
abund
due
metronidazol
observ
c
perfringen
lactobacillu
spp
administr
metronidazol
led
signific
chang
fecal
microbiom
evalu
qpcr
interestingli
metronidazol
led
decreas
bacteri
group
constitut
major
abund
group
gi
tract
healthi
dog
thought
import
maintain
intestin
health
faecalibacterium
blautia
ruminococcacea
chang
revers
day
end
antibiot
administr
evalu
bacteri
group
remain
significantli
alter
week
administr
conclus
metronidazol
profound
effect
fecal
microbiom
lead
variabl
microbiom
time
studi
need
evalu
function
chang
microbiom
occur
due
metronidazol
better
understand
mechan
antibiot
gastrointestin
diseas
gastrokin
gkn
bioactiv
substanc
secret
select
gastric
cell
evid
support
function
role
gkn
gastric
homeostasi
immun
respons
tumour
suppress
downregul
report
helicobact
pylori
associ
gastriti
inflammatori
gastrointestin
condit
aim
studi
develop
quantit
polymeras
chain
reaction
qpcr
assay
util
evalu
gkn
gene
express
helicobact
spp
posit
dog
treatment
express
mrna
studi
endoscop
biopsi
sampl
collect
seven
dog
three
timepoint
pre
week
posttreat
helicobact
spp
colon
rel
express
softwar
tool
rest
use
provid
effici
correct
express
ratio
comparison
group
result
compar
standard
methodolog
compar
mrna
express
upregul
mean
factor
se
p
se
p
differ
attenu
comparison
made
histopatholog
evid
gastriti
present
helicobact
spp
posit
sampl
compar
immedi
posterad
sampl
gkn
gene
express
upregul
presenc
helicobact
spp
dog
without
evid
concurr
inflamm
evalu
requir
identifi
relev
find
howev
given
suspect
role
gastric
homeostasi
upregul
could
contribut
limit
develop
gastriti
helicobact
spp
posit
dog
accumul
evid
shown
signific
relationship
gastrointestin
gi
microbiota
host
gi
health
microbi
metabolit
believ
play
critic
role
hostmicrobi
interact
shortchain
fatti
acid
major
endproduct
bacteri
carbohydr
ferment
intestin
tract
constitut
import
energi
sourc
intestin
epitheli
cell
help
maintain
intestin
mucos
integr
decreas
concentr
shortchain
fatti
acid
observ
human
gi
diseas
howev
larg
scale
clinic
data
lack
small
anim
medicin
therefor
aim
studi
evalu
fecal
concentr
shortchain
fatti
acid
healthi
pet
dog
dog
chronic
enteropathi
one
fresh
fecal
sampl
collect
healthi
control
dog
dog
chronic
enteropathi
fecal
concentr
shortchain
fatti
acid
ie
acet
propion
butyr
total
shortchain
fatti
acid
measur
use
ga
chromatographymass
spectrometri
fecal
shortchain
fatti
acid
concentr
normal
dri
matter
compar
group
use
wilcoxon
ranksum
test
benjamini
hochberg
fals
discoveri
rate
use
correct
multipl
comparison
adjust
p
consid
statist
signific
fecal
concentr
median
rang
acet
significantli
decreas
p
dog
chronic
enteropathi
lmolg
dri
matter
compar
healthi
control
dog
lmolg
dri
matter
also
fecal
concentr
propion
significantli
decreas
p
dog
chronic
enteropathi
lmolg
dri
matter
compar
healthi
control
dog
lmolg
dri
matter
moreov
fecal
concentr
total
shortchain
fatti
acid
significantli
decreas
p
dog
chronic
enteropathi
lmolg
dri
matter
compar
healthi
control
dog
lmolg
dri
matter
howev
signific
differ
p
fecal
concentr
butyr
healthi
control
dog
lmolg
dri
matter
dog
chronic
enteropathi
lmolg
dri
matter
studi
dog
chronic
enteropathi
decreas
fecal
concentr
acet
propion
total
shortchain
fatti
acid
relationship
fecal
shortchain
fatti
acid
concentr
microbi
composit
investig
main
function
lipoprotein
transport
lipid
blood
stream
lipoprotein
classifi
major
class
base
densiti
chylomicron
low
densiti
lipoprotein
vldl
intermedi
densiti
lipoprotein
idl
low
densiti
lipoprotein
ldl
high
densiti
lipoprotein
hdl
base
human
literatur
alter
proport
lipoprotein
class
describ
certain
diseas
state
cardiovascular
diseas
metabol
diseas
inflammatori
diseas
includ
inflammatori
bowel
diseas
system
lupu
erythematosu
sle
known
infect
chronic
inflamm
impair
lipoprotein
metabol
caus
varieti
chang
plasma
concentr
lipid
lipoprotein
human
patient
sle
howev
littl
known
lipoprotein
profil
dog
chronic
enteropathi
ce
aim
studi
investig
serum
lipoprotein
profil
cholesterol
triglycerid
concentr
dog
ce
healthi
control
dog
analysi
serum
lipoprotein
profil
perform
healthi
control
dog
dog
ce
use
densiti
gradient
ultracentrifug
imag
tube
follow
ultracentrifug
convert
densiti
profil
use
commerci
avail
softwar
program
originpro
area
curv
auc
triglyceriderich
lipoprotein
ldl
hdl
total
lipoprotein
calcul
analysi
addit
serum
cholesterol
triglycerid
concentr
measur
use
commerci
avail
clinic
chemistri
analyz
sirru
stanbio
boern
tx
usa
data
analyz
use
wilcoxon
rank
sum
test
ttest
appropri
signific
set
p
total
lipoprotein
ldl
hdl
level
healthi
dog
significantli
higher
dog
ce
p
p
p
respect
serum
cholesterol
concentr
healthi
control
dog
mean
aesd
ae
mg
dl
significantli
higher
dog
ce
mean
ae
sd
ae
mgdl
p
studi
suggest
lipoprotein
profil
alter
dog
ce
investig
clinic
import
lipoprotein
profil
dog
ce
warrant
human
hyperhomocysteinemia
multifactori
incomplet
understood
condit
increas
serum
homocystein
hci
concentr
associ
cardiovascular
diseas
peripher
arteri
occlus
diseas
venou
thrombosi
recent
cardiovascularthrombot
diseas
hypocobalaminemia
describ
greyhound
also
suggest
hyperhomocysteinemia
greyhound
suspect
gastrointestin
diseas
due
hypocobalaminemia
hypofolatemia
condit
also
link
hypoalbuminemia
may
affect
hci
level
shown
previous
dog
howev
unknown
low
level
micronutri
cobalamin
andor
folat
present
greyhound
gastrointestin
diseas
also
healthi
greyhound
therefor
aim
studi
evalu
serum
hci
cobalamin
folat
concentr
greyhound
diarrhea
thrombot
diseas
well
healthi
greyhound
serum
sampl
healthi
greyhound
n
greyhound
diarrhea
n
histori
thrombot
event
n
collect
ohio
state
univers
texa
univers
serum
hci
concentr
refer
interv
ri
lmoll
measur
ga
chromatographi
mass
spectrometri
concentr
cobalamin
ri
ngl
folat
ri
lgl
measur
use
autom
chemiluminesc
assay
concentr
serum
hci
cobalamin
folat
compar
among
three
group
greyhound
use
anova
nonparametr
kruskalw
test
applic
correl
analysi
perform
test
possibl
correl
hyc
two
b
vitamin
serum
hci
concentr
differ
among
three
group
greyhound
p
healthi
greyhound
significantli
higher
serum
hci
concentr
mean
aesd
ae
lmoll
greyhound
diarrhea
ae
lmoll
p
thrombosi
ae
lmoll
p
healthi
greyhound
serum
hci
concentr
upper
limit
ri
serum
cobalamin
folat
concentr
differ
among
group
greyhound
p
neg
correl
observ
serum
hci
serum
cobalamin
q
ci
p
serum
folat
concentr
q
ci
p
analyz
sampl
togeth
howev
correl
observ
analyz
three
group
greyhound
separ
p
healthi
greyhound
higher
serum
hci
concentr
greyhound
diarrhea
thrombot
diseas
healthi
greyhound
hyperhomocysteinem
suggest
greyhound
could
serv
novel
canin
model
investig
hyperhomocysteinemia
human
howev
studi
warrant
character
model
object
studi
determin
preval
fecal
enteropathogen
weanl
kitten
assess
whether
administr
enterococcu
faecium
sf
affect
fecal
qualiti
kitten
week
age
enter
trial
kitten
maintain
petag
kmr
milk
replac
week
acclim
period
prior
random
group
probiot
placebo
administr
kitten
maintain
kmr
treat
week
prior
wean
onto
commerci
can
diet
week
fresh
fece
kitten
score
daili
consist
score
liquid
diarrhea
soft
unform
soft
form
normal
fece
evalu
enteropathogen
via
centrifug
flotat
bacteri
cultur
toxin
immunoassay
pcr
kitten
complet
trial
placebo
n
probiot
n
enteropathogen
detect
includ
isospora
feli
cryptosporidium
spp
clostridium
difficil
toxin
ab
c
perfringen
enterotoxin
salmonella
panleukopenia
coronaviru
median
fecal
consist
score
week
group
associ
significantli
improv
score
placebo
versu
probiot
group
p
administr
probiot
enterococcu
faecium
sf
weanl
kitten
result
improv
fecal
score
prior
wean
joseph
cyru
parambeth
jan
suchodolski
joerg
steiner
gastrointestin
laboratori
texa
univers
colleg
station
texa
usa
exocrin
pancreat
insuffici
epi
syndrom
character
inadequ
synthesi
secret
pancreat
digest
enzym
result
maldigest
mast
cell
within
gastrointestin
tract
contribut
pathogenesi
canin
chronic
enteropathi
abil
releas
inflammatori
mediat
histamin
nmethylhistamin
nmh
major
metabolit
histamin
increas
fecal
concentr
nmethylhistamin
report
dog
chronic
gastrointestin
diseas
epi
dog
complic
chronic
enteropathi
quantif
fecal
nmh
may
serv
potenti
prognost
marker
aim
studi
evalu
fecal
nmethylhistamin
concentr
dog
epi
surplu
fecal
sampl
dog
enrol
unrel
clinic
trial
gastrointestin
laboratori
util
includ
studi
dog
least
year
age
clinic
sign
epi
ie
polyphagia
weight
loss
steatorrhea
andor
loos
volumin
andor
malodor
stool
serum
ctli
concentr
lgl
pregnant
lactat
free
clinic
appar
diseas
epi
three
natur
void
fecal
sampl
collect
three
consecut
day
immedi
frozen
collect
use
studi
fecal
nmethylhistamin
concentr
measur
use
previous
valid
inhous
assay
use
stabl
isotop
dilut
ga
chromatographymass
spectrometri
gcm
liquid
extract
fecal
sampl
dilut
use
nmh
analysi
fecal
nmh
concentr
backcalcul
wet
weight
fecal
sampl
express
ngg
fece
result
compar
establish
refer
interv
healthi
dog
mean
threeday
fecal
nmh
ngg
fece
maximum
fecal
nmh
one
individu
sampl
ngg
fece
consid
abnorm
forti
three
percent
epi
dog
increas
fecal
nmh
concentr
median
rang
lgg
fece
german
shepherd
german
shepherd
cross
breed
dog
made
dog
studi
dog
increas
fecal
nmh
concentr
odd
ratio
confid
interv
ci
p
compar
breed
studi
show
fecal
nmethylhistamin
concentr
may
increas
dog
epi
especi
german
shepherd
german
shepherd
mix
studi
necessari
elucid
mechan
respons
find
increas
fecal
nmh
concentr
associ
alter
clinic
outcom
pathogenesi
chronic
constip
cc
idiopath
megacolon
imc
poorli
understood
human
anim
particular
unknown
whether
abnorm
involv
extrins
nerv
enter
nerv
plexus
interstiti
cell
cajal
icc
intestin
smooth
muscl
abnorm
compon
could
lead
gut
dilat
impair
motil
chronic
constip
megacolon
occur
often
cat
dog
human
probiot
increasingli
investig
manag
colon
motil
dysfunct
particularli
effect
gut
transit
time
stool
output
constip
relief
probiot
use
frequent
small
anim
practic
publish
studi
regard
clinic
efficaci
cat
cc
imc
aim
studi
investig
clinic
histolog
effect
commerci
multistrain
probiot
sivoy
tm
contain
billion
lactic
acid
bacteria
compris
follow
strain
l
acidophilu
l
plantarum
l
paracasei
dsm
l
delbrueckii
subsp
bulgaricu
l
brevi
streptococcu
thermophilu
dsm
b
longum
dsm
b
infanti
dsm
ten
pet
cat
differ
breed
age
diagnosi
chronic
constip
nonrespons
medic
manag
select
basi
recurr
clinic
sign
absenc
antibiot
treatment
month
three
cat
suffer
imc
full
thick
biopsi
sampl
histolog
anim
enrol
studi
colon
found
dilat
impact
faec
sever
dilat
occur
transvers
descend
colon
observ
via
imag
cc
n
imc
n
cat
receiv
oral
billion
lyophil
bacteria
daili
day
cat
assess
clinic
endoscop
histolog
baselin
end
treatment
histolog
sampl
score
evalu
immunohistochem
ihc
express
icc
enter
neuron
glial
cell
gangliar
cell
apoptosi
three
latter
paramet
evalu
full
thick
biopsi
obtain
cat
imc
concern
ihc
icc
evalu
mast
cell
known
express
antigen
differenti
stain
alcian
blue
number
data
constip
cat
compar
therapi
obtain
healthi
control
tissu
archiv
materi
five
healthi
cat
use
pair
ttest
wilcoxon
match
pair
test
appropri
statist
signific
set
p
constip
cat
display
signific
decreas
icc
cat
imc
significantli
apoptot
enter
neuron
control
treatment
sivoy
tm
signific
decreas
observ
fceai
clinic
index
p
histolog
score
p
contrast
signific
increas
icc
observ
p
probiot
therapi
cat
cc
imc
show
signific
clinic
improv
sivoy
tm
treatment
histolog
paramet
suggest
potenti
antiinflammatori
effect
sivoy
tm
associ
reduct
mucos
infiltr
restor
number
icc
evalu
microbiota
composit
probiot
treatment
progress
understand
effect
probiot
therapi
chronic
constip
cat
chronic
pancreat
cp
dog
clinic
underdiagnos
condit
character
acinar
cell
atrophi
fibrosi
loss
exocrin
function
current
approv
pharmaceut
treatment
chronic
pancreat
dog
thu
manag
reli
heavili
support
care
camostat
mesil
cm
synthet
proteas
inhibitor
shown
inhibitori
effect
trypsin
kinin
system
well
inflammatori
fibrot
cascad
cm
approv
treatment
chronic
pancreat
human
japan
year
howev
data
efficaci
cm
dog
chronic
pancreat
lack
thu
purpos
studi
evalu
effect
oral
cm
therapi
marker
acinar
cell
damag
inflamm
fibrosi
dog
suspect
cp
thirti
one
privat
own
dog
suspect
chronic
pancreat
enrol
studi
dog
includ
base
two
consecut
canin
pancreat
lipas
immunoreact
cpli
measur
lgl
within
ae
day
serum
triglycerid
concentr
mgdl
dog
major
concurr
diseas
eg
renal
diseas
icteru
exclud
dog
either
treat
mgkgd
n
mgkg
n
oral
cm
ae
day
complet
blood
count
serum
biochemistri
profil
assay
measur
cpli
canin
trypsinlik
immunoreact
ctli
cobalamin
folat
concentr
perform
treatment
addit
serum
creactiv
protein
crp
concentr
evalu
complet
trial
batch
measur
preand
posttreat
result
compar
use
pair
ttest
normal
distribut
data
set
wilcoxon
matchedpair
test
gaussian
distribut
could
assum
signific
threshold
set
p
serum
cpli
concentr
significantli
decreas
pretreat
median
lgl
rang
lgl
posttreat
median
lgl
rang
lgl
p
treatment
group
combin
subgroup
dog
treat
mgkgd
oral
cm
pretreat
median
lgl
rang
lgl
posttreat
median
rang
lgl
p
dog
treat
mgkgd
oral
cm
serum
cpli
concentr
chang
significantli
pretreat
median
lgl
rang
lgl
posttreat
median
lgl
rang
lgl
p
measur
serum
cobalamin
concentr
decreas
significantli
pretreat
mean
ngl
sd
ae
ngl
posttreat
mean
ngl
sd
ae
ngl
p
treatment
group
combin
well
subgroup
mgkgd
oral
cm
pretreat
mean
ngl
sd
ae
ngl
posttreat
mean
ngl
sd
ae
ngl
p
mgkgd
oral
cm
pretreat
mean
ngl
sd
ae
ngl
posttreat
mean
ngl
sd
ae
ngl
p
treatment
result
signific
differ
serum
concentr
ctli
folat
crp
dog
combin
either
subgroup
decreas
cpli
concentr
would
suggest
attenu
acinar
cell
damag
evalu
efficaci
requir
control
studi
despit
mark
individu
decreas
signific
antiinflammatori
antifibrot
properti
identifi
oral
cm
therapi
dose
mgkgd
day
found
safe
dog
suspect
chronic
pancreat
mild
advers
effect
report
purpos
studi
investig
bhydroxybutyr
bohb
concentr
dog
acut
pancreat
ap
without
diabet
mellitu
dog
without
diabet
mellitu
prospect
enrol
one
three
group
dog
ap
sick
dog
without
ap
fast
dog
dog
ap
enrol
vomit
diarrhea
anorexia
ultrasonograph
find
consist
ap
includ
enlarg
irregular
hypoecho
pancrea
hyperecho
mesenteri
increas
pancreat
lipas
immunoreact
pli
mcgl
sick
dog
without
ap
enrol
vomit
diarrhea
anorexia
normal
pancreat
ultrasound
mcgl
dog
fast
hour
enrol
vomit
diarrhea
anorexia
bohb
measur
whole
blood
portabl
ketonemet
kruskal
walli
test
perform
confirm
bohb
significantli
differ
three
group
p
pairwis
comparison
perform
use
mannwhitney
test
bonferroni
correct
pvalu
report
median
bohb
significantli
higher
dog
ap
mmoll
compar
sick
mmoll
p
fast
dog
mmoll
p
sick
compar
fast
dog
p
signific
associ
detect
bohb
durat
anorexia
bodi
condit
bodi
temperatur
white
blood
cell
glucos
cholesterol
lactat
concentr
sick
ap
dog
conclud
bohb
significantli
higher
dog
ap
compar
dog
without
diabet
mellitu
diagnost
prognost
util
find
remain
investig
surgic
treatment
extrahepat
bile
duct
obstruct
ehbdo
veterinari
patient
high
morbid
mortal
endoscop
retrograd
cholangiographi
erc
endoscop
biliari
stent
placement
eb
minimallyinvas
altern
use
human
high
success
complic
purpos
studi
describ
technic
clinic
outcom
use
erceb
treatment
ehbdo
dog
cat
erceb
perform
use
mm
sideview
duodenoscop
sphincterotom
cannul
common
bile
duct
cbd
major
duoden
papilla
mdp
contrast
fluoroscopiccholangiographi
confirm
ehbdo
guidewir
advanc
cbd
stent
plastic
metal
advanc
endoscop
guidewir
cbd
cross
mdp
patient
follow
biochem
imag
overal
outcom
five
dog
kg
cat
kg
includ
median
tbili
mgdl
pancreatitisinduc
strictur
n
choledocholithiasi
n
granuloma
n
pylor
cannul
success
anim
erc
dog
cat
eb
dog
cat
cathet
perfor
duodenum
occur
one
cat
surgicallyassist
fluoroscopicguid
stent
place
cat
subcutaneousintestin
biliarybypass
devic
dog
fail
erceb
patient
surviv
discharg
resolut
ehbdo
median
followup
time
day
day
still
aliv
none
die
ehbdo
erc
eb
possibl
effect
dog
cat
ehbdo
procedur
technic
difficult
techniqu
may
potenti
altern
tradit
surgeri
futur
canin
gastrointestin
microbiom
divers
popul
microorgan
provid
number
host
benefit
stabl
microbiom
import
overal
host
health
alter
microbiom
report
period
stress
militari
work
dog
often
expos
stress
event
includ
initi
acquisit
period
procur
europ
place
quarantin
ten
day
arriv
unit
state
quarantin
period
histor
associ
high
incid
diarrhea
aim
studi
compar
effect
bifidobacterium
animali
tylosin
placebo
microbiom
tenday
quarantin
period
doubleblind
studi
militari
work
dog
n
randomli
assign
one
three
treatment
group
placebo
probiot
bifidobacterium
animali
tylosin
daili
routin
quarantin
period
includ
diet
handler
dog
fecal
sampl
collect
begin
end
quarantin
period
fecal
rrna
analysi
illumina
sequenc
fecal
score
record
daili
dog
character
diarrhea
fecal
score
diarrhea
fecal
score
alphaand
betadivers
measur
compar
three
treatment
group
treatment
dog
without
diarrhea
differ
bacteri
commun
analyz
use
unweight
unifrac
distanc
metric
analysi
similar
anosim
test
use
determin
group
studi
significantli
differ
bacteri
commun
linear
discrimin
analysi
lda
effect
size
lefs
perform
identifi
bacteri
group
significantli
associ
treatment
alphadivers
analysi
pretreat
sampl
show
significantli
decreas
speci
rich
shannon
divers
tylosin
group
compar
probiot
group
p
p
respect
signific
differ
alphadivers
analysi
treatment
dog
without
diarrhea
quarantin
period
compar
group
treatment
regardless
fecal
score
signific
differ
alphadivers
shannon
divers
probiot
p
p
respect
tylosin
p
p
respect
group
placebo
group
princip
coordin
analysi
plot
also
show
signific
differ
cluster
tylosin
group
compar
placebo
p
probiot
p
group
treatment
also
signific
differ
cluster
treatment
group
placebo
p
tylosin
p
probiot
p
largest
effect
seen
tylosin
group
r
bifidobacterium
spp
increas
group
treatment
clostridium
spp
decreas
group
treatment
studi
bacteri
divers
decreas
quarantin
period
group
largest
chang
seen
tylosin
group
bifidobacterium
spp
also
increas
treatment
group
studi
period
clostridium
spp
decreas
group
find
would
suggest
microbiom
quarantin
period
militari
work
dog
influenc
treatment
factor
treatment
impact
microbiom
view
express
articl
author
reflect
offici
polici
posit
depart
armi
depart
defens
us
govern
recent
survey
base
illustr
show
usa
cobalamin
defici
occur
frequent
tradit
type
chines
sharpei
sharpei
meatmouth
type
sharpei
also
alter
copi
number
kbduplic
kbduplic
describ
differ
type
sharpei
eg
meatmouth
tradit
type
duplic
locat
close
proxim
gene
investig
sharpei
cobalamin
defici
therefor
copi
number
two
duplic
determin
cobalamindefici
normocobalaminem
sharpei
genom
dna
extract
cobalamindefici
normocobalaminem
sharpei
use
genotyp
perform
use
two
assay
set
cnveastern
assay
kbduplic
assay
kbduplic
normal
assay
copi
number
obtain
compar
cobalamindefici
normocobalaminem
sharpei
use
mannwhitney
u
test
fisher
exact
test
use
odd
ratio
calcul
evalu
whether
low
high
copi
number
two
duplic
associ
cobalamin
defici
cobalamindefici
sharpei
higher
cnveastern
assay
copi
number
median
rang
lower
assay
copi
number
normocobalaminem
sharpei
respect
p
receiveroper
characterist
curv
use
determin
optim
copi
number
distinguish
cobalamindefici
normocobalaminem
sharpei
high
copi
number
cnveastern
assay
detect
cobalamindefici
sharpei
cobalamin
defici
associ
high
cnveastern
copi
number
ci
p
assay
reveal
low
copi
number
cobalamindefici
sharpei
cobalamin
defici
associ
low
copi
number
ci
p
high
cnveastern
copi
number
low
copi
number
high
cnveastern
low
copi
number
ci
p
distinguish
cobalamindefici
sharpei
normocobalaminem
sharpei
sensit
respect
specif
respect
copi
number
assay
identifi
cobalamindefici
sharpei
moder
sensit
high
specif
posit
cutoff
signal
least
one
assay
highest
diagnost
accuraci
character
fecal
microbi
composit
divers
differ
speci
demonstr
speciesspecif
associ
provid
insight
self
extern
factor
shape
bacteri
commun
inhabit
gastrointestin
tract
comparison
data
two
host
speci
genu
coyot
cani
latran
dog
cani
cani
known
feed
environment
behavior
use
model
access
aspect
futur
help
understand
influenc
microbiota
host
develop
nutrient
assimil
suscept
diseas
studi
aim
character
fecal
microbiom
coyot
compar
healthi
pet
dog
dna
extract
fecal
sampl
collect
rectum
coyot
n
hour
post
mortem
healthi
pet
dog
n
use
illumina
sequenc
bacteri
rrna
gene
quantit
insight
microbi
ecolog
softwar
use
character
sampl
differ
proport
bacteri
taxa
speci
evalu
use
kruskalw
test
total
median
rang
sequenc
per
sampl
obtain
fecal
microbiom
coyot
compos
predomin
bacteria
belong
phyla
bacteroidet
median
firmicut
fusobacteria
proteobacteria
common
class
identifi
includ
bacteroidia
fusobacteria
clostridia
erysipelotrichi
famili
level
fusobacteriacea
bacteroidacea
paraprevotellacea
lachnospiracea
erysipelotrichacea
common
bacteri
group
identifi
bacteria
belong
phyla
bacteroidet
versu
p
fusobacteria
vs
p
proteobacteria
vs
p
significantli
frequent
identifi
coyot
healthi
pet
dog
sampl
higher
proport
phyla
coyot
sampl
mostli
due
significantli
increas
proport
famili
bacteroidacea
vs
p
fusobacteriacea
vs
p
within
proteobacteria
class
betaproteobacteria
class
gammaproteobacteria
significantli
present
sampl
coyot
famili
paraprevotellacea
prevotellacea
odoribacteracea
phylum
bacterioidet
well
alcaligenacea
enterobacteriacea
phylum
proteobacteria
significantli
increas
coyot
sampl
fecal
sampl
healthi
pet
dog
show
higher
proport
bacteria
belong
phylum
firmicut
vs
p
influenc
significantli
increas
proport
bacteria
class
clostridia
vs
p
erysipelotrichi
vs
p
consequ
signific
higher
proport
famili
turicibacteracea
clostridiacea
lachnospiracea
shannon
divers
index
vs
metric
averag
number
observ
speci
median
vs
significantli
differ
dog
coyot
princip
coordin
analysi
plot
show
signific
cluster
sampl
healthi
pet
dog
coyot
studi
demonstr
fecal
microbiom
coyot
dog
much
divers
demonstr
studi
use
culturebas
method
signific
differ
fecal
microbiom
coyot
healthi
pet
dog
observ
numer
bacteri
group
differ
phylogenet
level
intriguingli
fecal
microbiom
coyot
contain
increas
proport
phyla
bacteriodet
fusobacteria
fecal
microbiom
healthi
dog
compos
mainli
phylum
firmicut
influenc
high
proport
class
clostridia
differ
type
diet
raw
vs
industri
food
environ
habit
outdoor
vs
indoor
well
genet
must
play
import
role
microbiom
two
speci
factor
diet
influenc
coyot
composit
mostli
raw
meat
well
fruit
insect
grass
may
impact
predomin
bacteri
group
studi
requir
verifi
import
identifi
factor
shape
bacteri
commun
speci
focal
lipogranulomat
lymphang
fll
rare
form
canin
ibd
character
transmur
granulomat
inflamm
involv
frequent
distal
ileum
ileocol
junction
result
stenos
masslik
thicken
region
intestin
aim
retrospect
studi
describ
clinic
histopatholog
featur
comparison
human
ibd
determin
presenc
absenc
invas
bacteria
respons
treatment
ten
dog
definit
histolog
diagnosi
focal
lipogranulomat
lymphang
includ
histopatholog
endoscop
biospi
surgic
resect
review
bacteri
colon
evalu
use
fish
eubacteria
e
coli
twoyear
followup
avail
dog
record
dog
eight
male
femal
smallbre
dog
includ
biochemistri
ultrasound
colonoscop
abnorm
evalu
enterectomi
abnorm
intestin
zone
perform
medic
treatment
standard
dog
metronidazol
mgkg
bid
immunosuppress
dose
prednison
taper
biopsi
evalu
human
veterinari
pathologist
histolog
reveal
mostli
non
mucos
coliti
orand
ileiti
lesion
inflamm
center
around
vessel
mainli
concern
musculari
serosa
extens
mesenteri
four
dog
remain
remiss
period
month
present
persist
diarrhea
dog
euthan
fish
base
evid
invas
bacteria
fll
deep
pariet
affect
intestin
preferenti
local
ileum
ileocol
junction
smallbre
dog
bacteri
implic
seem
unlik
specif
canin
pancreat
lipas
immunoreact
spec
cpl
creactiv
protein
crp
biomark
pancreat
inflamm
nonspecif
inflamm
dog
respect
biomark
increas
dog
acut
pancreat
ap
howev
concurr
serial
measur
spec
cpl
crp
monitor
progress
ap
evalu
studi
perform
serial
evalu
chang
spec
cpl
crp
dog
ceruleininduc
ap
dog
receiv
hour
cerulein
infus
lgkgh
iv
induc
ap
blood
sampl
obtain
thereaft
interv
cerulein
infus
spec
cpl
crp
return
refer
interv
ri
spec
cpl
lgl
crp
mgdl
spec
cpl
crp
increas
rapidli
cerulein
infus
progress
decreas
time
spec
cpl
reach
median
rang
peak
concentr
significantli
earlier
crp
versu
hour
p
although
statist
signific
spec
cpl
return
ri
earlier
versu
hour
p
median
peak
concentr
spec
cpl
crp
lgl
mgdl
respect
dog
show
peak
spec
cpl
ri
dog
show
peak
crp
ri
find
suggest
spec
cpl
crp
may
use
monitor
progress
dog
ap
without
presenc
complic
spec
cpl
crp
progress
return
ri
spec
cpl
peak
normal
faster
crp
valid
urinari
acid
assay
preliminari
use
dog
enteropathi
jessica
rigl
craig
ruaux
clincial
scienc
oregon
state
univers
corval
oregon
usa
neuroendocrin
system
gut
play
signific
role
regul
intestin
motor
sensori
function
well
modul
inflamm
intestin
serotonin
act
local
gastrointestin
tract
excess
shown
human
be
role
pathophysiolog
sever
gastrointestin
diseas
acid
main
stabl
metabolit
excret
urin
measur
compound
use
determin
degre
serotoninerg
system
activ
individu
make
potenti
marker
serotoninerg
system
activ
gastrointestin
diseas
aim
studi
valid
commerci
avail
elisa
assay
use
canin
urin
establish
refer
rang
creatinin
urin
sampl
clinic
healthi
dog
compar
valu
dog
enteropath
diseas
commerci
avail
competit
elisa
assay
valid
use
acidifi
canin
urin
sampl
matrix
valid
includ
determin
sensit
dynam
rang
accuraci
via
spike
recoveri
dilut
parallel
assess
interand
intraassay
precis
urin
sampl
dog
collect
clinic
healthi
show
sign
gastrointestin
diseas
per
manufactur
guidelin
sampl
acidifi
hcl
ph
methyl
prior
quantif
use
elisa
assay
observ
signific
matrix
effect
pool
canin
urin
dilut
studi
show
effect
overcom
use
dilut
sampl
urinari
creatinin
concentr
determin
oregon
state
univers
veterinari
diagnost
lab
use
nonacidif
aliquot
preliminari
refer
rang
urin
deriv
central
th
percentil
urinari
creatinin
clinic
healthi
dog
sensit
mgdl
observ
expect
oe
ratio
serial
dilut
urin
sampl
averag
rang
spike
recoveri
replic
urin
sampl
vari
specif
graviti
averag
rang
coeffici
variat
intraassay
variabl
rang
coeffici
variat
interassay
variabl
rang
three
urin
sampl
vari
specif
graviti
refer
rang
urin
creatinin
clinic
healthi
dog
urinari
creatinin
valu
dog
gastroenteropathi
significantli
greater
healthi
dog
median
creatinin
vs
healthi
dog
vs
dog
enteropathi
p
mann
whitney
test
show
signific
linear
relationship
p
r
urinari
creatinin
cibdai
score
system
sever
canin
gastrointestin
diseas
conclud
commerci
avail
elisa
describ
suffici
sensit
linear
accur
precis
reproduc
use
dilut
canin
urin
sampl
conclud
correl
excret
urin
sever
gastroenteropath
diseas
canin
assess
cibdai
score
system
use
marker
eosinophil
mediat
diseas
human
recent
studi
serum
concentr
shown
increas
dog
chronic
enteropathi
howev
fecal
sampl
may
prefer
serum
sampl
evalu
activ
eosinophil
within
gastrointestin
tract
method
measur
concentr
fecal
sampl
dog
yet
establish
therefor
aim
studi
develop
analyt
valid
method
measur
concentr
fecal
sampl
dog
use
electron
impact
ioniz
ga
chromatographymass
spectrometri
establish
refer
interv
fecal
concentr
healthi
control
dog
surplu
canin
fecal
sampl
prepar
analysi
extract
phosphat
buffer
salin
newborn
calf
serum
triton
mm
thimeros
analyt
assay
valid
limit
blank
lob
limit
detect
lod
linear
accuraci
precis
reproduc
determin
determin
refer
interv
consecut
fecal
sampl
collect
healthi
control
dog
lob
lod
assay
mmolg
fece
respect
observedtoexpect
oe
ratio
dilut
parallel
differ
fecal
sampl
dilut
rang
mean
aestandard
deviat
sd
ae
oe
spike
recoveri
rang
mean
ae
sd
ae
five
differ
fecal
sampl
spike
standard
lmoll
intraassay
coeffici
variat
cv
five
differ
fecal
sampl
interassay
cv
four
differ
fecal
sampl
refer
interv
mean
maximum
fecal
concentr
healthi
control
dog
establish
mmolg
fece
mmolg
fece
respect
conclus
measur
use
electron
impact
ioniz
ga
chromatographymass
spectrometri
sensit
linear
accur
precis
reproduc
use
fecal
sampl
dog
studi
assess
clinic
util
measur
fecal
sampl
dog
warrant
progress
spirocerca
lupi
nematod
infect
caudal
esophagu
dog
serv
final
host
lupi
induc
format
fibroinflammatori
nonneoplast
nodul
esophagu
transform
neoplast
lesion
eosinophil
infiltr
rare
found
within
nodul
earli
transient
eosinophilia
occur
experiment
biomark
eosinophil
activ
hypothes
serum
concentr
may
increas
dog
infect
lupi
may
use
discrimin
benign
malign
nodul
object
studi
compar
serum
concentr
dog
infect
lupi
healthi
dog
compar
serum
concentr
dog
benign
malign
nodul
serum
concentr
measur
dog
infect
lupi
benign
nodul
malign
nodul
healthi
control
dog
use
electron
impact
ioniz
ga
chromatographymass
spectrometri
mannwhitney
u
test
use
compar
serum
concentr
dog
lupi
infect
healthi
control
dog
comparison
dog
spirocercosi
base
malign
nodul
also
made
use
mannwhitney
u
test
signific
set
p
conclus
serum
concentr
significantli
higher
dog
esophag
infest
lupi
howev
serum
concentr
differ
dog
benign
malign
esophag
nodul
result
suggest
eosinophil
involv
canin
spirocercosi
might
overlook
previous
limit
studi
lack
data
preval
gastrointestin
parasit
be
import
caus
morbid
mechan
dilat
may
improv
dysphagia
howev
repeat
costli
treatment
common
anim
regain
normal
function
purpos
studi
determin
esophag
balloondil
feed
tube
ebdft
could
provid
effect
singleprocedur
altern
treatment
be
balloon
mount
esophag
feed
tube
would
place
similar
etub
remain
place
approxim
one
month
owner
perform
twice
daili
balloon
dilat
home
dog
diagnos
be
includ
follow
client
consent
exclus
criteria
includ
comorbid
prevent
gener
anesthesia
lack
followup
commun
four
femal
spay
dog
confirm
be
includ
preliminari
studi
dysphagia
score
abl
swallow
liquid
prior
ebdft
placement
patient
receiv
previou
esophag
balloon
dilat
patient
discharg
follow
day
postop
complic
occur
dog
includ
prematur
tube
remov
dog
prototyp
ebdft
failur
requir
exchang
one
dog
ultim
euthan
due
failur
improv
unrel
comorbid
one
dog
still
tube
place
two
dog
final
dysphagia
score
normal
eat
abl
swallow
kibbl
can
food
ebdft
placement
dog
feasibl
warrant
investig
determin
techniqu
provid
improv
outcom
be
thromboembol
event
common
complic
mani
diseas
veterinari
patient
antiplatelet
therapi
ineffect
prevent
polyunsatur
fatti
acid
pufa
inhibit
platelet
function
peopl
enhanc
efficaci
antiplatelet
therapi
object
studi
evalu
effect
lowdos
acetylsalicyl
acid
asa
mg
kgday
alon
pufa
mgkgday
alon
combin
asa
pufa
therapi
platelet
function
activ
marker
healthi
dog
platelet
function
measur
use
platelet
function
analyz
pfa
closur
time
whole
blood
aggregometri
flow
cytometri
use
measur
platelet
activ
pselectin
platelet
leukocyt
aggreg
test
evalu
baselin
therapi
asa
pufa
alon
combin
therapi
assess
effect
platelet
function
studi
demonstr
pufa
alon
caus
signific
chang
platelet
function
test
asa
alon
decreas
platelet
function
measur
pfaepinephrin
follow
one
week
therapi
p
asa
plu
pufa
decreas
platelet
function
significantli
versu
asa
alon
measur
whole
blood
aggregometri
agonist
arachidon
acid
p
collagen
p
chang
platelet
activ
detect
via
flow
cytometri
therapi
conclus
asa
plu
pufa
appear
synergist
effect
inhibit
platelet
function
healthi
dog
combin
therapi
may
increas
efficaci
antiplatelet
therapi
dog
risk
thromboembol
complic
neutrophil
extracellular
trap
net
web
dna
protein
protect
infect
prothrombot
mortal
canin
immunemedi
hemolyt
anemia
imha
larg
result
thrombosi
imha
associ
two
trigger
net
format
heme
hypoxia
therefor
net
may
prognost
marker
therapeut
target
imha
howev
net
previous
demonstr
dog
studi
aim
develop
method
vitro
gener
net
canin
neutrophil
determin
dog
primari
imha
higher
circul
nucleosom
marker
correl
net
healthi
dog
neutrophil
isol
healthi
pet
dog
cultur
increas
concentr
phorbol
pma
plateletactiv
factor
paf
extracellular
dna
releas
measur
use
sytox
green
fluoresc
confoc
immunofluoresc
imag
perform
visual
net
use
dapi
label
antielastas
antibodi
nucleosom
measur
serum
healthi
dog
imha
dog
use
commerci
elisa
four
imha
dog
exclud
due
posit
interfer
hemolysi
icteru
cell
stimul
paf
lm
pma
lm
releas
significantli
dna
unstimul
cell
p
dna
releas
maxim
hour
paf
hour
pma
imag
confirm
net
format
imha
dog
significantli
higher
nucleosom
control
median
absorb
arbitrari
unit
respect
p
conclus
show
canin
neutrophil
make
net
provid
preliminari
evid
net
elev
imha
leukoreduct
perform
process
pack
cell
fresh
frozen
plasma
ffp
human
transfus
decreas
risk
immun
febril
reaction
howev
leukoreduct
shown
reduc
coagul
factor
content
ffp
sinc
ffp
prefer
transfus
product
dog
coagulopathi
investig
effect
leukoreduct
canin
ffp
crossov
studi
whole
blood
unit
collect
two
separ
occas
healthi
dog
half
unit
leukocyteand
plateletdeplet
use
leukoreduct
filter
terumo
leukoreduc
lr
nonleukoreduc
nlr
unit
centrifug
prepar
ffp
comparison
follow
hemostat
paramet
prothrombin
time
pt
partial
thromboplastin
time
ptt
fibrinogen
coagul
factor
v
vii
viii
x
xi
antithrombin
protein
c
assay
measur
function
procoagul
anticoagul
factor
activ
use
pool
normal
canin
plasma
refer
standard
compar
nlr
ffp
leukoreduct
result
rel
prolong
pt
ptt
respect
also
found
lr
ffp
rel
decreas
activ
factor
v
factor
viii
factor
x
increas
activ
factor
vii
factor
xi
studi
reveal
variat
coagul
factor
content
lr
ffp
howev
chang
consid
unlik
influenc
efficaci
canin
ffp
factor
replac
transfus
trial
lr
ffp
warrant
assess
benefit
reduc
advers
transfus
reaction
dog
coagulopathi
dal
blood
type
high
frequenc
antigen
associ
product
antid
antibodi
may
result
ineffect
transfus
hemolyt
transfus
reaction
dea
test
dal
remain
depend
avail
polyclon
antid
antibodi
obtain
follow
sensit
dalneg
dog
literatur
littl
known
timecours
antibodi
posttransfus
led
present
studi
purpos
studi
produc
character
antid
antibodi
follow
standard
blood
transfus
notabl
determin
rate
appear
agglutin
titer
time
immunoglobulin
class
secondari
object
produc
polyclon
antid
antibodi
increas
avail
dal
blood
type
follow
dal
blood
type
adult
beagl
one
dalneg
individu
identifi
index
dog
healthi
base
physic
exam
hematolog
biochemistri
profil
index
dog
potenti
blood
donor
extens
blood
type
dea
dal
use
tube
gel
column
techniqu
well
alvedia
dea
lab
test
avoid
fluid
overload
mlkg
blood
first
collect
index
dog
follow
mild
sedat
butorphanol
mgkg
transfus
dal
pack
red
blood
cell
administ
hour
ml
mlkg
follow
transfus
week
index
dog
close
monitor
includ
pcvt
bilirubinemia
hematuria
hemoglobinuria
blood
sampl
collect
posttransfus
day
mlsampl
month
ml
one
year
sever
coomb
test
perform
day
week
soon
antid
antibodi
detect
agglutin
titer
defin
highest
serum
dilut
posit
agglutin
reaction
observ
perform
duplic
use
twofold
dilut
fresh
serum
gel
column
techniqu
immunoglobulin
type
determin
week
follow
sulfhydryl
treatment
agglutin
titer
also
perform
frozen
serum
aliquot
time
evalu
stabil
polyclon
antid
antibodi
freez
final
dog
blood
type
use
polyclon
antid
antibodi
produc
index
dog
well
previous
document
antid
reagent
index
dog
blood
type
dea
dal
blood
donor
dea
dal
transfus
unev
clinic
andor
laboratori
sign
hemolyt
transfus
reaction
observ
pcvt
remain
stabl
time
except
expect
increas
pcv
hour
posttransfus
return
initi
valu
hour
later
coomb
test
neg
weak
posit
antid
agglutin
reaction
first
observ
day
titer
agglutin
titer
progress
thereaft
reach
maximum
week
follow
gradual
decreas
one
year
posttransfus
antid
antibodi
appear
igg
class
antid
antibodi
produc
prior
day
longer
detect
follow
freez
period
howev
freez
caus
decreas
agglutin
titer
antid
antibodi
collect
day
ie
titer
level
thereaft
use
daltyp
purpos
dog
blood
type
dal
concord
result
use
polyclon
antid
antibodi
daland
dal
studi
dalneg
dog
sensit
dal
via
first
blood
transfus
sign
acut
delay
hemolyt
transfus
reaction
observ
antid
antibodi
like
igg
detect
earli
day
posttransfus
highest
agglutin
titer
reach
week
antid
titer
decreas
time
remain
detect
one
year
posttransfus
storag
blood
product
creat
unnatur
environ
acceler
red
blood
cell
rbc
degrad
one
well
recogn
indic
rbc
degrad
transloc
phosphatidylserin
outer
cell
membran
layer
unit
store
human
blood
increas
phosphatidylserin
express
associ
subsequ
reduct
circul
surviv
time
transfus
rbc
increas
incid
transfusionrel
complic
addit
leukoreduct
step
extract
leukocyt
platelet
blood
product
prior
storag
remov
cell
unabl
influenc
degrad
rbc
within
unit
dog
unknown
leukoreduct
subsequ
storag
blood
product
influenc
express
phosphatidylserin
rbc
crossov
studi
unit
fresh
whole
blood
collect
healthi
dog
two
separ
occas
half
leukoreduc
use
leukoreduct
filter
prior
centrifug
creat
unit
pack
rbc
unit
refriger
store
day
storag
blood
collect
unit
rbc
phosphatidylserin
express
quantit
via
flow
cytometri
sampl
collect
remov
refriger
five
hour
room
temperatur
simul
transfus
condit
nonleukoreduc
unit
median
rbc
express
phosphatidylserin
decreas
increas
day
storag
respect
leukoreduc
unit
phosphatidylserin
express
decreas
increas
day
storag
respect
held
room
temperatur
hour
phosphatidylserin
express
nonleukoreduc
unit
decreas
day
day
leukoreduc
unit
decreas
day
day
respect
studi
suggest
canin
pack
rbc
phosphatidylserin
express
significantli
affect
leukoreduct
storag
warm
transfus
portal
vein
thrombosi
pvt
rare
potenti
fatal
complic
splenectomi
dog
mechan
behind
postop
pvt
develop
unclear
may
includ
alter
portal
blood
flow
follow
surgeri
acquir
hypercoagul
endotheli
dysfunct
aim
studi
evalu
hemostat
biomark
hemodynam
stabl
heart
rate
beatsminut
blood
lactat
mmoll
nonanem
hematocrit
dog
prior
splenectomi
splenic
mass
hypothes
dog
would
preoper
coagul
derang
present
risk
postop
thrombosi
preoper
abdomin
ultrasonographi
perform
blood
collect
platelet
enumer
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
kaolinactiv
thromboelastographi
teg
fibrinogen
von
willebrand
factor
activ
vwf
ag
antithrombin
thrombinantithrombin
complex
tat
histopatholog
diagnosi
surviv
record
none
enrol
dog
preoper
sonograph
evid
pvt
three
fifteen
dog
thrombocytopen
three
thrombocytosi
three
hyperfibrinogenem
one
low
vwf
ag
three
mild
prolong
pt
none
abnorm
aptt
base
teg
g
valu
dog
hypercoagul
meanaesd
ae
antithrombin
defici
identifi
dog
mean
ae
sd
ae
concurr
elev
tat
suggest
activ
thrombin
gener
signific
differ
hemostat
biomark
outcom
dog
malign
compar
benign
lesion
p
dog
develop
pvt
achiev
surviv
preoper
hypercoagul
recogn
commonli
may
part
contribut
risk
postop
pvt
dog
splenectomi
activ
clot
time
healthi
sedat
cat
use
maxact
system
anthoni
abramsogg
kimberli
ho
shauna
bloi
karol
mathew
mari
holowaychuk
alexa
bersena
darren
wood
univers
guelph
guelph
ontario
canada
activ
clot
time
act
cat
base
visual
first
clot
use
tube
longer
avail
report
mean
sec
median
sec
ci
sec
effect
sedat
j
vet
re
use
current
avail
maxact
tube
visual
end
clot
format
report
mean
sec
rang
sec
aust
vet
j
present
studi
maxact
measur
healthi
clientown
cat
normal
hematolog
hemostasi
cat
sedat
ketamin
mgkg
butorphanol
mgkg
given
via
saphen
vein
use
jugular
venipunctur
butterfli
needl
blood
draw
vacuum
tube
hematolog
blood
collect
syring
blood
draw
qualiti
grade
easi
difficult
ml
dispens
maxact
tube
warm
axillari
incub
sec
visual
inspect
first
clot
format
end
clot
format
anoth
ml
synchron
dispens
second
maxact
tube
incub
instrument
mechan
detect
end
clot
format
actalyk
mini
ii
blood
collect
qualiti
score
cat
cat
actalyk
valu
obtain
cat
insuffici
quantiti
act
median
geometr
mean
varianc
differ
qualiti
valu
combin
describ
normal
rang
ie
ci
tabl
visual
end
clot
actalyk
valu
correl
p
geometr
mean
respect
varianc
differ
p
actalyk
valu
visual
end
clot
valu
factor
xii
activ
measur
cat
maxact
sec
normal
blood
collect
qualiti
score
cat
actalyk
fail
end
incub
sec
cat
visual
actalyk
valu
cat
consid
outlier
remov
analysi
visual
valu
cat
normal
rang
cat
normal
rang
healthi
facil
cat
maxact
measur
day
tabl
collect
score
valu
within
normal
rang
overal
median
mean
varianc
differ
day
although
individu
valu
vari
visual
clot
pair
observ
ident
differ
sec
sec
actalyk
pair
observ
differ
sec
differ
sec
intraclass
correl
coeffici
studi
maxact
similar
first
report
act
cat
repeat
high
within
rang
ae
sec
visual
clot
repeat
actalyk
procabarbazin
alkyl
agent
use
treatment
granulomat
meningoenceph
gme
side
effect
procarbazin
includ
gastrointestin
hematolog
side
effect
purpos
studi
describ
procarbazin
associ
cytopenia
dog
medic
record
retrospect
review
data
collect
includ
signal
dosag
durat
procarbazin
therapi
clinicopatholog
find
outcom
eight
dog
five
castrat
male
three
spay
femal
includ
final
analysi
seven
dog
receiv
procarbazin
gme
one
inflammatori
myositi
dog
small
breed
pug
chihuahua
havanes
corgi
fox
terrier
rat
terrier
dosag
procarbazin
rang
mgm
twice
daili
everi
day
median
durat
procarbazin
therapi
week
rang
week
onset
clinic
sign
includ
fever
lethargi
median
white
cell
count
time
diagnosi
rang
median
platelet
count
rang
median
hematocrit
rang
procarbazin
discontinu
dog
antibiot
initi
case
addit
treatment
eg
blood
transfus
discret
primari
clinician
seven
eight
dog
surviv
discharg
one
patient
discharg
lost
followup
advers
hematolog
effect
associ
procarbazin
toxic
sever
commonli
fatal
dog
unclear
bone
marrow
recoveri
possibl
dog
time
requir
achiev
bone
marrow
recoveri
known
blood
ga
analyz
commonli
use
assess
respiratori
function
metabol
derang
small
anim
patient
pointofcar
analyz
becom
increasingli
popular
way
provid
fast
patientsid
result
emerg
situat
enterpris
pointof
care
epoc
blood
ga
analyz
newli
avail
yet
valid
canin
patient
object
studi
compar
analyt
perform
epoc
analyz
bench
top
rapidlab
blood
ga
analyz
arteri
blood
ga
sampl
prospect
collect
healthi
dog
variabl
age
analyz
use
epoc
rapidlab
analyz
concord
correl
blandaltman
plot
use
assess
agreement
bia
two
analyz
concord
correl
ccc
show
excel
agreement
three
analyt
lactat
pao
paco
ccc
respect
analyt
ph
hematocrit
sodium
potassium
ioniz
calcium
glucos
agreement
vari
slight
substanti
ccc
glucos
analyt
blandaltman
plot
measur
bia
two
analyz
sodium
haematocrit
wide
varianc
could
potenti
clinic
signific
epoc
analyz
easi
use
reliabl
portabl
although
ccc
show
unsatisfactori
agreement
analyt
major
accept
clinic
varianc
blandaltman
plot
conclus
epoc
analyz
suitabl
use
small
anim
patient
analyt
except
sodium
hematocrit
studi
warrant
evalu
epoc
nonhealthi
anim
osmot
fragil
erythrocyt
determin
fragil
hypoton
solut
goal
studi
determin
mean
mof
cat
anemia
evalu
suitabl
test
diagnos
anem
patient
studi
includ
anem
cat
variou
form
anemia
anemia
categor
follow
group
acutechron
blood
loss
anemia
ba
hemolyt
anemia
ha
anemia
inflammatori
neoplast
diseas
aid
intramedullari
inr
extramedullari
nonregen
anemia
enr
perform
mix
red
blood
cell
serial
dilut
nacl
solut
mof
determin
lysi
curv
concentr
nacl
erythrocyt
hemolys
test
assess
three
differ
peopl
statist
analysi
done
use
spss
ib
version
cat
use
control
exhibit
mof
mean
signific
differ
measur
mof
among
three
examin
kruskalwallistest
pvalu
therefor
percentil
use
refer
valu
ie
mof
regard
increas
decreas
cat
ha
n
exhibit
highest
mof
median
two
cat
chronic
ba
lowest
mof
valu
overal
group
exhibit
follow
rate
increas
mof
ha
inr
enr
aid
acut
ba
n
respect
mof
may
use
tool
diagnos
ha
ba
help
differenti
nonregen
immunemedi
hemolyt
anemia
form
nonregen
anemia
low
mof
valu
indic
chronic
ba
measur
plasma
fibrinogen
dog
hepatobiliari
diseas
sara
wennogl
allison
bradley
christin
olver
david
twedt
colorado
state
univers
fort
collin
co
usa
hypofibrinogenemia
describ
human
advanc
liver
diseas
dog
chronic
hepat
addit
hypofibriongenemia
recent
correl
periop
bleed
liver
transplant
human
plasma
fibrinogen
concentr
compar
among
differ
categori
liver
diseas
dog
goal
studi
retrospect
evalu
fibrinogen
concentr
dog
variou
histolog
type
liver
diseas
fibrinogen
measur
store
citrat
plasma
dog
underw
liver
biopsi
colorado
state
univers
june
fibrinogen
assay
perform
destini
amax
plu
tm
analyz
result
report
mgdl
report
normal
refer
rang
assay
mgdl
base
histolog
diagnosi
dog
group
one
follow
categori
nonspecif
reactiv
hepatopathynsr
n
chronic
hepatitisch
n
hydropicvacuolar
hepatopathi
n
cholangiohepat
n
neoplasia
n
n
group
compar
via
oneway
anova
tukey
adjust
pairwis
comparison
signific
defin
p
plasma
fibrinogen
summari
data
shown
figur
dog
histolog
confirm
ch
significantli
lower
mean
fibrinogen
concentr
histolog
categori
nsr
p
hydropicvacuolar
p
cholangiohepat
p
neoplasia
p
p
mean
fibrinogen
level
differ
among
histolog
type
liver
diseas
hypofibrinogenemia
like
occur
dog
ch
type
hepatobiliari
diseas
plasma
fibrinogen
concentr
may
use
indirect
indic
hepat
function
hypofibrinogenemia
may
also
predispos
patient
periop
bleed
studi
need
better
character
hypofibrinogenemia
dog
hepatobiliari
diseas
preval
cobalamin
defici
cat
hepat
lipidosi
fhl
unknown
cobalamin
serv
cofactor
metabol
reaction
respons
gener
carnitin
promot
oxid
fatti
acid
antioxid
glutathion
cobalamin
defici
could
therefor
play
role
pathogenesi
fhl
aim
studi
determin
preval
hypocobalaminemia
cat
fhl
compar
serum
methylmalon
acid
mma
homocystein
hci
concentr
healthi
cat
cat
fhl
sixteen
cat
cytolog
diagnos
fhl
divid
two
group
group
cat
definit
diagnos
underli
diseas
year
fs
mc
group
cat
definit
diagnos
underli
diseas
serum
folat
cobalamin
concentr
measur
use
autom
chemiluminesc
assay
serum
mma
hci
concentr
measur
use
inhous
gcm
assay
preval
hypocobalaminemia
refer
interv
ngl
hypofolatemia
refer
interv
lgl
compar
among
three
group
use
v
test
serum
mma
hci
concentr
compar
amongst
three
group
use
anova
kruskalw
test
appropri
statist
signific
set
p
preval
hypocobalaminemia
follow
group
respect
p
preval
hypofolatemia
follow
group
respect
p
serum
cobalamin
concentr
mean
aesd
lower
group
ae
ngl
group
ae
ngl
p
serum
folat
concentr
mean
ae
sd
lower
group
ae
lgl
group
ae
lgl
group
ae
lgl
p
serum
mma
concentr
median
higher
group
nmoll
group
nmol
l
group
nmoll
p
p
respect
serum
hci
concentr
significantli
differ
among
three
group
p
overal
preval
hypocobalaminemia
cat
fhl
rel
low
associ
presenc
definit
diagnos
underli
diseas
howev
cat
suffer
fhl
without
definit
diagnos
underli
diseas
higher
serum
mma
concentr
healthi
cat
possibl
indic
cobalamin
defici
cellular
level
overal
preval
hypofolatemia
cat
fhl
higher
associ
presenc
definit
diagnos
underli
diseas
diagnost
cholecystocentesi
frequent
perform
evalu
hepatobiliari
diseas
small
anim
clinic
experi
cytolog
bactibilia
alway
associ
posit
microbiolog
cultur
larg
studi
describ
cytolog
find
bile
lack
veterinari
literatur
aim
retrospect
studi
evalu
agreement
cytolog
microbiolog
find
bile
dog
cat
hepatobiliari
diseas
electron
medic
record
texa
univers
search
dog
cat
cholecystocentesi
concurr
bile
cytolog
bile
cultur
perform
cohen
kappa
coeffici
j
use
measur
agreement
differ
diagnost
techniqu
fiftytwo
patient
met
inclus
criteria
bactibilia
cytolog
identifi
sampl
bacteri
cultur
growth
identifi
sampl
one
neg
cytolog
result
posit
bacteri
growth
good
agreement
bile
cytolog
cultur
growth
sampl
j
ci
enterococcu
spp
common
isol
sampl
follow
escherichia
coli
sampl
fair
agreement
cytolog
evid
inflamm
cytolog
evid
bactibilia
j
final
poor
agreement
cytolog
evid
inflamm
posit
bacteri
growth
j
ci
patient
popul
good
agreement
exist
presenc
absenc
bacteria
bile
cytolog
posit
neg
cultur
result
respect
evid
inflamm
alon
poorli
associ
cultur
bactibilia
empir
antimicrobi
therapi
target
enterococcu
spp
ecoli
isol
may
consid
clinic
ill
patient
cytolog
bactibilia
confirmatori
bacteri
cultur
result
pend
standard
poodl
suggest
suffer
breedrel
chronic
hepat
poodl
club
america
list
chronic
hepat
health
issu
purpos
prospect
studi
character
liver
histolog
clinic
cours
standard
poodl
suspect
chronic
hepat
liver
tissu
standard
poodl
suspect
chronic
hepat
solicit
period
approxim
three
year
patient
receiv
immunosuppress
therapi
exclud
veterinarian
owner
contact
longterm
outcom
inform
liver
sampl
submit
histolog
diagnosi
case
histori
review
inflamm
group
follow
categori
acut
hepat
chronic
hepat
includ
copperassoci
hepat
cirrhosi
reactiv
hepat
lesion
also
assign
total
score
point
histolog
featur
lobular
collaps
bile
duct
hyperplasia
interfac
hepat
focal
lytic
necrosisapoptosisrandom
inflamm
portal
inflamm
zonal
necrosi
fibrosi
hepat
metal
quantif
copper
zinc
iron
perform
adequ
tissu
avail
remaind
copper
iron
content
assess
semiquantit
histochem
stain
elig
liver
biopsi
receiv
avail
quantit
histolog
review
result
summar
chronic
hepat
common
diagnosi
submiss
group
standard
poodl
clinicopatholog
evid
liver
diseas
gener
patient
respond
well
immunomodulatori
therapi
howev
patient
total
histolog
score
greater
poor
prognosi
nonspecif
reactiv
hepat
also
common
submiss
dog
group
frequent
also
affect
gastrointestin
pancreaticobiliari
diseas
group
standard
poodl
chronic
reactiv
hepat
frequent
identifi
reactiv
hepat
nonspecif
often
associ
concurr
extrahepat
diseas
consist
histolog
featur
chronic
hepat
appear
uniqu
breed
primari
copperassoci
hepat
main
etiolog
group
dog
whether
chronic
hepat
breedspecif
condit
standard
poodl
remain
elucid
studi
caus
gallbladd
mucocel
format
dog
unknown
drug
use
prevent
flea
tick
infest
heartworm
infect
commonli
use
adjunct
treatment
degen
joint
diseas
repres
newergener
xenobiot
dog
chronic
expos
specul
pharmacogenom
differ
drug
metabol
may
reason
gallbladd
mucocel
develop
studi
examin
medic
record
dog
diagnos
institut
gallbladd
mucocel
match
control
ratio
base
age
breed
admiss
date
aim
determin
associ
gallbladd
mucocel
diagnosi
report
administr
prevent
drug
seventi
seven
dog
histolog
diagnosi
gallbladd
mucocel
match
control
singl
referr
institut
includ
studi
select
case
control
done
medic
record
access
review
period
owner
contact
verif
drug
histori
standard
mail
questionnair
report
use
type
heartworm
flea
tick
prevent
nonsteroid
antiinflammatori
drug
oral
analges
corticosteroid
medic
use
adjunct
treatment
osteoarthr
hyperadrenocortic
hypothyroid
diabet
mellitu
record
data
describ
use
basic
statist
analyz
use
condit
logist
regress
identifi
univari
associ
gallbladd
mucocel
diagnosi
use
mention
medic
odd
ratio
confid
interv
odd
ratio
use
identifi
variabl
analysi
dog
diagnos
gallbladd
mucocel
rang
age
year
median
year
shetland
sheepdog
cocker
spaniel
chihuahua
significantli
overrepres
rel
gener
hospit
popul
dog
gallbladd
mucocel
time
like
report
treatment
thyroxin
proxi
diagnosi
hypothyroid
control
dog
ci
p
time
like
report
treatment
cush
diseas
ci
p
time
like
report
use
product
contain
imidacloprid
ci
p
lower
side
ci
imidacloprid
cross
result
interpret
caution
base
uniqu
pharmacogenom
differ
shetland
sheepdog
eg
gene
mutat
analyz
two
data
subset
consid
shetland
sheepdog
one
group
case
control
breed
differ
group
multivari
analysi
possibl
due
spars
data
result
indic
shetland
sheepdog
mucocel
diagnosi
time
like
report
use
imidacloprid
control
dog
ci
p
subset
dog
indic
associ
result
studi
suggest
possibl
associ
shetland
sheepdog
diagnos
gallbladd
mucocel
format
use
product
contain
imidacloprid
although
result
interpret
caution
due
larg
confid
interv
margin
pvalu
result
suggest
studi
imidacloprid
larger
popul
shetland
sheepdog
may
warrant
evalu
liver
fibrosi
lf
major
import
manag
chronic
liver
diseas
predict
prognosi
although
liver
biopsi
gold
standard
evalu
fibrosi
noninvas
test
human
medicin
enabl
clinician
success
stage
monitor
wide
varieti
liver
diseas
veterinari
medicin
would
desir
simpl
quick
noninvas
way
earli
identifi
dog
lf
aim
studi
develop
blood
score
system
help
clinician
screen
dog
lf
decid
need
investig
forti
seven
adult
dog
prospect
enrol
base
persist
elev
alt
exclus
focal
lesion
ultrasound
examin
four
healthi
dog
includ
control
approv
ethic
committe
dog
underw
liver
biopsi
serum
blood
collect
lf
stage
accord
wsava
criteria
amount
collagen
measur
morphometr
analysi
combin
sever
hepat
injuri
biomark
fibrogen
activ
biomark
gave
neg
predict
valu
moder
fibrosi
mean
score
system
enabl
identifi
dog
without
lf
also
distinguish
dog
signific
fibrosi
auroc
curv
posit
predict
valu
new
blood
score
system
might
prove
use
clinician
earli
classifi
patient
lf
pursu
liver
biopsi
part
investig
despit
correct
prothrombin
time
pt
activ
partial
thromboplastin
time
ptt
parenter
vitamin
k
presenc
normal
platelet
count
mani
cat
cholestat
hepatobiliari
diseas
develop
progress
anemia
hospit
provoc
procedur
hypothes
bleed
tendenc
cat
might
associ
decreas
clot
strength
fibrinolysi
monitor
thromboelastographi
teg
thu
studi
conduct
compar
teg
analysi
cat
cholestasi
convent
coagul
test
seventeen
cat
serum
hyperbilirubinemia
time
upper
limit
normal
serum
alanin
aminotransferas
alt
activ
time
upper
limit
normal
pcv
greater
recruit
cat
treat
dose
vitamin
subcutan
hr
prior
coagul
test
mean
valu
teg
paramet
r
k
angl
pt
aptt
platelet
count
cholestat
cat
differ
significantli
refer
rang
one
except
significantli
increas
g
ae
dyness
vs
ae
dynessec
p
teg
g
valu
label
cat
hypercoagul
normocoagul
hypocoagul
respect
compar
normal
cat
hypercoagul
cat
signific
decreas
aptt
ae
vs
p
k
ae
vs
ae
p
increas
angl
ae
vs
ae
p
compar
normal
cat
hypocoagul
cat
significantli
lower
platelet
count
kul
ae
kul
vs
kul
ae
kul
p
prolong
k
ae
vs
ae
p
decreas
angl
ae
vs
ae
p
increas
one
cat
normal
hypocoagul
conclus
teg
analysi
cholestat
cat
replet
vitamin
k
rare
hyperfibrinolysi
varieti
coagul
profil
tendenc
normoor
hypercoagul
hepat
whitney
fri
carri
lester
nahv
etedali
armel
delaforcad
cynthia
webster
cum
school
veterinari
medicin
tuft
univers
grafton
usa
due
liver
role
synthesi
major
proand
anticoagul
well
regul
fibrinolysi
complex
rebal
coagul
exist
dog
chronic
hepat
ch
convent
plasma
base
coagul
test
thrombocytopenia
prolong
prothrombin
pt
activ
partial
thromboplastin
time
aptt
well
decreas
fibrinogen
report
dog
ch
despit
alter
result
hypocoagul
spontan
bleed
rare
fact
ch
risk
factor
portal
vein
thrombosi
presum
relat
decreas
product
anticoagul
endotheli
dysfunct
secondari
portal
hypertens
aim
current
studi
gain
better
perspect
state
coagul
dog
ch
perform
thromboelastographi
teg
compar
convent
coagul
test
seventeen
dog
biopsi
proven
ch
dog
clinic
evid
end
stage
liver
diseas
recruit
pt
aptt
platelet
count
pcv
kaolin
activ
teg
perform
accord
publish
standard
dog
fibrinogen
antithrombin
activ
protein
c
activ
pc
ddimer
vwf
activ
perform
eleven
breed
mean
age
ae
yr
enrol
dog
pcv
normal
rang
compar
refer
rang
dog
ch
longer
r
ae
p
k
ae
p
valu
smaller
angl
ae
p
increas
p
fibrinogen
p
activ
p
pc
activ
p
significantli
decreas
teg
g
valu
defin
dog
normocoagul
hypercoagul
hypocoagul
respect
g
posit
correl
pc
activ
p
p
neg
correl
pt
p
aptt
p
four
dog
hyperfibrinolyt
mean
ae
conclus
teg
analysi
dog
ch
varieti
coagul
state
pt
aptt
pc
activ
predict
state
coagul
determin
teg
dog
ch
hyperfibrinolyt
condit
would
miss
convent
coagul
test
alexi
lecoindr
patrick
lecoindr
michel
chevalli
hecham
azrak
mari
destro
veroniqu
miett
jeanluc
cador
e
vetagrosup
veterinari
campu
lyon
franc
cvc
veterinari
clinic
lyon
franc
biomni
lyon
franc
echosen
pari
franc
clinic
cours
chronic
liver
diseas
significantli
depend
progress
rate
fibrosi
liver
biopsi
consid
gold
standard
stage
fibrosi
scottish
terrier
st
breedspecif
syndrom
associ
vacuolar
hepatopathi
vh
character
differ
grade
hepatocyt
vacuol
fibrosi
aim
studi
evalu
correl
serum
biomark
liver
fibrosi
st
valid
method
use
breed
forti
nine
st
enrol
retrospect
basi
presenc
vh
histolog
biochemistri
panel
includ
alp
alt
ast
cholesterol
gldh
ldh
bilirubin
basal
cortisol
basal
bile
acid
ggt
total
triglycerid
liver
biopsi
perform
basi
alp
activ
presenc
diffus
hepat
parenchym
modif
ultrasound
examin
fibrosi
evalu
use
metavir
score
system
agreement
wsava
guidelin
signific
sever
fibrosi
predict
logist
regress
use
biolog
paramet
accord
metavir
score
preval
diagnost
target
select
popul
signific
fibrosi
sever
fibrosi
auroc
curv
deriv
score
probabl
respect
se
sp
se
sp
studi
show
interest
correl
noninvas
method
liver
fibrosi
st
howev
singl
marker
ideal
predict
fibrosi
combin
sever
marker
might
help
offer
diagnost
test
liver
fibrosi
accept
sensit
specif
canin
immunemedi
thrombocytopenia
itp
immunemedi
hemolyt
anemia
imha
associ
high
morbid
risk
mortal
thymidin
kinas
tk
enzym
import
dna
synthesi
cell
divis
may
correl
uncontrol
replic
regener
follow
destruct
canin
creactiv
protein
ccrp
use
inflammatori
diseas
biomark
oh
involv
innat
adapt
immun
hypovitaminosi
associ
increas
incid
autoimmun
diseas
human
hypothes
plasma
tk
ccrp
would
significantli
higher
dog
poorlyversu
wellcontrol
itp
imha
dog
would
vitamin
insuffici
plasma
collect
clientown
dog
n
present
univers
missouri
veterinari
medic
teach
hospit
sampl
collect
dog
serial
sampl
collect
initi
diagnosi
n
recheck
examin
n
diseas
control
determin
hematocritpack
cell
volum
platelet
count
plasma
tk
ccrp
oh
measur
commerci
veterinari
diagnost
institut
ca
tk
ccrp
significantli
increas
poorlyversu
wellcontrol
dog
p
p
respect
poorlyv
wellcontrol
median
concentr
tk
ul
ref
ccrp
mgl
ref
mgl
two
dog
vitamin
insuffici
defin
ngml
meanaesd
sampl
ae
ngml
tk
ccrp
warrant
investig
biomark
monitor
immunemedi
diseas
control
vitamin
insuffici
may
suggest
supplement
could
improv
therapeut
respons
reduc
diseas
risk
though
addit
studi
need
adiposederiv
mesenchym
stem
cell
amsc
recent
investig
immunomodulatori
therapi
cat
chronic
kidney
diseas
asthma
influenc
age
prolif
immunomodulatori
potenti
felin
amsc
explor
implic
autolog
versu
allogen
therapi
purpos
studi
compar
telomer
length
abil
prolifer
cultur
abil
suppress
lymphocyt
prolifer
amsc
gener
young
geriatr
cat
adipos
tissu
six
young
year
six
geriatr
year
cat
harvest
cryopreserv
subsequ
amsc
isol
cultur
amsc
prolifer
cultur
compar
via
determin
time
passag
two
mtt
prolifer
assay
immunomodulatori
capac
assess
use
lymphocyt
prolifer
assay
telomer
length
measur
use
fluoresc
situ
hybrid
assay
perform
amsc
cell
adiposederiv
msc
geriatr
cat
took
significantli
longer
p
reach
median
day
rang
day
compar
amsc
young
cat
median
day
rang
day
differ
mtt
prolifer
assay
perform
detect
signific
differ
found
two
group
telomer
length
abil
suppress
lymphocyt
prolifer
compar
young
felin
amsc
geriatr
amsc
impair
abil
rapidli
prolifer
follow
initi
cultur
present
concern
autolog
therapi
howev
replic
potenti
repres
telomer
length
immunomodulatori
potenti
similar
two
age
group
autoimmun
diseas
common
lifethreaten
diseas
dog
mani
canin
autoimmun
diseas
strong
breed
predisposit
believ
inherit
howev
genet
mutat
caus
predict
diseas
mostli
unknown
mani
autoimmun
diseas
human
share
polymorph
among
common
set
gene
conduct
candid
gene
studi
assess
whether
caus
predict
polymorph
might
exist
similar
gene
dog
initi
perform
target
resequenc
gene
dog
immunemedi
hemolyt
anemia
imha
base
upon
find
sequenc
allel
exon
gene
addit
dog
dog
evalu
across
breed
autoimmun
diseas
imha
atop
dermat
immunemedi
thrombocytopenia
immunemedi
polyarthr
impa
dog
serv
control
frequenc
variant
allel
significantli
higher
dog
autoimmun
diseas
control
dog
vs
p
rang
dog
impa
dog
atop
dermat
altern
allel
caus
two
nonsynonym
substitut
result
amino
acid
chang
mutat
occur
antigen
bind
pocket
homolog
human
protein
variant
gene
may
associ
multipl
autoimmun
diseas
dog
studi
warrant
confirm
find
broadli
determin
specif
mechan
identifi
variant
may
alter
canin
immun
system
function
type
regulatori
cell
play
pivot
role
mainten
peripher
toler
contrast
extens
character
human
mice
littl
known
cell
dog
import
veterinari
speci
anim
model
variou
human
diseas
secret
highlevel
consid
defin
hallmark
cell
date
wellvalid
assay
intracellular
dog
describ
goal
develop
robust
flow
cytometr
assay
canin
intracellular
precursor
studi
cell
speci
screen
three
commerci
avail
antibodi
ab
monoclon
antihuman
ab
clone
market
use
flow
cytometri
western
blot
polyclon
catalog
number
monoclon
clone
anticanin
ab
market
use
western
blot
crossreact
antihuman
monoclon
ab
predict
basi
amino
acid
sequenc
ident
canin
human
protein
canin
clone
two
vector
pmig
construct
use
transfect
human
embryon
kidney
hek
cell
surprisingli
canin
express
transfect
cell
fail
detect
antihuman
monoclon
ab
either
western
blot
flow
cytometri
anticanin
ab
detect
canin
express
transfect
hek
cell
polyclon
ab
perform
better
set
western
blot
monoclon
ab
perform
better
set
flow
cytometri
summari
two
commerci
avail
ab
valid
detect
canin
intracellular
studi
examin
express
cytokin
vitrogener
cell
peripher
blood
monoclon
cell
dog
immunemedi
neoplast
diseas
ongo
use
mesenchym
stem
cell
msc
therapi
treat
clinic
diseas
may
optim
select
precondit
method
would
enhanc
immunomodulatori
function
investig
effect
sever
precondit
method
gender
tissu
donor
paramet
felin
adiposederiv
msc
vitro
may
applic
optim
clinic
effect
msc
applic
speci
passag
felin
msc
gener
cryopreserv
subcutan
adipos
tissu
healthi
cat
three
male
three
femal
msc
subject
six
differ
precondit
agent
condit
hour
control
poli
c
ifnc
tgfb
serumfre
hypoxia
supernat
msc
harvest
hour
aliquot
frozen
batch
analysi
level
supernat
determin
elisa
pretreat
gender
donor
significantli
affect
measur
cytokin
level
hour
supernat
felin
adiposederiv
msc
affect
donor
gender
wherea
measur
cytokin
affect
least
one
pretreat
although
studi
necessari
initi
studi
show
specif
precondit
method
hold
promis
tailor
augment
felin
adiposederiv
msc
immunomodulatori
properti
treat
specif
diseas
gender
donor
cat
may
signific
speci
depend
desir
therapeut
outcom
infecti
pathogen
link
canin
immunemedi
hemolyt
anemia
imha
immunemedi
thrombocytopenia
itp
includ
viral
bacteri
protozoan
rickettsi
organ
purpos
studi
retrospect
screen
canin
vector
born
diseas
cvbd
use
serolog
pcr
method
imhaitp
case
southeastern
region
unit
state
archiv
serum
popul
dog
test
tickborn
diseas
ifa
ehrlichia
cani
rickettsia
rickettsii
babesia
cani
bartonella
hensela
bartonella
vinsonii
subsp
berkhoffii
snap
e
cani
anaplasma
spp
borrelia
burgdorferi
immiti
character
retrospect
screen
use
snap
experiment
diagnost
elisa
assay
use
synthet
speciesspecif
peptid
differenti
exposur
e
cani
e
chaffeensi
e
ewingii
anaplasma
phagocytophilum
plati
borrelia
burgdorferi
retrospect
screen
canin
sera
dog
identifi
access
clinic
data
diagnosi
imha
andor
itp
correspond
store
edtaanticoagul
whole
blood
retrospect
pcr
test
total
dog
seroreact
cvbd
pathogen
snap
identifi
addit
dog
initi
nonseroreact
pathogen
ifa
snap
preval
antibodi
reactiv
r
rickettsii
antigen
follow
b
burgdorferi
anaplasma
spp
e
ewingii
e
cani
e
chaffeensi
b
hensela
dog
screen
vectorborn
pathogen
pcr
initi
diagnosi
request
babesia
pcr
ehrlichia
pcr
babesia
ehrlichia
pcr
request
babesia
bartonella
ehrlichia
pcr
base
pcr
result
done
time
diagnosi
dog
pcr
posit
vectorborn
pathogen
e
ewingii
retrospect
pcr
test
includ
rtpcr
assay
detect
anaplasma
spp
babesia
spp
bartonella
spp
canin
hemotrop
mycoplasma
ehrlichia
spp
hepatozoon
spp
leishmania
spp
neorickettsia
risticii
rickettsia
rickettsia
identifi
pcr
posit
dog
mycoplasma
hemocani
e
ewingii
result
underscor
import
multimod
diagnost
approach
detect
tickborn
pathogen
support
evalu
potenti
role
e
ewingii
cvbd
pathogenesi
imha
itp
dog
leutenegg
jane
robertson
marko
estrada
paulin
young
idexx
laboratori
inc
westbrook
usa
idexx
laboratori
inc
sacramento
ca
usa
definit
diagnosi
felin
infecti
periton
fip
remain
challeng
difficulti
diagnosi
includ
lack
specif
clinic
sign
nonspecif
laboratori
abnorm
low
specif
antibodi
titer
realtim
pcr
test
detect
specif
virul
form
felin
coronaviru
recent
develop
idexx
laboratori
base
fusion
peptid
mutat
spike
gene
fip
viru
realpcr
test
report
one
two
biotyp
felin
infecti
periton
fipv
felin
enter
coronaviru
fecv
biotyp
possibl
specimen
report
either
limit
detect
indetermin
depend
viral
load
fifti
domest
cat
initi
suspect
submit
veterinarian
fip
includ
studi
cat
rang
age
month
month
year
major
cat
year
younger
cat
adult
year
age
geriatr
year
breed
repres
domest
shorthair
domest
longhair
burmes
one
bengal
persian
american
shorthair
ragamuffin
unknown
breed
case
grade
board
intern
medicin
specialist
clinic
score
system
rang
confirm
fip
confirm
fip
case
grade
unlik
like
fip
clinic
grade
scale
includ
specif
inform
histori
signal
avail
laboratori
diagnost
test
result
cat
grade
confirm
fip
base
histopatholog
immunohistochem
stain
coronaviru
cat
initi
suspect
fip
determin
unlik
fip
base
grade
system
grade
less
none
cat
obtain
fipv
biotyp
result
three
cat
unabl
grade
given
avail
data
remain
cat
grade
like
fip
grade
higher
cat
fipv
biotyp
result
one
sampl
none
cat
fecv
biotyp
result
twenti
cat
viral
load
limit
detect
fipv
biotyp
posit
result
obtain
whole
blood
sampl
pericardi
effus
pleural
effus
periton
effus
aqueou
humor
sampl
aspir
abdomin
lymph
node
cat
one
biopsi
submit
cat
least
one
biopsi
sampl
posit
fipv
biotyp
tissu
highest
rate
fipv
biotyp
spleen
omentum
mesenter
lymph
node
tissu
posit
fipv
biotyp
includ
pancrea
bladder
wall
eye
heart
liver
kidney
lung
also
note
tissu
obviou
gross
patholog
like
provid
fipv
biotyp
result
result
studi
show
fip
viru
realpcr
test
use
confirm
diagnosi
fip
clinic
suspect
cat
sensit
test
appear
highli
depend
specimen
submit
whole
blood
specimen
least
like
provid
posit
biotyp
result
abdomin
effus
specimen
moder
sensit
test
pleural
effus
specimen
tissu
aspir
biopsi
sampl
especi
spleen
omentum
mesenter
lymph
node
provid
highest
likelihood
posit
biotyp
result
anaplasma
phagocytophilum
ap
borrelia
burgdorferi
bb
infect
vectorborn
diagnos
cat
natur
expos
ixod
spp
laboratori
diagnost
test
includ
blood
smear
ap
pcr
ap
elisa
ap
bb
recent
studi
wildcaught
scapulari
allow
feed
day
spf
cat
four
cat
test
posit
ap
bb
use
commerci
avail
kit
dog
snap
plu
idexx
laboratori
ap
morula
neutrophil
blood
smear
ap
dna
blood
pcr
howev
none
cat
develop
clinic
sign
diseas
suggest
clinic
sign
ap
bb
would
occur
cat
repeat
pathogen
transmiss
exposur
compet
vector
two
followup
experi
design
test
hypothesi
repeat
exposur
lead
clinic
sign
experi
spf
cat
infest
femal
male
wild
caught
rhode
island
approxim
bb
ap
infect
rate
respect
place
chamber
approxim
cm
shave
area
skin
day
maxim
potenti
feed
edta
blood
serum
sampl
collect
cat
prior
infest
everi
week
week
blood
sampl
assay
ap
dna
pcr
serum
sampl
evalu
presenc
ap
bb
antibodi
snap
plu
mm
skin
biopsi
punch
use
collect
full
thick
biopsi
shave
area
cat
week
infest
bb
dna
amplif
pcr
experi
nine
cat
infest
femal
male
tick
releas
fur
flank
sedat
cat
dexmedetomidin
count
attach
perform
day
later
blood
sera
assay
describ
experi
everi
week
week
experi
nine
cat
attach
engorg
develop
evid
either
bb
infect
alon
four
cat
ap
infect
alon
three
cat
dual
infect
one
cat
experi
nine
cat
also
attach
engorg
total
previous
infect
cat
experi
develop
evid
new
ap
two
cat
repeat
bb
two
at
repeat
ap
infect
one
cat
howev
clinic
sign
diseas
note
experi
studi
demonstr
cat
repeatedli
infect
ap
bb
without
develop
clinic
sign
diseas
tick
infest
method
led
transmiss
ap
bb
natur
infect
dirofilaria
immiti
antigen
ehrlichia
cani
antibodi
use
sampl
high
low
risk
region
michael
lappin
rebecca
ruch
galli
emili
bryan
camil
lehman
lauri
droke
scott
moroff
colorado
state
univers
fort
collin
co
usa
san
pedro
anim
hospit
san
pedro
beliz
antech
diagnost
lake
success
ny
usa
dirofilaria
immiti
ehrlichia
cani
import
vector
born
diseas
dog
number
assay
avail
detect
immiti
antigen
e
cani
antibodi
canin
sampl
differ
reagent
method
use
differ
assay
result
discord
purpos
studi
compar
result
commerci
avail
assay
use
sampl
dog
low
high
risk
area
target
organ
adult
dog
n
screen
immiti
antigen
san
pedro
beliz
august
select
like
concurr
infest
rhipicephalu
sanguin
high
risk
e
cani
exposur
sera
also
collect
dog
enter
two
shelter
northern
colorado
may
octob
area
consid
low
risk
e
cani
immiti
commerci
avail
kit
snap
plu
idexx
laboratori
use
assess
serum
dog
site
beliz
thaw
serum
colorado
sera
store
ship
cold
pack
commerci
laboratori
antech
diagnost
lake
success
ny
evalu
assay
accuplex
agreement
assay
determin
use
kappa
statist
result
assay
immiti
antigen
ehrlichia
spp
antibodi
use
sera
region
list
follow
tabl
high
risk
area
agreement
assay
perfect
immiti
good
ehrlichia
spp
low
risk
area
agreement
assay
wors
chanc
ehrlichia
spp
fair
immiti
region
compar
agreement
good
organ
low
risk
area
accuplex
detect
immiti
antigen
dog
sinc
necropsi
avail
whether
find
repres
previous
describ
increas
sensit
accuplex
determin
low
risk
area
detect
ehrlichia
spp
antibodi
dog
accuplex
accuplex
e
cani
specif
wherea
detect
antibodi
organ
like
e
ewingii
e
chaffeensi
may
explain
discord
result
bartonella
hensela
import
vector
born
diseas
agent
associ
clinic
diseas
mani
speci
includ
human
cat
dog
cat
known
definit
host
ctenocephalid
feli
proven
vector
bartonella
hensela
grown
c
feli
frass
least
day
previou
experi
research
beagl
infect
b
hensela
nasal
inocul
infect
c
feli
frass
cat
frequent
ingest
c
feli
frass
groom
purpos
studi
assess
potenti
oral
b
hensela
transmiss
ingest
infect
c
feli
studi
purpos
bred
year
old
kitten
barrier
facil
free
vector
shown
neg
felv
antigen
fiv
antibodi
bartonella
spp
antibodi
bartonella
spp
dna
blood
pcr
assay
two
cat
infect
strain
b
hensela
concurr
experi
use
current
experi
cat
shown
still
strongli
posit
b
hensela
dna
blood
use
previous
publish
pcr
assay
target
intergen
region
total
femal
male
c
feli
purchas
commerci
laboratori
place
two
separ
flea
chamber
one
place
flank
two
b
hensela
kitten
c
feli
allow
feed
day
time
c
feli
chamber
remov
chamber
assess
b
hensela
infect
pcr
assay
remaind
c
feli
cold
stun
mix
togeth
egg
frass
slurri
babi
food
administ
oral
one
bartonella
spp
cast
blood
sera
collect
weekli
week
assay
bartonella
spp
antibodi
bartonella
spp
dna
pcr
assay
aliquot
c
feli
collect
chamber
b
hensela
infect
cat
strongli
posit
b
hensela
dna
cours
week
studi
neither
oral
inocul
cat
develop
bartonella
spp
antibodi
serum
bartonella
spp
dna
blood
two
cat
oral
inocul
b
hensela
infect
c
feli
frass
evid
dental
diseas
stomat
develop
evid
infect
time
period
studi
defin
assay
result
suggest
normal
cat
ingest
b
hensela
infect
c
feli
unlik
becom
infect
howev
experi
perform
assess
rout
transmiss
use
sensit
assay
like
bapgm
cultur
plu
pcr
assay
use
kitten
teeth
cat
affect
oral
caviti
diseas
provid
potenti
portal
entri
b
hensela
bacteri
cystiti
common
dog
primari
disord
complic
comorbid
condit
increas
urinari
isol
resist
antimicrobi
drug
report
recent
year
multipl
drug
resist
mdr
organ
defin
organ
acquir
resist
least
one
member
class
antimicrobi
seem
commonplac
veterinari
medic
diagnost
laboratori
univers
missouri
undertook
descript
retrospect
studi
drug
resist
urinari
isol
muvmdl
jan
nov
urin
cultur
perform
use
calibr
loop
deliv
urin
blood
agar
macconkey
agar
plate
aerob
bacteri
isol
plate
incub
routin
cultur
condit
antimicrobi
suscept
test
result
isol
accomplish
mic
techniqu
use
commerci
prepar
lyophil
tray
breakpoint
determin
resist
suscept
base
standard
set
nation
committe
clinic
laboratori
standard
antimicrobi
includ
routin
suscept
profil
differ
slightli
depend
organ
exclud
intrins
resist
includ
aminoglycosid
amikacin
gentamicin
potenti
penicillin
carboxypenicillin
amoxicillinclavulan
ticarcillinclavulan
natur
synthet
penicillin
carboxypenicillin
ampicillin
penicillin
oxacillin
nacl
ticarcillin
gener
cephalosporin
cefazolin
cephalothin
gener
cephalosporin
cefoxitin
ceftiofur
gener
cephalosporin
cefovecin
cefpodoxim
chloramphenicol
clindamycin
doxycyclin
erythromycin
fluoroquinolon
enrofloxacin
marbofloxacin
imipenem
rifampin
trimethoprim
sulfa
tm
common
isol
e
coli
staphylococcu
spp
enterococcu
spp
streptococcu
spp
evalu
innat
antimicrobi
resist
defin
four
microb
interest
follow
e
coliclindamycin
erythromycin
penicillin
staphylococcu
sppaminoglycosid
streptococcu
sppaminoglycosid
enterococcu
sppaminoglycosid
gener
cephalosporin
tm
total
canin
urin
sampl
submit
cs
result
bacteri
isol
e
coli
isol
resist
member
antimicrobi
group
two
group
three
group
group
resist
like
synthet
penicillin
rifampin
flouroquinolon
staphylococcu
spp
isol
resist
group
group
group
group
staphylococcu
spp
like
resist
member
antimicrobi
group
penicillin
clindamycin
erythromycin
enterococcu
spp
isol
resist
group
group
group
enterococcu
spp
like
resist
penicillin
clindamycin
rifampin
streptococcu
spp
isol
resist
member
antimicrobi
group
group
group
group
streptococcu
spp
like
resist
doxycyclin
fluoroquinolon
isol
resist
penicillin
gen
cephalosporin
erythromycin
tm
expect
e
coli
isol
often
mdr
mdr
isol
far
common
among
staphylococc
isol
enterococcu
spp
isol
fewer
streptococcu
spp
isol
least
like
mdr
say
mdr
isol
common
past
state
problemat
bacteria
commonli
encount
canin
urin
sampl
submit
vmdl
filippo
ferri
silvia
ferro
edoardo
auriemma
massimo
castagnaro
luigi
michel
coppola
andrea
peano
vito
martella
nicola
decaro
eric
zini
istituto
veterinario
di
novara
granozzo
con
monticello
novara
itali
depart
compar
biomedicin
food
scienc
univers
padova
legnaro
padova
itali
depart
anim
medicin
product
health
univers
padova
legnaro
padova
itali
depart
veterinari
scienc
univers
turin
grugliasco
turin
itali
depart
veterinari
medicin
univers
bari
valenzano
bari
itali
vetsuiss
faculti
univers
zurich
zurich
switzerland
dog
spleniti
rare
describ
report
case
associ
splenic
abscess
pseudotumor
system
mycosi
aim
studi
defin
preval
spleniti
dog
describ
clinic
find
outcom
character
histolog
pattern
splenic
inflamm
investig
possibl
caus
formalinfix
paraffinembed
splenic
sampl
dog
diagnosi
spleniti
gather
patholog
archiv
new
slide
obtain
stain
hematoxylineosin
gram
greengram
giemsa
period
acidschiff
pa
ziehlneelsen
slide
examin
two
pathologist
furthermor
aliquot
specimen
process
pcr
analysi
detect
bacteri
fungal
protozo
dna
dog
owner
contact
achiev
inform
pertain
clinic
find
outcom
avail
splenic
sampl
histolog
diagnosi
spleniti
clinic
find
outcom
avail
dog
present
complaint
weak
dog
fever
abdomin
effus
sixteen
surviv
discharg
follow
splenectomi
without
addit
abdomin
surgeri
remain
three
dog
die
day
admiss
splenic
histolog
find
dog
includ
neutrophil
granulomat
haemorrhag
lymphocyt
spleniti
splenic
abscess
base
clinic
record
necropsi
find
dog
concurr
diseas
along
spleniti
includ
gastric
dilationvolvulu
neoplasia
granulomat
hepat
pyometra
hepat
lobar
torsion
system
mycosi
seven
dog
bacteria
identifi
spleen
base
histolog
four
dog
gram
cocci
gramcocci
gram
cocci
bacilli
bacteri
cultur
one
dog
pseudomona
aeruginosa
three
dog
protozoa
identifi
pcr
three
dog
leishmania
infantum
histolog
leishmaniaposit
dog
concurr
hepatozoon
cani
one
dog
ifa
detect
histolog
pcr
identifi
bacteria
fungi
spleen
includ
microscop
evid
infect
associ
histolog
find
caus
observ
present
studi
show
spleniti
uncommon
disord
dog
spleniti
frequent
secondari
inflamm
organ
system
infect
although
numer
dog
may
associ
obviou
diseas
prognosi
favour
major
affect
dog
sever
histolog
pattern
inflamm
identifi
dog
spleniti
whether
reflect
differ
caus
deserv
studi
pcr
may
sensit
tool
detect
bacteria
fungi
dna
formalinfix
paraffinembed
splenic
sampl
cyniclomyc
guttulatu
commens
yeast
rodent
rabbit
gastrointestin
tract
infrequ
describ
dog
fecal
sampl
environment
sourc
c
guttulatu
dog
unclear
howev
frequent
presum
dog
diagnos
c
guttulatu
ingest
rabbit
fece
studi
aim
conduct
compar
sequenc
analysi
fragment
larg
subunit
rdna
variabl
domain
c
guttulatu
dog
pet
rabbit
laboratori
rabbit
elucid
differ
genotyp
affect
speci
void
fecal
sampl
domest
dog
rabbit
new
zealand
white
laboratori
rabbit
client
own
domest
pet
rabbit
obtain
fecal
dna
extract
standard
pcr
amplif
base
pair
bp
fragment
rdna
use
custom
primer
perform
amplicon
submit
bidirect
dna
sequenc
nucleotid
sequenc
align
made
exist
genbank
c
guttulatu
sequenc
sequenc
ident
matrix
analys
conduct
partial
rdna
sequenc
obtain
seven
dog
rabbit
high
qualiti
sequenc
exclud
primer
use
analysi
dog
trim
bp
region
pcr
product
compar
across
seven
dog
two
addit
c
guttulatu
dog
sequenc
deposit
genbank
polymorph
among
dog
sequenc
rang
nucleotid
substitut
result
rang
similar
rabbit
trim
bp
region
pcr
product
compar
seven
new
zealand
white
laboratori
rabbit
sequenc
share
sequenc
ident
similar
previous
report
brazilian
new
zealand
white
rabbit
genotyp
deposit
genbank
pet
rabbit
addit
pet
rabbit
sequenc
genbank
share
homolog
compar
laboratori
rabbit
align
data
partial
c
guttulatu
rdna
sequenc
obtain
seven
dog
rabbit
examin
studi
addit
sequenc
genbank
demonstr
nucleotid
posit
wherein
polymorph
dog
rabbit
c
guttulatu
genotyp
identifi
among
nucleotid
posit
reveal
conserv
differ
dog
genotyp
laboratori
rabbit
genotyp
pet
rabbit
genotyp
larg
ident
observ
dog
pet
rabbit
includ
studi
share
histori
exposur
dog
dog
studi
share
histori
exposur
pet
rabbit
result
studi
demonstr
partial
rdna
genotyp
c
guttulatu
amplifi
fecal
dna
dog
similar
observ
domest
pet
rabbit
genet
distinct
sequenc
amplifi
fecal
dna
laboratori
rabbit
studi
identifi
signific
genet
divers
c
guttulatu
differ
popul
rabbit
suggest
possibl
transmiss
c
guttulatu
genotyp
dog
domest
pet
rabbit
ehrlichia
cani
e
chaffeensi
e
ewingii
vector
born
pathogen
dog
peopl
amplif
specif
dna
commonli
use
diagnosi
ehrlichia
spp
pcr
assay
agent
commonli
avail
commerci
posit
pcr
assay
result
often
occur
prior
detect
specif
antibodi
ehrlichia
spp
purpos
studi
compar
result
two
differ
commerci
avail
usa
pcr
assay
amplif
ehrlichia
spp
dna
use
sampl
natur
expos
dog
endem
area
dog
n
steril
low
cost
clinic
checotah
ok
juli
select
like
expos
ambloymma
americanum
high
risk
e
ewingii
e
chaffeensi
exposur
rhipicephalu
sanguineu
also
found
region
e
cani
infect
also
possibl
total
ml
blood
edta
collect
tube
store
refriger
overnight
next
day
sent
cold
pack
first
test
laboratori
via
overnight
ship
arriv
sampl
split
aliquot
aliquot
frozen
aliquot
prepar
evalu
commerci
avail
convent
ehrlichia
spp
pcr
assay
wwwdlabcolostateedu
frozen
edta
blood
ship
second
pcr
laboratori
dri
ice
evalu
commerci
avail
real
time
multiplex
ehrlichia
spp
pcr
assay
wwwantechcom
result
sampl
sequenc
confirm
compar
use
kappa
statist
first
laboratori
dna
e
cani
one
dog
e
ewingii
six
dog
e
chaffeensi
one
dog
amplifi
dog
second
laboratori
dna
e
ewingii
amplifi
nine
dog
agreement
assay
genu
level
good
kappa
se
ci
overal
percentag
agreement
dog
dna
homolog
e
chaffeensi
first
laboratori
show
dna
homolog
e
ewingii
second
laboratori
ehrlichia
ewingii
infect
transmit
americanum
common
oklahoma
agreement
laboratori
good
even
though
discord
result
detect
second
laboratori
appear
higher
sensit
e
ewingii
dna
howev
concord
expect
sampl
handl
ident
assay
use
differ
technolog
sequenc
homolog
e
ewingii
e
chaffeensi
high
differ
result
two
differ
sequenc
laboratori
occur
altern
dog
may
dual
infect
babesia
conrada
small
intraerythrocyt
piroplasm
found
dog
southern
california
domest
dog
b
conrada
infect
caus
lethargi
hemolyt
anemia
march
greyhound
use
hunt
coyot
oklahoma
present
lethargi
pale
mucou
membran
evalu
stain
blood
film
reveal
small
piroplasm
red
blood
cell
subsequ
dna
extract
whole
blood
pcr
amplif
use
piroplasmspecif
primer
dna
sequenc
confirm
infect
b
conrada
index
case
dog
euthan
owner
due
deterior
condit
followup
evalu
major
dog
owner
kennel
reveal
greyhound
walker
hound
pcr
posit
infect
b
conrada
dog
known
travel
histori
west
oklahoma
two
greyhound
subclin
infect
b
conrada
treat
day
cours
azithromycin
mgkg
mglb
po
q
hour
plu
atovaquon
mgkg
mglb
po
q
hour
third
b
conradaeinfect
dog
sold
lost
followup
approxim
month
complet
azithromycin
atovaquon
treatment
dog
pcr
neg
infect
b
conrada
author
knowledg
first
report
b
conrada
dog
outsid
california
crossspeci
transmiss
canin
parvoviru
healthi
shelter
kitten
christian
leutenegg
hongwei
liu
niel
pedersen
idexx
laboratori
inc
west
sacramento
ca
usa
center
companion
anim
health
univers
california
davi
davi
ca
usa
recent
studi
shelter
cat
uk
provid
strong
evid
healthi
cat
may
shed
strain
canin
parvoviru
type
purpos
studi
confirm
find
among
healthi
cat
shelter
privat
own
sick
cat
usa
develop
valid
realtim
pcr
assay
discrimin
felin
panleukopenia
viru
fpv
specif
type
assay
confirm
sequenc
type
assay
use
test
strain
obtain
puppi
natur
acquir
parvoviru
infect
high
fecal
viral
load
sampl
could
type
success
confirm
sequenc
confirm
specif
strain
type
assay
puppi
assay
use
test
fece
healthi
shelter
kitten
group
healthi
shelter
cat
shed
parvoviru
fece
low
level
parvoviru
shed
explain
chronic
infect
gastrointestin
passag
environment
parvoviru
presenc
vaccin
viru
shed
high
parvoviru
load
indic
infect
within
group
high
shedder
kitten
test
posit
canin
parvoviru
strain
import
crossspeci
transmiss
shelter
multianim
environ
yet
determin
howev
implic
studi
healthi
cat
may
sourc
infect
suscept
dog
suggest
appropri
husbandri
practic
adopt
reduc
risk
addit
current
investig
appli
type
assay
cat
panleukopenia
determin
import
strain
caus
infecti
panleukopenia
chandrashekar
jennif
ketzi
linda
shell
phylli
tyrrel
melissa
beall
christian
leuteneggar
diana
scorpio
idexx
laboratori
westbrook
usa
ross
univers
basseterr
saint
kitt
nevi
island
st
kitt
west
indi
larg
feral
semifer
dog
popul
semifer
dog
present
uniqu
opportun
studi
sinc
mostli
outdoor
compar
better
taken
care
compar
feral
dog
care
tend
rang
minim
adequ
though
mani
owner
use
ministri
agricultur
veterinari
servic
prevent
medicin
rather
veterinari
hospit
set
histor
dog
island
endem
infect
infest
intern
ectoparasit
bring
numer
vectorbon
diseas
due
high
preval
tick
rhipicephalu
sanguineu
unusu
see
preval
ehrlichia
cani
immun
toward
recent
group
veterinarian
student
ross
univers
school
veterinari
medicin
conduct
islandwid
field
studi
semifer
dog
advantag
feral
dog
gather
pet
inform
interact
owner
period
month
veterinarian
student
visit
parish
island
st
kitt
thu
cover
divers
geograph
area
wide
divers
ecosystem
landscap
one
hundr
eleven
dog
identifi
visit
given
complet
physic
exam
blood
fece
collect
demograph
data
also
collect
includ
breed
age
hous
anim
household
evid
tick
flea
deworm
vaccin
administr
import
data
primari
focu
sampl
analysi
studi
blood
process
immedi
separ
whole
blood
serum
plasma
tick
flea
also
collect
seen
dog
immedi
environ
blood
analyz
snap
test
idexx
follow
tickvector
comprehens
realpcr
panel
detect
differ
vectorborn
pathogen
genera
anaplasma
ehrlichia
babesia
hepatozoon
leishmania
bartonella
neorickettsia
rickettsia
mycoplasma
data
collect
studi
reveal
great
major
dog
expos
infect
mani
vectorborn
organ
includ
e
cani
anaplasma
plati
babesia
spp
mostli
b
gibsonii
mycoplasma
hemocani
mani
dog
coinfect
pathogen
case
dog
exhibit
clinic
sign
except
pale
mucou
membran
low
bodi
weight
icteru
one
dog
posit
four
pathogen
dog
also
heavili
infest
ancylostoma
hookworm
therefor
clinic
evid
anemia
frequent
confound
mani
red
celldestroy
pathogen
potenti
act
synergist
manner
signific
find
studi
high
rate
infect
hemocani
diagnos
qpcr
mycoplasma
infect
common
differenti
island
dog
due
wellknown
high
level
exposur
elisa
infect
qpcr
e
cani
respect
import
mycoplasma
infect
requir
studi
howev
data
implic
import
includ
exhaust
list
differenti
suspect
vectorborn
infect
island
geographi
ecosystem
tick
burden
dog
demograph
may
aid
veterinarian
diagnosi
clinic
diseas
pathogen
cytauxzoonosi
deadli
tickborn
diseas
domest
wild
felid
cytauxzoon
feli
transmit
amblyomma
americanum
dermacentor
variabili
bobcat
feli
rufu
wild
reservoir
host
larg
remain
clinic
unaffect
although
c
feli
infect
domest
cat
fatal
document
subclin
c
felisinfect
found
may
provid
addit
sourc
infect
cat
mani
factor
habitat
bobcat
exposur
outdoor
domest
felid
presenc
tick
vector
lack
tick
control
contribut
c
feli
infect
tradit
distribut
c
feli
southcentr
southeastern
unit
state
howev
c
feli
recent
detect
bobcat
domest
cat
nonenzoot
area
iowa
consid
nonenzoot
state
although
one
known
confirm
case
proxim
known
enzoot
state
missouri
arkansa
kansa
grow
bobcat
popul
presenc
tick
vector
put
cat
iowa
risk
becom
wide
infect
whole
blood
sampl
n
obtain
cat
present
iowa
state
univers
feral
cat
trapneuterreleas
program
august
cat
variabl
health
statu
caretak
cat
sign
waiver
blood
ml
drawn
minim
laboratori
infecti
diseas
screen
includ
pcr
c
feli
sampl
neg
c
feli
sinc
c
feli
emerg
infecti
diseas
continu
surveil
prudent
rang
americanum
continu
expand
veterinarian
iowa
state
border
c
feli
enzoot
area
must
remain
vigil
prompt
diagnosi
treatment
patient
role
type
clostridium
perfringen
acut
hemorrhag
necrot
gastroenter
dog
necrot
enterocol
foal
long
suspect
confirm
character
supernat
isol
made
dog
foal
die
diseas
highli
cytotox
equin
ovarian
eo
cell
line
partial
genom
sequenc
dog
isol
reveal
three
novel
put
toxin
gene
relat
poreform
leukocidinhemolysinsuperfamili
design
nete
netf
netg
nete
netf
locat
one
larg
conjug
plasmid
netg
locat
cpe
enterotoxin
gene
second
larg
conjug
plasmid
nete
netf
found
eocytotox
isol
cpe
netg
less
consist
present
mutat
complement
three
gene
show
netf
associ
cytotox
eo
cell
equin
antisera
prepar
recombin
net
protein
show
antiserum
netf
neutral
cytotox
supernat
strain
although
nete
netg
associ
cytotox
immunoblot
specif
antisera
prepar
protein
show
nete
netg
express
vitro
highli
signific
associ
presenc
netf
type
strain
isol
case
canin
hemorrhag
gastroenter
compar
type
isol
dog
undifferenti
diarrheal
ill
p
neonat
foal
necrot
enter
compar
foal
undifferenti
enterocol
p
pulsedfield
gel
electrophoresi
pfge
show
netfposit
isol
belong
clonal
popul
canin
equin
isol
genet
indistinguish
identif
netf
novel
toxin
strongli
associ
canin
hemorrhag
gastroenter
necrot
enter
neonat
foal
open
way
improv
diagnosi
treatment
control
import
seriou
diseas
previou
studi
show
cat
hous
anim
shelter
acquir
felin
infect
within
day
entri
thu
use
vaccin
induc
rapid
protect
indic
previou
studi
cat
administ
one
sq
dose
inactiv
felin
caliciviru
fcv
panleukopenia
viru
fpv
vaccin
fvrcp
develop
protect
antibodi
titer
significantli
faster
cat
administ
modifi
live
fvrcp
vaccin
mlv
howev
challeng
perform
object
studi
determin
effect
one
dose
inactiv
fvrcp
vaccin
one
dose
mlv
fvrcp
vaccin
clinic
sign
spf
kitten
challeng
day
vaccin
total
male
femal
purpos
bred
kitten
barrier
facil
shown
pcr
assay
neg
nucleic
acid
mycoplasma
spp
fcv
materi
collect
oropharynx
seroneg
antibodi
purchas
randomli
divid
three
group
eight
kitten
four
male
four
femal
group
kitten
maintain
unvaccin
control
group
kitten
administ
dose
inactiv
fvrcp
vaccin
sq
day
ultra
tm
felovax
boehringeringelheim
vetmedica
inc
group
kitten
administ
dose
mlv
fvrcp
vaccin
sq
day
purevax
merial
ltd
kitten
hous
handl
separ
avoid
crosscontamin
mlv
vaccin
viru
among
group
durat
studi
standard
clinic
score
system
appli
group
kitten
mask
observ
minut
day
studi
clinic
score
collect
day
kitten
administ
tcid
usda
challeng
strain
ml
per
nostril
ml
oropharynx
group
clinic
score
compar
among
studi
period
use
kruskal
walli
pairwis
comparison
signific
defin
p
day
day
challeng
group
vaccin
cat
less
like
clinic
ill
indic
lower
cumul
clinic
score
control
cat
p
statist
differ
total
clinic
score
two
vaccin
group
p
parenter
administr
either
inactiv
modifi
live
fvrcp
vaccin
decreas
clinic
sign
ill
due
day
challeng
compar
control
use
either
vaccin
product
indic
cat
risk
acut
exposur
anaplasma
phagocytophilum
test
result
ramaswami
chandrashekar
melissa
beall
brendon
thatcher
jiayou
liu
brett
stillman
phylli
tyrrel
michael
lappin
idexx
laboratori
westbrook
usa
colorado
state
univers
fort
collin
co
usa
anaplasma
phagocytophilum
ap
borrelia
burgdorferi
bb
share
ixod
spp
tick
vector
associ
clinic
ill
infect
dog
cat
purpos
studi
evalu
canin
antibodi
respons
genu
speciesspecif
ap
peptid
respect
bb
peptid
doxycyclin
treatment
total
eight
young
adult
mix
sex
laboratoryrear
research
dog
use
iacuc
approv
dog
shown
neg
antibodi
ap
bb
use
commerci
avail
kit
snap
idexx
laboratori
dog
infect
exposur
wildcaught
ixod
scapulari
week
blood
collect
dog
prior
tick
attach
week
week
tick
attach
blood
assay
ap
dna
pcr
sera
separ
clot
blood
assess
ap
bb
antibodi
multianalyt
research
snap
snap
ap
ifa
ap
peptid
quantit
elisa
quantit
elisa
quant
idexx
laboratori
commerci
kit
week
doxycyclin
administ
mkg
po
daili
day
pair
ttest
use
assess
chang
optic
densiti
snap
approxim
antibodi
level
ap
dna
amplifi
blood
dog
ap
antibodi
serum
multianalyt
snap
research
elisa
antibodi
ap
detect
prior
detect
commerci
avail
kit
dog
antibodi
bb
detect
dog
first
detect
week
posttick
attach
seroposit
day
dog
seroposit
ap
week
snap
ap
ifa
elisa
modest
declin
seroreact
posttreat
five
dog
bb
seroposit
week
antibodi
level
declin
week
mean
declin
rel
pretreat
valu
optic
densiti
read
ap
bb
snap
demonstr
signific
decreas
week
howev
magnitud
differ
significantli
greater
bb
ap
p
result
suggest
antibodi
peptid
may
use
earli
detect
ap
infect
doxycyclin
administr
use
protocol
decreas
antibodi
level
greater
extent
antibodi
measur
ap
peptid
elisa
dirofilaria
immiti
endem
certain
area
unit
state
caus
detriment
diseas
heartworm
diseas
rel
costli
treat
financi
regard
anim
welfar
though
colorado
climat
conduc
yearround
replic
mosquito
speci
carri
organ
microclim
exist
wherev
human
inhabit
thu
potenti
allow
yearround
transmiss
immiti
propag
strain
dog
enter
colorado
shelter
system
anim
shelter
northern
colorado
front
rang
frequent
transport
dog
state
includ
high
risk
immiti
infect
hypothesi
studi
shelter
dog
higher
preval
gener
pet
dog
popul
purpos
studi
determin
preval
immiti
antigen
serum
dog
enter
anim
shelter
northern
colorado
sampl
collect
dog
enter
three
shelter
northern
colorado
may
octob
studi
area
restrict
foothil
rocki
mountain
west
high
plain
east
larim
weld
counti
dog
month
age
includ
studi
blood
sera
dog
evalu
immiti
antigen
one
three
differ
commerci
avail
kit
heska
solostep
idexx
snap
plu
abaxi
vetscan
follow
manufactur
instruct
posit
result
immiti
antigen
confirm
second
test
differ
origin
test
use
though
confirmatori
test
vari
among
sampl
total
five
sampl
shelter
dog
posit
immiti
antigen
three
posit
dog
came
area
consid
lowrisk
northern
colorado
south
dakota
two
posit
dog
came
arkansa
known
highrisk
state
immiti
preval
rate
shelter
dog
describ
three
time
greater
current
report
preval
rate
colorado
dog
popul
time
greater
rate
report
particip
counti
capcvetorg
result
studi
indic
immiti
test
consid
receiv
procedur
northern
colorado
anim
shelter
inarea
outofarea
intak
result
also
emphas
import
use
immiti
prevent
gener
popul
hh
ss
h
pylori
hp
pcr
investig
unclassifiedhelicobact
spp
partial
ureas
gene
amplifi
primer
respect
sequenc
compar
ncbigenbank
helicobact
spp
valid
publish
name
includ
phylogenet
analysi
use
clustal
phylogenet
tree
construct
use
neighborjoin
method
pcr
result
indic
dog
infect
helicobact
spp
hh
ss
hb
hf
hp
unclassifiedhelicobact
spp
ureas
gene
sequenc
unclassifiedhelicobact
spp
show
respect
similar
hh
ss
strain
close
relat
speci
sequenc
partial
ureas
gene
demonstr
unclassifiedhelicobact
spp
constitut
separ
taxa
helicobact
spp
gastric
patholog
diagnos
canin
unclassifiedhelicobact
spp
mild
moder
sever
chronic
gastriti
adenocarcinoma
highgrad
lymphoma
polyphas
taxonom
studi
result
suggest
novel
helicobact
strain
prevail
japan
ascertain
pathogen
strain
studi
includ
vitro
cultiv
must
conduct
giardia
spp
cryptosporidium
spp
capabl
zoonot
transmiss
data
avail
assess
genotyp
organ
peopl
pet
primari
object
studi
identifi
molecularli
character
giardia
duodenali
cryptosporidium
spp
isol
obtain
fece
senior
veterinari
student
dog
cat
senior
veterinari
student
provid
inform
concern
anonym
elect
studi
hard
copi
email
student
request
complet
survey
design
assess
risk
factor
enter
zoonos
suppli
person
fecal
sampl
well
fecal
sampl
one
dog
one
cat
present
household
fece
analyz
use
microscop
examin
parasit
egg
cyst
oocyst
use
sheather
sugar
centrifug
detect
cryptosporidium
spp
oocyst
giardia
spp
cyst
commerci
avail
fa
merifluor
cryptosporidiumgiardia
meridian
bioscienc
use
dna
extract
fecal
sampl
assay
g
duodenali
use
pcr
assay
glutam
dehydrogenas
triosephosph
isomeras
gene
dna
extract
human
fecal
sampl
assay
cryptosporidium
spp
use
pcr
assay
gene
wherea
dog
cat
dna
extract
evalu
pcr
assay
heat
shock
protein
gene
date
senior
veterinari
student
suppli
person
fecal
sampl
concurr
suppli
dog
fecal
sampl
concurr
suppli
cat
fecal
sampl
giardia
spp
cryptosporidium
spp
crypto
parasit
detect
human
dog
cat
sampl
test
date
distribut
result
speci
assay
list
posit
peopl
own
neg
dog
own
neg
dog
cat
own
neg
dog
own
dog
posit
giardia
cryptosporidium
neg
cat
owner
cryptosporidium
spp
posit
dog
cat
posit
either
organ
own
peopl
neg
organ
none
human
cat
dual
infect
wherea
two
dog
infect
protozoan
dna
sequenc
complet
two
dog
posit
g
duodenali
assemblag
use
tpi
gdh
gene
one
dog
posit
cryptosporidium
spp
use
gene
sequenc
analysi
pcr
posit
sampl
fail
due
low
dna
concentr
result
studi
show
protozoan
common
human
dog
cat
region
giardia
posit
dog
success
sequenc
harbor
hostadapt
assemblag
owner
neg
suggest
zoonot
transfer
occur
famili
addit
sampl
requir
evalu
risk
zoonot
transfer
g
duodenali
cryptosporidium
spp
ongo
studi
viru
induc
high
level
viremia
primari
serum
diagnost
test
detect
antibodi
fiv
howev
fiv
vaccin
readili
induc
antibodi
indistinguish
induc
natur
exposur
commerci
avail
kit
western
blot
immunoassay
new
fiv
antibodi
test
introduc
around
world
purpos
studi
evalu
whether
kit
wit
felvfiv
zoeti
market
countri
detect
antibodi
induc
vaccin
studi
two
experi
perform
use
purpos
bred
kitten
seroneg
felv
antigen
fiv
antibodi
snap
felvfiv
combo
idexx
laboratori
kitten
inocul
sq
inactiv
fiv
vaccin
week
sera
collect
store
multipl
time
vaccin
kitten
boost
either
week
cat
eight
cat
sera
collect
week
inocul
store
sampl
thaw
assay
fiv
antibodi
felv
antigen
use
commerci
avail
kit
wit
felvfiv
zoeti
follow
manufactur
recommend
none
kitten
posit
felv
antigen
fiv
antibodi
prior
vaccin
howev
first
two
vaccin
fiv
antibodi
detect
multipl
sampl
week
week
week
week
week
week
none
cat
test
week
first
vaccin
posit
test
howev
booster
vaccin
week
week
fiv
antibodi
detect
serum
collect
week
booster
sampl
cat
account
sampl
vaccin
fiv
product
induc
antibodi
detect
transient
commerci
avail
kit
assay
use
alon
accur
distinguish
cat
natur
occur
fiv
infect
cat
vaccin
fiv
attempt
understand
immun
respons
cat
infect
leishmania
infantum
chagasi
aim
studi
evalu
level
express
gene
encod
interleukin
ifnc
spleen
sampl
natur
infect
cat
quantit
revers
transcript
pcr
qrtpcr
diseas
diagnosi
base
find
amastigot
form
parasit
cytolog
examin
confirm
dna
amplif
l
infantum
chagasi
bone
marrow
tissu
three
group
cat
evalu
first
group
compos
six
symptomat
natur
infect
cat
second
compos
six
asymptomat
natur
infect
cat
third
compos
six
clinic
healthi
uninfect
cat
prior
cat
inclus
studi
owner
inform
necessari
intervent
consent
obtain
cat
studi
approv
committe
ethic
anim
research
paulo
state
univers
total
rna
extract
spleen
convert
cdna
cytokin
gene
express
measur
final
quantit
evalu
ddc
method
endogen
housekeep
gene
betaactin
quantifi
use
normal
result
mrna
express
reduc
group
comparison
healthi
cat
gene
express
symptomat
asymptomat
cat
supress
time
respect
mrna
express
gene
reduc
natur
infect
cat
reduct
slightli
higher
symptomat
supress
time
asymptomat
supress
time
cat
compar
control
group
mrna
express
reduc
group
comparison
healthi
cat
gene
express
asymptomat
symptomat
cat
supress
time
respect
comparison
healthi
cat
mrna
express
ifnc
gene
reduc
natur
infect
cat
regardless
presenc
absenc
symptom
compar
control
group
reduct
signific
asymptomat
supress
time
symptomat
supress
time
cat
result
studi
suggest
reduc
express
eventu
product
four
cytokin
spleen
cat
natur
infect
l
infantum
chagasi
regardless
clinic
statu
anim
spleen
cell
studi
cat
elicit
specif
immun
respons
leishmania
infect
stull
teresa
mill
ohio
state
univers
columbu
oh
usa
dog
often
livestock
farm
serv
import
manag
companion
role
howev
may
also
involv
diseas
transmiss
livestock
peopl
increas
canin
raw
diet
canin
companion
famili
member
increas
popul
immunecompromis
peopl
make
understudi
diseas
pathway
particularli
import
object
studi
quantifi
qualifi
dog
ownership
among
livestock
produc
husbandri
biosecur
practic
concern
zoonot
anim
human
diseas
potenti
questionnair
develop
household
individuallevel
data
collecteddemograph
number
livestock
own
dog
ownership
husbandri
practic
attach
level
prevent
veterinari
care
dog
mail
ohio
livestock
owner
randomli
select
farm
magazin
mail
list
respond
dog
livestock
dog
fecal
sampl
kit
mail
return
kit
test
salmonella
spp
extendedspectrum
betalactamaseproduc
organ
use
standard
enrich
select
media
survey
respons
rate
livestock
dogown
ldo
approxim
ldo
household
includ
least
one
highrisk
individu
ie
year
year
diagnos
immunocompromis
condit
dogown
respond
frequent
report
higherrisk
husbandri
practic
outdooronli
dog
never
leash
fenc
dog
rarelynev
pick
dog
fece
doglivestock
contact
often
report
indic
highrisk
manag
practic
eg
access
sick
pen
new
arriv
raw
meat
anim
product
fed
household
mani
respond
littleno
concern
dog
transmit
diseas
livestock
famili
member
household
highrisk
member
report
similar
husbandri
biosecur
concern
level
p
fecal
sampl
test
ongo
highrisk
practic
regularli
report
level
zoonot
diseas
concern
low
indic
need
improv
educ
outreach
livestock
dog
own
commun
healthcar
provid
area
particularli
work
children
elderli
immunocompromis
conditon
last
year
sever
vector
born
diseas
sporad
associ
pericardi
effus
human
veterinari
medicin
name
bartonellosi
leishmaniosi
babesiosi
lyme
diseas
aim
work
evalu
select
canin
vector
born
pathogen
nucleic
acid
sampl
dog
pericardi
effus
archiv
edtablood
pericardi
sampl
dog
pericardi
sampl
retrospect
includ
quantit
pcr
perform
leishmania
infantum
convent
pcr
perform
ehrlichiaanaplasma
spp
hepatozoon
cani
babesia
spp
theileria
anna
ricketssia
spp
bartonella
spp
partial
sequenc
pcr
product
posit
sampl
ehrlichiaanaplasma
spp
babesia
spp
use
confirm
speci
specif
edtablood
sampl
pericardi
effus
sampl
dog
pericardi
effus
analys
studi
includ
femal
male
rang
age
year
twenti
dog
present
idiopath
pericardi
effus
neoplast
effus
five
dog
unknown
canin
vector
born
pathogen
found
dog
posit
dog
reveal
dna
leishmania
infantum
blood
pericardi
effus
n
blood
n
plati
blood
n
coinfect
leishmania
infantum
babesia
cani
cani
blood
n
babesia
cani
cani
pericardi
effus
n
babesia
equi
pericardi
effus
n
babesia
gibsoni
blood
n
hepatozoon
cani
blood
n
relationship
ethiolog
pericardi
effus
presenc
cvbd
studi
perform
ascertain
ethiopathogenesi
pericardi
effus
focus
bacteri
viral
pathogen
show
rare
find
dog
although
relev
human
pericard
moreov
previou
research
suggest
immun
respons
domin
humor
effector
mechan
support
primari
immunemedi
pathogenesi
idiopath
pericard
dog
studi
add
new
inform
potenti
role
canin
vector
born
diseas
cvbd
canin
pericardi
effus
frequent
pathogen
detect
babesiosi
leishmaniosi
corrobor
previou
literatur
find
dog
infect
leishmaniosi
heavi
parasitaemia
minim
pericardi
effus
present
usual
resolv
spontan
infecti
diseas
babesiosi
heart
may
suffer
patholog
process
describ
organ
inflamm
hypoxia
caus
pericardi
effus
howev
studi
cbvd
found
often
dog
pericardi
effus
compar
neoplast
effus
therefor
causeeffect
relationship
stablish
result
interestingli
infecti
diseas
bartonellosi
suggest
oncogen
potenti
research
need
clarifi
possibl
role
infecti
diseas
dog
neoplast
pericardi
effus
worth
note
sensit
pcr
protocol
use
present
investig
may
high
enough
detect
pathogen
bartonella
spp
moreov
borrelia
spp
includ
blood
sampl
ideal
sampl
detect
pathogen
anoth
limit
retrospect
natur
studi
inform
previou
treatment
receiv
may
alter
result
pcr
conclud
molecular
biolog
investig
seem
provid
addit
tool
diagnost
pericardi
effus
unknown
etiolog
cvbd
warrant
consider
research
must
perform
dog
pericardi
effus
current
studi
conduct
molecularli
investig
presenc
select
vectorborn
pathogen
anaplasma
spp
ehrlichia
spp
rickettsia
spp
babesia
spp
bartonella
spp
hematotrop
mycoplasma
spp
dog
without
tick
flea
infest
chiang
mai
thailand
total
dog
includ
studi
dog
dog
without
tick
flea
infest
regardless
health
statu
whole
blood
serum
sampl
collect
complet
blood
count
blood
chemistri
profil
twenti
tick
nine
flea
pool
sampl
collect
dog
tick
flea
infest
morpholog
identifi
dna
sampl
extract
whole
blood
tick
flea
polymeras
chain
reaction
pcr
target
pathogen
perform
dna
sequenc
perform
posit
dna
fragment
genet
inform
associ
vectorborn
pathogen
infect
age
sex
presenc
anemia
thrombocytopenia
evid
tick
flea
infest
use
tick
flea
control
product
allow
free
roam
assess
use
fisher
exact
test
overal
preval
least
one
vectorborn
pathogen
detect
dog
tick
flea
respect
tick
flea
identifi
rhipicephalu
sanguineu
ctenocephalid
feli
preval
pathogen
dog
e
cani
follow
anigen
rapid
test
kit
chromatograph
immunoassay
qualit
detect
dirofilaria
immiti
antigen
antibodi
phagocytophilum
plati
antibodi
b
burgdorferi
antibodi
e
cani
canin
serum
plasma
whole
blood
report
compar
perform
anigen
test
detect
heartworm
antigen
sera
dog
necropsyconfirm
infect
detect
antibodi
phagocytophilum
plati
b
burgdorferi
e
cani
indirect
immunoflouresc
assaycharacter
canin
sampl
total
character
sampl
evalu
summari
anigen
test
poor
sensit
b
burgdorferi
detect
ifa
posit
sampl
diagnost
sensit
three
tickborn
diseas
rang
specif
four
assay
addit
test
protocol
anigen
complic
two
differ
sampl
volum
requir
two
drop
heartworm
analyt
tick
born
diseas
marker
diarrhea
commonli
found
shelter
cat
caus
differ
factor
stress
dietari
chang
enter
parasit
protozoan
commonli
detect
often
includ
cryptosporidium
spp
giardia
spp
tritrichomona
foetu
blagburni
cyclospora
cayetanensi
anoth
enter
protozoan
infect
peopl
littl
known
potenti
zoonot
transfer
thu
object
studi
optim
c
cayetanensi
pcr
assay
appli
fece
cat
diarrhea
shelter
colorado
usa
optim
publish
sybr
green
base
quantit
pcr
qpcr
fragment
intern
transcrib
spacer
gene
c
cayetanensi
follow
melt
curv
analysi
perform
publish
determin
linear
rang
reaction
serial
dilut
synthet
oligonucleotid
perform
regress
analysi
perform
result
standard
curv
use
instrument
softwar
intra
interassay
variabl
determin
run
five
replic
dilut
seri
three
differ
run
specif
c
cayentanensi
determin
includ
genom
dna
g
duodenali
c
parvum
toxoplasma
gondii
duplic
along
c
cayentanesi
dna
optim
anneal
temperatur
determin
perform
anneal
gradient
rang
fecal
sampl
total
cat
estim
week
year
age
acut
diarrhea
least
day
durat
recogn
hous
shelter
north
central
colorado
evalu
fece
analyz
use
microscop
examin
parasit
egg
cyst
oocyst
use
sheather
sugar
centrifug
detect
cryptosporidium
spp
oocyst
giardia
spp
cyst
commerci
ifa
use
merifluor
cryptosporidiumgiardia
meridian
bioscienc
dna
extract
perform
use
method
previous
describ
pcr
assay
target
rrna
heat
shock
gene
cryptosporidium
spp
glutam
dehydrogenas
bgiardin
trios
phosphat
isomeras
gene
giardia
spp
use
speciat
posit
sampl
extract
dna
also
evalu
optim
c
cayetanensi
pcr
assay
lowest
reliabl
level
detect
c
cayetanensi
dna
dnareact
assay
linear
rang
four
dilut
r
valu
reaction
effici
melt
curv
show
tm
valu
c
cayetanensi
oligonucleotid
rang
amplif
g
duodenali
c
parvum
gondii
dna
observ
optim
anneal
temperatur
enter
parasit
detect
cat
includ
cryptosporidium
spp
giardia
spp
feli
dna
c
cayetanensi
amplifi
sampl
sampl
adequ
dna
sequenc
rrna
assay
type
cryptosporidium
spp
four
isol
two
isol
type
c
feli
bgiardin
glutam
dehydrogenas
gene
type
one
giardia
spp
assemblag
f
parasit
detect
studi
similar
similar
studi
felin
host
adapt
strain
cryptosporidium
giardia
detect
sinc
cat
neg
c
cayetanensi
like
diarrhea
caus
agent
research
need
done
investig
whether
c
cayetanensi
potenti
infect
cat
kidney
diseas
one
common
caus
morbid
mortal
cat
earli
detect
key
slow
diseas
progress
gfr
accur
mean
determin
renal
function
howev
bolu
intraven
inject
techniqu
use
measur
gfr
vari
accuraci
precis
new
accur
precis
method
gfr
measur
use
gfr
error
adapt
tikhonov
regular
gamma
variat
tkgv
fit
human
data
appli
first
time
veterinari
patient
compar
standard
exogen
creatinin
plasma
clearanc
use
noncompartment
area
curv
crcl
iohexol
computer
tomograph
patlak
plot
ctpp
seven
laboratori
rais
cat
deem
healthi
evalu
routin
blood
work
urinalysi
urin
cultur
cat
gfr
measur
twice
method
day
apart
evalu
accuraci
precis
gfrvalu
median
gfrvalu
tkgv
crcl
ctpp
respect
similar
interquartil
rang
iqr
howev
precis
gfrkgvalu
measur
studi
vari
markedli
tkgv
crcl
ctpp
iqr
respect
use
wilcoxon
signedrank
test
differ
first
second
studi
cat
tkgv
crcl
ctpp
pvalu
tkgv
method
detect
borderlin
signific
decreas
median
gfr
mlminkg
two
serial
studi
three
method
test
provid
gfr
measur
within
report
refer
rang
cat
mlkgmin
howev
recent
develop
tkgv
method
provid
stabl
precis
result
allow
detect
differ
sequenti
studi
suggest
superior
util
detect
interv
chang
kidney
function
healthi
cat
due
heighten
preval
number
cat
diagnos
obstruct
ureterolithiasi
recent
year
surgeri
felin
upper
urinari
tract
becom
commonplac
sever
techniqu
describ
treatment
ureter
patholog
cat
includ
ureterotomi
neoureterocystostomi
ureter
stent
subcutan
ureter
bypass
howev
current
pauciti
veterinari
literatur
document
success
procedur
object
studi
report
periop
complic
mortal
rate
cat
undergo
ureterotomi
neoureterocystostomi
surgic
ureter
stent
placement
also
describ
longterm
success
intervent
regard
preval
persist
clinic
sign
urinari
tract
dysfunct
preval
urinari
tract
reobstruct
medic
record
univers
pennsylvania
veterinari
teach
hospit
cat
underw
ureter
surgeri
ureterotomi
neoureterocystostomi
open
ureter
stent
placement
review
signal
clinic
sign
clinicopatholog
test
result
imag
find
record
surgic
procedur
perform
periop
complic
periop
mortal
describ
longterm
follow
obtain
via
medic
record
review
client
interview
preval
chronic
lower
urinari
tract
sign
urinari
tract
infect
ureter
reobstruct
document
one
hundr
seventeen
cat
includ
studi
major
cat
domest
short
hair
cat
median
age
time
surgeri
year
rang
year
median
weight
kg
rang
kg
case
evenli
distribut
sex
femal
male
ureterotomi
perform
cat
neoureterocystostomi
cat
fortytwo
cat
ureter
stent
place
periop
complic
relat
urinari
tract
identifi
case
includ
uroabdomen
eight
cat
stent
migrat
two
cat
periop
mortal
rate
major
death
attribut
progress
renal
failur
median
durat
hospit
day
rang
day
longterm
follow
avail
cat
aliv
dead
cat
dead
follow
death
occur
median
day
postop
rang
day
death
attribut
progress
chronic
renal
failur
cat
ureter
reobstruct
seven
cat
diseas
process
unrel
urinari
tract
five
cat
unknown
caus
death
assign
remain
deceas
cat
cat
aliv
follow
median
interv
surgeri
follow
day
rang
day
cat
longterm
follow
avail
suffer
ureter
reobstruct
chronic
lower
urinari
tract
sign
urinari
tract
infect
stent
encrust
result
studi
suggest
periop
mortal
rate
ureter
surgeri
lower
previous
report
importantli
death
commonli
due
progress
renal
failur
surgic
complic
chronic
lower
urinari
tract
sign
urinari
tract
infect
common
particularli
cat
ureter
stent
place
high
incid
reobstruct
warrant
appropri
client
counsel
judici
follow
derang
sodium
water
balanc
clinic
signific
consequ
kidney
failur
hemodialysi
sodium
equilibr
patient
dialys
provid
opportun
chang
occur
patient
plasma
sodium
concentr
pna
current
known
dialysatepati
sodium
gradient
dpna
may
affect
pna
purpos
studi
compar
dialys
sodium
concentr
dna
preand
postdialysi
sodium
concentr
dog
undergo
intermitt
hemodialysi
identifi
paramet
use
better
prescrib
dna
correct
alter
plasma
sodium
medic
record
two
institut
evalu
retrospect
identifi
dog
underw
intermitt
hemodialysi
util
gambro
phoenix
platform
dog
exclud
differ
chemistri
methodolog
use
measur
preand
postdialysi
sodium
concentr
concurr
intraven
fluid
administ
dialys
sodium
profil
perform
linear
regress
util
determin
correl
dialys
patient
sodium
concentr
two
hundr
eleven
treatment
perform
dog
found
fit
inclus
criteria
statist
signific
correl
found
dpna
chang
post
dialysi
pna
dna
final
pna
start
dpna
final
dpna
initi
dpna
strongest
correl
observ
chang
patient
sodium
predict
chang
pna
predict
dpna
regress
coeffici
ci
r
p
dna
moder
correl
final
pna
regress
coeffici
ci
r
p
initi
dpna
weakest
correl
final
dpna
regress
coeffici
ci
r
p
mmol
dpna
gradient
produc
mmol
chang
pna
cours
dialysi
treatment
result
suggest
initi
dpna
best
correl
final
pna
potenti
use
prescript
dna
correct
disord
predialysi
sodium
concentr
predict
final
pna
chronic
kidney
diseas
ckd
common
condit
age
cat
predomin
patholog
diagnosi
tubulointerstiti
inflamm
fibrosi
cytokin
wide
implic
develop
progress
renal
fibrosi
experiment
model
kidney
diseas
total
demonstr
elev
urin
cat
ckd
aim
studi
firstli
valid
method
quantif
activ
felin
urin
secondli
assess
associ
urinari
activ
develop
azotem
ckd
crosssect
studi
b
deterior
renal
function
longitudin
studi
record
first
opinion
practic
search
cat
year
age
without
renal
azotemia
renal
azotemia
defin
plasma
creatinin
concentr
mg
dl
concurr
urin
specif
graviti
usg
demonstr
azotemia
consecut
occas
least
day
apart
without
evid
preren
caus
cat
exclud
concurr
hyperthyroid
signific
system
diseas
suspect
activ
concentr
measur
felin
urin
use
activ
elisa
develop
use
human
sampl
valid
intraand
interassay
variabl
assess
dilut
parallel
spike
recoveri
exogen
purpos
crosssect
studi
case
classifi
base
upon
baselin
statu
subsequ
renal
function
result
three
group
cat
renal
azotemia
group
nonazotem
cat
remain
nonazotem
month
group
nonazotem
cat
develop
azotemia
within
month
group
comparison
group
made
use
kruskalw
test
purpos
longitudin
studi
case
three
consecut
urin
sampl
lead
deterior
renal
function
classifi
two
group
nonazotem
cat
develop
azotemia
month
azotem
cat
progress
ckd
month
progress
defin
repeat
increas
plasma
creatinin
baselin
comparison
visit
within
two
group
made
use
friedman
test
posthoc
wilcoxon
sign
rank
test
appropri
result
report
median
rang
mean
ae
sd
appropri
intraassay
interassay
cv
urinari
activ
measur
n
n
respect
dilut
parallel
indic
mean
recoveri
ae
n
spike
exogen
result
mean
recoveri
ae
n
cross
section
analysi
reveal
signific
differ
urinari
activ
tgf
conclus
signific
differ
found
cat
differ
degre
renal
function
cross
section
studi
utgf
c
increas
prior
document
deterior
renal
function
healthi
cat
develop
ckd
longitudin
analysi
suggest
urinari
follow
longitudin
individu
cat
may
indic
develop
ckd
cat
investig
role
mediat
warrant
bleed
complic
chronic
kidney
diseas
ckd
human
partial
caus
platelet
dysfunct
abnorm
plateletvessel
wall
interact
dog
experiment
induc
ckd
prolong
buccal
mucos
bleed
time
coagul
platelet
function
evalu
compar
platelet
function
healthi
dog
dog
ckd
use
thromboelastographi
teg
platelet
gpib
gpiibiiia
pselectin
express
eleven
dog
natur
occur
iri
stage
iv
ckd
control
dog
enrol
complet
blood
count
serum
biochemistri
urinalysi
urin
protein
creatinin
ratio
prothrombin
time
partial
thromboplastin
time
fibrinogen
concentr
antithrombin
activ
perform
closur
time
ct
use
collagen
epinephrin
colepi
coladp
agonist
measur
reaction
time
r
clot
format
time
k
aangl
maxim
amplitud
global
clot
strength
g
teg
variabl
analyz
platelet
gpib
gpiibiiia
pselectin
express
assess
flow
cytometri
ckd
dog
prolong
coladp
ct
p
differ
colepi
ct
found
teg
p
g
p
increas
ktime
p
decreas
ckd
dog
ckd
dog
increas
platelet
gpiibiiia
pselectin
mean
fluoresc
intens
compar
control
p
differ
remain
variabl
correl
found
platelet
receptor
express
variabl
dog
ckd
may
platelet
dysfunct
hypercoagul
base
elev
teg
valu
platelet
receptor
express
may
explain
chang
platelet
function
coagul
eighteen
healthi
beagl
dog
use
group
n
nm
administ
dose
mgkgh
hour
ihd
group
n
nm
administ
lower
dose
mgkgh
ihd
group
n
control
group
unfraction
heparin
administ
ihd
evalu
paramet
includ
residu
blood
clot
blood
chamber
dialyz
arteri
side
hemoglobin
hematocrit
platelet
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
activ
clot
time
act
group
group
success
complet
ihd
without
seriou
coagul
extracorpor
circul
statist
signific
identifi
clot
format
residu
blood
clot
blood
chamber
dialyz
arteri
side
group
group
p
group
p
group
group
statist
signific
chang
pt
p
respect
aptt
p
respect
act
p
respect
observ
group
statist
signific
elev
act
observ
p
result
studi
suggest
possibl
use
lowdos
nm
mgkgh
altern
anticoagul
patient
bleedingrisk
ihd
human
studi
intravesicular
instil
exogen
gag
replac
reduc
uti
recurr
infect
per
year
veterinari
medicin
bladder
instil
therapi
impract
requir
regular
catheter
urin
retent
intramuscularli
administ
gag
primarili
excret
urinari
tract
may
provid
altern
method
urinari
gag
administr
aim
describ
studi
determin
magnitud
durat
urinari
gag
excret
intramuscular
inject
polysulf
glycosaminoglycan
psgag
studi
client
own
dog
receiv
singl
intramuscular
mgkg
inject
psgag
n
treatment
n
urin
sampl
collect
prior
psgag
inject
day
day
afterward
day
day
treatment
control
group
urin
gag
quantifi
use
spectrophotometr
dimethylmethylen
blue
assay
variabl
urin
output
henc
gag
dilut
account
divid
result
optic
densiti
urin
creatinin
ugag
ucrea
ratio
day
compar
baselin
day
valu
calcul
fold
chang
gag
excret
dog
intramuscular
inject
psgag
median
ugag
ucrea
increas
day
day
day
valu
signific
compar
control
dog
ugag
ucrea
rang
baselin
gag
concentr
data
indic
increas
urinari
gag
concentr
intramuscular
inject
psgag
unlik
achiev
concentr
use
intravesicular
instil
instead
psgag
excret
low
level
period
day
therapeut
benefit
low
level
gag
infus
prevent
uti
unknown
time
yann
queau
laurenc
le
verger
alexandr
feugier
vincent
biourg
royal
canin
research
center
aimargu
franc
sodium
chlorid
nacl
use
diet
promot
water
intak
urin
dilut
dog
cat
risk
urolithiasi
one
studi
speci
show
dietari
g
kcal
decreas
rel
supersatur
rss
calcium
oxal
caox
threshold
unclear
object
determin
dose
respons
relationship
dietari
nacl
caox
rss
cat
thirteen
cat
seven
femal
age
year
fed
sequenti
four
dri
diet
day
follow
day
individu
urin
collect
diet
b
c
ident
nacl
ad
obtain
sodium
kcal
respect
volum
ph
concentr
ten
ion
measur
individu
urin
pool
caox
rss
calcul
use
supersat
linear
mix
model
assess
effect
diet
fix
effect
level
includ
cat
random
term
data
express
least
squar
meansaes
residu
model
normal
distribut
calor
intak
similar
diet
p
tabl
superscript
indic
signific
differ
diet
scheff
adjust
test
multipl
kidney
play
import
role
magnesium
homeostasi
renal
handl
magnesium
highli
adapt
renal
function
declin
significantli
increas
serum
magnesium
detect
howev
hypomagnesemia
also
common
chronic
kidney
diseas
ckd
human
associ
develop
vascular
calcif
poor
clinic
outcom
studi
serum
magnesium
concentr
veterinari
medicin
relat
diseas
felin
canin
diabet
mellitu
canin
parvovir
enter
proteinlos
enteropathi
dog
far
data
dog
ckd
goal
studi
evalu
serum
total
magnesium
dog
chronic
kidney
diseas
stage
iri
sixteen
ckd
dog
includ
studi
stage
n
stage
n
followedup
two
month
measur
serum
total
magnesium
kit
randox
perform
monthli
serum
total
magnesium
also
measur
clinic
normal
dog
mean
ae
sd
ae
mgdl
normal
rang
consid
studi
mgdl
mean
serum
magnesium
concentr
ckd
dog
stage
stage
mgdl
sem
ae
mgdl
ae
respect
hypermagnesemia
mg
dl
detect
dog
stage
dog
stage
notic
point
followup
usual
associ
highest
level
serum
creatinin
hypomagnesemia
mgdl
detect
dog
stage
dog
stage
point
usual
detect
begin
followup
correl
observ
serum
magnesium
serum
urea
creatinin
ioniz
calcium
total
calcium
bicarbon
phosphoru
conclus
magnesium
may
consid
indic
marker
progress
ckd
dog
sinc
impair
renal
function
may
result
hypermagnesemia
observ
human
ckd
hand
well
proven
human
rat
hypomagnesemia
associ
faster
deterior
kidney
function
vascular
calcif
role
magnesium
dog
ckd
investig
yet
clinic
import
could
underestim
thu
addit
studi
need
better
understand
magnesium
pathophysiolog
miner
metabol
dog
chronic
kidney
diseas
prospect
evalu
periop
outcom
cat
benign
ureter
obstruct
undergo
ureter
stent
secondari
goal
compar
similar
case
undergo
ureterotomi
cohort
studi
sixtytwo
clientown
cat
underw
ureter
stent
n
ureterotomi
treatment
benign
ureter
obstruct
cat
diagnos
benign
ureter
obstruct
treat
ureter
stent
histor
group
cat
benign
ureter
obstruct
treat
ureterotomi
identifi
comparison
data
record
prospect
ureter
stent
case
collect
retrospect
medic
record
ureterotomi
case
variabl
statist
compar
cat
treat
ureter
stent
significantli
greater
decreas
blood
urea
nitrogen
bun
creatinin
postop
discharg
compar
cat
underw
ureterotomi
cat
develop
abdomin
effus
postop
significantli
less
like
discharg
hospit
cat
ureter
stent
group
significantli
like
develop
abdomin
effus
ureterotomi
perform
conjunct
stent
placement
cat
ureter
stent
significantli
like
resolut
azotemia
inhospit
cat
resolut
azotemia
hospit
significantli
like
discharg
hospit
cat
undergo
ureter
stent
placement
demonstr
earli
postop
improv
azotemia
greater
chanc
resolut
azotemia
compar
cat
undergo
ureterotomi
earli
postop
result
ureter
stent
encourag
urethr
sphincter
mechan
incompet
usmi
common
caus
acquir
urinari
incontin
neuter
femal
dog
sever
factor
may
impact
risk
usmi
includ
weight
bodi
condit
score
bc
age
neuter
object
studi
describ
popul
spay
femal
dog
usmi
investig
initi
present
diagnosi
treatment
inform
collect
dog
usmi
ui
diagnos
januari
decemb
contin
neuter
femal
dog
c
neither
age
bc
differ
group
ui
dog
weigh
c
dog
p
signific
differ
age
neuter
ui
dog
c
dog
howev
everi
month
delay
neuter
first
year
life
usmi
risk
declin
p
median
time
neuter
ui
sign
year
first
sign
veterinari
consult
day
dog
diagnos
usmi
initi
present
phenylpropanolamin
ppa
prescrib
diethylstilbestrol
combin
therapi
dog
data
support
previou
studi
show
heavier
dog
increas
risk
usmi
onset
occur
within
year
neuter
risk
associ
age
neuter
remain
controversi
owner
appear
like
seek
veterinari
care
rel
soon
onset
clinic
sign
case
diagnosi
usmi
prompt
treatment
choic
may
reflect
differ
avail
ppa
estrogen
compound
period
studi
viyo
nutrit
supplement
may
increas
appetit
water
consumpt
pilot
studi
evalu
effect
viyo
recuper
tm
renal
vrr
biochem
paramet
cat
chronic
kidney
diseas
ckd
compar
palat
ckd
cat
normal
appetit
versu
ckd
cat
decreas
appetit
pilot
studi
total
cat
stabl
ckd
creatinin
concentr
mgdl
mgdl
enrol
two
group
ckd
cat
normal
appetit
ckd
cat
decreas
appetit
cbc
serum
biochemistri
urinalysi
blood
pressur
measur
prior
enrol
ml
vrr
offer
prior
meal
daili
day
amount
voluntarili
consum
hour
measur
owner
score
appetit
water
consumpt
daili
bodi
weight
biochem
profil
assess
day
wilcoxon
test
use
compar
result
pre
post
treatment
prior
start
trial
median
amount
food
consum
cat
normal
appetit
group
rang
median
amount
food
consum
cat
decreas
appetit
group
rang
signific
differ
biochem
paramet
group
ckd
cat
normal
appetit
consum
total
day
volum
vrr
statist
signific
decreas
serum
phosphoru
p
detect
signific
differ
biochem
paramet
bodi
weight
ckd
cat
decreas
appetit
cat
consum
total
day
volum
vrr
obviou
differ
measur
biochem
paramet
cat
consum
total
day
volum
vrr
howev
number
case
enter
date
small
statist
comparison
overal
vrr
palat
cat
ckd
decreas
serum
phosphoru
level
ckd
cat
normal
appetit
cat
ckd
decreas
appetit
less
like
voluntarili
consum
vrr
data
collect
continu
determin
overal
effect
appetit
biochem
find
greater
number
cat
marker
urinari
clusterin
uclu
jack
quinn
mirole
zieba
murthi
yerramilli
idexx
laboratori
inc
westbrook
usa
clusterin
apolipoprotein
j
kda
disulphid
link
heterodimer
protein
clusterin
shown
upregul
proxim
distal
tubular
injuri
uclu
part
fda
ich
renal
toxic
biomark
panel
drug
develop
clusterin
chang
profound
signific
urin
compar
serum
kidney
injuri
event
commerci
eia
kit
biovendor
avail
quantif
canin
clusterin
serum
urin
recent
studi
valid
biomark
use
kit
dog
leishmaniasi
healthi
dog
serum
concentr
clusterin
higher
lgml
urinari
concentr
ngml
report
uclu
aki
biomark
increas
result
kidney
injuri
dog
contamin
canin
urin
sampl
blood
commonli
observ
occurr
due
infect
trauma
neoplasia
inflamm
accident
contamin
cather
cystocentisi
henc
import
ensur
quantif
uclu
impact
contamin
serum
clusterin
blood
failur
could
result
fals
posit
neg
canin
urin
sampl
valu
assign
use
kit
spike
variou
amount
neg
canin
serum
vv
result
mixtur
analyz
use
kit
result
obtain
shown
result
show
present
assay
impact
even
minut
amount
blood
visibl
nake
eye
mean
patient
sampl
hint
blood
contamin
evalu
care
sinc
possibl
fals
posit
lead
fals
clinic
diagnos
increas
measur
urin
protein
creatinin
ratio
upcr
import
detect
evalu
monitor
renal
diseas
studi
knowledg
evalu
effect
hematuria
upcr
felin
urin
purpos
consecut
felin
urin
sampl
yellow
rbc
wbc
per
hpf
use
sampl
pool
final
volum
ml
n
pool
felin
blood
dilut
blood
urin
ad
aliquot
pool
serial
dilut
perform
remaind
pool
undilut
pool
dilut
evalu
blind
fashion
urin
sampl
color
record
light
yellow
dark
yellow
light
pink
dark
pink
red
pool
centrifug
supernat
collect
store
protein
colorimetr
assay
creatinin
concentr
measur
via
autom
clinic
chemistri
analyz
sign
rank
test
use
compar
upcr
undilut
sampl
color
also
result
light
dark
yellow
averag
call
yellow
light
dark
pink
red
averag
call
color
data
compar
undilut
yellow
color
use
repeat
measur
anova
rank
post
hoc
comparison
made
via
tukey
test
chisquar
use
compar
categor
normal
borderlin
high
color
signific
set
p
level
upcr
significantli
increas
p
color
yellow
sampl
compar
undilut
sampl
individu
color
compar
undilut
proteinuria
categor
differ
significantli
p
undilut
color
except
light
yellow
see
tabl
proteinuria
categor
differ
significantli
undilut
color
undilut
yellow
previou
studi
use
canin
urin
suggest
hematuria
consid
differenti
diagnosi
proteinuria
sampl
visibl
hematur
contrast
data
suggest
presenc
hematuria
significantli
increas
upcr
felin
urin
sampl
visibl
hematur
thu
presenc
blood
may
greater
effect
upcr
cat
dog
sediment
examin
result
must
taken
account
interpret
upcr
mani
dog
respond
current
treatment
regimen
remain
incontin
women
minim
invas
procedur
low
temperatur
urethr
thermoplasti
ltut
restor
contin
reduc
complianc
periurethr
tissu
control
applic
heat
goal
studi
determin
feasibl
ltut
femal
dog
evalu
acut
complic
follow
treatment
addit
treat
canin
urethr
tissu
examin
histolog
chang
previous
associ
success
ltut
three
femal
purpos
bred
mongrel
dog
kg
treat
ltut
thermoplasti
probe
posit
proxim
urethra
via
fluoroscop
guidanc
heat
periurethr
tissu
perform
three
differ
plane
total
treatment
site
within
hour
treatment
bladder
urethra
remov
en
bloc
distend
salin
investig
leakag
treatment
site
evalu
grossli
seros
lesion
bladder
urethra
fix
evalu
histolog
urethr
thermoplasti
perform
success
case
without
complic
leakag
seros
lesion
note
gross
examin
chang
typic
thermal
therapi
consist
focal
congestionedema
connect
tissu
muscl
note
histolog
urethr
thermoplasti
feasibl
safe
acut
set
induc
acut
histopatholog
chang
requir
success
treatment
long
termstudi
research
dog
eventu
clinic
patient
necessari
determin
efficaci
ltut
treatment
canin
incontin
dri
reagent
strip
dipstick
commonli
use
part
routin
urinalysi
knowledg
studi
evalu
effect
blood
dipstick
result
depend
color
reagent
pad
discolor
urin
could
potenti
affect
final
read
therefor
purpos
studi
determin
effect
hematuria
manual
urin
dipstick
evalu
dog
cat
consecut
urin
sampl
dog
cat
submit
urinalysi
yellow
rbc
wbc
per
hpf
sediment
exam
use
sampl
supernat
pool
obtain
final
volum
ml
pool
evalu
speci
canin
felin
whole
blood
ad
aliquot
pool
obtain
dilut
blood
urin
serial
dilut
perform
remaind
pool
undilut
pool
dilut
evalu
siemen
multistix
sg
reagent
strip
random
blind
fashion
per
manufactur
instruct
visual
inspect
greatest
dilut
result
urinari
sediment
rbchpf
color
urin
sampl
record
light
yellow
dark
yellow
light
pink
dark
pink
red
specif
graviti
sg
measur
handheld
refractomet
reichert
ts
statist
comparison
result
light
dark
yellow
averag
call
yellow
result
light
dark
pink
red
averag
call
color
repeat
measur
anova
rank
use
compar
read
analyt
undilut
yellow
color
post
hoc
comparison
made
tukey
test
signific
set
p
level
canin
sampl
bilirubin
keton
ph
protein
sg
significantli
differ
undilut
yellow
sampl
color
sampl
significantli
differ
undilut
yellow
sampl
despit
color
sampl
presenc
blood
result
significantli
increas
read
blood
blood
ad
read
felin
sampl
keton
ph
protein
sg
significantli
differ
undilut
yellow
sampl
howev
color
significantli
differ
undilut
yellow
sampl
despit
color
sampl
presenc
blood
result
significantli
increas
read
blood
bilirubin
understand
effect
hematuria
urin
dipstick
necessari
accur
interpret
result
glucos
read
affect
regardless
amount
blood
sampl
keton
read
significantli
higher
color
urin
dog
cat
bilirubin
significantli
increas
cat
urin
addit
rbc
even
sampl
remain
visibl
yellow
dog
urin
bilirubin
significantli
affect
sampl
visibl
pink
dipstick
protein
read
significantli
elev
either
speci
sampl
visibl
pink
degre
hematuria
despit
color
sampl
affect
blood
reagent
pad
blood
dog
cat
yerramilli
idexx
laboratori
inc
westbrook
usa
cystatin
c
kda
protein
freeli
filter
kidney
human
medicin
shown
superior
marker
ckd
compar
serum
creatinin
small
number
studi
investig
potenti
marker
dog
cat
mix
result
goal
current
studi
investig
serum
cystatin
c
could
differenti
healthi
anim
cat
ckd
especi
earli
diseas
total
felin
serum
sampl
obtain
analyz
serum
creatinin
serum
cystatin
c
serum
creatinin
determin
use
olympu
assay
serum
cystatin
c
determin
use
human
commerci
plate
assay
commerci
assay
valid
cat
use
felin
recombin
cystatin
c
sampl
group
accord
iri
stage
healthi
cat
creatinin
mgdl
earli
diseas
mgdl
late
diseas
mgdl
serum
cystatin
c
quantil
determin
rang
serum
cystatin
c
three
group
determin
healthi
group
rang
ngml
earli
diseas
group
rang
ngml
late
diseas
group
rang
ngml
data
suggest
cat
earli
diseas
hard
differenti
either
healthi
group
late
stage
diseas
group
therefor
studi
serum
cystatin
c
appear
better
serum
creatinin
classifi
kidney
diseas
find
agreement
work
publish
martin
et
al
martin
et
al
revu
de
medicin
veterinair
vol
p
recommend
cystatin
c
use
diagnos
kidney
failur
cat
meropenem
second
carbapenem
antimicrobi
agent
broad
spectrum
activ
use
treat
sepsi
resistantbacteri
infect
veterinari
medicin
object
studi
identifi
pharmacokinet
meropenem
dog
receiv
intermitt
hemodialysi
ihd
determin
proper
dose
patient
renal
failur
receiv
ihd
five
healthi
beagl
dog
given
singl
iv
dose
mgkg
meropenem
receiv
ihd
ihd
initi
end
infus
meropenem
fx
pa
use
artifici
kidney
blood
flow
rate
mlmin
dialys
flow
rate
ultrafiltr
rate
mlmin
mlh
respect
blood
sampl
collect
hour
jugular
vein
extracorpor
arteri
venou
line
urin
sampl
dialys
collect
concentr
meropenem
measur
use
hplcmsm
determin
pharmacokinet
data
simul
dose
regimen
analyz
winnolin
program
mean
peak
plasma
concentr
ae
mg
minut
mean
total
bodi
clearanc
ae
mlhkg
mean
steadi
state
volum
distribut
ae
lkg
approxim
administ
drug
excret
urin
unchang
form
dialysi
clearanc
ae
mlhkg
extract
ratio
dialysi
ae
halflif
meropenem
dog
renal
failur
prolong
compar
dog
renal
failur
receiv
ihd
conclus
meropenem
remov
dog
dialysi
base
simul
data
addit
dose
mgkg
meropenem
dialysi
suggest
recent
shown
serum
symmetr
dimethylarginin
sdma
biomark
canin
felin
ckd
earlier
serum
creatinin
use
highli
sensit
specif
liquid
chromatographymass
spectrometri
lcm
analyt
method
valid
per
fda
clia
guidelin
report
describ
high
throughput
immunoassay
develop
correl
gold
standard
lcm
assay
part
method
valid
perform
characterist
includ
sensit
precis
recoveri
accuraci
linear
interfer
carryov
stabil
robust
investig
perform
metric
within
establish
ncsli
guidanc
lower
limit
quantit
lloq
found
lg
dl
five
point
standard
curv
rang
lgdl
establish
linear
r
intra
inter
day
cv
found
signific
interfer
hemolysi
lipemia
icteru
observ
relat
compound
arginin
monomethylarginin
mma
asymmetr
dimethylarginin
adma
signific
impact
perform
correl
lcm
method
r
dog
cat
use
standard
linear
fit
conclus
develop
valid
high
throughput
immunoassay
correl
lcm
accur
quantifi
sdma
biolog
sampl
dog
cat
felin
chronic
kidney
diseas
ckd
character
chronic
tubulointerstiti
nephriti
inflamm
contribut
progress
renal
fibrosi
mesenchym
stem
cell
msc
therapi
may
reduc
intraren
inflamm
fibrosi
follow
system
deliveri
demonstr
modest
effect
felin
ckd
follow
intraven
deliveri
howev
effect
perinephr
msc
deliveri
evalu
previous
purpos
present
studi
evalu
clinic
effect
retroperiton
deliveri
msc
cat
ckd
six
stabl
ckd
cat
iri
stage
ii
iri
stage
iii
concurr
diseas
treat
allogen
msc
cultur
cryopreserv
adipos
tissu
spf
research
cat
msc
inject
left
retroperiton
space
via
ultrasound
guidanc
week
cbc
serum
biochemistri
urinalysi
upc
perform
week
glomerular
filtrat
gfr
via
nuclear
scintigraphi
perform
week
renal
function
paramet
gfr
analys
repeat
measur
anova
pair
ttest
respect
retroperiton
deliveri
msc
elicit
advers
effect
signific
chang
weight
serum
biochemistri
paramet
gfr
global
left
right
upc
pcv
seen
cat
treat
msc
except
transient
mild
increas
serum
creatinin
week
comparison
week
conclud
ultrasoundguid
perinephr
msc
ckd
cat
feasibl
appear
safe
longterm
follow
larger
studi
number
necessari
determin
whether
signific
benefici
effect
slow
progress
diseas
recurr
urinari
tract
infect
uti
problem
dog
women
often
treat
numer
antimicrobi
associ
bacteri
resist
asymptomat
bacteriuria
e
coli
strain
asb
investig
altern
therapi
shown
signific
analges
properti
reduc
pathogen
bacteri
reservoir
experiment
mous
model
aim
studi
investig
safeti
asb
six
healthi
femal
beagl
dog
dog
sedat
dexmedetomidin
mgkg
butorphanol
im
cathet
insert
urinari
bladder
cfuml
asb
strain
instil
dilut
ml
steril
salin
dog
monitor
clinic
sign
urin
collect
cystocentesi
day
instil
day
bladder
infus
asb
urin
collect
day
instil
posit
aerob
bacteri
cultur
e
coli
spp
obtain
four
dog
day
instil
asb
one
dog
posit
cultur
day
instil
second
infus
two
dog
posit
cultur
pathogen
antimicrobi
suscept
pattern
malditof
spectra
puls
field
gel
electrophoresi
confirm
pathogen
isol
beagl
cystocentesi
asb
dog
exhibit
lower
urinari
tract
sign
advers
event
protocol
appear
easi
safe
investig
dog
clinic
recurr
uti
tsz
hong
law
pan
yuanlong
brian
zanghi
elizabeth
want
holger
volk
royal
veterinari
colleg
london
uk
nestl
e
purina
research
st
loui
mo
usa
imperi
colleg
london
london
uk
epilepsi
common
chronic
neurolog
disord
human
dog
despit
appropri
antiepilept
drug
treatment
approxim
one
third
human
dog
epilepsi
continu
experienc
seizur
emphasis
import
new
treatment
strategi
improv
welfar
epilept
patient
prospect
randomis
doubleblind
placebo
control
crossov
dietari
trial
design
compar
medium
chain
triglycerid
ketogen
diet
mctd
standardis
placebo
diet
chronic
treat
dog
idiopath
epilepsi
seizur
month
prior
enrol
dog
fed
either
mctd
placebo
diet
month
follow
subsequ
respect
switch
diet
month
seizur
frequenc
clinic
laboratori
data
collect
prospect
evalu
dog
complet
studi
seizur
frequenc
significantli
lower
dog
mctd
comparison
placebo
diet
p
three
dog
achiev
seizur
freedom
seven
dog
reduct
seizur
frequenc
overal
reduct
seizur
show
respons
number
seizur
day
also
significantli
less
dog
mctd
month
comparison
placebo
diet
month
p
signific
chang
serum
concentr
glucos
p
phenobarbit
p
potassium
bromid
p
weight
p
group
conclus
data
shown
accord
studi
show
antiepilept
properti
mctd
provid
evid
implic
mctd
therapeut
option
treatment
epilepsi
nutrit
modif
diet
cat
chronic
kidney
diseas
ckd
shown
significantli
improv
surviv
time
therapeut
diet
ckd
cat
modifi
restrict
protein
phosphoru
supplement
fatti
acid
particularli
eicosapentaeno
acid
epa
docosahexaeno
acid
dha
supplement
dietari
fatti
acid
shown
benefici
dog
direct
evid
cat
lack
fatti
acid
defici
document
human
ckd
fatti
acid
statu
unknown
cat
ckd
purpos
studi
evalu
serum
fatti
acid
cat
ckd
cat
iri
stage
ckd
recruit
multipl
clinic
studi
assign
one
two
group
base
dietari
histori
previou
month
group
r
cat
fed
prescript
renal
diet
group
cat
fed
adult
mainten
diet
healthi
agematch
cat
fed
adult
mainten
diet
serv
control
group
c
serum
fatti
acid
profil
measur
fast
state
cat
serum
fatti
acid
level
express
percentag
total
fatti
acid
two
hypothes
cat
ckd
adult
mainten
diet
would
lower
measur
fatti
acid
concentr
healthi
control
cat
would
differ
serum
fatti
acid
concentr
cat
ckd
fed
prescript
renal
diet
healthi
control
fed
adult
mainten
diet
parametr
data
analys
use
oneway
anova
commerci
statist
softwar
program
nonparametr
data
analys
use
kruskalw
test
total
cat
ckd
enrol
studi
includ
cat
group
cat
group
r
along
control
signific
differ
age
three
group
p
mean
percentag
arachidon
acid
group
r
group
group
c
p
mean
percentag
epa
group
r
group
group
c
p
mean
percentag
dha
group
r
group
group
c
p
signific
differ
three
group
fatti
acid
analys
cat
ckd
studi
appear
alter
fast
serum
fatti
acid
level
compar
agematch
healthi
control
particular
differ
serum
fatti
acid
epa
dha
feed
therapeut
veterinari
diet
formul
renal
diseas
studi
appear
result
signific
differ
serum
epa
dha
level
compar
mainten
commerci
diet
cat
develop
countri
year
age
either
overweight
obes
need
effect
weight
manag
diet
promot
weight
loss
overweight
cat
object
studi
compar
effect
two
diet
compar
level
dietari
fat
differ
proteincarbohydr
ratio
hpc
lpc
weight
loss
fat
loss
bodi
composit
overweight
cat
thirti
overweight
cat
divid
two
equal
group
base
measur
mainten
energi
requir
mer
bodi
weight
bodi
fat
randomli
assign
one
two
diet
cat
group
fed
mer
month
daili
food
intak
weekli
bodi
weight
monthli
quantit
magnet
reson
bodi
composit
perform
trial
month
signific
differ
loss
bodi
weight
two
group
bodi
fat
loss
doubl
hpc
cat
ae
compar
lpc
cat
ae
mean
bodi
fat
hpc
cat
end
studi
ae
significantli
p
lower
baselin
ae
mean
bodi
fat
lpc
cat
end
studi
ae
significantli
p
differ
baselin
ae
result
show
hpc
diet
effect
lpc
diet
promot
loss
bodi
fat
evalu
impact
environment
dogspecif
factor
influenc
core
bodi
temperatur
cbt
follow
exercis
exercis
condit
dog
n
age
month
own
train
detect
dog
univers
pennsylvania
evalu
separ
occas
week
exercis
train
includ
search
agil
ball
retriev
rest
bout
exercis
period
one
design
trainer
determin
dog
perform
adequ
eg
pant
excess
seek
shade
reluct
retriev
preand
postexercis
heart
rate
cbt
ingest
temperatur
monitor
coretemp
venou
blood
lactat
lactat
scout
blood
ga
istat
collect
backward
stepwis
regress
use
evalu
factor
predict
cbt
combin
exercis
occas
median
exercis
time
minut
rang
minut
median
outdoor
temperatur
rang
median
humid
rang
mean
postexercis
cbt
rang
dog
show
sign
heat
stress
requir
veterinari
intervent
regress
analysi
determin
depend
variabl
peak
cbt
could
predict
linear
combin
independ
variabl
averag
durat
exercis
p
peak
heart
rate
beatsmin
p
postexercis
blood
ph
p
lactat
p
p
model
significantli
influenc
individu
dog
dogag
outdoor
temperatur
humid
chang
baselin
bodi
weight
venou
hematocrit
studi
suggest
influenc
temperatur
humid
less
import
peak
bodi
temperatur
metabol
paramet
associ
exert
safeti
ghrelin
agonist
capromorelin
administ
daili
beagl
dog
year
bill
zoller
linda
rhode
lesley
rauschderra
glenda
armintrout
margi
bell
aratana
therapeut
inc
kansa
citi
ks
usa
clindata
servic
fort
collin
co
usa
capromorelin
ghrelin
agonist
develop
use
dog
appetit
stimul
capromorelin
dose
oral
shown
stimul
food
intak
weight
gain
increas
serum
growth
hormon
gh
insulinlik
growth
laboratori
dog
zoller
et
al
increas
owner
appetit
assess
score
bodi
weight
clinic
field
studi
dog
inappet
zoller
rhode
studi
evalu
safeti
capromorelin
dog
thirtytwo
beagl
dog
randomli
assign
four
group
n
receiv
mgkg
capromorelin
dose
calcul
per
tartrat
salt
daili
oral
gavag
consecut
month
safeti
paramet
evalu
includ
clinic
sign
food
consumpt
bodi
weight
clinic
patholog
urinalysi
ophthalmolog
electrocardiogram
vital
sign
capromorelin
gh
measur
plasma
sampl
collect
variou
timepoint
studi
end
dose
period
dog
euthan
necropsi
select
organ
weigh
tissu
sampl
collect
process
microscop
examin
capromorelin
daili
dose
mgkg
approxim
activ
ingredi
concentr
propos
clinic
dose
dog
month
result
minim
toxic
neg
effect
food
consumpt
bodi
weight
ophthalm
exam
vital
sign
gross
patholog
clinic
sign
relat
capromorelin
limit
saliv
loos
stool
note
sporad
studi
occasion
episod
emesi
observ
consid
unrel
treatment
higher
dose
treatment
associ
increas
incid
reddeningswollen
paw
one
dog
mgkg
group
die
capromorelin
accident
deliv
respiratori
tract
gavag
confirm
necropsi
electrocardiogram
data
indic
slight
increas
prq
interv
mgkg
mgkg
group
hour
follow
dose
howev
histolog
lesion
observ
heart
gener
clinic
patholog
urinalysi
paramet
within
normal
rang
lack
consist
dosetim
relationship
howev
slight
decreas
red
blood
cell
hemoglobin
hematocrit
appear
clinic
signific
mg
kg
group
cholesterol
hdl
alkalin
phosphatas
serum
level
statist
significantli
increas
mgkg
group
compar
placebo
individu
anim
valu
tend
high
end
slightli
normal
refer
rang
increas
absolut
liver
weight
dog
treat
mgkg
dose
capromorelin
note
slight
increas
hepatocellular
cytoplasm
vacuol
seen
capromorelin
treat
group
capromorelin
plasma
level
increas
increas
dose
similar
day
indic
accumul
drug
genderrel
differ
gh
plasma
level
increas
modestli
expect
day
follow
capromorelin
treatment
gh
respons
control
physiolog
neg
feedback
magnitud
gh
respons
capromorelin
treatment
lessen
time
expect
plasma
level
increas
follow
capromorelin
treatment
increas
level
sustain
time
evidenc
plasma
collect
result
studi
demonstr
capromorelin
welltoler
dog
dose
mgkg
month
studi
indic
expect
wide
safeti
margin
capromorelin
high
dose
approxim
propos
clinic
dose
contrera
david
twedt
michael
lappin
lauren
sullivan
colorado
state
univers
fort
collin
co
usa
dog
infect
canin
parvoviru
cpv
develop
sever
enter
requir
support
care
voluntari
food
water
consumpt
return
oral
recuper
fluid
orf
viyo
recuper
tm
contain
essenti
nutrient
prebiot
design
restor
support
gastrointestin
immun
system
may
assist
overal
recoveri
cpv
hypothes
studi
natur
infect
cpv
dog
would
prefer
orf
water
dog
consum
orf
would
rapid
return
voluntari
appetit
improv
calor
intak
initi
recoveri
period
compar
dog
consum
water
total
dog
clinic
sign
consist
cpv
prior
treatment
enrol
detect
cpv
antigen
fece
dog
exclud
voluntari
food
water
intak
present
time
studi
enrol
hospit
admiss
day
dog
random
either
orf
water
group
design
fluid
offer
throughout
hospit
follow
offer
opposit
fluid
hour
later
design
fluid
refus
standard
treatment
protocol
includ
intraven
fluid
cefoxitin
mgkg
iv
maropit
mgkg
iv
use
dog
begin
day
dog
offer
gastrointestin
diet
record
paramet
includ
fluid
prefer
orf
vs
water
vs
neither
day
return
appetit
percentag
prescrib
rest
energi
requir
rer
consum
within
first
hour
appetit
return
higher
percentag
cpv
dog
prefer
orf
design
fluid
compar
offer
water
design
fluid
p
dog
refus
design
fluid
orf
dog
ultim
prefer
water
water
dog
prefer
orf
p
dog
consum
orf
demonstr
rapid
return
voluntari
appetit
median
day
rang
p
compar
consum
water
median
day
rang
neither
fluid
median
day
rang
addit
dog
consum
orf
ingest
higher
rer
median
rang
p
compar
prefer
water
median
rang
neither
fluid
median
rang
studi
suggest
cpv
dog
voluntarili
consum
orf
recoveri
phase
ill
consumpt
orf
may
foster
rapid
return
voluntari
appetit
well
improv
calor
intak
addit
studi
warrant
assess
addit
effect
orf
recoveri
cpv
effect
singledos
treatment
synthet
ghrelin
canin
anorex
patient
preliminari
studi
daigo
azakami
eri
onozawa
katsumi
ishioka
masahiro
miyab
takeshi
hanada
yujiro
hayashi
noboru
murakami
toshinori
sako
nippon
veterinari
life
scienc
univers
musashino
tokyo
japan
asubio
pharma
co
ltd
kobe
hyogo
japan
univers
miyazaki
miyazaki
miyazaki
japan
ghrelin
peptid
hormon
produc
stomach
known
physiolog
pharmacolog
action
stimul
appetit
human
veterinari
medicin
physiolog
effect
ghrelin
healthi
dog
establish
howev
clinic
applic
ghrelin
ever
report
investig
potenti
clinic
use
ghrelin
dog
perform
preliminari
studi
singledos
treatment
synthet
canin
ghrelin
clinic
anorex
dog
ten
clientown
dog
admit
veterinari
medic
teach
hospit
nippon
veterinari
life
scienc
univers
use
dog
confirm
poor
appetit
veterinarian
hospit
degre
appetit
score
amount
food
intak
appetit
score
evalu
serv
meal
administ
singledos
synthes
canin
ghrelin
lgkg
intraven
lgkg
subcutan
follow
reevalu
appetit
score
dog
show
appetit
score
ghrelin
administr
singledos
ghrelin
treatment
effect
eight
case
six
dog
improv
appetit
score
dog
appetit
chang
observ
remain
two
dog
advers
effect
behavior
chang
observ
treat
dog
conclus
appetitestimulatori
effect
singledos
treatment
ghrelin
seen
preliminari
studi
suggest
ghrelin
could
effect
treatment
canin
anorex
patient
safeti
ghrelin
agonist
capromorelin
administ
daili
cat
day
oral
dose
mgkg
bill
zoller
juli
allen
chelsey
kennedi
linda
rhode
aratana
therapeut
inc
kansa
citi
ks
usa
capromorelin
ghrelin
agonist
develop
use
cat
control
nonglp
studi
evalu
safeti
capromorelin
laboratori
cat
two
treatment
group
includ
follow
acclim
phase
adult
cat
receiv
oral
placebo
solut
group
adult
cat
receiv
oral
capromorelin
solut
mgkg
group
consecut
day
cat
weigh
day
physic
examin
perform
day
anim
observ
least
daili
throughout
studi
period
day
anim
administ
flavor
oral
solut
placebo
capromorelin
daili
via
syring
hematolog
serum
chemistri
includ
fructosamin
urinalys
conduct
day
acclim
day
approxim
hour
follow
dose
administr
day
blood
sampl
collect
prior
daili
dose
administr
hour
postdos
serum
gh
level
measur
begin
hour
postdos
cat
offer
food
period
variabl
interest
includ
weight
gainloss
food
consumpt
clinic
patholog
hematolog
chemistri
urinalysi
serum
analysi
gh
studi
abnorm
detect
upon
physic
examin
common
clinic
observ
ptyalism
lip
smack
emesi
headshak
find
seen
immedi
postdos
usual
resolv
within
five
minut
abnorm
gener
health
clinic
observ
note
cat
treat
capromorelin
gain
weight
wherea
placebo
control
cat
maintain
consist
bodi
weight
weight
gain
trend
expect
base
previou
pilot
studi
data
capromorelin
treat
cat
trend
toward
increas
food
consumpt
compar
placebo
treat
cat
certainli
treatment
capromorelin
dose
mgkg
neg
affect
food
consumpt
cat
gener
statist
signific
differ
clinic
patholog
safeti
paramet
clinic
relev
serum
glucos
level
increas
capromorelin
group
compar
placebo
group
increas
trend
time
howev
glucos
valu
exceed
normal
limit
addit
capromorelinrel
serum
fructosamin
level
trend
fructosamin
valu
exceed
normal
limit
treat
cat
final
urin
glucos
level
neg
except
trace
read
one
capromorelin
treat
cat
one
placebo
treat
cat
bun
creatinin
level
similar
cat
treatment
group
valu
within
normal
refer
rang
sinc
renal
diseas
preval
cat
lack
chang
renal
paramet
might
suggest
capromorelin
may
use
patient
need
confirm
safeti
studi
patient
serum
gh
level
increas
cat
treat
capromorelin
compar
placebo
control
expect
increas
gh
pronounc
day
capromorelin
treatment
howev
increas
attenu
daili
capromorelin
treatment
progress
indic
intact
neg
feedback
gh
secret
contrast
increas
becam
sustain
daili
treatment
capromorelin
continu
peak
day
decreas
time
conclus
capromorelin
welltoler
cat
dose
oral
mgkg
consecut
day
studi
indic
expect
adequ
safeti
margin
capromorelin
dose
use
propos
clinic
dose
capromorelin
ghrelin
agonist
dose
oral
laboratori
dog
shown
stimul
food
intak
weight
gain
growth
hormon
gh
insulinlik
growth
zoller
et
al
random
placebocontrol
studi
perform
determin
capromorelin
would
also
increas
food
consumpt
promot
weight
gain
increas
serum
level
laboratori
cat
thirtytwo
cat
neuter
male
femal
divid
four
treatment
group
includ
four
anim
sex
per
group
cat
acclim
studi
environ
day
prior
studi
start
cat
oral
dose
placebo
group
capromorelin
mgml
oral
solut
mgkg
group
mgkg
group
mgkg
group
day
dose
start
day
physic
examin
perform
day
gener
health
observ
made
daili
bodi
weight
evalu
day
day
cat
fed
approxim
hour
dose
g
commerci
dri
cat
food
provid
hour
remov
amount
food
consum
g
calcul
per
cat
day
blood
sampl
collect
prior
daili
dose
administr
hour
postdos
serum
process
measur
level
day
two
studi
anim
one
male
group
remov
reason
unrel
studi
includ
data
analysi
treatment
group
observ
increas
mean
food
consumpt
baselin
averag
day
studi
period
averag
day
day
placebo
cat
group
mean
food
intak
increas
baselin
three
capromorelin
group
group
mean
food
intak
increas
baselin
respect
group
show
statist
signific
p
increas
food
consumpt
compar
placebo
group
mean
bodi
weight
capromorelin
treatment
group
increas
exposur
period
group
increas
respect
wherea
placebo
group
lost
small
amount
weight
minu
statist
signific
differ
placebo
p
mean
percent
bodi
weight
chang
observ
group
time
point
measur
increas
day
respect
addit
group
mean
percent
bodi
weight
chang
statist
significantli
increas
p
compar
placebo
day
day
day
interact
treatment
sex
statist
signific
p
either
food
consumpt
weight
gain
indic
effect
treatment
similar
male
femal
cat
group
level
remain
baselin
level
throughout
studi
day
group
mean
serum
level
increas
postdos
group
respect
day
level
sustain
higher
level
hour
therefor
group
mean
increas
serum
level
lessen
postdos
group
conclus
capromorelin
increas
food
intak
promot
weight
gain
caus
sustain
increas
laboratori
cat
amoxicillinclavulan
frequent
prescrib
veterinarian
wide
varieti
felin
condit
includ
bite
wound
abscess
upper
respiratori
infect
drug
broad
spectrum
mani
bacteria
includ
anaerob
diarrhea
vomit
loss
appetit
occur
prescrib
cat
one
object
studi
quantifi
frequenc
gastrointestin
sign
induc
amoxicillinclavulan
second
object
determin
administr
enterococcu
faecium
strain
could
amelior
side
effect
probiot
shown
effect
manag
diarrhea
cat
doubl
blind
placebocontrol
studi
total
young
adult
healthi
mix
sex
purpos
bred
cat
random
two
room
bodi
condit
cat
cage
clinic
find
includ
appetit
could
monitor
cat
monitor
daili
appetit
attitud
hydrat
vomit
consist
fece
fs
use
follow
scale
wateri
puddl
textur
shape
moist
pile
moist
log
shape
normal
day
equilibr
period
cat
develop
fecal
score
twice
block
studi
predispos
stress
diarrhea
cat
administ
amoxicillinclavulan
clavamox
zoeti
mgcat
po
twice
day
day
two
hour
prior
antibiot
administr
can
food
mix
either
e
faecium
equival
commerci
product
cat
palat
enhanc
cat
use
commerci
product
palat
enhanc
clinic
score
continu
addit
day
stop
antibiot
vomit
note
equilibr
period
antibiot
administr
period
cat
placebo
cat
vomit
least
howev
total
number
vomit
episod
antibiot
administr
period
significantli
differ
group
vomit
resolv
cat
stop
antibiot
antibiot
period
stool
fs
detect
least
cat
placebo
cat
fs
detect
cat
contrast
placebo
cat
fs
detect
placebo
cat
percentag
sampl
differ
fs
compar
group
antibiot
administr
period
shown
cat
placebo
group
sampl
greater
number
p
sampl
fs
group
sampl
sampl
fs
detect
placebo
group
sampl
p
percentag
cat
sampl
fs
decreas
group
postantibiot
period
sampl
placebo
cat
sampl
differ
group
signific
p
overal
attitud
hydrat
normal
cat
cours
studi
pilot
studi
conclud
amoxicillinclavulan
caus
gastrointestin
symptom
diarrhea
episod
fs
like
placebo
group
suggest
concurr
administr
may
decreas
sever
amoxicillinclavulan
diarrhea
cat
mariana
bail
afonso
bruna
duart
pacheco
gisel
vieira
sechi
rayan
sol
amar
silva
sgarbossa
sthefani
buba
lucina
andressa
tha
roncoski
stefan
schwanz
claudia
turra
bianca
hasselmann
cottar
marian
miranda
gonc
ana
paula
sarraff
lope
carolina
zaghi
cavalcant
pucpr
curitibaparan
brazil
physicalpet
curitibaparan
brazil
obes
defin
excess
accumul
adipos
tissu
bodi
enough
affect
physiolog
function
predispos
variou
diseas
obes
treatment
base
reduc
calori
intak
increas
energi
consumpt
vibrat
platform
investig
biophys
type
exercis
provid
altern
intervent
obes
peopl
studi
aim
evalu
effici
vibrat
platform
weight
control
obes
overweight
dog
effect
reduct
bodi
condit
laboratori
find
particip
obes
overweight
dog
divid
two
group
group
submit
hypocalor
diet
group
submit
hypocalor
diet
two
weekli
workout
vibrat
platform
studi
last
month
perform
weigh
morphometr
laboratori
assess
measur
subcutan
fat
deposit
ultrasound
reduct
bodi
weight
morphometr
subcutan
fat
measur
dog
signific
differ
weight
also
compar
group
regard
laboratori
abnorm
observ
reduct
serum
cholesterol
level
group
vibrat
platform
import
tool
treat
obes
sinc
use
method
allow
reduct
weight
bodi
condit
promot
benefici
laboratori
result
veterinari
medicin
sever
studi
need
larger
number
anim
confirm
efficaci
vibratori
platform
obes
dog
romi
heilmann
niel
utzner
jame
barr
brittani
thame
jan
suchodolski
org
steiner
texa
univers
colleg
station
tx
usa
vetsuiss
univers
bern
bern
switzerland
alpha
proteinas
inhibitor
mainli
synthes
hepatocyt
major
serum
proteinas
inhibitor
protect
bodi
detriment
effect
neutrophil
proteinas
contrast
human
canin
pi
ca
pi
convincingli
demonstr
acutephas
protein
may
due
speciesspecif
physiolog
pathophysiolog
role
howev
serum
ca
pi
concentr
increas
group
dog
pancreat
diseas
process
often
associ
activ
system
inflammatori
cascad
dog
proteinlos
diseas
hand
shown
decreas
serum
ca
pi
concentr
evalu
ca
pi
dog
system
inflammatori
respons
syndrom
sir
would
understand
pathophysiolog
role
therefor
studi
investig
serum
ca
pi
concentr
dog
sir
sepsi
serum
sampl
dog
noninfecti
sir
n
sepsi
n
collect
day
enrol
day
follow
day
ie
day
group
healthi
control
dog
n
use
sampl
surplu
materi
previou
studi
criteria
hauptmann
et
al
use
diagnosi
sir
sourc
infect
confirm
septic
dog
via
histolog
microbiolog
andor
cytolog
examin
concentr
ca
pi
measur
sampl
use
establish
inhous
ria
test
among
group
dog
use
nonparametr
multiplegroup
comparison
serum
ca
pi
concentr
significantli
lower
dog
sir
p
sepsi
p
healthi
control
dog
day
serum
ca
pi
concentr
differ
dog
sir
sepsi
p
dog
sepsi
significantli
lower
serum
ca
pi
concentr
day
p
p
dog
noninfecti
sir
serum
ca
pi
concentr
significantli
differ
survivor
n
nonsurvivor
n
p
studi
serum
ca
pi
concentr
significantli
lower
dog
sir
sepsi
healthi
control
dog
septic
patient
lower
serum
ca
pi
concentr
day
dog
noninfecti
sir
result
would
argu
role
ca
pi
neg
acutephas
protein
dog
may
suggest
proteinproteinas
inhibitor
balanc
alter
dog
system
inflamm
studi
evalu
role
ca
pi
acutephas
respons
well
util
biomark
diagnosi
differenti
dog
sir
sepsi
warrant
dog
ibuprofen
intox
common
occur
either
administr
owner
dietari
indiscret
intox
result
acut
gastrointestin
sign
kidney
injuri
histor
treat
support
care
publish
studi
report
use
tpe
reduc
serum
ibuprofen
concentr
hypothes
tpe
could
use
adjunct
altern
treatment
ibuprofen
toxic
measur
amount
inject
ibuprofen
apport
ml
canin
whole
blood
blood
volum
equival
kg
dog
incub
minut
tpe
perform
hour
achiev
filtrat
plasma
volum
heparin
blood
ml
effluent
ml
sampl
collect
hour
sampl
centrifug
g
minut
serum
rbc
fraction
separ
collect
ibuprofen
concentr
determin
high
perform
liquid
chromatographi
percentag
remov
siev
coeffici
calcul
assess
ibuprofen
clearanc
blood
sharp
rise
siev
coeffici
note
within
minut
tpe
plateau
attain
minut
median
siev
coeffici
rang
calcul
median
serum
ibuprofen
concentr
reduct
rang
calcul
median
rbc
ibuprofen
concentr
reduct
rang
serum
ibuprofen
concentr
reduct
less
expect
attribut
sequestr
drug
red
blood
cell
nonetheless
result
suggest
tpe
may
use
rapidli
reduc
ibuprofen
concentr
follow
acut
toxic
ingest
medic
record
dog
hospit
sp
review
inclus
criteria
requir
cbc
serum
chemistri
nova
admiss
diagnosi
sp
base
intracellular
bacteria
andor
posit
cultur
abdomin
fluid
appl
score
calcul
patient
data
check
normal
use
shapirowilk
dagostino
pearson
omnibu
test
parametr
nonparametr
data
compar
use
unpair
ttest
mannwhitney
test
respect
fisher
exact
test
odd
ratio
construct
compar
proport
variabl
categor
data
alpha
set
fiftyfour
dog
met
inclus
criteria
surviv
rate
gastrointestin
origin
sp
compris
case
ecoli
enterococcu
speci
compris
bacteri
isol
differ
median
circul
neutrophil
count
vs
p
total
wbc
count
vs
l
p
time
surgeri
vs
hour
p
appl
full
score
vs
p
survivor
nonsurvivor
exact
test
reveal
associ
presenc
dohl
bodi
p
toxic
chang
p
band
neutrophil
p
ioniz
hypocalcemia
mmoll
p
ioniz
hypomagnesemia
mmoll
p
appropri
initi
antibiot
therapi
associ
surviv
p
howev
dog
receiv
appropri
antibiot
time
like
surviv
initi
antibiot
choic
appropri
case
mean
appl
fast
score
factor
associ
death
vs
p
popul
dog
sp
test
commonli
associ
sever
diseas
time
surgeri
appropri
initi
antibiot
choic
predict
case
outcom
interestingli
initi
antibiot
choic
correct
minor
case
prospect
studi
incorpor
antibiot
therapi
address
common
isol
dog
sp
warrant
determin
surviv
benefit
exist
cardiopulmonari
resuscit
often
perform
hospit
patient
typic
base
upon
prior
establish
cpr
code
base
upon
convers
owner
veterinari
team
member
anim
may
place
donotresuscit
dnr
code
statu
howev
human
medicin
often
exist
confus
dnr
order
mean
purpos
studi
assess
whether
differ
exist
among
popul
veterinarian
veterinari
technician
veterinari
student
regard
respons
clinic
scenario
involv
donotresuscit
dnr
order
hyperlink
onlin
survey
distribut
via
email
varieti
veterinari
listserv
survey
consist
question
regard
respond
characterist
follow
five
case
exampl
interpret
dnr
order
could
question
includ
four
hypothet
case
patient
preexist
dnr
suffer
unexpect
cardiopulmonari
arrest
one
case
termin
ill
dog
owner
request
cpr
data
evalu
use
chisquar
fisher
exact
test
appropri
pvalu
consid
signific
seven
hundr
thirtythre
individu
includ
veterinarian
veterinari
technician
veterinari
student
respond
major
veterinarian
either
acvim
acvecc
diplom
signific
differ
individu
question
found
base
gender
frequenc
cpr
event
practic
year
experi
geograph
locat
men
veterinarian
practic
longer
respond
particip
multipl
cpr
event
per
year
like
perform
cpr
face
preexist
dnr
order
extenu
circumst
exist
cpr
code
routin
suspend
pet
undergo
anesthesia
code
statu
may
reevalu
hospit
even
face
chang
patient
statu
studi
support
potenti
confus
surround
cpr
dnr
veterinari
patient
definit
dnr
univers
may
result
differ
clinic
interpret
veterinari
profess
would
benefit
educ
discuss
regard
topic
aim
studi
evalu
impact
choic
statist
method
refer
interv
accuraci
gaussian
lognorm
asymmetr
bimod
analyt
distribut
studi
gaussian
distribut
deriv
normal
canin
glycemia
distribut
distribut
deriv
serum
alt
distribut
normal
dog
distribut
popul
valu
simul
use
statist
softwar
r
sampl
n
n
n
n
valu
randomli
extract
time
popul
refer
interv
obtain
six
differ
statist
method
compar
quantil
valu
popul
although
statist
signific
differ
accuraci
detect
among
statist
method
consid
clinic
relev
relev
inaccuraci
found
parametr
robust
method
use
untransform
data
nongaussian
popul
distribut
specif
shapirowilk
test
predict
popul
gaussian
declin
sampl
size
decreas
n
n
n
n
respect
apart
parametr
robust
method
untransform
data
choic
statist
method
minim
clinicallyrelev
impact
refer
interv
accuraci
parametr
robust
method
untransform
data
appropri
analyt
popul
distribut
gaussian
alway
ascertain
sampl
distribut
consequ
use
discourag
refer
interv
construct
accuraci
like
reli
nonstatist
step
choic
anim
includ
rather
statist
analysi
increas
awar
myocardi
injuri
occur
primari
noncardiac
diseas
often
goe
unrecogn
myocardi
injuri
associ
increas
morbid
death
human
canin
patient
noncardiac
diseas
prospect
studi
assess
presenc
myocardi
damag
character
acut
phase
respons
popul
cat
system
diseas
two
specif
cardiac
biomark
high
sensit
cardiac
troponin
hsctni
amino
termin
prohormon
brain
natriuret
peptid
ntprobnp
four
acut
phase
protein
app
creactiv
protein
crp
glycoprotein
agp
serum
amyloid
saa
haptoglobin
hp
measur
cat
system
diseas
popul
divid
four
group
hyperthyroid
group
h
neoplast
group
n
inflammatori
group
miscellan
condit
group
signific
differ
group
ntprobnp
hsctni
agp
crp
found
group
h
significantli
higher
concentr
ntprobnp
group
group
h
significantli
higher
hsctni
group
n
group
group
h
significantli
lower
agp
concentr
group
n
lower
crp
group
multivari
analysi
hsctni
ntprobnp
associ
azotaemia
app
anaemia
associ
saa
agp
hsctni
ntprobnp
saa
hp
cat
noncardiac
diseas
experi
myocardi
damag
appear
relat
system
inflamm
agp
appear
sensit
app
cat
identifi
dog
year
age
mean
median
neither
sex
predomin
femal
male
case
includ
small
dog
kg
medium
kg
larg
dog
kg
n
diagnos
winter
owner
recogn
lame
dog
n
limb
affect
hindlimb
affect
p
correl
sever
joint
inflamm
temperatur
peripher
neutrophilia
hospit
rate
uncompl
impa
type
n
type
ii
reactiv
impa
enteropath
type
iii
malignancyassoci
type
iv
impa
uncommon
hospit
like
p
dog
type
iiiv
treatment
includ
prednison
azathioprin
mycophenol
mofetil
cyclosporin
leflunomid
also
use
tetracyclin
given
outcom
inform
avail
dog
achiev
clinic
remiss
cytolog
remiss
relaps
remiss
less
like
dog
type
iiiv
type
impa
p
dog
size
may
develop
impa
usual
warm
month
owner
often
alway
recogn
lame
good
respons
therapi
common
remiss
less
like
type
iiiv
impa
purpos
studi
determin
effect
variou
storag
condit
canin
lactat
concentr
prospect
ml
blood
collect
form
healthi
dog
blood
promptli
divid
storag
aliquot
use
storag
condit
consist
gold
standard
anaerob
chill
three
compar
group
aerob
chill
anaerob
room
temperatur
rt
aerob
rt
time
point
analysi
minut
gold
standard
group
minut
compar
group
nonparametr
statist
use
assess
clinic
signific
valu
compar
gold
standard
calcul
absolut
percent
differ
versu
mean
chang
valu
consid
clinic
unaccept
time
point
statist
signific
differ
lactat
concentr
within
anaerob
chill
sampl
gold
standard
group
aerob
chill
sampl
statist
signific
chang
lactat
compar
anaerob
chill
time
point
anaerob
rt
sampl
statist
signific
increas
time
point
minut
aerob
rt
sampl
statist
signific
chang
lactat
time
point
result
support
analyz
lactat
sampl
immedi
find
indic
time
temperatur
storag
condit
caus
signific
chang
lactat
lactat
analysi
delay
anaerob
chill
sampl
analyz
within
minut
aerob
chill
sampl
analyz
within
minut
aerob
rt
anaerob
rt
sampl
storag
avoid
clinician
awar
preanalyt
factor
includ
storag
time
sampl
handl
may
caus
chang
lactat
valu
aim
studi
determin
cat
urinari
obstruct
inflammatori
acut
phase
respons
concentr
haptoglobin
hp
serum
amyloid
saa
determin
cat
clinic
urinari
tract
obstruct
time
diagnosi
thirtyfour
cat
includ
studi
anim
month
year
old
cat
assign
group
accord
clinic
sign
hemogram
urinalysi
cat
show
clinic
sign
urinari
tract
obstruct
cat
clinic
healthi
control
cat
hp
serum
concentr
measur
via
haemoglobin
bind
assay
modifi
autom
abx
pentra
analys
horiba
medic
montpelli
franc
saa
concentr
determin
use
lat
eiken
chemic
co
japan
modifi
autom
abx
pentra
analys
hp
concentr
control
group
rang
gl
median
gl
saa
concentr
group
mgl
clinic
obstruct
cat
hp
concentr
rang
gl
median
gl
saa
concentr
rang
mgl
median
mgl
white
blood
cell
wbc
rang
median
neutrophil
rang
median
paramet
significantli
higher
p
compar
clinic
healthi
cat
increas
seen
hp
saa
valu
accompani
increas
wbc
neutrophil
clinic
obstruct
cat
demonstr
acut
phase
respons
cat
urinari
tract
obstruct
howev
correl
hp
wbc
indic
analyt
respond
differ
dynam
urinari
obstruct
measur
acut
phase
protein
could
add
valu
diagnost
regim
condit
cat
serum
amyloid
saa
major
acut
phase
protein
mani
speci
saa
report
sensit
biomark
inflamm
dog
cat
hors
high
level
ident
saa
differ
speci
allow
measur
canin
felin
equin
saa
use
immunoassay
aim
studi
select
antibodi
crossreact
canin
felin
equin
saa
panel
murin
monoclon
antibodi
mab
develop
either
human
canin
saa
studi
also
includ
develop
recombin
speciesspecif
calibr
saa
immunoassay
recombin
canin
felin
equin
saa
express
e
coli
crossreact
antibodi
differ
mab
test
recombin
endogen
saa
among
test
antibodi
mab
recogn
recombin
endogen
saa
three
speci
direct
elisa
western
blot
studi
mab
evalu
sandwich
elisa
sandwich
elisa
strong
nonspecif
bind
saa
polystyren
surfac
costar
plate
observ
problem
earlier
report
human
saa
well
optim
plate
block
protocol
wash
dilut
buffer
help
reduc
nonspecif
bind
saa
plate
surfac
variou
mab
combin
test
serum
sampl
healthi
anim
anim
acut
inflamm
use
optim
sandwich
elisa
protocol
one
mab
combin
select
recogn
saa
canin
felin
equin
serum
high
sensit
conclus
monoclon
antibodi
describ
present
studi
use
develop
immunoassay
applic
saa
measur
blood
three
major
companion
anim
speci
archer
clair
fellman
john
stoke
evangel
kummari
john
thomason
jenica
haraschak
lesya
pinchuk
robert
will
andrew
mackin
mississippi
state
univers
mississippi
state
ms
usa
north
carolina
state
univers
raleigh
nc
usa
cyclosporin
aspirin
routin
use
treat
immunemedi
hemolyt
anemia
imha
dog
cyclosporin
potent
immunosuppress
agent
exert
effect
decreas
cytokin
product
lymphocyt
especi
tcell
product
ifnc
recent
research
dog
shown
high
dose
cyclosporin
reliabl
reduc
express
ifnc
lower
dose
cyclosporin
affect
cytokin
express
variabl
lowdos
aspirin
commonli
use
concurr
immunosuppress
agent
cyclosporin
dog
imha
inhibit
platelet
function
sinc
patient
hypercoagul
prone
lifethreaten
thromboembol
diseas
regulatori
tcell
treg
necessari
mainten
healthi
immun
system
prevent
autoimmun
patholog
abnorm
treg
number
function
implic
multipl
autoimmun
infecti
allerg
diseas
rodent
human
aspirin
cyclosporin
shown
affect
treg
number
function
tcell
cytokin
product
dog
howev
yet
determin
either
drug
influenc
treg
number
determin
concurr
aspirin
alter
immunosuppress
effect
cyclosporin
studi
design
determin
effect
cyclosporin
lowdos
aspirin
highdos
aspirin
concurr
cyclosporin
lowdos
aspirin
canin
treg
number
tcell
cytokin
express
crossov
studi
design
seven
healthi
young
adult
dog
given
either
oral
cyclosporin
immunosuppress
dose
mgkg
hour
oral
lowdos
aspirin
mgkg
hour
oral
highdos
aspirin
mgkg
hour
lowdos
aspirin
combin
cyclosporin
day
washout
least
week
crossov
blood
drawn
prior
last
day
drug
treatment
flow
cytometr
analysi
heparin
whole
blood
activ
pma
ionomycin
evalu
tcell
express
ifnc
percent
treg
evalu
freshli
drawn
edtaanticoagul
whole
blood
differ
preand
posttreat
valu
group
well
differ
treatment
group
evalu
pair
ttest
compar
baselin
posttreat
valu
within
treatment
group
outcom
perform
differ
group
assess
use
mix
effect
model
p
consid
signific
cyclosporin
significantli
decreas
ifnc
express
use
alon
combin
lowdos
aspirin
highdos
aspirin
lowdos
aspirin
significantli
decreas
express
although
decreas
mark
seen
cyclosporin
alon
combin
aspirin
neither
lowdos
highdos
aspirin
significantli
affect
ifnc
express
cyclosporin
alon
unlik
lowdos
highdos
aspirin
alon
significantli
decreas
treg
number
cyclosporin
combin
lowdos
aspirin
also
associ
decreas
treg
number
although
magnitud
reduct
enough
achiev
statist
signific
p
lowdos
aspirin
given
cyclosporin
creat
degre
tcell
cytokin
suppress
cyclosporin
alon
suggest
two
drug
use
concurr
without
alter
cyclosporin
immunosuppress
effect
high
dose
aspirin
also
suppress
tcell
express
although
suppress
mark
seen
cyclosporin
cyclosporin
also
significantli
decreas
treg
number
dog
sinc
low
treg
number
associ
immunemedi
diseas
find
suggest
effect
cyclosporin
canin
immun
system
may
complex
immunosuppress
alon
esther
bijsman
rosann
jepson
henri
pratt
hatti
syme
jonathan
elliott
ludov
pelligand
royal
veterinari
colleg
london
uk
ab
laboratori
ltd
welwyn
garden
citi
uk
amlodipin
firstlin
antihypertens
agent
use
cat
dose
mgcatday
recommend
human
medicin
recommend
exist
initi
aggress
antihypertens
plan
patient
sever
hypertens
cat
monotherapi
amlodipin
standard
practic
dose
adjust
use
achiev
control
aim
studi
investig
whether
dose
amlodipin
requir
control
blood
pressur
adequ
depend
individu
variat
drug
pharmacokinet
pharmacodynam
plasma
sampl
hypertens
cat
treat
amlodipin
two
first
opinion
practic
identifi
retrospect
hypertens
diagnos
base
systol
blood
pressur
sbp
mmhg
consecut
visit
sbp
mmhg
concurr
evid
hypertens
retinopathi
cat
start
mg
amlodipin
invit
back
blood
pressur
recheck
week
later
adequ
control
defin
sbp
mmhg
sbp
mmhg
dose
increas
mgcatday
anoth
recheck
week
later
blood
sampl
collect
first
visit
sbp
control
adequ
plasma
amlodipin
concentr
determin
use
highperform
liquid
chromatographi
tandem
mass
spectrometr
lc
msm
detect
linear
mix
effect
model
bonferroni
post
hoc
comparison
use
compar
sbp
hypertens
visit
sbp
first
control
visit
cat
mg
mg
b
plasma
amlodipin
concentr
compar
b
use
mannwhitney
utest
result
present
mean
ae
sd
median
iqr
univari
linear
regress
model
perform
absolut
chang
sbp
amlodipin
treatment
depend
variabl
plasma
amlodipin
concentr
dose
mgkg
time
sinc
last
dose
treatment
time
day
plasma
potassium
creatinin
concentr
explanatori
variabl
variabl
log
transform
need
meet
normal
criteria
variabl
signific
p
level
includ
multivari
model
plasma
amlodipin
concentr
determin
cat
adequ
sbp
control
cat
b
cat
sbp
hypertens
visit
differ
significantli
group
ae
mmhg
b
ae
mmhg
p
compar
posttreat
sbp
achiev
ae
mmhg
b
ae
mmhg
ns
plasma
amlodipin
concentr
twice
high
cat
mg
compar
receiv
mg
ngml
vs
ngml
dose
mgkg
cat
receiv
ae
mgkg
b
ae
mgkg
dose
mgkg
plasma
amlodipin
concentr
potassium
associ
absolut
chang
sbp
univari
analysi
p
plasma
amlodipin
concentr
dose
mgkg
remain
posit
significantli
associ
decreas
sbp
multivari
model
p
studi
show
decreas
sbp
associ
amlodipin
treatment
independ
posit
associ
plasma
amlodipin
concentr
cat
requir
higher
dose
control
sbp
mmhg
significantli
higher
sbp
diagnosi
hypertens
therefor
requir
greater
decreas
sbp
order
achiev
normotens
control
administr
higher
dose
need
achiev
target
sbp
associ
proportion
higher
plasma
amlodipin
concentr
suggest
differ
dose
amlodipin
requir
unlik
due
differ
individu
cat
pharmacokinet
owner
complianc
base
result
could
suggest
cat
mmhg
start
mg
amlodipin
daili
studi
warrant
determin
whether
differ
exist
pathophysiolog
mechan
underli
hypertens
sever
hypertens
group
sucralf
gastroprotect
report
impair
absorpt
certain
antimicrobi
object
determin
coadministr
sucralf
fluoroquinolon
impair
fluoroquinolon
bioavail
dog
determin
effect
delay
sucralf
fluoroquinolon
pharmacokinet
five
greyhound
incorpor
random
crossov
design
administ
either
ciprofloxacin
mgkg
po
enrofloxacin
mgkg
po
alon
concurr
sucralf
g
oral
suspens
po
ciprofloxacin
enrofloxacin
sucralf
administ
hour
either
fluoroquinolon
fluoroquinolon
concentr
evalu
liquid
chromatographymass
spectrometri
area
curv
auc
time
maximum
plasma
concentr
max
maximum
plasma
concentr
c
max
compar
group
dog
variabl
absorpt
ciprofloxacin
auc
rang
hour
lgml
compar
enrofloxacin
hour
lgml
rel
bioavail
f
ciprofloxacin
administ
concurr
sucralf
one
dog
improv
sucralf
delay
hour
contrast
signific
differ
absorpt
demonstr
base
auc
c
max
enrofloxacin
administ
concurr
sucralf
compar
enrofloxacin
alon
f
concurr
administr
studi
confirm
oral
bioavail
ciprofloxacin
variabl
could
lead
treatment
failur
drug
toxic
treat
dog
sucralf
ciprofloxacin
indic
hour
delay
consid
allow
improv
bioavail
contrari
drug
interact
document
concurr
sucralf
enrofloxacin
concurr
administr
may
improv
complianc
transderm
mirtazapin
tm
would
benefici
ill
cat
intoler
pill
administr
purpos
studi
evalu
pharmacodynam
transderm
mirtazapin
tm
clientown
cat
ten
clientown
cat
year
unremark
cbc
chemistri
urinalys
enrol
random
doubleblind
placebocontrol
threeway
crossov
studi
treatment
consist
day
aural
applic
mgdose
tm
placebo
gel
owner
mg
mirtazapin
oral
clinic
washout
period
day
owner
document
appetit
rate
food
ingest
beg
activ
vocal
daili
home
environ
day
cat
observ
hour
hospit
food
consum
activ
vocal
document
hourli
trough
peak
serum
level
obtain
serum
alanin
aminotransferas
alt
level
measur
tm
administr
serum
mirtazapin
compound
gel
concentr
measur
use
liquid
chromatographi
tandem
mass
spectrometri
cat
receiv
tm
day
signific
increas
appetit
p
rate
food
ingest
p
activ
level
p
beg
p
vocal
p
compar
placebo
day
cat
receiv
tm
signific
increas
food
consumpt
hospit
p
compar
placebo
vocal
activ
statist
differ
treatment
gel
concentr
ae
target
dose
averag
ae
sd
trough
peak
serum
mirtazapin
concentr
day
tm
administr
ae
ngml
ae
ng
ml
respect
serum
alt
remain
normal
day
tm
administr
averag
ae
sd
peak
serum
mirtazapin
concentr
one
oral
dose
mg
mirtazapin
ae
ngml
daili
mg
tm
administr
healthi
cat
result
signific
increas
appetit
comparison
placebo
serum
concentr
within
rang
singl
oral
mg
mirtazapin
administr
evid
suggest
nonsteroid
antiinflammatori
drug
nsaid
help
postop
pain
control
anim
antiinflammatori
properti
nsaid
involv
inhibit
cyclooxygenas
cox
isoform
includ
nontheless
efficaci
nonselect
cox
inhibitor
tolfenam
acid
select
inhibitor
robenacoxib
postop
pain
control
cat
compar
purpos
present
studi
studi
postop
analges
effect
tolfenam
acid
robenacoxib
cat
undergo
ovariohysterectomi
twenti
four
cat
divid
three
group
includ
control
medicin
tolfenam
mgkgday
robenacoxib
mgkgday
group
nsaid
oral
administ
hour
induct
propofol
mgkg
iv
anesthesia
maintain
isofluran
inhal
buccal
mucos
bleed
time
bmbt
measur
surgeri
cat
colorado
pain
score
record
blind
fashion
induct
base
line
hour
follow
recoveri
opiat
analgesia
morphin
mgkg
im
provid
control
group
base
clinic
sign
experiment
protocol
approv
kasetsart
univers
anim
care
use
committe
averag
bmbt
mean
ae
se
control
tolfenam
acid
robenacoxib
differ
ae
ae
ae
second
respect
pvalu
averag
baselin
colorado
pain
score
control
tolfenam
acid
robenacoxib
group
differ
ae
ae
ae
respect
pvalu
averag
colorado
pain
score
record
hour
postoper
tolfenam
acid
ae
robenacoxib
ae
group
significantli
lower
control
group
ae
pvalu
nonetheless
signific
differ
compar
tolfenam
acid
robenacoxib
group
pvalu
conclus
preoper
administr
either
tolfenam
acid
robenacoxib
significantli
reduc
postop
pain
cat
ovariohysterectomi
without
affect
bleed
time
signific
differ
could
detect
postop
pain
control
cat
compar
nonselect
cox
inhibitor
tolfenam
acid
select
inhibitor
robenacoxib
kakiuchi
atsushi
nakamura
asako
kawaraishimamura
atsushi
ogawa
kensuk
orito
school
veterinari
medicin
azabu
univers
kanagawa
japan
trva
anim
medic
center
tokyo
jonan
region
veterinari
medicin
promot
associ
tokyo
japan
anicom
hold
inc
tokyo
japan
japan
intraven
tranexam
acid
ta
use
empir
induc
vomit
accident
ingest
dog
found
receptor
may
play
pivot
role
tainduc
emesi
reveal
ta
induc
emesi
dosedepend
manner
dog
understand
efficaci
safeti
tainduc
emesi
critic
care
precis
manag
accident
ingest
purpos
studi
evalu
emet
action
side
effect
ta
clinic
set
studi
popul
compris
dog
singl
intraven
ta
dose
administ
need
addit
dose
administ
data
collect
case
report
form
includ
age
breed
bodi
weight
gender
anamnesi
clinic
sign
time
emesi
intraven
ta
durat
emesi
number
incid
emesi
side
effect
ta
induc
vomit
dog
median
time
onset
vomit
second
rang
second
median
durat
emesi
second
rang
second
median
number
incid
emesi
rang
second
third
administr
ta
induc
vomit
dog
dog
respect
side
effect
includ
one
tonicclon
convuls
hemostat
disord
differ
dog
receiv
medic
care
later
recov
ta
induc
emesi
high
probabl
follow
singledos
doseescal
administr
side
effect
consid
mild
selflimit
applic
appetit
stimul
mirtazapin
attract
option
cat
resist
pill
purpos
studi
evalu
pharmacodynam
pharmacokinet
pk
transderm
mirtazapin
tm
three
purposebr
cat
unremark
cbc
serum
biochemistri
urinalys
util
follow
procedur
perform
minimum
day
wash
mg
mg
tm
aural
hour
pk
sampl
serum
sampl
obtain
via
jugular
cathet
hour
b
mg
tm
placebo
daili
aural
six
consecut
day
hour
pk
c
mg
mirtazapin
oral
limit
serum
sampl
hour
kibbl
weight
record
everi
hour
b
c
serum
mirtazapin
compound
gel
concentr
measur
use
liquid
chromatographytandem
mass
spectrometri
noncompartment
pharmacokinet
model
perform
oral
dose
auc
valu
estim
use
limit
sampl
model
develop
previou
studi
data
daili
mg
tm
result
significantli
food
consum
placebo
hour
p
gel
concentr
vari
target
dose
grapipr
new
analges
select
block
receptor
prostaglandin
may
use
treatment
osteoarthr
dog
cat
object
studi
evalu
felin
safeti
toxicokinet
profil
grapipr
twenti
four
domest
shorthair
cat
randomli
assign
receiv
either
placebo
mgkg
grapipr
capsul
formul
three
male
three
femal
per
group
daili
day
cat
receiv
assign
medic
per
protocol
food
consumpt
behavior
observ
daili
bodi
weight
measur
weekli
clinic
patholog
analys
blood
run
urinalysi
run
day
serial
blood
sampl
toxicokinet
analys
obtain
follow
day
day
dose
full
necropsi
histopatholog
evalu
perform
follow
human
euthanasia
day
grapipr
well
toler
advers
effect
note
daili
dose
mgkg
day
anim
appear
normal
throughout
studi
grapipr
caus
death
drugrel
effect
bodi
weight
food
consumpt
clinic
patholog
organ
weight
gross
patholog
histopatholog
grapipr
rapidli
reach
peak
serum
concentr
maintain
substanti
level
throughout
studi
grapipr
exposur
vari
dose
mgkg
mgkg
group
show
similar
mean
auc
last
valu
day
maximum
grapipr
serum
concentr
rang
ngml
ngml
reach
hour
administr
mean
halfliv
day
rang
approxim
hour
median
valu
approxim
hour
grapipr
capsul
formul
well
toler
given
day
serum
exposur
ngml
aim
studi
compar
pharmacokinet
pd
depend
bodi
surfac
area
bsa
bodi
weight
bw
small
larg
breed
dog
group
five
beagl
dog
given
mgkg
oral
pd
twice
day
week
group
b
five
larg
breed
dog
given
dose
oral
pd
twice
day
week
group
c
five
larg
breed
dog
given
dose
oral
pd
twice
day
week
day
blood
sampl
collect
hour
oral
administr
pharmacokinet
curv
analyz
hplcmsm
determin
group
time
reach
maximum
concentr
max
similar
hour
group
peak
plasma
concentr
c
max
area
curv
auc
ngml
ng
hml
group
b
c
max
auc
ngml
ng
hml
extrem
higher
group
c
group
c
c
max
auc
ngml
ng
hml
notabl
lower
group
b
slightli
lower
group
pharmacokinet
bwbase
pd
dose
found
differ
small
larg
breed
dog
therefor
clinician
suggest
adjust
dose
consid
pk
differ
pd
base
bsa
bw
chronic
bronchiti
cb
common
diseas
dog
result
chronic
cough
month
inflamm
lower
airway
advers
effect
risk
secondari
infect
associ
lifelong
steroid
administr
prompt
investig
altern
therapi
neurogen
pathway
mediat
tachykinin
bind
neurokinin
nk
receptor
may
contribut
airway
inflamm
maropit
cerenia
receptor
antagonist
use
cb
base
anecdot
improv
without
support
evid
hypothes
maropit
would
blunt
clinic
sign
airway
inflamm
associ
cb
clientown
dog
n
cough
month
thorac
radiograph
evid
airway
diseas
steril
airway
inflamm
nondegener
neutrophilseosinophil
bronchoalveolar
lavag
bal
enrol
dog
receiv
maropit
mgkg
everi
hour
day
studi
endpoint
includ
client
percept
clinic
sign
survey
baselin
day
visual
analogu
scale
va
baselin
day
object
assess
balf
neutrophil
eosinophil
baselin
day
oneway
repeat
measur
anova
va
mann
whitney
rank
sum
test
bal
cytolog
use
p
consid
signific
pilot
data
show
maropit
reduc
clinic
sign
base
client
survey
mild
improv
mark
improv
significantli
decreas
va
score
p
differ
balf
neutrophil
eosinophil
note
treatment
p
p
subject
clinic
improv
could
reflect
antituss
properti
maropit
placebo
effect
preliminari
result
suggest
lack
reduct
airway
inflamm
make
maropit
unsuit
treatment
canin
cb
stent
placement
shown
decreas
clinic
sign
improv
qualiti
life
dog
tracheal
collaps
medic
manag
fail
stent
fractur
occasion
occur
complic
postop
care
rais
cost
decreas
oper
owner
satisfact
cough
like
play
caus
role
variat
clinic
sign
diseas
sever
oper
prefer
make
compar
stent
base
clinic
outcom
problemat
aim
studi
evalu
fatigu
properti
two
type
tracheal
stent
control
environ
simul
chronic
cough
twelv
tracheal
stent
similar
size
two
manufactur
test
fatiguetest
fixtur
use
simul
forc
cough
use
parallel
compress
plate
stent
precompress
nomin
diamet
simul
vivo
condit
stress
frequenc
hz
equival
cough
per
hour
year
stent
complet
test
intact
cycl
fractur
stent
inspect
everi
cycl
data
compar
use
fisher
exact
wilcoxon
rank
sum
test
p
valu
consid
signific
group
stent
infin
medic
significantli
durabl
complet
trial
intact
compar
group
b
dextronix
p
mean
number
cycl
fractur
group
compar
group
b
p
although
vivo
stent
perform
multi
factori
stent
appear
better
abl
toler
stress
chronic
cough
seven
databas
search
identifi
studi
compar
rate
isol
mycoplasma
speci
respiratori
tract
symptomat
asymptomat
cat
qualiti
evid
assess
use
modifi
newcastleottawa
scale
metaanalysi
stratifi
urt
lrt
diseas
report
retriev
initi
twelv
met
inclus
criteria
qualiti
evid
moder
mycoplasma
significantli
preval
lrt
symptomat
cat
compar
control
odd
ratio
howev
sampl
urt
symptomat
cat
twice
like
posit
mycoplasma
healthi
cat
studi
urt
show
associ
heterogen
p
heterogen
could
come
differ
popul
shelter
cat
heterogen
p
versu
nonshelt
cat
heterogen
p
choic
control
asymptomat
past
versu
asymptomat
present
result
metaanalysi
might
suggest
pathogen
role
mycoplasma
felin
urt
possibl
asymptomat
carriag
initi
infect
case
control
popul
care
select
futur
studi
evid
requir
determin
whether
mycoplasma
truli
pathogen
felin
lrt
shih
tzu
dog
ami
brida
elizabeth
rozanski
kristen
antoon
john
rush
tuft
univers
north
grafton
usa
pulmonari
hypertens
phtn
defin
increas
pulmonari
arteri
pressur
mmhg
rest
may
develop
due
varieti
caus
dog
often
classifi
one
five
mechan
use
classif
scheme
phtn
due
left
heart
diseas
term
postcapillari
classif
ii
precapillari
caus
phtn
includ
classif
type
iii
iv
v
may
result
mani
caus
includ
heartworm
diseas
copd
pulmonari
vascular
diseas
pulmonari
hypertens
caus
associ
guard
prognosi
dog
practic
precapillari
phtn
typic
without
heartworm
diseas
without
thrombot
diseas
common
caus
respiratori
sign
shih
tzu
dog
purpos
studi
describ
clinic
attribut
seri
shih
tzu
dog
sever
precapillari
phtn
cardiolog
databas
search
shih
tzu
dog
evalu
echocardiographi
identifi
phtn
pulmonari
arteri
pressur
estim
use
modifi
bernoulli
equat
measur
veloc
regurgit
jet
across
tricuspid
valu
phtn
defin
sever
estim
pulmonari
arteri
pressur
mm
hg
dog
evid
left
atrial
enlarg
consist
type
ii
pulmonari
hypertens
exclud
popul
characterist
outcom
describ
phtn
document
shih
tzu
dog
identifi
precapillari
phtn
classifi
postcapillari
phtn
eleven
dog
precapillari
phtn
sever
phtn
median
estim
pa
pressur
mm
hg
rang
mmhg
median
age
affect
dog
year
rang
six
castrat
male
intact
femal
spay
femal
intact
male
median
surviv
time
day
rang
day
dog
receiv
supplement
oxygen
initi
evalu
eight
dog
treat
sildenafil
median
mgkg
q
hour
rang
mgkg
four
dog
also
receiv
pimobendan
clopidogrel
four
dog
surviv
year
three
dog
diedwer
euthan
within
hour
diagnosi
none
dog
treat
sildenafil
precapillari
phtn
appear
common
shih
tzu
breed
often
sever
associ
variabl
surviv
time
pulmonari
fluid
dynam
edema
format
govern
starl
forc
furosemid
often
use
reduct
transmur
pulmonari
hydrostat
pressur
prevent
treat
fluid
accumul
pulmonari
interstitium
pulmonari
transmur
hydrostat
forc
reflect
pulmonari
circul
transvascular
fluid
flux
j
never
defin
dog
hypothes
test
durat
anesthesia
influenc
j
furosemid
reduc
j
twenti
dog
male
femal
underw
castrationovariectomi
randomli
assign
furosemid
fur
mgkg
placebo
treat
group
plc
dog
premed
morphin
mgkg
sc
anesthesia
induc
midazolam
mgkg
iv
propofol
mgkg
iv
maintain
sevofluran
oxygen
thereaft
dog
instrument
pulmonari
arteri
dorsal
pedal
arteri
cathet
dog
treat
lactat
ringer
solut
anesthesia
mlkgh
iv
baselin
bl
arteri
mix
venou
blood
sampl
treatment
fur
plc
minut
posttreat
cardiac
output
q
pulmonari
arteri
pap
mean
arteri
blood
pressur
map
measur
transvascular
fluid
flux
pulmonari
circul
calcul
chang
plasma
protein
hemoglobin
hematocrit
q
valu
variabl
analyz
use
random
intercept
mix
model
p
data
express
mean
ci
durat
anesthesia
signific
effect
map
plc
mmhg
ci
bl
mmhg
ci
minut
p
wherea
q
pap
affect
durat
anesthesia
treatment
furosemid
effect
q
p
map
p
pap
p
bl
plc
efflux
fluid
pulmonari
circul
mlmin
ci
chang
minut
mlmin
ci
minut
mlmin
ci
minut
mlmin
ci
anesthesia
p
bl
fur
influx
fluid
pulmonari
circul
mlmin
ci
chang
efflux
minut
mlmin
ci
minut
mlmin
ci
minut
mlmin
ci
anesthesia
durat
anesthesia
affect
j
p
treatment
furosemid
also
affect
j
p
neither
hypothes
verifi
although
signific
increas
map
time
plc
fur
durat
anesthesia
affect
j
similarli
fur
chang
transmur
hydrostat
forc
extent
would
chang
j
healthi
dog
gener
anesthesia
hyuck
joo
yang
jae
hoon
kim
tae
heon
kim
hyung
jin
park
tae
sung
koo
kyoung
seo
kun
ho
song
chungnam
nation
univers
deajeon
korea
daegu
anim
medic
center
deagu
korea
tulobuterol
contain
b
adrenerg
agonist
first
bronchodil
avail
transderm
patch
pharmacokinet
tulobuterol
veterinari
medicin
well
studi
studi
human
well
investig
studi
pharmacokinet
tulobuterol
beagl
dog
transderm
intraven
administr
compar
evalu
util
tulobuterol
patch
dog
fifteen
beagl
dog
use
intraven
bolu
inject
tulobuterol
solut
prepar
concentr
mg
ml
intraven
dose
salin
dosevolum
mlkg
dog
group
transderm
administr
mg
patch
tulobuterol
use
dose
mgkg
mgkg
group
b
c
system
advers
effect
dog
either
treatment
follow
day
tulobuterol
rapidli
absorb
intraven
administr
max
hour
tulobuterol
well
absorb
transderm
administr
absorpt
lagtim
hour
c
max
tulobuterol
dog
reach
ngml
hour
reach
ngml
hour
transderm
administr
mgkg
exist
literatur
report
effect
blood
level
tulobuterol
human
medicin
ngml
evid
studi
ideal
blood
drug
concentr
reach
appli
mgkg
patch
believ
tulobuterol
patch
use
treat
chronic
respiratori
diseas
dog
sustain
releas
studi
investig
accuraci
oscillometr
blood
pressur
monitor
cardel
invas
blood
pressur
ibp
stand
hors
pharmacolog
induc
hyperand
hypotens
ibp
measur
eight
mare
use
facial
transvers
facial
arteri
noninvas
blood
pressur
nibp
correct
heart
level
measur
simultan
use
coccyg
arteri
heart
rate
rhythm
record
continu
use
digit
telemetri
hyper
hypotens
induc
administr
phenylephrin
lgkgminiv
minut
acepromazin
mgkgiv
respect
signific
correl
nibp
ibp
r
p
systol
diastol
mean
pressur
respect
mean
bia
upperlow
limit
agreement
mmhg
systol
mmhg
diastol
mmhg
mean
blood
pressur
averag
nibp
higher
phenylephrin
mean
nibp
meanaesd
ae
lower
acepromazin
ae
compar
baselin
ae
p
normohyperand
hypotens
phase
studi
separ
correl
detect
normotens
phase
r
p
systol
diastol
mean
pressur
respect
hors
show
frequent
second
degre
atrioventricular
andor
sinu
blockarrest
phenylephrin
administr
nibp
strongli
correl
ibp
differenti
chang
pressur
consist
underestim
blood
pressur
low
accuraci
devic
meet
valid
criteria
propos
acvim
small
anim
inaccuraci
hypertens
hypotens
need
evalu
phenylephrin
induc
arrhythmia
could
affect
nibp
angiotensinconvert
enzym
inhibitor
use
empir
hors
cardiovascular
disord
despit
pauciti
data
avail
object
studi
determin
lowest
dose
benazepril
attenu
rise
blood
pressur
administr
exogen
angiotensin
angi
five
healthi
hors
instrument
direct
measur
arteri
blood
pressur
receiv
increas
oral
dose
benazepril
mgkg
intragastr
washout
period
day
dose
prior
hour
benazepril
administr
hors
receiv
iv
bolu
angi
ngkg
attenu
systol
arteri
pressur
sap
respons
percentag
inhibit
quantifi
data
analyz
use
anova
repeat
measur
mean
ae
sd
increas
sap
ae
mm
hg
obtain
administr
angi
baselin
signific
effect
benazepril
dose
p
time
p
percentag
inhibit
systol
pressor
respons
angi
regardless
dose
percentag
inhibit
significantli
greater
hour
administr
benazepril
compar
hour
hour
percentag
inhibit
administr
benazepril
mgkg
ae
significantli
greater
achiev
mgkg
significantli
differ
achiev
higher
dosag
benazepril
dose
mgkg
oral
provid
adequ
attenu
rise
blood
pressur
administr
angi
reason
perform
studi
obes
hyperinsulinemia
risk
factor
develop
lamin
clear
whether
obes
induc
hyperinsulinemia
hyperinsulinemia
induc
obes
examin
effect
induc
obes
feed
high
energi
fat
rich
diet
insulin
sensit
oral
glucos
toler
shetland
poni
seven
shetland
mare
test
group
fed
mainten
digest
energi
de
requir
week
induc
weight
gain
six
shetland
mare
control
group
fed
digest
energi
requir
poni
underw
oral
glucos
toler
test
five
time
point
baselin
start
dietari
regim
period
week
period
week
period
week
period
week
post
onset
feed
regim
poni
weigh
weekli
statist
analys
perform
use
gener
linear
mix
model
bonferrroni
post
hoc
test
differ
consid
signific
p
test
group
show
increas
bodi
weight
cours
studi
area
curv
auc
plasma
glucos
concentr
significantli
reduc
test
group
period
compar
baselin
significantli
lower
control
group
period
test
group
mare
show
greater
p
ogtt
insulin
respons
period
baselin
exhibit
significantli
greater
insulin
respons
period
control
group
induc
obes
feed
fat
rich
diet
mainten
de
requir
induc
earli
stage
hyperinsulinemia
oral
glucos
load
result
improv
glucos
metabol
evidenc
signific
decreas
plasma
auc
glucos
hors
chronic
fatigu
character
reduct
perform
possibl
plasma
hormon
variat
could
object
biomark
fatigu
exercis
test
monitor
iberian
show
hors
geld
stallion
ae
year
bodyweight
ae
kg
bc
ae
work
season
plasma
adrenocorticotrop
hormon
acth
cortisol
free
thyroxin
ft
testosteron
prolactin
insulinlik
factori
igfi
insulin
leptin
concentr
assess
monthli
workload
intens
score
determin
accord
exercis
data
group
four
categori
w
w
repeatedmeasur
anova
post
hoc
bonferroni
test
use
evalu
effect
workload
plasma
hormon
concentr
bodi
condit
paramet
workload
intens
significantli
increas
acth
testosteron
insulin
energi
ration
significantli
decreas
cortisol
ft
leptin
prolactin
p
increas
significantli
w
w
decreas
w
w
p
testosteronecortisol
ratio
bc
increas
significantli
w
w
decreas
w
w
p
heavi
exercis
hors
show
signific
decreas
bodyweight
despit
signific
increas
energi
intak
p
acth
insulin
energi
ration
bc
posit
correl
workload
cortisol
leptin
ft
prolactin
neg
correl
workload
differ
hormon
respons
significantli
link
chang
physic
perform
might
possibl
use
marker
monitor
exercis
stress
indic
possibl
overtrain
case
neg
energi
balanc
hors
present
sign
fatigu
sepsi
remain
main
caus
death
neonat
foal
hypothalamicpituitaryadren
axi
regul
respons
sepsisassoci
stress
other
shown
rel
adren
insuffici
rai
character
impair
cortisol
respons
acth
common
associ
mortal
foal
studi
evalu
adrenocort
function
foal
focus
cortisol
adrenocort
steroid
steroid
precursor
neurosteroid
extens
investig
hypothes
rai
critic
ill
foal
involv
multipl
adrenocort
layer
result
decreas
glucocorticoid
mineralocorticoid
increas
steroid
precursor
neurosteroid
secret
associ
sever
diseas
mortal
also
propos
respons
steroid
exogen
acth
alter
foal
day
age
categor
group
septic
sick
nonsept
healthi
baselin
blood
sampl
collect
admiss
time
foal
receiv
lg
acth
cosyntropin
blood
sampl
also
collect
minut
post
acth
time
minut
steroid
steroid
precursor
concentr
determin
immunoassay
delta
steroid
defin
percent
chang
steroid
concentr
time
minut
delta
time
minut
minut
delta
septic
foal
higher
cortisol
pregnenolon
progesteron
androstenedion
three
time
point
higher
aldosteron
time
minut
compar
healthi
foal
p
nonsurviv
septic
foal
lower
cortisol
concentr
time
minut
compar
surviv
septic
foal
p
delta
lower
septic
compar
healthi
foal
cortisol
progesteron
aldosteron
p
suggest
rai
progesteron
decreas
howev
dhea
increas
respons
acth
time
minut
septic
foal
acth
stimul
influenc
pregnenolon
androstenedion
concentr
time
minut
delta
differ
group
foal
studi
rai
indic
alter
steroidogenesi
respons
acth
critic
ill
foal
hypocortisolemia
associ
poor
prognosi
surviv
septic
foal
endocrinopathi
equin
metabol
syndrom
em
pituitari
par
intermedia
dysfunct
ppid
lead
abnorm
distribut
adipos
tissu
hyperinsulinemia
glucos
intoler
insulin
resist
recent
studi
shown
intraven
administ
insulin
glucos
caus
lamin
addit
insulin
infus
hors
develop
mild
colic
sign
diarrhea
might
hyperinsulinemia
caus
alter
larg
intestin
ion
transport
transepitheli
resist
factor
might
critic
colon
ph
decreas
intak
feed
high
solubl
carbohydr
content
purpos
studi
determin
effect
ph
colon
mucosa
insulin
resist
hors
use
invitro
uss
chamber
system
tissu
sampl
right
dorsal
colon
collect
suspect
insulin
resist
n
normal
hors
n
immedi
euthanasia
colon
mucosa
dissect
muscular
layer
mount
uss
chamber
uss
chamber
use
measur
ion
transport
transepitheli
resist
gut
mucosa
indic
viabil
permeabl
colon
tissu
expos
ph
control
mucos
side
ph
submucos
side
potenti
differ
pd
short
circuit
current
isc
measur
everi
minut
tissu
transepitheli
resist
ter
calcul
opencircuit
pd
isc
use
ohm
law
r
pdisc
mean
isc
ter
chang
colon
tissu
control
hors
expos
differ
ph
howev
insulin
resist
hors
mean
isc
decreas
rapidli
right
dorsal
colon
tissu
expos
ph
signific
chang
seen
ph
also
mean
ter
decreas
significantli
p
colon
tissu
expos
ph
insulin
resist
hors
compar
tissu
expos
ph
low
ph
colon
mucos
ion
transport
transepitheli
resist
decreas
insulin
resist
hors
compar
control
hors
insulin
resist
hors
might
predispos
alter
mucos
ion
flux
transepitheli
resist
especi
drop
ph
feed
diet
high
solubl
carbohydr
decreas
ion
flux
ter
might
result
colic
diarrhea
seen
hors
afflict
em
ppid
data
preliminari
research
indic
confirm
find
pituitari
par
intermedia
dysfunct
ppid
describ
common
endocrinolog
disord
age
hors
studi
exist
describ
epidemiolog
characterist
hors
ppid
addit
epidemiolog
studi
need
determin
preval
ppid
larger
popul
age
hors
purpos
studi
obtain
epidemiolog
inform
includ
age
breed
sex
clinic
sign
insulinglucos
statu
initi
ppid
diagnosi
new
case
larg
popul
hors
hors
age
breed
sex
continent
us
elig
studi
enrol
long
document
exhibit
one
follow
clinic
sign
gener
region
hypertrichosi
muscl
wast
abnorm
fat
distribut
lethargi
lamin
unknown
etiolog
polyuria
polydipsia
suscept
infect
abnorm
sweat
andor
inappropri
lactat
normal
hors
exclud
studi
initi
visit
demograph
data
signal
physic
examin
conduct
clinic
sign
document
blood
drawn
basal
acth
fast
insulin
glucos
blood
sampl
process
ship
overnight
anim
health
diagnost
center
cornel
univers
ithaca
ny
analysi
associ
ppid
statu
base
acth
insulin
result
demograph
variabl
age
sex
breed
geograph
region
two
test
result
variabl
insulin
glucos
statist
evalu
individu
use
pearson
chisquar
test
odd
ratio
signific
predictor
ppid
statu
comput
use
correspond
confid
interv
appli
multipl
logist
regress
analysi
fivehundr
fifteen
ninehundr
eighti
two
hors
complet
epidemiolog
inform
includ
final
data
analysi
hors
ppid
ir
hors
stratifi
group
base
acth
insulin
laboratori
result
ppid
ir
ppid
ir
ppid
ir
ppid
ir
hors
ppid
ir
ppid
ir
ppid
ir
ppid
ir
hors
evalu
hors
year
age
ppid
hors
year
age
ppid
hors
year
age
ppid
hors
year
age
ppid
particular
odd
ppid
hors
year
age
approxim
twice
hors
year
old
compar
hors
youngest
age
group
odd
ratio
ppid
increas
hors
year
age
hors
year
age
even
adjust
age
hors
insulinresist
hors
seen
approxim
twice
odd
ppid
compar
hors
normal
insulin
level
enrol
hors
diagnos
endocrin
disord
ppid
andor
hyperinsulinemia
expect
ppid
preval
increas
significantli
p
age
significantli
higher
hors
abovenorm
level
insulin
glucos
p
p
respect
fortythre
percent
ppid
hors
also
hyperinsulinem
therefor
evalu
hors
suspect
endocrin
diseas
minimum
acth
insulin
glucos
evalu
long
term
studi
need
conduct
larg
popul
hors
evalu
endocrinopathi
hors
often
necessari
test
pituitari
par
intermedia
dysfunct
ppid
insulin
dysregul
hors
hypothes
result
thyrotropinreleas
hormon
trh
stimul
test
would
affect
feed
condit
oral
sugar
test
ost
thirti
adult
hors
age
year
age
mare
geld
facil
test
occas
across
period
hors
underw
trh
stimul
test
fed
day
fast
day
condit
ost
alon
day
combin
osttrh
stimul
test
day
test
result
compar
use
wilcoxon
ranksum
test
pair
student
ttest
agreement
assess
blandaltman
analysi
fast
feed
affect
plasma
adrenocorticotropin
hormon
acth
concentr
p
minut
p
trh
stimul
test
baselin
time
acth
concentr
differ
p
trh
stimul
test
perform
alon
fast
combin
ost
plasma
acth
concentr
increas
trh
administr
test
lower
minut
p
combin
test
compar
trh
stimul
test
fast
mean
bia
pgml
confid
interv
pgml
detect
feed
condit
impact
trh
stimul
test
result
acth
concentr
increas
lower
magnitud
test
combin
ost
combin
test
recommend
time
sever
test
evalu
hors
human
quantifi
system
insulin
resist
mani
test
evalu
agreement
studi
evalu
agreement
four
method
insulin
sensit
test
hors
includ
basal
serum
insulin
glucos
concentr
oral
sugar
test
ost
combin
glucoseinsulin
test
cgit
insulinmodifi
frequent
sampl
intraven
glucos
toler
test
fsigtt
test
perform
random
order
healthi
lightbre
hors
minim
model
analysi
fsigtt
classifi
seven
hors
insulin
resist
ir
insulin
sensit
ir
si
lmumin
contrast
basal
insulin
ost
classifi
hors
insulin
min
liuml
calcul
kappa
statist
cgit
fsigtt
ir
ppd
glu
minut
ir
insulin
min
liuml
sensit
cgit
ppdglu
min
specif
sensit
cgit
in
min
specif
area
glucos
curv
aucg
ost
cgit
fsigtt
show
signific
linear
relationship
blandaltman
comparison
show
lack
agreement
test
current
criteria
diagnosi
ir
use
basal
insulin
ost
highli
specif
lack
sensit
test
may
use
diagnos
sever
ir
individu
may
adequ
detect
mildli
affect
hors
cgit
display
better
sensit
specif
howev
liber
criteria
may
necessari
improv
agreement
minim
model
analysi
hypocalcemia
frequent
find
septic
foal
associ
mortal
hypovitaminosi
critic
ill
peopl
link
hypocalcemia
mortal
howev
inform
vitamin
metabolit
associ
clinic
laboratori
inform
well
mortal
critic
ill
foal
lack
hypothes
hypovitaminosi
hypocalcemia
hyperphosphatemia
increas
parathyroid
hormon
pth
concentr
frequent
critic
ill
hospit
foal
also
propos
vitamin
metabolit
associ
sever
diseas
likelihood
mortal
septic
foal
total
neonat
foal
hour
old
divid
hospit
n
septic
sick
nonsept
sn
healthi
n
group
includ
studi
blood
sampl
collect
admiss
serum
oh
oh
pth
concentr
measur
immunoassay
calcium
phosphoru
concentr
determin
colorimetr
method
data
analyz
nonparametr
method
univari
logist
regress
preval
hypovitaminosi
oh
ng
ml
hospit
septic
sn
foal
serum
oh
oh
concentr
significantli
lower
septic
sn
compar
healthi
foal
p
p
septic
foal
significantli
lower
calcium
higher
phosphoru
pth
concentr
healthi
sn
foal
p
low
oh
concentr
pmoll
associ
increas
pth
concentr
hospit
foal
septic
foal
oh
ngml
oh
pmoll
like
die
compar
septic
foal
normal
oh
oh
concentr
ngml
pmoll
respect
howev
vitamin
metabolit
associ
mortal
sn
foal
p
hypovitaminosi
hypocalcemia
hyperphosphatemia
elev
pth
concentr
frequent
critic
ill
foal
associ
vitamin
metabolit
sever
diseas
mortal
septic
foal
support
role
vitamin
pathogenesi
equin
neonat
disord
human
medicin
rapidli
develop
area
metabolom
emerg
promis
approach
identifi
biomark
diabet
insulin
resist
develop
overt
patholog
date
howev
minim
applic
metabolom
equin
medicin
object
studi
report
examin
serum
metabolom
welsh
poni
without
evid
insulin
dysregul
oral
sugar
test
ost
twenti
welsh
poni
ae
year
mean
ae
sd
select
cohort
poni
studi
examin
genet
metabol
risk
factor
metabol
syndrom
lamin
poni
classifi
healthi
con
n
insulin
mul
insulin
dysregul
id
n
insulin
mul
minut
post
administr
karo
syrup
mlkg
per
os
metabolom
analysi
complet
commerci
laboratori
metabolon
use
combin
ga
chromatographi
mass
spectrometri
gcm
liquid
chromatographi
mass
spectrometri
lcm
perform
serum
sampl
obtain
baselin
minut
ost
plasma
glucos
glucos
oxidas
serum
insulin
radioimmunoassay
concentr
also
measur
baselin
minut
data
analyz
twoway
repeat
measur
anova
follow
log
transform
signific
set
p
identifi
differ
group
time
point
mean
insulin
concentr
ost
significantli
higher
id
compar
con
poni
baselin
mean
ae
sd
id
ae
mul
con
ae
mul
minut
id
ae
mul
con
ae
mul
wherea
mean
glucos
concentr
differ
group
baselin
id
ae
mgdl
con
ae
mgdl
minut
id
ae
mg
dl
con
ae
mgdl
serum
metabolom
profil
compris
biochem
compound
known
ident
statist
signific
differ
id
con
identifi
biochem
particularli
metabolit
involv
tricarboxyl
acid
tca
cycl
fatti
acid
metabol
branchedchain
amino
acid
bcaa
oxid
mannos
produc
enzymat
isomer
glucos
higher
p
id
con
baselin
group
fructos
pyruv
mannos
significantli
higher
minut
compar
baselin
citrat
fumar
malat
metabolit
associ
mitochondri
use
pyruv
lower
id
con
minut
suggest
lower
tca
cycl
activ
id
poni
sever
longchain
fatti
acid
eg
palmitol
eicosapentano
acylcarnitin
eg
palmitolycarnitin
laurylcarnitin
higher
id
vs
con
baselin
minut
addit
intermedi
bcaa
metabol
includ
isovalerylglycin
significantli
higher
id
compar
con
poni
suggest
reduc
bcaa
oxid
id
poni
cohort
welsh
poni
examin
serum
metabolom
reveal
differ
tca
cycl
fatti
acid
metabol
bcaa
oxid
compar
anim
without
evid
insulin
dysregul
collect
differ
may
repres
state
mitochondri
dysfunct
id
compar
con
poni
thorough
neurolog
examin
question
atax
hors
crucial
differenti
normal
abnorm
help
neuroanatom
local
unfortun
agreement
amongst
experienc
clinician
poor
assess
presenc
sever
ataxia
especi
sign
mild
consequ
object
gait
character
might
benefici
hypothes
assess
variabl
spatial
characterist
swing
durat
deriv
motion
captur
kinemat
good
sensit
specif
detect
ataxia
hors
twentyon
hors
underw
gait
laboratori
measur
live
neurolog
assess
rater
gait
laboratori
hors
walk
across
runway
surround
motion
captur
system
sampl
rate
hz
walk
normal
blindfold
least
three
trial
stride
subsequ
process
use
semiautom
customwritten
matlab
ii
script
displac
reflect
marker
head
fetlock
hoof
tuber
coxa
sacrum
process
hors
consid
atax
median
rater
ataxia
grade
statist
softwar
r
use
gener
receiv
oper
characterist
determin
diagnost
sensit
se
specif
sp
area
curv
auc
object
measur
pelvic
limb
coeffici
variat
time
point
fetlock
joint
reach
maximum
vertic
displac
greater
diagnost
valu
thorac
limb
blindfold
exacerb
object
sign
ataxia
compar
normal
hors
auc
se
sp
coeffici
variat
durat
swing
normal
walk
auc
se
sp
conclud
motion
captur
use
assess
quantifi
ataxia
object
furthermor
greater
variat
pelvic
limb
gait
paramet
atax
hors
walk
blindfold
compar
nonatax
hors
walk
blindfold
object
assess
neurolog
examin
might
futur
improv
diagnost
accuraci
qualisi
ab
gothenburg
sweden
ii
mathwork
inc
natick
usa
fresh
frozen
plasma
ffp
transfus
common
critic
ill
healthi
neonat
foal
anaphylact
reaction
report
extent
natur
ffp
transfusionassoci
immun
activ
foal
unknown
hypothes
ffp
transfus
evok
detect
system
inflammatori
respons
healthi
foal
thirtysix
healthi
standardbr
foal
hour
old
alloc
either
group
n
receiv
commerci
ffp
transfus
group
n
receiv
isoton
crystalloid
intraven
infus
jugular
blood
collect
transfus
hour
postadministr
evalu
serum
amyloid
saa
turbidometr
assay
fibrinogen
fib
modifi
clauss
method
tnfa
commerci
elisa
kit
statist
comparison
group
across
time
perform
use
chi
squar
repeat
measur
anova
fib
significantli
increas
p
hour
compar
baselin
foal
receiv
ffp
saa
increas
hour
foal
receiv
ffp
compar
crystalloid
p
serum
undetect
time
compar
baselin
mani
foal
show
increas
tnfa
fold
p
p
concentr
hour
hour
number
foal
increas
significantli
greater
group
tnfa
group
tnfa
p
combin
find
indic
ffp
transfus
evok
balanc
proantiinflammatori
system
immun
respons
healthi
foal
presenc
inflamm
control
foal
impli
dualist
immunogen
mechan
serum
immunoglobulin
g
igg
assess
neonat
foal
consid
standard
care
equin
hospit
determin
immun
overal
health
howev
cutoff
valu
igg
predict
complet
partial
failur
transfer
passiv
immun
ftpi
develop
year
ago
larg
empir
littl
prospect
statist
data
support
use
associ
outcom
object
comprehens
evalu
tradit
cutoff
valu
igg
assess
ftpi
igg
mg
dl
gener
novel
igg
cutoff
valu
determin
associ
likelihood
nonsurviv
multicent
prospect
crosssect
studi
evalu
clinicopatholog
variabl
foal
day
old
includ
serum
igg
hematolog
serum
biochemistri
foal
divid
three
group
diagnosi
healthi
n
sick
nonsept
n
septic
n
five
igg
cutoff
valu
gener
univari
multivari
logist
regress
use
comput
odd
ratio
nonsurviv
foal
find
support
use
tradit
cutoff
valu
mgdl
adequ
transfer
passiv
immun
atpi
stepwis
decreas
igg
valu
mgdl
proport
associ
nonsurviv
hospit
foal
degre
ftpi
time
like
die
statist
differ
nonsurviv
foal
igg
concentr
mgdl
compar
mgdl
foal
hyperproteinemia
also
higher
mortal
rate
recommend
immedi
assess
igg
concentr
hospit
foal
ftpi
receiv
prompt
immunotherapi
purpos
pilot
studi
compar
system
local
immun
respons
follow
intranas
oral
vaccin
streptococcu
equi
var
equi
eight
healthi
hors
streptococcu
equi
protein
titer
vaccin
liveattenu
vaccin
intranas
per
label
instruct
transmucos
oral
twovaccin
seri
serum
nasal
secret
collect
baselin
post
booster
vaccin
detect
igg
iga
antibodi
assess
perform
use
commerci
avail
elisa
protein
titer
use
novel
microbead
assay
analyz
luminex
tm
magpix
instrument
util
flow
cytometr
principl
hors
vaccin
intranas
rout
demonstr
substanti
increas
serum
igg
serum
iga
protein
antibodi
level
post
vaccin
p
p
respect
hors
vaccin
oral
rout
also
demonstr
increas
serum
igg
protein
antibodi
level
post
vaccin
p
though
increas
approxim
one
third
magnitud
observ
intranas
vaccin
orallyvaccin
hors
show
evid
respons
serum
iga
post
vaccin
p
small
scale
studi
studi
design
limit
unknown
protect
level
igg
equi
find
studi
interpret
care
result
studi
indic
hors
receiv
liveattenu
pinnacl
streptococcu
equi
var
equi
vaccin
either
intranas
oral
rout
show
increas
serum
igg
protein
titer
though
magnitud
respons
differ
administr
rout
major
histocompat
complex
mhc
ii
express
detect
normal
muscl
appear
prerequisit
autoimmun
cytotox
occur
muscl
human
dog
immunemedi
myositi
imm
purpos
studi
character
lymphocyt
subtyp
muscl
biopsi
suspect
imm
hors
determin
mhc
ii
express
occur
myocyt
immunohistochem
stain
mhc
class
ii
lymphocyt
perform
muscl
sampl
quarter
hors
histori
recent
muscl
atrophi
degre
lymphocyt
infiltr
muscl
around
vessel
score
lymphocyt
subtyp
sarcolemm
mhc
express
detect
muscl
biopsi
major
n
hors
mhc
class
ii
express
strong
posit
correl
occur
mhc
class
ii
express
r
score
lymphocyt
subtyp
infiltr
myocyt
significantli
correl
mhc
ii
express
rang
r
p
hors
rather
lymphocyt
predomin
conclus
immunemedi
basi
equin
imm
support
mhc
ii
express
myocyt
myocyt
express
mhc
class
ii
present
process
selfand
nonself
antigen
peptid
tlymphocyt
respect
activ
immun
respons
within
skelet
muscl
studi
describ
compar
first
time
bacteri
composit
differ
locat
equin
respiratori
tract
use
high
throughput
sequenc
sampl
collect
healthi
adult
hors
immedi
euthanasia
upper
respiratori
tract
sampl
nasal
swab
nasopharyng
swab
guttur
pouch
lavag
bronchoalveolar
lavag
bal
bronchial
protect
brush
sampl
perform
surgic
prepar
tracheostomi
high
throughput
sequenc
rrna
gene
pcr
product
region
perform
sequenc
classifi
oper
taxonom
unit
otu
total
sequenc
pass
qualiti
control
test
firmicut
proteobacteria
main
phyla
found
site
rang
respect
rel
abund
site
overal
similar
member
gammaproteobacteria
class
member
moraxellacea
bacillacea
famili
commonli
found
site
acinetobact
main
genu
present
site
rang
staphylococcu
p
anoxybacillu
p
repres
nasal
swab
compar
bronchial
brush
expect
significantli
greater
observ
estim
otu
nasal
caviti
compar
site
p
subsampl
read
per
site
otu
detect
nasal
swab
nasopharyng
swab
guttur
pouch
lavag
bronchial
brush
bal
respect
differ
even
shannon
even
index
p
divers
invers
simpson
index
p
signific
differ
commun
membership
jaccard
index
nasal
swab
compar
sampl
site
parsimoni
test
p
differ
commun
structur
yue
clayton
index
dissimilar
p
sampl
categor
upper
lower
respiratori
tract
similar
result
obtain
differ
membership
p
structur
p
differ
membership
structur
along
greater
rich
nasal
caviti
compar
site
may
result
addit
larg
number
member
low
abund
someth
could
reflect
transient
colon
contamin
environ
compar
organ
system
respiratori
tract
harbor
homogen
less
rich
microbiota
decreas
rich
vari
littl
commun
structur
upper
lower
airway
studi
establish
baselin
data
healthi
equin
airway
microbiota
human
studi
previous
document
strong
associ
vitamin
defici
bronchial
asthma
condit
similar
equin
inflammatori
airway
diseas
iad
goal
studi
therefor
evalu
relationship
serum
level
iad
hors
twentythre
hors
fulfil
diagnost
criteria
iad
previous
defin
acvim
consensu
recruit
studi
addit
asymptomat
control
anim
sampl
compar
stabl
environ
serum
analysi
nmoll
bronchoalveolarlavag
fluid
balf
cytolog
noninvas
pulmonari
function
test
forc
oscillatori
mechan
fom
respiratori
induct
plethysmographi
rip
assess
airway
hyperreact
ahr
perform
hors
balf
slide
stain
modifi
wright
stain
toluidin
blue
data
present
descript
mean
ae
standard
deviat
base
normal
data
distribut
categor
data
compar
group
use
chisquar
analysi
continu
variabl
use
independ
sampl
ttest
p
consid
signific
diagnosi
iad
either
associ
ahr
abnorm
balf
analysi
sixteen
iad
hors
show
airway
neutrophillia
mean
balf
neutrophil
ae
demonstr
airway
eosinophilia
mean
balf
eosinophil
ae
hors
increas
balf
mast
cell
mean
ae
serum
level
significantli
lower
iad
ae
nmoll
versu
control
hors
ae
nmoll
p
statist
associ
airway
neutrophillia
neutrophil
p
conclus
serum
level
invers
associ
diagnosi
iad
hors
relat
balf
neutrophillia
investig
signal
histori
physic
examin
find
clinicopatholog
bacteriolog
data
treatment
outcom
hors
diagnos
septic
pleuropneumonia
retrospect
studi
perform
hors
includ
studi
diagnos
sepsi
base
criteria
sir
confirm
infect
admiss
demonstr
pleural
effus
via
transthorac
ultrasonographi
studi
period
ninetyseven
hors
met
inclus
criteria
median
age
year
travel
within
week
admiss
common
risk
factor
common
histor
complaint
includ
fever
case
lethargi
inappet
common
physic
examin
find
admiss
includ
tachycardia
tachypnea
fever
hyperfibrinogenemia
hypoalbuminemia
present
case
respect
common
bacteria
isol
tracheal
aspir
pleural
fluid
streptococcu
equi
subsp
zooepidemicu
within
individu
anim
tracheal
aspir
pleural
fluid
sampl
yield
result
tracheal
aspir
cultur
sensit
pleural
fluid
cultur
lamin
diagnos
hors
surviv
rate
discharg
hospit
thoracotomi
perform
hors
posit
associ
surviv
p
azotemia
neg
associ
surviv
p
return
work
p
hors
azotemia
time
like
die
hors
without
azotemia
everi
unit
increas
creatinin
increas
risk
death
racehors
recent
histori
travel
risk
develop
septic
pleuropneumonia
upper
respiratori
tract
flora
continu
repres
common
bacteria
isol
lower
airway
hors
pleuropneumonia
tracheal
aspir
cultur
superior
pleural
fluid
cultur
lamin
uncommon
hors
pleuropneumonia
azotemia
neg
prognost
indic
like
reflect
sever
ill
upon
admiss
final
thoracotomi
consid
hors
pleuropneumonia
data
extract
clinic
record
royal
veterinari
colleg
case
identifi
invoic
spl
cathet
bill
time
period
one
brand
spl
cathet
use
mila
kentucki
usa
data
collat
includ
age
breed
gender
clinician
stage
type
train
ophthalm
condit
pharmacolog
agent
administ
cathet
posit
durat
placement
whether
cathet
manag
hospit
home
complic
report
action
taken
data
enter
code
spreadsheet
data
initi
interrog
use
chisquar
test
two
binari
logist
regress
model
built
stepwis
fashion
evalu
factor
associ
posit
cathet
insert
complic
rate
data
extract
hors
spl
cathet
age
day
year
gender
reflect
hospit
admiss
femal
male
rang
ophthalm
condit
treat
spl
common
corneal
ulcer
n
squamou
cell
carcinoma
n
uveiti
n
durat
spl
day
median
iqr
complic
rate
lowest
medicin
resid
compar
intern
medicin
clinician
surgeon
differ
complic
rate
spl
manag
home
compar
hospit
p
posit
cathet
placement
influenc
stage
train
p
board
clinician
like
place
cathet
lower
eyelid
associ
durat
treatment
p
longer
treatment
time
associ
spl
upper
eyelid
complic
associ
cathet
posit
p
upper
eyelid
lower
eyelid
antimicrobi
administr
p
complic
rate
use
plasma
administr
p
complic
rate
use
conclus
spl
placement
upper
eyelid
associ
fewer
complic
use
antimicrobi
appear
protect
complic
plasma
administ
indic
increas
likelihood
complic
placent
steroid
suggest
use
diagnost
marker
pregnanc
loss
mare
howev
control
studi
examin
chang
steroid
mare
placent
object
compar
plasma
concentr
estradiol
estron
sulfat
mare
placent
gestat
agematch
control
mare
pregnant
mare
gestat
alloc
control
group
n
group
experiment
induc
placent
n
induct
placent
achiev
via
intracerv
inocul
streptococcu
equi
ssp
zooepidemicu
plasma
collect
inocul
mare
placent
group
commenc
control
mare
day
daili
abort
day
post
inocul
dpi
estron
sulfat
concentr
determin
elisa
wherea
estradiol
determin
chemiluminesc
immunoassay
data
analyz
mix
model
dpi
day
abort
dfa
differ
steroid
mare
experiment
induc
placent
abort
within
dpi
signific
effect
time
dpi
p
dfa
p
time
group
interact
dpi
dfa
p
concentr
estradiol
concentr
estradiol
significantli
reduc
dpi
dfa
p
analys
estron
sulfat
reveal
effect
time
dpi
p
dfa
p
time
group
interact
dpi
p
dfa
p
estron
sulfat
concentr
significantli
reduc
dpi
day
abort
dfa
mare
experiment
induc
placent
concentr
estrogen
chang
significantli
mare
experiment
induc
ascend
placent
vaccin
hors
foal
wnv
eee
vaccin
might
illicit
igm
antibodi
respons
could
interfer
captur
elisa
diagnost
test
especi
hors
foal
test
vaccin
hypothesi
studi
hors
foal
vaccin
multival
vaccin
contain
wn
eee
antigen
elicit
igm
antibodi
respons
six
adult
hors
year
six
month
old
poni
foal
dam
use
studi
hors
foal
vaccin
commerci
avail
combin
vaccin
vetera
gold
boehring
ingelheim
vetmedica
st
joseph
mo
usa
contain
kill
wn
eee
antigen
adult
hors
dam
poni
previou
histori
yearli
vaccin
wherea
poni
foal
previous
vaccin
blood
sampl
collect
jugular
vein
hors
dam
foal
day
prior
vaccin
day
vaccin
day
foal
given
booster
vaccin
addit
blood
sampl
obtain
day
post
booster
vaccin
addit
blood
sampl
obtain
dam
foal
time
use
sentinel
viru
exposur
foal
dam
hous
togeth
pastur
louisiana
state
univers
veterinari
scienc
farm
blood
sampl
centrifug
serum
collect
frozen
shipment
serolog
assay
wn
eee
includ
igm
antibodi
captur
elisa
macelisa
plaqu
reduct
neutral
assay
prnt
perform
nation
veterinari
servic
laboratori
nvsl
ame
ia
usa
macelisa
titer
wn
eee
neg
hors
foal
dam
foal
studi
period
adult
hors
prnt
titer
rang
eee
wn
time
poni
foal
prnt
titer
eee
wn
rang
neg
prior
vaccin
administr
second
vaccin
one
foal
neg
prnt
titer
eee
throughout
experi
vaccin
multival
vaccin
contain
wn
eee
elicit
antibodi
respons
hors
poni
foal
howev
vaccin
wn
eee
increas
igm
titer
day
vaccin
adult
hors
poni
initi
vaccin
poni
foal
therefor
vaccin
interfer
serolog
test
natur
occur
wn
eee
infect
salmonella
enterica
import
factor
healthcareassoci
epidem
zoonot
diseas
veterinari
hospitalswith
outbreak
multidrug
resist
mdr
salmonella
among
equin
patient
result
high
case
fatal
rate
substanti
financi
cost
object
studi
determin
factor
associ
fecal
shed
mdrsalmonella
determin
effect
salmonella
shed
may
health
outcom
previous
hospit
hors
stablem
patient
elig
casecontrol
studi
includ
fecal
cultur
enterica
part
surveil
program
januari
decemb
data
regard
exposur
interest
collect
retrospect
medic
record
inform
longterm
outcom
obtain
owner
phone
survey
multivari
regress
techniqu
use
determin
factor
associ
shed
mdrsalmonella
subsequ
health
outcom
equin
patient
enrol
studi
includ
cultureposit
cultureneg
least
fecal
sampl
hors
farm
hors
experienc
diarrhea
hospit
like
shed
salmonella
compar
hors
without
diarrhea
hors
decreas
feed
intak
hospit
like
shed
mdrstrain
compar
hors
normal
feed
intak
gener
shed
increas
longterm
risk
nonsurviv
colic
abnorm
fece
discharg
hospit
hors
increas
risk
hospit
abnorm
fece
stablem
despit
find
still
recommend
manag
hors
shed
salmonella
separ
resid
hors
employ
rigor
person
environment
hygien
mani
field
veterinarian
eschew
diagnost
test
rhodococcu
equi
pneumonia
time
labor
risk
foal
associ
obtain
tracheobronchi
aspir
realtim
quantit
pcr
qpcr
method
detect
r
equi
fece
develop
noninvas
rapid
diagnost
test
r
equi
pneumonia
evalu
larg
popul
foal
object
studi
evalu
clinic
util
fecal
pcr
diagnost
test
detect
foal
r
equi
pneumonia
use
receiv
oper
characterist
roc
method
studi
includ
foal
born
r
equiendem
ranch
texa
fecal
sampl
collect
everi
week
foal
time
onset
clinic
sign
affect
foal
n
foal
pneumonia
match
age
dateofbirth
healthi
n
subclin
n
control
foal
concentr
r
equi
fece
determin
qpcr
differ
significantli
p
among
group
area
roc
curv
use
fecal
qpcr
diagnosi
r
equi
pneumonia
ci
sensit
specif
data
indic
realtim
quantit
pcr
fece
may
use
diagnosi
r
equi
foal
clinic
sign
pneumonia
summer
fall
month
kansa
neighbor
state
central
midwestern
unit
state
wit
unpreced
number
pigeon
fever
case
typic
arid
region
diseas
hors
studi
present
retrospect
bayesian
geostatist
analysi
environment
risk
factor
associ
pigeon
fever
case
receiv
kansa
state
univers
veterinari
health
center
kansa
state
veterinari
diagnost
lab
diseas
caus
corynebacterium
pseudotuberculosi
hors
determin
posit
test
result
characterist
abscess
format
posit
bacteri
cultur
purul
materi
obtain
lanc
abscess
n
posit
serolog
evid
exposur
organ
n
hors
neg
test
n
consid
absenc
diseas
hors
demograph
stabl
locat
well
stabl
histori
month
prior
develop
clinic
sign
obtain
review
medic
record
contact
client
via
telephon
environment
covari
inform
collect
publicli
avail
sourc
use
geograph
inform
system
gi
remotesens
method
soil
attribut
usda
state
soil
geograph
survey
ssurgo
land
useland
cover
attribut
usg
nation
land
cover
dataset
nlcd
climat
data
nasa
moder
resolut
imag
spectroradiomet
modi
predict
worldwid
renew
resourc
power
candid
covari
screen
use
linear
univari
regress
model
individu
test
covari
signific
p
kept
bayesian
geostatist
model
perform
without
covari
dic
lower
covari
ad
give
spatial
autocorrel
pigeon
fever
statu
among
hors
covari
remain
static
signific
addit
covari
bayesian
model
includ
soil
moistur
total
edg
contrast
index
land
surfac
temperatur
increas
soil
moistur
appear
protect
total
edg
contrast
land
surfac
temperatur
risk
factor
develop
diseas
data
may
lead
futur
investig
regard
prevent
better
manag
diseas
outbreak
studi
repres
small
compon
larger
studi
look
identifi
potenti
risk
factor
equin
infecti
anemia
eia
canada
smaller
studi
use
inform
accompani
serum
sampl
submiss
canadian
food
inspect
agenc
cfia
nation
refer
laboratori
purpos
diseas
investig
export
test
countri
us
mexico
exclud
test
feedlot
hors
confirmatori
test
laboratori
referr
diseas
investig
export
sampl
taken
cfia
veterinarian
veterinari
inspector
laboratori
referr
sampl
taken
cfiaaccredit
privat
veterinarian
anim
consid
posit
eia
test
posit
agar
gel
immunodiffus
agid
one
posit
test
per
anim
retain
analysi
associ
potenti
risk
factor
equid
speci
breed
sex
age
coat
color
month
year
submiss
provinc
region
eastern
vs
western
canada
posit
test
result
examin
use
binari
logist
regress
binomi
distribut
calcul
odd
ratio
confid
interv
ci
final
multivari
model
base
nonmodifi
hors
characterist
creat
dataset
p
consid
signific
sampl
miss
data
exclud
analysi
inform
avail
submiss
includ
anim
test
posit
base
univari
analysi
breed
provinc
region
year
month
submiss
signific
risk
factor
posit
eia
result
age
breed
retain
final
multivari
model
show
signific
interact
conclus
breed
provinceregion
may
risk
factor
eia
canada
may
indic
effect
usespecif
manag
factor
deplet
phenylbutazon
residu
equin
urin
tissu
patricia
dowl
ron
johnson
joe
boison
western
colleg
veterinari
medicin
saskatoon
sk
canada
ontario
veterinari
colleg
guelph
canada
canadian
food
inspect
agenc
saskatoon
sk
canada
phenylbutazon
pbz
nonsteroid
antiinflammatori
drug
commonli
use
treat
musculoskelet
pain
inflamm
hors
approv
use
hors
canada
unit
state
product
label
carri
warn
use
hors
intend
human
food
legal
prohibit
use
pbz
hors
intend
slaughter
canada
rather
disclaim
legal
maximum
residu
limit
mrl
establish
pbz
hors
tissu
detect
amount
pbz
constitut
residu
violat
global
use
pbz
hors
may
eventu
use
food
controversi
detect
undeclar
hors
meat
food
product
european
union
eu
caus
much
concern
peopl
expos
unsaf
residu
pbz
effect
inexpens
gener
safe
hors
pbz
continu
extens
use
mani
countri
human
safeti
concern
lack
residu
deplet
data
mrl
pbz
european
union
adopt
precautionari
principl
ban
pbz
use
food
anim
valid
wide
spread
use
pbz
north
american
hors
lifetim
ban
impract
detriment
equin
welfar
project
undertaken
provid
inform
deplet
pbz
urin
tissu
hors
address
concern
regard
risk
pbz
residu
hors
meat
valid
liquid
chromatographymass
spectrophotometri
lcmsm
assay
develop
detect
pbz
metabolit
oxyphenbutazon
oxpbz
equin
serum
urin
maxxam
analyt
tissu
canadian
food
inspect
agenc
limit
quantif
loq
assay
ngml
pbz
ngml
oxpbz
residu
serum
urin
ngg
pbz
oxpbz
equin
tissu
loq
well
eu
minimum
requir
perform
limit
mrpl
analyt
method
phenylbutazon
ngg
util
hors
destin
slaughter
high
dose
pbz
treatment
regimen
mgkgday
day
conduct
pilot
studi
determin
sampl
time
point
full
drug
deplet
studi
predict
pilot
studi
result
indic
blood
concentr
pbz
oxpbz
deplet
rapidli
reflect
tissu
concentr
pbz
oxpbz
deplet
rapidli
equin
muscl
readili
detect
first
slaughter
time
point
day
postpbz
administr
full
deplet
studi
use
hors
slaughter
group
confirm
even
high
dose
treatment
regimen
pbz
deplet
rapidli
equin
muscl
liver
tissu
pbz
residu
deplet
slowest
rate
oxpbz
concentr
exceed
pbz
concentr
urin
still
detect
day
postpbz
administr
residu
oxpbz
detect
muscl
kidney
liver
day
postpbz
administr
result
indic
pbz
regulatori
marker
compound
liver
target
tissu
regulatori
enforc
conclus
even
high
dose
pbz
treatment
regimen
pbz
oxpbz
deplet
rapidli
equin
muscl
lifetim
ban
use
hors
intend
human
food
justifi
medic
histori
hors
question
preslaught
test
urin
postslaught
test
liver
prevent
pbz
contamin
hors
meat
enter
human
food
chain
previou
work
author
show
erythromycinassoci
hyperthermia
caus
impair
sweat
effect
rifampin
erythromycininduc
anhidrosi
unknown
studi
compar
terbutalineinduc
sweat
erythromycintr
foal
sweat
respons
foal
given
rifampin
alon
combin
erythromycin
separ
experiment
session
ponycross
foal
nine
femal
three
male
month
old
enrol
treat
day
erythromycin
base
mgkg
oral
three
time
daili
rifampin
mgkg
oral
twice
daili
combin
medic
accord
duplic
counterbalanc
measur
design
quantit
intraderm
terbutalin
sweat
test
perform
three
success
day
treatment
baselin
day
treatment
began
signific
p
suppress
sweat
foal
given
erythromycin
without
rifampin
effect
p
rifampin
alon
compar
terbutalineinduc
sweat
baselin
valu
significantli
reduc
p
foal
given
erythromycin
without
rifampin
evalu
day
except
addit
rifampin
treatment
standard
erythromycin
regimen
chang
overal
sweat
respons
intraderm
terbutalin
p
result
show
despit
evid
rifampin
reduc
bioavail
relat
macrolid
clarithromycin
potent
antisudorif
effect
erythromycin
undiminish
concurr
rifampin
administr
develop
voriconazolecontain
thermogel
subconjunctiv
space
sc
inject
could
allow
sustain
drug
deliveri
target
tissu
improv
success
treat
keratomycosi
purpos
studi
determin
sustainedreleas
voriconazol
occur
combin
thermosensit
poli
lacticcoglycol
acid
bpoli
ethylen
glycol
bpoli
lacticcoglycol
acid
plgapegplga
hydrogel
vitro
character
sc
thermogel
inject
ex
vivo
equin
eye
six
group
defin
thermogel
mg
voriconazol
thermogel
mg
voriconazol
ethanol
thermogel
mg
voriconazol
thermogel
mg
voriconazol
ethanol
thermogel
mg
voriconazol
thermogel
sampl
maintain
phosphat
buffer
salin
pb
pb
collect
daili
day
voriconazol
concentr
determin
via
highperform
liquid
chromatographi
ten
normotherm
ex
vivo
hors
eye
inject
thermogel
evalu
via
highresolut
mhz
ultrasound
voriconazol
success
combin
thermogel
crystallin
form
ethanol
solut
voriconazol
releas
thermogel
follow
first
order
kinet
rang
group
day
group
voriconazol
concentr
releas
exceed
target
mic
lgml
day
group
day
group
addit
ethanol
inconsist
alter
voriconazol
releas
welldemarc
hypoecho
structur
form
sc
follow
thermogel
inject
voriconazol
releas
sustain
manner
plgapegplga
thermogel
vitro
sc
inject
liquid
thermogel
feasibl
equin
eye
result
format
welldefin
gel
deposit
bodi
temperatur
speci
human
cat
markedli
reduc
halflif
transfus
red
blood
cell
rbc
donor
recipi
blood
crossreact
hors
natur
occur
alloantibodi
crossmatch
alway
perform
prior
whole
blood
transfus
hypothes
crossmatch
incompat
predict
shorten
rbc
surviv
time
autolog
transfus
hors
twenti
healthi
adult
hors
use
blood
type
antirbc
antibodi
screen
major
minor
crossmatch
determin
pair
two
pair
crossmatch
compat
remaind
incompat
donor
blood
collect
citrat
phosphat
dextros
label
nhsbiotin
transfus
recipi
posttransfus
sampl
collect
hour
day
proport
biotinyl
rbc
detect
flow
cytometri
use
streptavidinphycoerythrin
crossmatch
incompat
significantli
associ
decreas
surviv
time
p
half
life
transfus
incompat
crossmatch
allogen
equin
rbc
day
versu
day
compat
rbc
crossmatch
significantli
associ
febril
transfus
reaction
p
crossmatch
test
prior
transfus
recommend
whenev
feasibl
despit
low
incid
natur
occur
alloantibodi
hors
equin
fecal
microbiom
rachel
liepman
jacob
swink
greg
habe
ramiro
toribio
ohio
state
univers
columbu
oh
usa
acut
coliti
common
devast
complic
antibiot
therapi
hors
fecal
cultur
often
fail
identifi
etiolog
agent
low
sensit
detect
organ
difficult
cultiv
metagenom
studi
util
ribosom
rna
rrna
sequenc
bacteri
identif
classif
produc
profil
genet
divers
microbi
commun
limit
data
explain
antibiot
affect
fecal
microbiom
hors
time
object
provid
comprehens
descript
bacteri
phylum
structur
within
fece
normal
hors
determin
commonli
use
antibiot
affect
commun
time
day
treatment
long
enough
detect
chang
also
investig
chang
persist
period
sixteen
healthi
hors
recent
histori
underli
diseas
use
studi
randomli
assign
one
four
treatment
group
n
hors
per
group
group
treat
intraven
antibiot
ceftiofur
enrofloxacin
oxytetracyclin
salin
control
standard
dose
five
consecut
day
fecal
sampl
collect
daili
treatment
bacteri
dna
extract
pcr
amplifi
analyz
pyrosequenc
rrna
gene
baselin
treatment
three
five
day
posttreat
composit
divers
microbiota
determin
compar
use
mothur
linear
mix
model
use
analyz
differ
treatment
group
time
point
use
subject
random
effect
overal
phyla
identifi
hors
averag
sequenc
remain
unclassifi
divers
within
subject
alpha
divers
significantli
alter
treatment
time
howev
commun
structur
sampl
chang
differ
observ
proteobacteria
firmicut
bacteroidet
verrucomicrobia
p
treatment
durat
day
suffici
identifi
chang
fecal
microbiota
chang
commun
structur
frequent
specif
antibiot
ceftiofur
enrofloxacin
treatment
result
reduct
proteobacteria
compar
treatment
ceftiofur
oxytetracyclin
treatment
led
signific
chang
major
phyla
time
within
treatment
group
sever
chang
phylum
structur
persist
day
howev
return
near
baselin
scarc
literatur
regard
accuraci
either
transabdomin
ultrasound
transrect
abdomin
palpat
compar
surgic
diagnosi
case
equin
acut
abdomin
pain
aim
studi
evalu
level
agreement
modifi
flash
protocol
mflash
thorac
left
middl
third
window
exclud
surgic
diagnosi
transrect
abdomin
palpat
surgic
diagnosi
specif
diagnos
interest
includ
nephrosplen
entrap
right
dorsal
displac
larg
colon
volvulu
surgic
small
intestin
lesion
sequenti
case
clientown
hors
present
evalu
acut
abdomin
pain
enrol
studi
hors
year
age
larg
enough
transrect
abdomin
palpat
includ
transrect
abdomin
palpat
perform
first
attend
clinician
descript
find
tent
diagnosi
record
standard
record
sheet
mflash
complet
descript
find
ultrasound
diagnosi
record
hors
underw
exploratori
celiotomi
within
hour
evalu
includ
statist
analysi
kappa
twoway
agreement
comparison
perform
assess
agreement
sixtyon
case
fit
inclus
criteria
result
show
mflash
moder
agreement
surgic
diagnosi
kappa
p
transrect
abdomin
palpat
slight
agreement
surgic
diagnosi
kappa
p
conclus
mflash
accur
tool
transrect
abdomin
palpat
predict
specif
surgic
diagnos
case
equin
acut
abdomen
pedersen
clair
windey
emma
read
dan
french
alastair
cribb
heath
macleod
heidi
bans
univers
calgari
calgari
ab
canada
td
equin
veterinari
group
calgari
ab
canada
gastric
ulcer
common
find
perform
hors
recognit
ulcer
may
impair
perform
led
investig
preval
multipl
perform
disciplin
previou
research
focus
primarili
risk
factor
squamou
ulcer
role
specif
risk
factor
develop
glandular
ulcer
remain
unclear
purpos
studi
determin
preval
identifi
risk
factor
develop
squamou
andor
glandular
gastric
ulcer
popul
activ
compet
warmblood
showjump
hors
eightynin
warmblood
barn
includ
studi
gastroscopi
perform
april
juli
hour
fast
glandular
squamou
ulcer
record
score
scale
egu
council
trainer
complet
manag
survey
includ
question
regard
feed
hous
competit
level
train
practic
previou
medic
histori
includ
medic
administ
continu
variabl
examin
use
student
ttest
categor
data
examin
use
chi
squar
test
fisher
exact
test
spss
preval
glandular
ulcer
hors
grade
greater
glandular
ulcer
preval
squamou
ulcer
hors
grade
greater
ulcer
concurr
glandular
squamou
ulcer
identifi
hors
preliminari
risk
factor
identifi
grade
greater
ulcer
kind
exercis
day
per
week
p
feed
hay
daili
p
glandular
ulcer
grade
greater
hors
compet
nationallevel
event
show
increas
risk
compar
compet
fei
level
p
studi
suggest
daili
hay
feed
increas
exercis
frequenc
associ
increas
risk
gastric
ulcer
decreas
risk
glandular
ulcer
observ
feilevel
hors
unexpect
may
suggest
glandular
ulcer
associ
reduc
perform
intestin
microbiota
import
health
diseas
factor
disturb
equin
intestin
microbiota
incomplet
studi
object
studi
determin
effect
transport
fast
anesthesia
fecal
microbiota
healthi
adult
hors
use
next
gener
sequenc
fecal
sampl
eight
hors
baselin
transport
hour
fast
hour
anesthesia
studi
next
gener
sequenc
region
rrna
gene
follow
use
assess
microbi
composit
alpha
divers
phylogenet
structur
beta
divers
assess
use
mothur
chang
rel
abund
differ
taxonom
group
higher
taxonom
level
phylum
level
hors
significantli
less
cyanobacteria
fast
p
anesthesia
p
baselin
chang
lower
taxonom
level
notabl
order
clostridial
decreas
anesthesia
p
alpha
divers
significantli
differ
time
point
p
parsimoni
analysi
appli
anesthesia
signific
effect
commun
membership
jacquard
index
p
commun
structur
yue
clayton
index
p
effect
fast
anesthesia
structur
microbiota
healthi
hors
reduct
clostridial
also
seen
hors
affect
coliti
indic
stress
factor
equin
intestin
microbiota
could
relat
develop
diseas
postop
period
studi
investig
chang
noninvas
oscillometr
blood
pressur
nibp
clinic
set
home
environ
white
coat
hypertens
normal
daili
variat
nibp
splenic
volum
interobserv
variat
splenic
volum
nibp
measur
hors
clinic
home
environ
consecut
day
compar
nibp
spleen
volum
measur
three
consecut
day
splenic
volum
repeat
two
ultrasonograph
time
mare
nibp
correct
heart
level
measur
use
coccyg
arteri
systol
mean
nibp
significantli
p
p
respect
lower
home
mean
ae
sd
ae
ae
systol
mean
nibp
respect
hospit
environ
ae
ae
systol
mean
nibp
respect
repeat
measur
anova
p
show
differ
splenic
volum
nibp
day
correl
chang
splenic
volum
nibp
differ
day
differ
splenic
volum
observ
bia
upperlow
limit
agreement
splenic
volum
observ
liter
power
anova
calcul
lower
hors
white
coat
hypertens
similarli
speci
marker
sympathet
tone
chang
splenic
volum
correl
physiolog
day
day
chang
blood
pressur
lack
interday
interobserv
differ
interpret
caution
due
risk
type
ii
error
correl
blood
pressur
splenic
volum
hematocrit
phenylephrin
acepromazin
administr
daniela
casoni
olivia
lorello
natali
helicz
cristob
nava
de
soli
univers
bern
bern
bern
switzerland
object
determin
correl
invas
blood
pressur
ibp
splenic
volum
hematocrit
stand
hors
administr
drug
caus
hypertens
splenic
contract
increas
hematocrit
phenylephrin
hypotens
splenic
relax
decreas
hematocrit
acepromazin
ibp
ultrasonograph
splenic
volum
hematocrit
measur
mare
phenylephrin
lgkg
min
iv
minut
acepromazin
mgkg
iv
ibp
measur
use
facial
transvers
facial
arteri
differ
time
point
assess
use
pair
test
correl
use
pearson
product
correl
valu
intervent
meanaesd
ae
ml
splenic
volum
ae
mmhg
systol
ae
mmhg
diastol
ae
mmhg
mean
ibp
ae
pcv
phenylephrin
caus
signific
decreas
splenic
volum
ae
ml
signific
increas
systol
ae
mmhg
diastol
ae
mmhg
mean
ae
mmhg
ibp
hematocrit
ae
p
acepromazin
induc
signific
decreas
systol
ae
mmhg
diastol
ae
mmhg
mean
ae
mmhg
ibp
p
nonsignific
increas
splenic
volum
ae
ml
decreas
hematocrit
ae
p
baselin
splenic
volum
correl
mean
ibp
phenylephrin
administr
p
r
addit
trend
correl
baselin
splenic
volum
hematocrit
phenylephrin
p
r
ibp
hematocrit
phenylephrin
p
r
correl
chang
blood
pressur
hematocrit
phenylephrin
administr
partial
explain
chang
splenic
volum
previous
suggest
smaller
chang
nonsignific
correl
found
chang
acepromazin
administr
bodi
condit
score
bc
cresti
neck
score
cn
mean
neck
circumfer
mnc
tailhead
fat
depth
tfd
significantli
correl
proxi
measur
howev
signific
correl
observ
morphometr
data
insulin
sensit
si
signific
differ
observ
ir
hors
respect
morphometr
paramet
signific
correl
observ
si
quicki
risqi
g
homa
basal
insulin
concentr
acut
insulin
respons
glucos
airg
significantli
correl
mirg
morphometr
data
differ
ir
hors
mani
morphometr
measur
correl
proxi
measur
insulin
sensit
cn
display
strongest
correl
consist
report
util
identif
hors
risk
equin
metabol
syndrom
hair
cortisol
hors
ppid
heidi
bans
michel
levi
fitsum
getachew
alycia
chrenek
candic
crosbi
casey
gruber
suzon
schaal
ashley
whitehead
judit
smit
univers
calgari
calgari
ab
canada
moor
equin
rocki
view
counti
ab
canada
td
equin
veterinari
group
calgari
ab
canada
pituitari
par
intermedia
dysfunct
ppid
common
endocrin
disord
age
hors
affect
hors
year
age
diagnost
test
good
sensit
specif
earli
diseas
remain
identifi
cortisol
accumul
hair
reflect
chronic
cortisol
level
ie
entir
period
hair
growth
therefor
hair
may
use
matric
evalu
chronic
hypercortisolemia
hair
cortisol
concentr
shown
higher
peopl
dog
hyperadrenocortic
hypothes
hors
ppid
higher
hair
cortisol
concentr
compar
age
control
hors
studi
six
hors
ppid
six
control
hors
includ
hors
consid
ppid
rest
acth
concentr
fall
pmoll
rang
exhibit
hypertrichosi
delay
shed
hors
consid
healthi
age
hors
acth
concentr
pmoll
rang
evid
hypertrichosi
delay
shed
hair
collect
jugular
furrow
use
clipper
blade
late
august
late
septemb
hair
cortisol
measur
use
enzym
immunoassay
hair
cortisol
concentr
normal
distribut
mannwhitney
u
test
use
compar
hair
cortisol
concentr
age
control
hors
ppidaffect
hors
differ
hair
cortisol
identifi
hors
ppid
age
control
hors
p
howev
hair
ppid
hors
divid
axial
proxim
segment
proxim
segment
hair
hors
ppid
median
iqr
pgml
higher
entir
fragment
hair
age
control
hors
median
iqr
p
find
increas
cortisol
proxim
fragment
hors
ppid
may
reflect
enhanc
season
accumul
hair
cortisol
sepsi
major
caus
morbid
mortal
neonat
foal
rel
adren
insuffici
rai
defin
inadequ
low
cortisol
concentr
sever
diseas
associ
sepsi
newborn
foal
addit
cortisol
adren
gland
synthes
number
biolog
import
steroid
steroid
precursor
neurosteroid
howev
dynam
multipl
adrenocort
hormon
hospit
associ
sever
diseas
mortal
critic
ill
foal
evalu
hypothes
addit
cortisol
foal
rai
alter
concentr
adren
steroid
precursor
also
propos
septic
foal
higher
concentr
adren
steroid
healthi
foal
steroid
concentr
persist
increas
hospit
nonsurviv
septic
foal
foal
day
age
categor
three
group
septic
sick
nonsept
sn
healthi
blood
sampl
collect
admiss
time
hour
time
hour
hour
postadmiss
time
hour
concentr
cortisol
progesteron
pregnenolon
aldosteron
dehydroepiandrosteron
dhea
aohprogesteron
androstenedion
measur
immunoassay
cortisol
progesteron
pregnenolon
aldosteron
dhea
aohprogesteron
higher
septic
compar
healthi
foal
time
p
septic
foal
time
dhea
cortisol
also
significantli
higher
sn
foal
p
cortisol
dhea
elev
aohprogesteron
lower
septic
compar
healthi
foal
hour
p
time
hour
cortisol
concentr
increas
nonsurviv
foal
decreas
surviv
foal
respect
critic
ill
neonat
foal
appropri
respons
sepsi
associ
stress
character
increas
concentr
steroid
steroid
precursor
neurosteroid
admiss
decreas
steroid
concentr
group
attribut
adren
dysfunct
septic
foal
well
physiolog
postnat
steroidogenesi
healthi
foal
persist
increas
cortisol
concentr
associ
nonsurviv
septic
foal
insulin
statu
assess
hors
perform
oral
sugar
test
ost
incretin
hormon
adipokin
also
measur
investig
mechan
hyperinsulinemia
howev
repeat
measur
determin
therefor
hypothes
glucos
insulin
activ
total
glucagonlik
peptid
high
molecular
weight
hmw
adiponectin
result
oral
sugar
teat
would
repeat
defin
withinhors
coeffici
variat
cv
twentythre
hors
suspect
em
tennesse
research
facil
evalu
along
hors
suspect
em
control
privat
practic
missouri
two
oral
sugar
test
perform
day
apart
fast
condit
plasma
glucos
insulin
concentr
measur
minut
incretin
hormon
hmw
adiponectin
measur
withinhors
cv
valu
measur
agreement
calcul
median
rang
withinhors
cv
valu
glucos
insulin
concentr
respect
activ
r
p
r
p
concentr
minut
rest
hmw
adiponectin
concentr
r
p
posit
correl
day
agreement
test
interpret
insulin
result
tennesse
missouri
group
respect
hypothesi
support
conclud
ost
result
accept
repeat
incretin
hormon
concentr
strongli
correl
test
day
rest
hmw
adiponectin
concentr
cortisol
bind
globulin
cbg
bind
circul
cortisol
plasma
regul
amount
free
cortisol
avail
circul
influenc
metabol
clearanc
rate
free
cortisol
form
abl
enter
cell
bind
cytosol
cortisol
receptor
thu
long
presum
biolog
activ
form
cortisol
howev
recent
research
rodent
human
suggest
cbgbound
cortisol
may
interact
cellsurfac
receptor
neutrophil
mediat
cortisol
antiinflammatori
effect
previou
research
shown
neonat
foal
dramat
increas
serum
free
cortisol
level
compar
adult
hors
mani
septic
neonat
foal
still
exhibit
exagger
proinflammatori
respons
consist
criticalil
relat
cortisol
insuffici
circi
dispar
increas
circul
free
cortisol
clinic
evid
cortisol
insuffici
septic
neonat
foal
could
explain
limit
cbg
avail
foal
cbgbound
cortisol
import
regul
cortisol
antiinflammatori
effect
foal
speci
howev
current
understand
cortisol
bind
dynam
neonat
foal
limit
measur
cbg
concentr
septic
foal
report
date
object
studi
compar
cbg
concentr
among
healthi
foal
variou
age
septic
foal
healthi
adult
hors
hypothes
sick
foal
significantli
lower
cbg
concentr
healthi
foal
adult
hors
healthi
foal
significantli
lower
cbg
concentr
adult
hors
lowest
concentr
birth
cbg
concentr
serum
sampl
measur
use
commerci
equin
cbg
elisa
valid
studi
recoveri
intraassay
coeffici
variat
interassay
coeffici
variat
healthi
foal
n
sampl
birth
hour
week
week
week
healthi
hors
n
sampl
septic
foal
group
n
archiv
serum
sampl
collect
sick
foal
day
age
diagnosi
sepsi
base
posit
blood
cultur
andor
sepsi
score
hospit
admiss
use
data
compar
anova
statist
signific
set
p
signific
effect
age
cbg
concentr
healthi
foal
p
healthi
foal
age
significantli
lower
serum
cbg
concentr
adult
hors
p
septic
foal
significantli
lower
serum
cbg
concentr
adult
hors
healthi
agematch
foal
p
result
support
hypothesi
septic
foal
exhibit
cbg
defici
compar
healthi
foal
adult
hors
cbgdefici
result
decreas
circul
cbgbound
cortisol
foal
cbgbound
cortisol
critic
mediat
cortisol
antiinflammatori
effect
foal
speci
cbgdefici
could
contribut
exagger
potenti
detriment
proinflammatori
respons
seen
septic
foal
circi
prospect
clinic
experiment
studi
need
confirm
find
larger
number
septic
foal
investig
effect
cbgbound
cortisol
equin
leukocyt
function
pituitari
par
intermedia
dysfunct
ppid
consid
common
endocrinolog
disord
age
hors
studi
exist
describ
epidemiolog
characterist
hors
ppid
addit
epidemiolog
studi
need
determin
preval
ppid
larger
popul
age
hors
purpos
studi
obtain
epidemiolog
inform
initi
ppid
diagnosi
new
case
larg
popul
hors
includ
age
breed
sex
clinic
sign
insulinglucos
statu
hors
age
breed
sex
continent
us
elig
studi
enrol
long
document
exhibit
one
follow
clinic
sign
gener
region
hypertrichosi
muscl
wast
abnorm
fat
distribut
lethargi
lamin
unknown
etiolog
polyuria
polydipsia
suscept
infect
abnorm
sweat
andor
inappropri
lactat
normal
hors
exclud
studi
initi
visit
demograph
data
signal
physic
examin
conduct
clinic
sign
document
blood
drawn
basal
acth
fast
insulin
glucos
blood
sampl
process
ship
overnight
anim
health
diagnost
center
cornel
univers
ithaca
ny
analysi
nonppid
hors
ppid
character
acth
level
pgml
novemberjuli
acth
pgml
augustoctob
ppid
hors
character
acth
level
pgml
novemb
juli
acth
pgml
augustoctob
hyperinsulinemia
character
fast
insulin
uluml
glucos
consid
elev
mgml
order
evalu
combin
effect
variabl
ppid
statu
multipl
logist
regress
mlr
analysi
appli
ppid
statu
use
backward
elimin
variabl
level
signific
odd
ratio
signific
predictor
ppid
statu
mlr
analys
comput
along
correspond
confid
interv
preval
ppid
significantli
p
greater
among
hors
found
clinic
sign
present
abnorm
sweat
decreas
athlet
behavior
delay
shed
loss
muscl
mass
weight
loss
although
statist
signific
p
ppid
preval
greater
three
remain
clinic
sign
present
excess
thirst
excess
urin
lamin
actual
less
four
remain
sign
absent
cresti
neck
fat
pad
pot
belli
weight
gain
recurr
infect
base
data
clinic
sign
delay
shed
weight
loss
found
significantli
associ
ppid
statu
p
specif
odd
ppid
among
hors
show
delay
shed
four
time
hors
show
delay
shed
odd
ppid
among
hors
show
weight
loss
approxim
twice
among
hors
show
weight
loss
base
combin
data
demograph
variabl
insulin
level
eleven
interpret
clinic
sign
age
insulin
statu
still
seen
significantli
associ
ppid
statu
one
clinic
sign
delay
shed
found
signific
predictor
ppid
account
age
insulin
statu
odd
ratio
ppid
hors
show
delay
shed
decreas
slightli
account
age
insulin
statu
hors
base
data
popul
hors
delay
hair
coat
shed
weight
loss
signific
predictor
ppid
statu
preval
ppid
also
significantli
greater
certain
cluster
clinic
sign
present
long
term
studi
need
conduct
evalu
occurr
progress
clinic
sign
hors
ppid
endocrin
diseas
purpos
studi
provid
object
evalu
wellb
popul
work
hors
studi
investig
wellb
paramet
popul
work
new
york
citi
carriag
hors
sampl
collect
cours
day
period
august
paramet
measur
includ
fecal
cortisol
salivari
cortisol
infrar
thermographi
irt
medial
canthu
paramet
use
studi
util
previou
investig
quantifi
stress
level
hors
varieti
set
collect
day
involv
hors
respect
collect
day
includ
four
collect
time
point
time
point
subject
rest
stall
prior
work
arriv
employe
est
occur
har
subject
hitch
carriag
prepar
work
occur
immedi
place
stall
conclus
work
day
occur
hour
hors
return
stall
fecal
cortisol
sampl
collect
use
evalu
chronic
glucocorticoid
level
salivari
cortisol
irt
collect
four
time
point
reflect
acut
state
wellb
preliminari
evalu
salivari
cortisol
show
differ
among
time
point
v
p
ae
ngml
greater
p
ae
ngml
howev
time
point
comparison
differ
p
irt
student
ttest
indic
measur
left
right
eye
differ
within
time
assess
u
p
therefor
measur
left
right
eye
averag
comparison
eye
chang
among
sampl
time
point
one
way
repeat
measur
analysi
varianc
reveal
differ
f
p
among
time
point
eye
measur
similar
trend
evid
cortisol
irt
data
set
salivari
cortisol
variat
among
reflect
increas
metabol
activ
driven
exercis
rather
stress
stress
drive
factor
behind
salivari
cortisol
increas
would
result
similar
increas
irt
observ
evid
collect
thu
far
indic
signific
perturb
state
wellb
popul
work
hors
colic
common
hors
accur
time
interpret
clinic
laboratori
data
admiss
import
determin
need
surgeri
probabl
surviv
mani
studi
evalu
clinic
laboratori
find
indic
surgeri
surviv
studi
comprehens
publish
reev
et
al
model
base
retrospect
evalu
medic
record
hors
present
referr
institut
model
valid
use
subpopul
hors
taken
medic
record
never
valid
prospect
popul
hors
acut
colic
purpos
studi
prospect
valid
surgic
prognosi
colic
predict
model
hypothes
previous
develop
surgic
prognosi
colic
model
accur
predict
probabl
surgeri
surviv
hors
present
louisiana
state
univers
veterinari
teach
hospit
lsuvth
acut
colic
hors
present
lsuvth
acut
colic
studi
clinic
paramet
includ
age
sex
breed
rectal
exam
normal
abnorm
frequenc
abdomin
pain
none
intermitt
continu
peripher
puls
charact
normal
abnorm
frequenc
abdomin
sound
normal
decreas
absent
increas
use
valid
surgic
model
wherea
peripher
puls
charact
pack
cell
volum
heart
rate
capillari
refil
time
medic
vs
surgic
treatment
use
valid
surviv
prognosi
model
hors
euthanat
due
financi
constraint
exclud
surviv
model
surviv
defin
discharg
vth
bay
theorem
util
calcul
posttest
probabl
surgeri
surviv
hosmerlemeshow
good
fit
chi
squar
gofc
formula
use
assess
model
fit
data
chi
squar
valu
use
degre
freedom
consid
signific
yield
p
seventyon
hors
present
acut
colic
includ
studi
thirtyf
hors
admit
june
august
hors
evalu
acut
colic
surgeri
treat
medic
also
hors
human
euthanat
die
surgeri
addit
hors
euthanat
surgeri
due
financi
reason
therefor
hors
surviv
discharg
paramet
use
model
accur
estim
surgeri
p
howev
model
accur
estim
probabl
surviv
p
one
hors
admit
studi
die
paramet
includ
abnorm
rectal
examin
continu
intermitt
abdomin
pain
decreas
absent
abdomin
sound
weak
peripher
puls
charact
success
identifi
hors
need
surgeri
popul
hors
wherea
paramet
use
surviv
fail
predict
surviv
clinic
paramet
import
predict
hors
need
surgic
treatment
acut
colic
wherea
cardiovascular
paramet
may
accur
predict
surviv
hors
acut
colic
could
proven
studi
present
one
hors
die
treatment
equin
gastric
glandular
ulcer
syndrom
eggu
highli
preval
condit
underli
pathophysiolog
larg
unresolv
endoscop
mucos
biopsi
propos
method
adapt
therapi
individu
hors
aim
studi
evalu
diagnost
inform
obtain
endoscop
mucos
biopsi
hors
twentyon
clinic
normal
hors
undergo
elect
human
slaughter
subject
gross
examin
glandular
mucosa
postmortem
glandular
patholog
grade
use
equin
gastric
ulcer
council
guidelin
imag
obtain
use
digit
camera
mucos
biopsi
obtain
use
singlebit
techniqu
use
fenestr
endoscop
biopsi
forcep
mm
group
mm
group
b
doubl
bite
techniqu
use
mm
instrument
full
thick
biopsi
also
obtain
adjac
tissu
biopsi
site
includ
lesion
identifi
use
nake
eye
tissu
formal
fix
process
stain
use
standard
protocol
histolog
appear
lesion
determin
sampl
type
sampl
qualiti
artefact
record
appear
inflammatori
infiltr
grade
mild
moder
sever
degre
inflamm
compar
ulcer
grade
subset
anim
shown
moder
sever
gastriti
full
thick
sampl
n
inflammatori
cell
count
per
high
power
field
hpf
compar
full
thick
biopsi
sampl
obtain
use
endoscop
instrument
agreement
cell
count
full
thick
sampl
mucos
biopsi
subsequ
compar
calcul
intraclass
correl
coeffici
icc
eggu
present
hors
tabl
sampl
three
anim
exclud
analysi
due
process
sampl
error
full
thick
sampl
free
artefact
allow
visualis
mucosa
submucosa
gland
villi
mucos
biopsi
sampl
contain
mucosa
sampl
submucosa
group
c
group
group
b
sampl
gland
group
b
group
group
c
group
sampl
often
small
histolog
assess
tissu
damag
commonli
seen
group
b
n
n
compar
group
c
n
hors
normal
glandular
appear
eggu
grade
n
often
demonstr
mild
gastriti
n
one
normal
anim
inflamm
one
moder
gastriti
sever
gastriti
identifi
anim
mild
eggu
grade
mild
moder
gastriti
identifi
eggu
grade
histolog
evid
ulcer
eros
poor
agreement
cell
number
sampl
techniqu
icc
tabl
occurr
eggu
hors
presenc
histolog
appear
gastriti
anim
three
hors
exclud
histolog
analysi
due
process
sampl
error
eggu
common
group
hors
consist
previou
studi
data
show
lack
ulcer
patholog
hors
eggu
identifi
actual
repres
inflamm
nomenclatur
review
reflect
underli
patholog
lesion
appear
poor
indic
underli
sever
lack
gross
lesion
view
lack
gastric
patholog
gastric
mucos
biopsi
offer
limit
valu
predict
underli
diseas
hors
eggu
howev
doubl
bite
techniqu
largest
possibl
biopsi
instrument
provid
highest
qualiti
sampl
histolog
review
michael
katz
david
lewi
univers
massachusett
amherst
usa
osmoregul
intestin
one
control
mechan
gastric
empti
studi
attempt
examin
effect
water
content
ingest
food
intestin
glucos
absorpt
six
miniatur
hors
averag
bodi
weight
kilo
fed
pound
timothi
hay
pellet
fast
differ
day
fed
amount
hay
pellet
mix
pint
water
rate
consumpt
pellet
whether
pellet
fed
dri
moist
frequent
sampl
taken
whole
blood
glucos
measur
hour
feed
everi
fifteen
minut
hour
pellet
composit
moistur
water
solubl
carbohydr
ethanol
solubl
carbohydr
starch
data
analyz
use
student
ttest
fed
dri
moist
pellet
increas
blood
glucos
within
fifteen
minut
onset
feed
significantli
larger
increas
blood
glucos
fed
moisten
pellet
fed
dri
pellet
glucos
concentrationtim
curv
auc
significantli
larger
fed
moisten
pellet
water
food
seem
encourag
rapid
present
glucos
intestin
stomach
may
indic
increas
rate
gastric
empti
gastric
ulcer
preval
evalu
mani
equin
perform
disciplin
polo
hors
uniqu
equin
popul
often
hous
exercis
group
therefor
ulcer
occurr
risk
factor
may
differ
perform
disciplin
compar
previous
studi
popul
purpos
studi
determin
preval
gastric
ulcer
polo
hors
identifi
potenti
risk
factor
squamou
glandular
ulcer
sixtythre
polo
hors
nine
barn
includ
studi
gastroscopi
perform
june
august
groom
fill
survey
manag
practic
includ
feed
hous
train
competit
level
medic
administ
hors
underw
gastroscopi
follow
hour
fast
sixtynin
percent
hors
glandular
ulcer
hors
squamou
lesion
ulcer
dichotom
grade
grade
statist
analysi
thirti
one
percent
hors
grade
glandular
ulcer
hors
grade
squamou
ulcer
preliminari
analysi
perform
use
chi
squar
test
identifi
possibl
risk
factor
gastric
ulcer
ulcer
dichotom
grade
grade
analysi
associ
presenc
grade
squamou
glandular
ulcer
p
hors
perform
goal
level
lower
preval
glandular
p
squamou
p
ulcer
perform
goal
paddock
turnout
also
associ
decreas
risk
squamou
ulcer
p
studi
hous
factor
perform
level
associ
presenc
gastric
ulcer
increas
preval
squamou
glandular
ulcer
low
goal
polo
hors
suggest
gastric
ulcer
may
associ
reduc
perform
equin
squamou
gastric
diseas
esgd
report
perform
hors
variou
studi
preval
equin
glandular
gastric
diseas
eggd
report
number
differ
hors
type
date
littl
inform
publish
preval
either
feral
hors
purpos
studi
compar
preval
esgd
eggd
feral
domest
hors
present
abattoir
slaughter
hors
includ
studi
randomli
select
two
separ
visit
certifi
abattoir
unit
kingdom
uk
month
june
august
hors
classifi
feral
basi
free
rang
littl
human
interact
class
domest
basi
care
human
design
purpos
assess
abattoir
employe
feral
popul
origin
dartmoor
exmoor
region
uk
histori
hors
age
sex
breed
disciplin
hors
avail
classifi
feral
domest
hors
slaughter
accord
appropri
uk
legisl
follow
slaughter
gastrointestin
tract
remov
stomach
separ
abattoir
employe
stomach
dissect
along
dorsal
plane
lower
oesophag
sphincter
pylor
sphincter
rins
water
photograph
captur
stomach
number
futur
analysi
grade
gastric
lesion
perform
singl
investig
blind
group
alloc
hors
lesion
grade
use
four
point
egu
council
system
squamou
glandular
region
stomach
grade
separ
hors
dichotom
classifi
esgd
eggd
posit
neg
assign
grade
squamou
glandular
mucosa
iiiv
iiv
respect
chisquar
test
use
compar
preval
esgd
eggd
feral
domest
hors
signific
set
p
total
domest
hors
feral
hors
randomli
select
data
two
feral
nine
domest
hors
exclud
due
inconclus
photograph
document
fiftyon
domest
feral
hors
includ
final
analysi
lesion
distribut
esgd
eggd
shown
tabl
dichotom
classifi
esgd
present
feral
domest
hors
respect
p
similarli
eggd
present
feral
domest
hors
respect
p
result
studi
suggest
preval
esgd
eggd
higher
domest
hors
feral
hors
well
recogn
risk
esgd
increas
increas
intens
manag
report
author
knowledg
first
report
document
similar
effect
may
present
eggd
purpos
report
describ
method
intragastr
ph
measur
use
ph
probe
connect
continu
data
logger
fit
retrograd
manner
endoscop
place
indwel
percutan
gastrotomi
tube
peg
hors
two
healthi
adult
thoroughbr
hors
use
hors
fast
hour
sedat
detomidin
lgkg
iv
gastroscopi
perform
per
standard
protocol
stomach
fulli
insuffl
air
stomach
identifi
percutan
ultrasound
intercost
space
g
cathet
angiocath
becton
dickinson
utah
usa
insert
skin
stomach
could
observ
endoscop
length
high
tensil
fish
line
pass
cathet
outsid
stomach
biopsi
forcep
use
grasp
fish
line
draw
endoscop
withdrawn
draw
fish
line
nostril
mm
button
attach
fish
line
gentl
traction
place
fish
line
draw
button
back
nostril
esophagu
stomach
endoscop
reinsert
confirm
posit
button
stomach
wall
second
button
place
approxim
cm
away
first
button
use
techniqu
end
two
line
tie
togeth
creat
gastropexi
similar
abomas
toggl
techniqu
describ
cattl
peg
tube
place
endoscop
use
similar
techniqu
previous
describ
hors
receiv
antimicrobi
antiinflammatori
day
periop
three
week
follow
peg
tube
placement
posit
confirm
endoscop
hors
tube
locat
within
ventral
glandular
fundu
approxim
cm
margo
plicatu
adjac
lesser
curvatur
point
ph
probe
comfortec
plu
sandhil
scientif
co
usa
fit
retrograd
peg
tube
locat
confirm
endoscop
probe
insert
distanc
note
futur
placement
hors
adapt
one
two
diet
hay
diet
hay
high
grainlow
fiber
hglf
diet
hglf
diet
consist
bw
grain
hay
per
day
divid
equal
two
meal
hors
monitor
diet
period
consecut
day
achiev
ph
probe
attach
continu
data
logger
zephyr
ph
sandhil
scientif
co
usa
probe
calibr
prior
placement
day
insert
previous
determin
distanc
secur
data
record
commenc
continu
hour
day
probe
contain
two
measur
point
cm
apart
locat
probe
approxim
cm
glandular
mucosa
second
probe
sat
cm
deeper
presum
within
ingesta
data
median
iqr
hors
shown
report
describ
success
instrument
hors
perman
peg
tube
use
measur
intragastr
ph
use
techniqu
allow
measur
multipl
point
within
stomach
techniqu
allow
monitor
intragastr
ph
without
disturb
hors
normal
eat
behavior
major
limit
mani
model
procedur
perform
stand
sedat
hors
minim
special
equip
report
describ
sever
myelosuppress
four
american
quarter
hors
associ
ingest
mycotoxincontamin
hay
index
case
year
old
mare
present
lethargi
acut
perin
edema
hematochezia
fever
patchi
alopecia
petechi
hors
recent
fed
new
batch
hay
later
reveal
improperli
cure
initi
caus
feed
avers
bloodwork
mare
show
sever
neutropenia
thrombocytopenia
prolong
prothrombin
time
profound
myeloid
megakaryocyt
hypoplasia
found
evalu
bone
marrow
mare
develop
septic
periton
treat
aggress
day
antiinflammatori
antibiot
blood
transfus
prior
acut
decompens
necessit
euthanasia
remain
hors
two
develop
similar
hematolog
find
three
alopecia
second
case
year
old
geld
refer
treatment
milder
sign
petechi
patchi
alopecia
note
similar
bone
marrow
find
mare
hors
recov
treatment
antiinflammatori
antibiot
two
remain
hors
old
mare
manag
conserv
recov
toxicolog
test
hay
reveal
high
level
mycotoxin
includ
toxin
vomitoxin
known
myelotoxic
ppb
ppm
respect
myelosuppress
case
consist
trichothecen
intox
poorli
document
hors
forag
sourc
clinic
cours
case
suggest
spontan
recoveri
possibl
follow
sever
myelosuppres
due
tricothecen
intox
hors
placent
import
caus
pregnanc
loss
neonat
death
mare
fetal
hypoxia
placent
abnorm
associ
hyperlactatemia
foal
howev
data
field
case
scant
object
studi
measur
lactat
plasma
foal
born
mare
suffer
placent
mare
carri
deliv
normal
pregnanc
total
thoroughbr
newborn
foal
includ
studi
immedi
placent
passag
fragment
chorioallantoi
amnion
collect
preserv
formalin
histopatholog
evalu
immedi
postdeliveri
hour
birth
foal
underw
clinic
examin
blood
sampl
plasma
lactat
determin
spectrophotometri
use
commerci
colorimetr
kit
base
placent
histopatholog
clinic
evalu
foal
alloc
four
group
follow
group
healthi
control
n
placent
lesion
appar
health
foal
group
ii
placent
appar
healthi
n
group
iii
placent
abnorm
upon
clinic
examin
group
iv
immatur
foal
placenta
histopatholog
lesion
compat
placent
n
normal
data
assess
shapirowilk
test
oneway
anova
use
evalu
lactat
concentr
differ
group
signific
set
p
concentr
lactat
significantli
increas
group
iii
iv
hour
birth
howev
foal
group
ii
concentr
present
reduct
lactat
birth
hour
postdeliveri
find
demonstr
lactat
use
identifi
sick
foal
screen
appar
normal
foal
born
mare
placent
import
emphas
group
ii
present
lactat
concentr
within
normal
rang
demonstr
full
capac
neonat
adapt
group
ii
despit
placent
patholog
borrelia
burgdorferi
caus
lyme
diseas
via
ixod
scapulari
pacificu
tick
vector
safe
effect
vaccin
essenti
prevent
equin
lyme
borreliosi
usda
canin
approv
outer
surfac
protein
ospa
vaccin
may
promis
regard
use
mani
equin
practition
purpos
studi
identifi
humor
immunogen
vaccin
horsess
fortythre
healthi
hors
identifi
studi
hors
select
improb
contact
borrelia
burgdorferi
due
life
long
desert
habitat
serolog
test
ospacf
complet
prior
vaccin
grouptd
hors
mix
breed
five
femal
geld
administ
ml
mlsite
vaccin
transderm
pector
region
groupsq
hors
mix
breed
four
femal
geld
administ
ml
right
cervic
region
groupc
hors
mix
breed
femal
geld
untreat
vaccin
administ
day
antibodi
ospa
c
f
quantifi
day
use
diagnost
laboratori
multiplex
assay
day
hors
respond
median
fluoresc
intens
mfi
ae
meanaes
grouptd
ae
fold
increas
baselin
groupsq
respond
ae
mfi
translat
ae
fold
increas
baselin
grouptd
respond
day
postvaccin
day
ae
mfi
translat
ae
fold
increas
baselin
groupsq
respond
day
ae
mfi
translat
ae
fold
increas
baselin
evid
differ
ospa
age
sex
breed
rout
lack
differ
rout
would
suggest
lesser
dose
via
transderm
rout
pector
region
elicit
equival
ospa
respons
ml
dose
administ
subcutan
minor
reaction
mm
swell
occur
vaccin
site
grouptd
groupsq
respect
reaction
occur
commonli
hors
time
td
sq
group
respect
data
may
aid
develop
effect
vaccin
strateg
vaccin
protocol
lyme
diseas
hors
pneumonia
common
caus
morbid
mortal
foal
month
age
contrast
pulmonari
immunocompeteni
adult
hors
appear
robust
given
resist
diseas
caus
clinic
manifest
foal
specul
would
quantit
qualit
differ
cell
popul
recov
bronchoalveolar
lavag
fluid
balf
could
provid
insight
progress
agerel
gain
immunocompet
serial
balf
collect
cohort
healthi
foal
week
month
age
balf
foal
compar
balf
collect
healthi
adult
hors
cellular
morpholog
evalu
cell
differenti
perform
cytocentrifug
balf
sampl
foal
significantli
higher
percentag
macrophag
adult
hors
week
month
month
month
age
differ
longer
note
month
age
foal
significantli
lower
percentag
lymphocyt
balf
adult
hors
week
month
furthermor
foal
significantli
higher
percentag
macrophag
compar
adult
character
progress
increas
percentag
macrophag
concurr
increas
age
better
defin
potenti
qualit
differ
pulmonaryalveolar
macrophag
pam
adult
hors
foal
longitudin
analysi
reactiv
intermedi
activ
adult
foal
pam
perform
sampl
subset
foal
n
age
week
month
vitro
measur
superoxid
peroxynitrit
obtain
use
oxid
dihydroethidium
dhe
dihydrorhodamin
dhr
indic
respect
pam
gate
sort
live
cell
express
seed
triplic
plate
allow
adher
hour
pam
stimul
lp
lgml
ifnc
ngml
opson
zymosan
mgml
r
equi
antigen
lgml
incub
hour
dhe
dhr
ad
minut
prior
fluorimetri
bmg
labtech
fluostar
omega
stimul
document
agerel
progress
increas
product
superoxid
peroxynitrit
foal
exhibit
lower
level
reactiv
intermedi
week
compar
month
p
taken
togeth
result
reveal
decreas
shift
percentag
pam
balf
foal
age
along
concurr
agerel
increas
reactiv
intermedi
product
pam
result
support
notion
pulmonari
cell
popul
chang
foal
age
larg
percentag
macrophag
decreas
capac
reactiv
intermedi
product
earli
life
collect
find
consist
agerel
suscept
foal
pneumonia
caus
macrophagetrop
bacterium
r
equi
corynebacterium
pseudotuberculosi
biovar
equi
infect
hors
also
call
pigeon
fever
report
alabama
previou
studi
surprisingli
identifi
posit
synergist
hemolysi
inhibit
shi
titer
number
healthi
hors
purpos
studi
investig
seropreval
c
pseudotuberculosi
nonendem
popul
determin
associ
detect
titer
exposur
small
rumin
without
histori
caseou
lymphaden
previou
travel
endem
state
serum
shi
c
pseudotuberculosi
titer
hors
alabama
counti
analyz
questionnair
complet
owner
time
blood
collect
hors
titer
neg
howev
posit
titer
found
appear
correl
exposur
small
rumin
high
antibodi
titer
hors
titer
histori
travel
outsid
alabama
caus
high
proport
lowlevel
posit
shi
c
pseudotuberculosi
titer
healthi
naiv
hors
appar
high
preval
posit
titer
naiv
popul
question
accuraci
shi
antibodi
titer
test
possibl
fals
posit
caus
crossreact
antibodi
phospholipas
soil
corynebacterium
spp
c
pseudotuberculosi
biovar
ovi
warrant
investig
equin
herp
viru
type
myeloencephalopathi
ehm
neurolog
diseas
hors
occur
complic
infect
neurolog
sign
result
endotheli
cell
damag
caus
vascul
ischem
insult
central
nervou
system
diseas
caus
consider
anim
suffer
econom
loss
hors
industri
genet
variat
viru
explain
diseas
occurr
total
hors
affect
unaffect
experiment
natur
infect
includ
genom
wide
associ
studi
gwa
identifi
host
genet
variat
associ
ehm
genotyp
perform
use
illumina
array
custom
sequenom
array
mix
linear
model
mlm
analysi
use
domin
model
identifi
one
marker
surpass
threshold
genomewid
signific
p
bonferroni
correct
marker
intron
gene
express
endothelium
platelet
four
top
marker
p
immun
gene
cluster
includ
interferon
gamma
receptor
separ
bayesian
analysi
marker
set
identifi
four
window
account
genet
varianc
harbor
signific
quantit
trait
loci
gwa
identifi
sever
region
hors
genom
associ
ehm
studi
popul
explor
understand
host
variat
contribut
ehm
enhanc
knowledg
diseas
pathophysiolog
improv
treatment
individu
case
manag
outbreak
matern
antibodi
report
exert
signific
inhibitori
effect
matern
antibodi
interfer
immun
respons
foal
variou
antigen
contain
commerci
vaccin
base
previou
inform
recommend
primari
immun
foal
born
vaccin
mare
begin
prior
month
age
follow
declin
maternallyderiv
antibodi
object
studi
evalu
wnv
antibodi
respons
foal
without
wnv
matern
antibodi
follow
vaccin
vetera
vewtwnv
proprietari
adjuv
carbimmun
fiftyon
sixteenweek
old
quarter
hors
foal
born
mare
receiv
booster
dose
multicompon
vaccin
last
month
gestat
random
five
group
base
prevaccin
wnv
igg
level
determin
wnvigg
elisa
wnv
assay
describ
previous
detail
wnvspecif
igm
detect
use
antiequin
igm
mab
mab
use
instead
antiigm
captur
equin
serum
elisa
result
express
pn
ratio
nonvaccin
foal
control
group
includ
confirm
field
exposur
wnv
occur
four
vaccin
group
design
group
prevaccin
respons
group
b
prevaccin
respons
group
c
pre
vaccin
respons
group
prevaccin
respons
foal
vaccin
blood
drawn
week
pre
vaccin
week
repeat
measur
analysi
varianc
use
analyz
data
covari
matrix
unequ
varianc
unequ
correl
draw
week
statist
signific
determin
p
control
group
wnv
igg
antibodi
level
time
point
throughout
studi
vaccin
foal
group
without
matern
antibodi
mean
wnv
igg
week
prevaccin
significantli
p
differ
wnv
igg
level
week
foal
group
significantli
differ
foal
group
b
c
prevaccin
elisa
wnv
igg
signific
p
increas
wnv
igg
antibodi
follow
first
vaccin
antibodi
level
continu
increas
time
point
throughout
studi
wnv
igg
antibodi
increas
foal
matern
group
prevaccin
elisa
wnv
igg
second
vaccin
find
suggest
begin
initi
seri
vaccin
foal
month
age
viabl
option
although
foal
higher
level
wnv
matern
antibodi
may
requir
dose
respons
observ
find
also
suggest
wait
vaccin
wnv
matern
antibodi
disappear
may
requir
current
mgkg
hour
gentamicin
mgkg
hour
amikacin
respect
commonli
use
treat
infect
hors
foal
dose
mgkg
gentamicin
mgkg
amikacin
suggest
reach
adequ
peak
concentr
minimum
inhibitori
concentr
mic
although
dose
critic
evalu
clinic
studi
object
studi
measur
peak
trough
plasma
concentr
hors
treat
mgkg
gentamicin
hour
iv
foal
treat
mgkg
amikacin
hour
iv
compar
peak
concentr
mic
local
gramneg
bacteria
hors
treat
gentamicin
eight
foal
treat
amikacin
includ
peak
trough
plasma
concentr
measur
minut
hour
administr
mic
gramneg
bacteria
isol
hospit
determin
compar
plasma
concentr
backward
stepwis
logist
regress
use
identifi
factor
associ
inadequ
aminoglycosid
peak
concentr
hors
reach
gentamicin
peak
lgml
hors
trough
lgml
foal
reach
amikacin
peak
lgml
trough
concentr
lgml
age
p
treatment
failur
p
significantli
associ
inadequ
gentamicin
peak
concentr
wherea
presenc
endotoxemia
p
prophylact
vs
therapeut
use
p
gram
neg
bacteria
resist
gentamicin
mic
lgml
bacteria
mic
lgml
amikacin
dose
mgkg
gentamicin
iv
mgkg
amikacin
iv
suffici
case
reach
mic
major
suscept
gram
neg
bacteria
hospit
use
daili
dose
trough
concentr
fell
renal
protect
threshold
anim
hour
next
dose
administ
abil
skin
synthesis
vitamin
influenc
factor
includ
melanin
pigment
season
latitudealtitud
type
cloth
sunlight
exposur
equin
vitamin
metabol
factor
influenc
vitamin
synthesi
remain
poorli
understood
major
hors
new
zealand
spend
larg
proport
time
outsid
paddock
often
blanket
may
alter
abil
synthesis
vitamin
studi
aim
determin
blanket
hors
lower
serum
vitamin
concentr
unblanket
hors
twenti
one
matur
hors
pastur
includ
five
cover
standard
hors
blanket
includ
neck
rug
fed
ad
libitum
grass
pastur
supplementari
hay
requir
blood
pastur
sampl
along
climat
data
collect
monthli
month
analys
oh
statist
analysi
consist
gener
addit
mix
model
main
form
detect
serum
concentr
zero
statist
signific
differ
serum
oh
concentr
group
p
vitamin
concentr
pastur
high
iubw
exceed
minimum
daili
recommend
intak
requir
serum
pastur
vitamin
concentr
directli
correl
averag
monthli
sunshin
result
suggest
blanket
affect
abil
matur
hors
pastur
synthesis
vitamin
skin
diet
import
factor
influenc
serum
vitamin
concentr
hors
equin
patient
refer
veterinari
healthcar
team
extend
primari
care
veterinarian
clinic
includ
specialist
staff
referr
center
increas
complex
commun
among
individu
integr
work
team
object
studi
explor
refer
veterinarian
expect
equin
veterinari
specialist
equin
referr
center
six
focu
group
equin
refer
veterinarian
n
conduct
convers
analyz
use
themat
analysi
recogn
form
qualit
research
overarch
theme
particip
discuss
specialist
referr
center
act
extens
care
refer
veterinarian
provid
client
patient
relationship
particip
client
signific
driver
expect
specialist
referr
care
particip
spoke
want
remain
involv
hors
care
hors
specialist
care
particip
spoke
desir
mutual
respect
collegi
profession
trust
relationship
specialist
commun
play
central
role
mani
posit
experi
particip
share
perceiv
essenti
compon
referr
process
displeasur
frustrat
voic
referr
center
compet
refer
veterinarian
practic
solicit
client
strengthen
relationship
refer
veterinarian
specialist
potenti
improv
referr
process
well
patient
client
outcom
function
epc
vascular
tubul
format
shown
alter
peopl
metabol
syndrom
indic
epc
may
integr
endotheli
dysfunct
microvascular
diseas
patient
group
recent
isol
character
epc
use
whole
blood
adher
method
ml
jugular
venou
sampl
hors
hors
produc
coloni
purpos
studi
optim
isol
epc
hors
futur
diagnost
therapeut
use
could
explor
thirti
ml
heparin
blood
sampl
collect
cephal
jugular
vein
healthi
adult
hors
epc
isol
use
densiti
gradient
centrifug
dgc
whole
blood
wb
adher
method
isol
coloni
character
use
vascular
tubul
format
uptak
acetyl
low
densiti
lipoprotein
ldl
indirect
immunofluoresc
epc
isol
hors
collect
cephal
vein
yield
epc
hors
versu
hors
jugular
vein
differ
dgc
wb
method
isol
epc
form
vascular
tubul
show
uptak
ldl
express
endotheli
marker
vessel
diamet
may
influenc
sampl
popul
circul
cell
collect
blood
site
noninvas
dramat
increas
yield
epc
consist
yield
epc
peripher
blood
allow
futur
studi
evalu
diagnost
therapeut
use
hors
previou
work
author
show
erythromycinassoci
hyperthermia
caus
impair
sweat
whether
macrolid
clarithromycin
azithromycin
also
induc
anhidrosi
unknown
studi
evalu
sweat
respons
foal
treat
azithromycin
clarithromycin
erythromycin
serial
experi
foal
four
femal
eight
male
age
month
treat
oral
day
erythromycin
mgkg
time
daili
azithromycin
mgkg
daili
clarithromycin
mgkg
twice
daili
accord
mask
duplic
counterbalanc
design
quantit
intraderm
terbutalin
sweat
test
perform
success
day
treatment
baselin
day
treatment
began
signific
p
suppress
sweat
foal
given
macrolid
compar
terbutalineinduc
sweat
baselin
valu
significantli
lower
evalu
day
foal
given
erythromycin
day
begin
treatment
given
clarithromycin
day
given
azithromycin
overal
suppress
sweat
erythromycin
dose
use
studi
significantli
greater
induc
either
clarithromycin
azithromycin
howev
differ
effect
clarithromycin
azithromycin
result
show
macrolid
commonli
use
treat
prevent
rhodococcu
equi
pneumonia
foal
suppress
sweat
respons
vari
degre
foal
treat
antibiot
consid
risk
hyperthermia
lower
airway
inflammatori
diseas
inflammatori
airway
diseas
heav
common
condit
variabl
sever
hors
alter
bronchoalveolar
lavag
fluid
balf
cytolog
characterist
find
affect
hors
degre
lower
airway
inflamm
correl
sever
lung
function
impair
furthermor
current
littl
known
inflammatori
remodel
process
affect
central
airway
hors
develop
semiquantit
score
system
assess
endobronchi
biopsi
morpholog
hypothes
would
allow
differenti
hors
heav
control
independ
clinic
statu
exacerb
remiss
six
healthi
hors
hors
heav
remiss
hr
exacerb
studi
hors
underw
respiratori
mechan
measur
use
impuls
oscillometri
system
io
six
endobronchi
biopsi
obtain
hors
process
histolog
select
morpholog
inflammatori
paramet
blindli
assess
three
oper
score
significantli
higher
hr
control
p
paramet
differenti
hr
primarili
relat
inflamm
presenceextens
submucos
mucou
gland
score
hr
significantli
correl
expiratori
reactanc
valu
hz
p
p
respect
semiquantit
score
system
reliabl
assess
bronchial
tissu
remodel
inflamm
hors
heav
develop
optim
requir
differenti
hr
possibl
hors
inflammatori
airway
diseas
control
heav
sever
debilit
inflammatori
airway
diseas
hors
associ
perman
structur
chang
bronchial
wall
whether
chronic
inflamm
present
heav
promot
format
new
vessel
phenomenon
known
angiogenesi
unknown
narrow
band
imag
nbi
endoscopi
noninvas
techniqu
enhanc
visual
submucos
vessel
detect
angiogenesi
employ
filter
produc
light
specif
blue
green
wavelength
correspond
peak
light
absorpt
hemoglobin
use
nbi
hypothes
central
airway
hors
heav
sustain
angiogenesi
hors
heav
exacerb
diseas
n
control
anim
n
studi
librari
nbi
imag
establish
record
endoscopi
four
site
studi
larynx
imag
trachea
imag
carina
imag
bronchi
imag
use
dedic
stereolog
softwar
newcast
visiopharm
volum
densiti
small
larg
vessel
calcul
site
hors
trachea
volum
densiti
small
vessel
increas
hors
heav
compar
control
p
differ
found
larg
vessel
p
volum
densiti
small
larg
vessel
larynx
carina
bronchi
similar
two
group
p
nbi
imag
airway
easili
perform
stand
sedat
hors
signific
increas
tracheal
vascular
heav
remain
ascertain
bovin
respiratori
diseas
brd
complex
major
problem
veal
calv
rear
unit
presenc
lung
lesion
inflamm
shown
neg
affect
subsequ
growth
ultrasonographi
antemortem
diagnost
tool
use
assess
extent
lung
lesion
first
object
studi
describ
preval
ultrasonograph
evid
lung
consolid
veal
calv
metaphylact
treat
tildipirosin
second
object
quantifi
impact
lung
consolid
averag
daili
weight
gain
adg
wean
total
veal
calv
prewean
fatten
unit
enrol
calv
follow
period
three
visit
day
day
day
arriv
adg
calcul
month
month
prewean
period
veal
calv
randomli
alloc
one
two
treatment
group
tildipirosin
tild
n
placebo
plac
n
label
dose
tildipirosin
zuprevo
amount
salin
blindli
administ
sq
calv
bled
jugular
vein
punction
quantifi
total
solid
order
identifi
case
failur
passiv
transfer
fpt
systemat
thorac
ultrasound
examin
use
mhz
linear
probe
focus
maxim
depth
consolid
depth
perform
visit
lung
consolid
defin
depth
cm
preval
fpt
calv
calv
lung
consolid
presenc
consolid
observ
calv
tild
group
plac
group
calv
lung
consolid
greater
odd
lung
consolid
ci
p
calv
without
consolid
calv
fpt
greater
odd
consolid
ci
p
calv
without
fpt
treatment
tild
vs
plac
associ
odd
lung
consolid
day
p
least
squar
mean
calv
lung
consolid
greater
calv
without
consolid
consolid
lbsd
sem
consolid
lbsd
sem
p
conclus
studi
show
ultrasonograph
evid
lung
consolid
veal
calv
month
arriv
predict
assess
fpt
presenc
lung
consolid
day
arriv
metaphylat
use
tildipirosin
nt
decreas
preval
lung
consolid
surprisingli
presenc
lung
consolid
associ
increas
adg
second
month
feed
appear
counterintuit
research
perform
understand
find
systemat
search
perform
medic
record
review
adult
year
beef
anim
diagnos
frontal
sinus
period
inform
previous
list
paramet
evalu
anim
diagnos
frontal
sinus
bull
breed
repres
crossbr
brahman
brangu
dexter
seventeen
rodeo
bull
median
age
present
year
mean
year
durat
clinic
sign
rang
day
year
mean
day
median
day
histori
includ
horn
tip
clinic
find
includ
nasal
discharg
dull
percuss
affect
sinu
abnorm
head
posit
palpabl
warmth
horn
affect
side
drainag
affect
horn
distort
frontal
bone
temperatur
within
normal
rang
bull
rang
hyperproteinemia
hyperglobulinemia
hyperfibrinogenemia
consist
abnorm
clinicopatholog
find
present
diagnost
imag
includ
skull
radiograph
ct
bacteri
cultur
infect
tissu
exud
perform
reveal
trueperella
pyogen
pseudomona
aeruginosa
pseudomona
fluorescen
unilater
frontal
sinus
diagnos
anim
left
frontal
sinu
affect
bull
treatment
includ
trephin
horn
remov
sinu
lavag
antimicrobi
nsaid
sodium
iodid
local
appli
antimicrobialimpregn
plaster
pari
bead
vacuumassist
closur
medicalgrad
maggot
sinusotomi
site
protect
via
pack
cotton
gauz
maintain
steril
bandag
seventeen
bull
discharg
hospit
follow
diagnosi
treatment
longterm
followup
year
avail
bull
made
full
recoveri
twelv
rodeo
bull
report
make
full
recoveri
perform
well
made
full
recoveri
perform
well
develop
abscess
right
papillari
muscl
die
year
later
frontal
sinus
consid
differenti
diagnosi
beef
cattl
present
nonloc
clinic
sign
ancillari
diagnost
find
may
also
nonspecif
buck
bull
perform
rodeo
requir
tip
horn
blunt
diamet
cm
inch
procedur
may
result
open
bacteri
transloc
frontal
sinu
contribut
develop
frontal
sinus
anim
particularli
young
adult
appropri
treatment
prognosi
longterm
surviv
good
even
chronic
case
object
studi
compar
plasma
pharmacokinet
profil
ceftiofur
crystallin
free
acid
ccfa
ceftiofur
sodium
neonat
calv
one
group
singl
dose
ccfa
administ
subcutan
sq
base
ear
dose
mgkg
bodi
weight
second
group
singl
dose
ceftiofur
sodium
administ
sq
neck
dose
mgkg
bodi
weight
concentr
desfuroylceftiofur
acetamid
determin
plasma
anim
administr
product
time
maximum
dca
concentr
hour
ccfa
hour
ceftiofur
sodium
maximum
plasma
dca
concentr
significantli
higher
calv
given
ceftiofur
sodium
lgml
calv
given
ccfa
lgml
auc
vdf
significantli
greater
calv
given
ccfa
calv
given
ceftiofur
sodium
termin
halflif
dca
plasma
significantli
longer
calv
given
ccfa
hour
calv
calv
given
ceftiofur
sodium
hour
clf
significantli
differ
group
durat
time
median
plasma
dca
concentr
remain
lg
ml
significantli
longer
calv
receiv
ccfa
hour
compar
calv
receiv
ceftiofur
sodium
hour
base
result
studi
ccfa
administ
sq
dose
mgkg
neonat
calv
provid
plasma
concentr
therapeut
target
lgml
least
day
follow
singl
dose
calcium
homeostat
mechan
challeng
periparturi
multipar
dairi
cattl
due
rapid
transport
larg
amount
calcium
mammari
gland
result
decreas
plasma
calcium
concentr
ca
unresolv
issu
time
decreas
plasma
ca
rel
time
parturit
consensu
view
plasma
ca
decreas
parturit
object
studi
therefor
character
chang
plasma
ca
time
periparturi
dairi
cattl
plasma
midstream
urin
sampl
collect
daili
start
day
calv
periparturi
holstein
friesian
dairi
cow
fed
acidogen
total
mix
ration
late
dri
period
mix
model
analysi
varianc
conduct
p
consid
signific
plasma
ca
correct
plasma
total
protein
concentr
decreas
multipar
cattl
n
primipar
cattl
n
compar
least
squar
mean
valu
hour
parturit
ca
mgdl
plasma
ca
multipar
cattl
first
decreas
hour
parturit
mgdl
lower
mgdl
hour
parturit
increas
mgdl
hour
decreas
mgdl
hour
parturit
time
plasma
ca
gradual
increas
urin
ca
creatinin
ratio
multipar
cattl
first
decreas
hour
parturit
remain
low
time
onward
conclud
calcium
supplement
administ
least
hour
anticip
time
calv
multipar
dairi
cattl
order
decreas
incid
hypocalcemia
accur
diagnosi
hypoglycemia
help
diagnosi
treatment
ketosi
periparturi
dairi
cattl
precis
xtra
meter
use
methodolog
assum
intraerythrocyt
glucos
concentr
glucos
e
plasma
glucos
concentr
glucos
p
equival
hematocrit
hct
typic
valu
human
blood
object
studi
therefor
determin
accuraci
precis
xtra
meter
measur
glucos
p
blood
plasma
dairi
cattl
determin
influenc
hct
measur
glucos
b
blood
plasma
sampl
refer
method
glucos
phexokinas
day
calv
n
rang
mgdl
median
mgdl
hematocrit
rang
median
plasma
protein
concentr
rang
gl
median
g
l
median
glucos
e
glucos
p
ratio
demonstr
glucos
e
glucos
p
equival
conclud
algorithm
precis
xtra
meter
calcul
glucos
p
glucos
b
optim
use
human
blood
accur
appli
bovin
blood
therefor
recommend
use
plasma
analyt
instead
blood
calcul
glucos
p
mgdl
use
follow
equat
glucos
p
glucos
pprecisionxtra
blood
measur
use
precis
xtra
recommend
use
follow
equat
express
intraepitheli
lymphocyt
calv
follow
infect
cryptosporidium
parvum
role
pathogenesi
diarrhea
unknown
studi
shown
knockout
mice
becom
resist
c
parvum
infect
oral
administr
chicken
egg
yolk
antibodi
mean
control
enter
diseas
calv
signific
interest
dairi
industri
egg
yolk
antibodi
shown
surviv
gastrointestin
transit
access
intestin
lumen
remain
local
activ
without
interfer
natur
immun
persist
system
residu
doubleblind
random
prospect
clinic
trial
conduct
investig
effect
feed
antibodi
calf
health
c
parvum
oocyst
shed
day
diarrhea
fecal
ph
antibiot
use
averag
daili
gain
dairi
calv
studi
includ
calv
randomli
assign
treatment
group
fed
g
egg
yolk
powder
antibodi
per
day
day
control
group
fed
g
egg
yolk
powder
without
antibodi
per
day
day
calf
receiv
health
score
base
attitud
appetit
temperatur
ocular
nasal
discharg
cough
ear
posit
navel
joint
assess
daili
day
hydrat
statu
fecal
ph
fecal
pathogen
c
parvum
coronaviru
rotaviru
salmonella
test
conduct
two
three
time
first
day
growth
respiratori
health
antibiot
use
assess
conclus
trial
day
result
show
calv
treatment
group
respiratori
diseas
compar
calv
control
group
day
p
addit
calv
treatment
group
administ
antibiot
farm
personnel
compar
control
calv
p
fecal
ph
significantli
increas
treatment
group
day
compar
enrol
day
p
averag
day
diarrhea
significantli
differ
two
group
except
first
day
treatment
group
day
diarrhea
compar
control
group
day
diarrhea
p
differ
group
fecal
shed
c
parvum
day
day
measur
rtpcr
ct
valu
although
signific
differ
averag
daili
gain
note
group
hipomet
estim
weight
day
significantli
greater
calv
treatment
group
compar
control
group
p
suggest
increas
fecal
ph
treatment
group
may
indic
improv
gastrointestin
health
use
common
mucos
immun
hypothesi
surmis
enhanc
mucos
immun
host
defens
gastrointestin
tract
result
less
respiratori
diseas
treat
calv
futur
direct
includ
dose
respons
durat
treatment
studi
detail
focu
paramet
gastrointestin
respiratori
tract
health
presumpt
fenbendazol
toxicosi
three
holstein
calv
emili
barrel
rebecca
rubi
belinda
thompson
theresa
southard
daryl
nydam
gillian
perkin
cornel
univers
ithaca
ny
usa
fenbendazol
fbz
wide
use
anthelmint
interfer
microtubul
format
consid
safe
rumin
studi
evalu
dose
mgkg
po
day
treatment
giardiainduc
diarrhea
without
complic
benzimidazol
toxic
varieti
speci
result
bone
marrow
hypoplasia
intestin
crypt
epitheli
necrosi
abstract
describ
clinic
find
necropsi
examin
three
holstein
heifer
calv
presumpt
fbz
toxicosi
calv
receiv
two
cours
greater
label
dose
fbz
day
fbz
day
anoth
day
treatment
presumpt
giardiainduc
diarrhea
clinic
sign
includ
fever
tachycardia
dyspnea
profus
diarrhea
recumb
three
anim
persist
absolut
neutropenia
despit
treatment
one
calf
euthan
due
poor
respons
one
calf
die
histolog
examin
liver
lung
intestin
epitheli
cell
reveal
hyperplasia
cell
atypia
irregular
mitot
figur
ring
mitosi
abnorm
clump
chromatin
bone
marrow
hypoplast
overal
cellular
fece
neg
salmonella
spp
bovin
viral
diarrhea
viru
rotaviru
parasit
posit
bovin
coronaviru
third
calf
treat
onfarm
recov
sever
week
base
histopatholog
histori
multipl
anim
affect
toxic
etiolog
suspect
common
exposur
repeat
administr
highdos
fbz
suggest
judici
use
fbz
calv
warrant
purpos
studi
use
molecular
techniqu
determin
dairi
heifer
colon
coagulas
neg
staphylococci
cn
speci
calv
caus
cn
intramammari
infect
imi
parturit
holstein
guernsey
heifer
univers
missouri
foremost
dairi
longitudin
enrol
studi
sampl
includ
prepartum
mammari
quarter
secret
swab
sampl
teat
muzzl
perineum
inguin
region
collect
approxim
day
expect
calv
date
swab
sampl
collect
use
gassteril
electrostat
duster
swiffer
calv
mammari
quarter
foremilk
sampl
collect
twice
approxim
day
postpartum
bacteri
cultur
somat
cell
count
bodi
site
swab
sampl
chill
ice
transport
process
day
swab
sampl
mix
ml
steril
salin
agit
plate
mannitol
salt
agar
msa
hour
plate
read
morpholog
distinct
staphylococc
coloni
subcultur
onto
columbia
blood
agar
cba
prepartum
secret
milk
sampl
cultur
accord
nation
mastiti
council
guidelin
sampl
consid
cultur
posit
one
coloni
observ
cfuml
staphylococc
isol
bank
phosphat
buffer
glycerol
staphylococci
isol
speciat
use
polymeras
chain
reaction
dna
sequenc
rpob
housekeep
gene
date
heifer
complet
studi
sampl
process
bacteri
speciat
complet
heifer
quarter
overal
chromogen
common
speci
identifi
prepartum
secret
postpartum
milk
sampl
nonaureu
staphylococc
speci
identifi
mammari
secret
sampl
includ
agneti
prepartum
quarter
devriesei
prepartum
quarter
pasteuri
postpartum
quarter
xylosu
postpartum
quarter
chromogen
speci
found
present
prepartum
mammari
secret
postpartum
milk
sampl
heifer
total
quarter
chromogen
isol
prepartum
first
postpartum
sampl
quarter
still
posit
chromogen
second
postpartum
sampl
eightyfour
bodi
site
sampl
heifer
yield
staphylococc
isol
isol
speciat
total
differ
speci
identifi
common
speci
includ
devriesei
chromogen
haemolyticu
three
cn
speci
isol
four
bodi
site
chromogen
speci
found
preval
mammari
secret
milk
isol
primarili
inguin
region
follow
perineum
teat
muzzl
cn
common
caus
subclin
mastiti
dairi
heifer
studi
chromogen
common
caus
cn
imi
speci
also
commonli
found
inguin
area
perineum
prepartum
heifer
bodi
site
could
import
sourc
chromogen
heifer
imi
strain
type
perform
use
pulsedfield
gel
electrophoresi
determin
whether
strain
chromogen
present
differ
bodi
site
mammari
gland
heifer
final
result
project
understand
epidemiolog
cn
infect
dairi
heifer
allow
develop
studi
method
control
prevent
infect
accur
bodyweight
necessari
correctli
dose
drug
goat
underdos
anthelmint
correl
develop
anthelmint
resist
toxic
risk
overdos
mani
goat
produc
lack
scale
therefor
visual
estim
bodi
weight
routin
perform
produc
veterinarian
final
year
doctor
veterinari
medicin
dvm
student
anim
scienc
undergradu
student
particip
studi
student
complet
questionnair
prior
livestock
experi
seventi
femal
goat
spanishbo
breed
digit
record
move
alley
footag
consolid
segment
anim
identif
follow
second
anim
stand
alley
student
view
video
estim
weight
nearest
pound
seventyon
student
particip
anim
scienc
dvm
student
goat
rang
lb
mean
lb
overal
student
underestim
weight
time
weight
estim
within
actual
weight
time
prior
livestock
experi
student
classif
signific
effect
number
estim
within
actual
weight
weight
goat
also
significantli
associ
accuraci
liveweight
estim
result
indic
underestim
goat
liveweight
frequent
livestock
experi
prior
veterinari
educ
signific
effect
weight
estim
accuraci
studi
highlight
defici
liveweight
estim
goat
anim
scienc
veterinari
traine
may
contributor
anthelmint
resist
chronic
vagal
indigest
refer
group
function
andor
mechan
disturb
stomach
result
impair
gastrointestin
transit
term
chronic
indigest
ci
gener
use
describ
rumin
present
follow
clinic
sign
poor
appetit
weight
loss
abdomin
rumin
distens
dehydr
reduc
fecal
output
bradycardia
mani
term
use
year
vagal
indigest
one
bring
confus
sinc
impli
vagu
nerv
necessarili
involv
pathophysiolog
diseas
purpos
studi
retrospect
describ
clinic
find
etiolog
outcom
adult
dairi
cattl
diagnos
ci
referr
teach
hospit
medic
archiv
search
includ
dairi
cattl
older
year
diagnosi
ci
present
centr
hospitali
universitair
v
et
erinair
universit
e
de
montr
eal
januari
novemb
patient
histori
clinic
sign
last
hour
neither
rumin
abdomin
distens
exclud
followup
inform
includ
longev
herd
obtain
access
free
onlin
databas
canadian
dairi
network
eight
record
could
retriev
medic
archiv
two
patient
suffer
acut
ill
one
patient
neither
rumin
abdomin
distens
exclud
fiftytwo
adult
dairi
cattl
final
includ
studi
bull
heifer
dri
cow
lactat
cow
age
patient
rang
year
old
median
year
holstein
abscess
omas
dilat
perfor
abomas
ulcer
advanc
pregnanc
also
identifi
primari
caus
ci
three
case
howev
precis
etiolog
remain
undetermin
case
necropsi
perform
case
vagal
nerv
lesion
detect
one
case
shortterm
prognosi
good
case
discharg
longterm
prognosi
fair
case
remain
herd
least
one
subsequ
lactat
three
cattl
perireticular
abscess
remain
herd
least
one
subsequ
lactat
cattl
abomas
dysfunct
euthan
die
hospit
two
frequent
identifi
etiolog
ci
adult
dairi
cattl
perireticular
abscess
complic
surgic
correct
right
abomas
displac
abomas
volvulu
adult
dairi
cattl
perireticular
abscess
treat
fair
prognosi
abomas
lesion
appear
associ
wors
outcom
inform
regard
presenc
lipopolysaccharid
lp
plasma
calv
diarrhea
lack
hypothes
lp
detect
diarrheic
calv
concentr
higher
nonsurviv
surviv
calv
also
hypothes
plasma
lp
associ
alter
demeanour
attitud
suckl
reflex
postur
biochem
variabl
prospect
studi
includ
calv
day
age
diarrhea
healthi
agematch
control
comparison
group
perform
use
tor
mannwhitney
u
test
anova
test
use
determin
associ
lp
postur
stand
sternal
later
recumb
attitud
bright
depress
comatos
suckl
reflex
strong
weak
absent
spearman
rank
r
test
use
evalu
correl
plasma
lp
detect
healthi
diarrheic
calv
lp
significantli
higher
diarrheic
healthi
ng
ml
ngml
respect
p
nonsurviv
surviv
calv
ng
ml
ngml
respect
p
lp
associ
calf
demeanor
p
howev
posit
associ
plasma
llactat
r
p
neg
associ
glucos
r
p
lp
higher
calv
hyperllactatemia
mmoll
versu
without
hyperllactatemia
ngml
ngml
respect
p
hypoglycem
mmol
l
calv
compar
normohyperglycem
ngml
ngml
respect
p
plasma
lp
higher
diarrheic
nonsurviv
calv
lp
higher
hyperllactatem
hypoglycem
calv
suggest
diarrheic
calv
endotoxemia
may
alter
metabol
pathway
determin
risk
factor
silica
urolithiasi
goat
evalu
chang
silica
urolith
submiss
rate
past
year
compar
januari
decemb
period
januari
decemb
period
studi
popul
includ
goat
silica
urolith
control
goat
inform
age
breed
sex
reproduct
statu
geograph
locat
season
year
anatom
locat
use
identifi
risk
factor
pygmi
nubian
nigerian
dwarf
mix
breed
like
develop
silica
urolithiasi
breed
breed
african
origin
includ
pygmi
nigerian
dwarf
compris
case
neuter
male
goat
significantli
increas
risk
develop
silica
urolith
signific
associ
found
breed
sex
reproduct
statu
geograph
locat
season
anatom
locat
detect
silica
urolith
goat
proport
silica
urolith
submiss
decreas
period
period
mean
age
goat
silica
increas
ae
year
period
ae
year
period
male
compris
femal
compris
period
period
two
male
compris
submiss
result
suggest
prototyp
goat
silica
urocystolith
neuter
male
year
african
descent
result
studi
indic
risk
factor
silica
urolith
associ
prove
caus
effect
relationship
doxycyclin
doxi
associ
left
ventricular
lv
dysfunct
calv
accident
overdos
experiment
model
evalu
classic
doppler
echocardiographi
twodimensionalspeckl
track
use
evelu
lv
dysfunct
numer
speci
cattl
aim
studi
evalu
cardiotox
effect
experiment
overdos
doxi
use
calv
ten
healthi
male
holstein
calv
group
calv
mean
age
ae
day
mean
bodi
weight
ae
kg
receiv
mgkg
doxi
oral
day
group
calv
mean
age
ae
day
mean
bodi
weight
ae
kg
receiv
placebo
electrocardiographi
ecg
echocardiographi
perform
day
day
ecg
trace
analys
occurr
arrhythmia
measur
includ
global
segment
peak
valu
radial
circumferenti
strain
sr
sc
strain
rate
srr
src
rotat
rot
rotat
rate
rotr
radial
displac
dr
calv
complet
studi
ecg
record
unremark
group
heart
rate
neither
significantli
differ
group
treatment
lv
systol
function
affect
calv
receiv
overdos
doxi
shown
signific
decreas
segment
sr
p
sc
p
dr
p
treat
calv
compar
placebo
group
sever
segment
src
earli
diastol
also
significantli
decreas
segment
calv
doxi
overdos
induc
lv
dysfunct
systol
lesser
extent
diastol
better
comprehens
pathophysiolog
involv
doxi
overdos
help
treatment
accident
case
twodimension
speckl
track
noninvas
techniqu
use
mani
speci
evalu
global
region
left
ventricular
lv
function
howev
receiv
littl
attent
bovin
speci
aim
studi
assess
feasibl
reliabl
evalu
circumferenti
radial
lv
wall
motion
calv
fourteen
holstein
black
calv
age
ae
day
bodi
weight
ae
kg
use
observ
studi
right
parastern
short
axi
view
level
papillari
muscl
record
subsequ
analys
global
region
radial
circumferenti
strain
strain
rate
radial
displac
rotat
rotat
rate
echocardiograph
examin
perform
unsed
stand
calv
two
differ
observ
evalu
intraand
interobserv
repeat
variabl
feasibl
calv
exclud
analys
ventricular
septum
defect
rest
heart
rate
bpm
respect
autom
track
better
systol
diastol
intraobserv
repeat
good
moder
systol
global
segment
peak
valu
systol
peak
valu
radial
strain
strain
rate
repeat
circumferenti
strain
circumferenti
strain
rate
diastol
measur
variabl
interobserv
measur
greater
intraobserv
measur
twodimension
speckl
track
feasibl
calv
speci
systol
radial
function
reliabl
evalu
circumferenti
diastol
function
hyperlactatemia
hypercapnia
low
ph
low
sat
commonli
observ
prematur
calv
effect
mortal
venou
lactat
ph
pco
level
prematur
calv
respiratori
distress
syndrom
rsd
investig
studi
studi
perform
prematur
calv
admit
clinic
within
hour
birth
addit
short
gestat
age
clinic
sign
low
birth
weight
includ
inabl
stand
short
silki
hair
incomplet
erupt
incisor
teeth
also
present
prematur
anim
ninetyfour
prematur
calv
holstein
swissbrown
bull
calv
blood
sampl
collect
anaerob
heparin
tube
jugular
vein
measur
immedi
use
blood
ga
analyz
data
express
mean
standard
deviat
mean
ae
sd
independ
sampl
test
use
compar
venou
blood
ga
indic
surviv
nonsurviv
prematur
calv
prematur
calv
low
venou
ph
low
po
high
pco
high
lactat
total
calv
surviv
calv
die
within
hour
birth
venou
ph
nonsurviv
prematur
calv
decreas
compar
surviv
prematur
calv
pco
lactat
concentr
nonsurviv
prematur
calv
increas
tabl
conclus
result
indic
posit
relationship
mortal
decreas
venou
ph
increas
lactat
concentr
pco
level
prematur
calv
rsd
concurr
evalu
paramet
could
use
prognosi
evalu
prematur
calv
rsd
object
studi
compar
effect
combin
intraven
isoton
sodium
bicarbon
sodium
lactat
sodium
acet
hyperton
sodium
chlorid
solut
oral
electrolyt
solut
treatment
calf
diarrhea
mildmoder
dehydr
metabol
acidosi
thirti
two
calv
day
old
diarrhea
dehydr
venou
ph
base
excess
meql
use
studi
four
differ
treatment
group
studi
treatment
group
isoton
sodium
bicarbon
mg
given
via
intraven
iv
rate
mlkgh
follow
oral
electrolyt
solut
mlkg
administr
treatment
group
isoton
sodium
acet
mlkg
given
via
iv
rate
mlkgh
follow
oral
electrolyt
solut
mlkg
administr
treatment
group
isoton
sodium
lactat
mlkg
given
via
iv
rate
mlkgh
follow
oral
electrolyt
solut
mlkg
administr
treatment
group
hyperton
salin
mlkg
given
via
iv
follow
oral
electrolyt
solut
ml
kg
administr
intraven
solut
given
calv
infus
machin
chang
clinic
hemodynam
hematolog
blood
ga
plasma
volum
serum
electrolyt
protein
determin
period
hour
follow
fluid
administr
calv
calv
receiv
intraven
isoton
sodium
bicarbon
hyperton
naci
sodium
lactat
sodium
acet
solut
along
oral
electrolyt
solut
increas
venou
blood
ph
hco
concentr
base
excess
within
hour
begin
administr
increas
plasma
volum
sodium
concentr
decreas
serum
total
protein
observ
within
hour
follow
administr
hyperton
naci
oral
electrolyt
solut
combin
compar
solut
result
studi
show
administr
iv
hyperton
naci
solut
small
volum
along
oral
electrolyt
solut
provid
fast
effect
improv
dehydr
acidbas
abnorm
within
short
time
treatment
calf
diarrhea
mild
moder
dehydr
metabol
acidosi
compar
treatment
group
studi
aim
describ
signal
histori
clinicopatholog
ultrasound
find
outcom
adult
cattl
histopatholog
diagnosi
cholangiohepatit
report
holstein
cow
older
week
age
suffer
cholangiohepat
diagnosi
cholangiohepat
base
presenc
portal
inflammatori
infiltr
surround
andor
infiltr
bile
duct
without
epitheli
damag
extend
adjac
lobul
six
case
diagnos
base
liver
biopsi
four
postmortem
examin
reason
veterinari
consult
mostli
decreas
appetit
obtund
median
age
cow
year
rang
year
admiss
five
cow
complet
anorexia
five
decreas
appetit
median
rectal
temperatur
median
heart
rate
bpm
bpm
icteru
present
three
cow
four
cow
mildli
dehydr
three
moder
one
sever
four
cow
absenc
scant
fece
one
diarrhea
melena
comorbid
includ
photosensibil
n
abomas
dilationdisplac
n
salmonellosi
n
periton
n
glomerulonephr
n
obstruct
bile
duct
n
remark
hematolog
find
includ
leucocytosi
cellsll
six
case
mark
neutophilia
cell
eight
case
four
cow
toxic
chang
identifi
neutrophil
hyperfibrinogenemia
mgdl
determin
seven
case
alter
serum
biochemistri
profil
includ
increas
globulin
level
mgdl
six
case
hypoalbuminemia
gdl
six
case
elev
ast
iul
six
case
elev
ggt
iul
six
case
increas
total
bilirubin
lmoll
detect
four
cow
ultrasonograph
examin
liver
gall
bladder
may
reveal
dilat
extrahepat
intrahepat
bile
duct
dilat
gallbladd
increas
thick
wall
two
six
cow
diagnos
biopsi
surviv
discharg
median
time
hospit
surviv
cow
day
rang
postmortem
examin
e
coli
isol
hepaticgallbladd
tissu
two
case
result
studi
suggest
cholangiohepat
rare
condit
adult
cattl
ant
mortem
diagnosi
may
challeng
clinic
sign
unspecif
laboratori
result
resembl
cow
suffer
hepat
lipidosi
combin
inflammatori
process
eg
acut
metriti
acut
mastiti
although
number
anim
includ
studi
small
appear
diagnosi
cholangioheapt
carri
guard
prognosi
valu
pharmacokinet
variabl
usual
obtain
healthi
anim
wherea
drug
frequent
administ
diseas
anim
therefor
urgent
need
determin
whether
dosag
protocol
need
alter
sick
anim
consequ
compar
pharmacokinet
valu
intramammari
cefquinom
healthi
goat
goat
experiment
induc
mastiti
five
lactat
goat
receiv
two
intramammari
treatment
cefquinom
sulfat
mgudder
half
hour
interv
induct
clinic
mastiti
infus
staphlococcu
aureu
atcc
cfu
goat
milk
hour
interv
milk
jugular
venou
blood
sampl
obtain
period
cefquinom
administr
skim
milk
plasma
concentr
cefquinom
determin
use
high
perform
liquid
chromatographi
pharmacokinet
valu
determin
use
noncompartment
method
p
signific
experiment
induc
mastiti
decreas
maxim
cefquinom
concentr
elimin
halftim
milk
compar
healthi
goat
mean
resid
time
cefquinom
milk
markedli
lower
mastit
goat
hour
healthi
goat
hour
cefquinom
concentr
milk
exceed
lgml
effect
mic
test
organ
hour
healthi
goat
hour
mastit
goat
cefquinom
detect
milk
hour
healthi
anim
hour
infect
anim
plasma
cefquinom
concentr
low
healthi
mastit
goat
exceed
lgml
mastiti
effect
mean
transient
time
cefquinom
plasma
conclud
experiment
induc
clinic
mastiti
facilit
absorpt
cefquinom
mammari
gland
lactat
goat
high
perform
liquid
chromatograph
hplc
techniqu
current
prefer
determin
withdraw
time
meat
milk
treatment
howev
hplc
methodolog
complic
expens
suscept
interfer
matrix
effect
develop
altern
analyt
methodolog
simpl
inexpens
agar
diffus
microbiolog
assay
would
advantag
object
studi
therefor
compar
hplc
determin
cefquinom
concentr
plasma
milk
five
adult
lactat
goat
receiv
follow
two
treatment
intramammari
cefquinom
sulfat
infus
mg
udder
half
intraven
inject
dose
cefquinom
induct
clinic
mastiti
intramammari
infect
induc
infus
cfu
staphylococcu
aureu
atcc
jugular
venou
blood
milk
sampl
obtain
period
cefquinom
administr
plasma
skim
milk
concentr
cefquinom
determin
use
hplc
accept
mean
coeffici
variat
skim
milk
plasma
compar
hplc
hplc
procedur
similar
limit
quantif
skim
milk
plasma
hplc
methodolog
yield
statist
similar
result
cefquinom
concentr
protein
bind
percentag
noncompartment
pharmacokinet
variabl
skim
milk
plasma
conclud
provid
sensit
accur
inexpens
method
determin
cefquinom
concentr
pharmacokinet
valu
skim
milk
plasma
goat
without
experiment
induc
staph
aureu
mastiti
